

CURRICULUM VITAE

Suzanne Oparil, M.D.

Born: April 10, 1941
Elmira, New York, U.S.A.

Citizenship: United States

Affiliations: **Suzanne Oparil, MD, FACC, FAHA, FASH, FAPS**
Distinguished Professor of Medicine
Professor of Cell, Developmental and Integrative Biology
Section Chief of Vascular Biology and Hypertension
Director, Vascular Biology and Hypertension Program
Division of Cardiovascular Disease
Department of Medicine
School of Medicine
University of Alabama at Birmingham
Birmingham, Alabama, U.S.A.

Campus: 703 19th Street South
Zeigler Research Building (ZRB)
Room 1034
Birmingham, Alabama 35294-0007

Email: soparil@uabmc.edu **eRA Commons:** oparil

Contact: (205) 934-2580 (Ph VB&H-main) (205) 934-0424 (facsimile)

Education:

08/1953 – 05/1957 Thomas A. Edison High School, Elmira Heights, New York
08/1957 – 05/1961 A.B., Cornell University, Ithaca, New York
08/1961 – 05/1965 M.D., Columbia University, College of Physicians and Surgeons, New York, New York

Fellowships:

07/1968 – 06/1971 National Institutes of Health, Fellow in Cardiology, (HE-5196-13)
07/1973 – 06/1978 American Heart Association Established Investigator

Positions:

07/1965 – 06/1966 Intern in Medicine, Presbyterian Hospital, New York
07/1966 – 06/1967 Junior Assistant Resident in Medicine, Presbyterian Hospital, New York, New York
07/1967 – 06/1968 Senior Assistant Resident in Medicine, Massachusetts General Hospital, Boston, Massachusetts
07/1968 – 06/1971 Clinical and Research Fellow in Medicine, Cardiac Unit, Massachusetts General Hospital, Boston, Massachusetts
07/1971 – 09/1975 Assistant Professor of Medicine, University of Chicago Medical School, Chicago, Illinois

Positions (Continued)

10/1975 – 09/1977	Associate Professor of Medicine, University of Chicago Medical School, Chicago, Illinois
10/1977 – 09/1981	Associate Professor of Medicine, Department of Medicine, University of Alabama at Birmingham, SOM
10/1980 – 09/1981	Assistant Professor of Physiology and Biophysics, Department of Medicine, University of Alabama at Birmingham, SOM
10/1981 – 02/2014	Professor of Medicine, Department of Medicine, University of Alabama at Birmingham, SOM
10/1985 – present	Director, Vascular Biology and Hypertension Program, Department of Medicine, University of Alabama at Birmingham, SOM
*10/1993 – 09/2012	Professor of Physiology and Biophysics, Department of Medicine, University of Alabama at Birmingham, SOM (<i>renamed</i>)
*10/1993 – present	Professor of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, SOM (<i>renamed</i>)
08/2005 – present	Senior Scientist, Center for Aging, University of Alabama at Birmingham, SOM
02/2014 – present	Distinguished Professor of Medicine, Department of Medicine, University of Alabama at Birmingham, SOM

Organizations:

Phi Beta Kappa
Phi Kappa Phi
Alpha Epsilon Delta
Alpha Omega Alpha
Sigma Xi
American College of Cardiology
Fellow (FACC), 1992
American Federation for Clinical Research/Medical Research
Midwest Councilor, 1974-1975
National Councilor, 1975-1978
Secretary-Treasurer, 1978-1980
President-Elect, 1980-1981
President, 1981-1982
American Society for Clinical Investigation
Secretary -Treasurer, 1983-1986
Association of American Physicians, 1983 – present
National Academy of Medicine (NAM) of the National Academies of Sciences,
Engineering, and Medicine (formerly Institute of Medicine),
Member, 1991 – present
Committee on Human Rights-Correspondent, 1992
Committee on Secondhand Smoke Exposure and Acute Coronary Events,
Member, 2008 – 2009
National Academy of Science, National Research Council,
Space Studies Board, 2004 – 2007
Central Society for Clinical Research, 1974 – 1986
Southern Society for Clinical Investigation, 1978 – present
American Physiological Society, 1978 – present
Fellow (FAPS), 2015
Clinical Physiology Advisory Committee, 1992
American Heart Association, 1985 – present
Fellow (FAHA), 1986
President-Elect, 1993 – 1994
President, 1994 – 1995
Past President, 1995 – 1996
Board of Directors Member at Large, 1992 – 1993
Council on High Blood Pressure Research, Honorary Fellow
Medical Advisory Board, 1973 – 1975
Nominating and Membership Committee, 1979 – 1982
Executive Committee, 1985 – 1990
Vice Chairman, 1986
Council on Basic Cardiovascular Sciences, Honorary Fellow
Member at Large, Executive Committee, 1979 – 1981
Chairman, Louis B. Katz Prize Committee, 1984 – 1986
Chairman, 1988 – 1990
Chairman Budget Committee, 1990 – 1991
Steering Committee for Research, Medical and Community Program, 1989 – 1991
President's Advisory Committee on Public Policy, 1989 – 1991
Chairman, 1990 – 1991

Chicago Heart Association
Hypertension Committee, Chairman, 1975 – 1977
Research Committee Member, 1973 – 1977
Alabama Affiliate
Research Review Committee, 1978 –
Chairman, 1981 – 1983
Vice President, 1986 – 1987
President-Elect, 1987 – 1988
President, 1988 – 1989
American Society of Hypertension,
Member, 1988 – present
Public Policy Committee, 1990 – 1993
Scientific Program Committee, 1990 – 1991
Executive Council Member, 1995 – 1998
President, 2006-2008
Board of Directors, 2009 – 2011
Executive Committee, 2008 – 2010
Compensation Committee, 2008 – 2010
Fellow (FASH), 2010
Nominating Committee, 2011 – 2012
Publications Committee, 2011 – 2012
Compliance Committee, 2011 – 2012
Chair, Publications Committee, 2012 – 2014
American Society of Hypertension, Advisory Board, Hypertension Writing Group
American Society of Hypertension, Educational Alliance to Improve the Prevention,
Detection, and Management of Hypertension, 2010 – present
The Association for Women in Science, 1980 – present
Inter-American Society of Hypertension, 1980 – present
American Association for the Advancement of Science, 1977
NIH Study Section (Pharmacology A), 1974 – 1978
NIH Task Force on Research Needs in Endocrinology and Metabolic Diseases-
Hypertension and Cardiovascular-Renal Area, 1978 –
NIH Hypertension Task Force, 1976 – 1978
NHLBI Hypertension Task Force, 1990
NIH Heart, Lung and Blood Research Review Committee B, 1982 – 1986
Diplomate, American Board of Internal Medicine, 1970
Society for Experimental Biology and Medicine Councilor, 1992 – 1996
Society for Neuroscience, 1985 –
The Endocrine Society,
Active Member, 1978 – present
Emeritus Member, 2012 – present
Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure,
JNC V, 1991; JNC 7, 2003, JNC 8, 2014
International Society for Heart Research, American Section NHLBI Clinical Guidelines
Leadership Group for Cardiovascular Disease Risk Reduction, 2007
NIH Research Training Review Committee, NHLBI, 1992 – 1996
Chairman, 1995
Committee to Advise Department of Defense on Its Breast Cancer Program,
Chairman, 1993
National Advisory Panel for the ADA's Nutrition and Health Campaign for Women, 1993

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Steering Committee, 1994 –
Editorial Subcommittee Member, 1994 –
Stroke Working Group, Chair, 2012 – present
Czechoslovak Society of Arts and Sciences, 1995
American Society for Nutritional Sciences, 1996
North American Vascular Biology Organization, 1996
American College of Cardiology, Extramural Continuing Education Committee, 1997 –
NIH Advisory Committee on Research on Women's Health, 1997 – 2000
LIFE Steering Committee, 1998
Texas Biotechnology Corporation/Encysive Pharmaceuticals, Board of Directors,
1999 – 2008
President's Council of Cornell Women,
Member, 1999 –
Meeting Planning and Development Committee, 1999 – 2004
Donald W. Reynolds Foundation, Cardiovascular Clinical Research Scientific Advisory
Panel, 1999 – 2002
NIH Center for Scientific Review: Panel on Scientific Boundaries for Review,
Panel Member 1999 – present
Alton Ochsner Award Selection Committee, 2000
International Council for Research into Fetal Origins of Adult Diseases (FOAD), 2000
Heart and Stroke Ambassadors – American Heart Association, 2001
Doris Duke Charitable Foundation, Consultant, 2001
International Society of Hypertension, 2002 –
Scientific Council Member
International Forum
Membership Committee
Novartis Award Nominating Committee, 2006
Preeclampsia Foundation Medical Board, 2007 –
Systolic Blood Pressure Intervention Trial (SPRINT), *NHLBI Sponsored Trial*
Principal Investigator/Director, UAB Clinical Center Network, 2009 – present
Steering Committee, Member, 2009 – present
Mortality and Morbidity Subcommittee, *Chair*, 2009 – present
Presentations and Publications Subcommittee, Member, 2009 – present
Intervention Subcommittee, Member, 2009 – present
ACCF/AHA/NHLBI 2010 Expert Consensus Document on Hypertension in the Elderly,
Hypertension in the Elderly Expert Consensus Document, Writing Committee
Member, 2010
American Heart Association, 2011 Update: Effectiveness-Based Guidelines for the
Prevention of Cardiovascular Disease in Women, Expert Panel Member, 2010-2011
Kidney Disease Improving Global Outcomes (KDIGO) Guideline for Blood Pressure
Management in CKD, Work Group Member, 2010 – 2011
American Society of Hypertension Gulf Central Regional Chapter (ASH-GC),
Board Member, 2010 – 2014
Medtronic Symplicity HTN-3
Steering Committee Member, 2011 – 2014
Medtronic Power over Pressure Program
Steering Committee Co-Chair, 2011 – 2013
NIH-NHLBI Grant Review Panel, "Reducing the Impact of Hypertension in Low and Middle
Income Countries" Review Panel Chair, 2011

International Academy of Cardiovascular Sciences (IACS), Global Network to Fight Cardiovascular Diseases, Steering Committee Member, 2011 – present

NIH, Center for Scientific Review Special Emphasis Panel, Transformative Research Projects Program (R01), Editor, 2012

University of Alabama at Birmingham Comprehensive Cardiovascular Center (CCVC) Member, 2012 – present

Steering Committee, 2012 – present

Pilot Grant/Exploratory Grant Working Group, 2012 – present

Continuing Education Credit (CEC) Course on the AHA/ACC guidelines on treatment and management of hypertension, principles on cultural competency and behavioral modifications, Program Chair and Physician Expert, 2012

Association of University Cardiologists
Honorary Member, 2013 – present

NIH, Center for Scientific Review Special Emphasis Panel, (U10) NHLBI Initiative, Panel Member, 2013

WHF/AHA Scientific Program Planning Committee, 4th International Conference on Women, Heart Disease and Stroke, in conjunction with World Congress of Cardiology (WCC) Scientific Sessions (May 4-7, 2014), 2013 – 2014

American College of Cardiology (ACC), Douglas P. Zipes Distinguished Young Scientist Award Selection Panel Member, 2014

Planning/Selection Committee Member, 2020 Impact Program to Highlight AHA-Supported Research and Researchers, AL State Chapter, American Heart Association, 2014

Event Ad Hoc Planning Committee Member for the National Council, American Federation for Medical Research (formerly the AFMR) 75th Anniversary (2015), 2014

“Antihypertensive Therapy for Mild Chronic Hypertension during Pregnancy: A Pragmatic Multicenter Randomized Trial (CHAP Project)”, UAB Clinical Coordinating Center (CCC) Key Investigator, Cardiologist-Hypertension Expert, 2014 – present

Senior Review Committee Member, Alpha Omega Alpha (AOA) Honor Medical Society, Alabama Chapter, 2014

Global Working Group on Optimal Salt Consumption and Cardiovascular Health, Global Work Group Member, 2015 – present

Writing Group, for the *White Paper on Salt and Cardiovascular Disease*, World Heart Federation (WHF), European Society of Hypertension (ESH), European Public Health Association (EPH), Writing Group Member, 2015 – present

Cardiovascular Small Business Innovation Research (SBIR)/Small Technology Transfer Research (STTR) Program, Grant Review Panel, 2016 – 2017

Selection Committee Member, *American Journal of the Medical Sciences (AJMS)* Editor-in-Chief, Southern Society for Clinical Investigation (SSCI), 2016

Member, Peer-Review Committee, American Heart Association (AHA) Merit Award, AWRP-AHA Merit Award Review, 2017

Member, University of Alabama at Birmingham (UAB) Distinguished Faculty Lecturer Selection Committee, 2016 – 2018

EDITORIAL RESPONSIBILITIES

Editorial Boards (Member, Consulting Ed., Guest Ed., Associate Ed., Emeritus Ed.)

American Journal of Clinical Nutrition, Guest Scientific Editor, 1997

American Journal of Physiology: Heart and Circulatory Physiology
Editorial Board, 1977 – 1979, 1981 – 1987

American Journal of Physiology: Renal Physiology
Associate Editor, 1989 – 1991

Blood Pressure

Editorial Board, 2002

Editor, 2006 – present

Cardiology Update: Review for Physicians

Editorial Board, 1979

Circulation

Editorial Board, 1978 – present

Circulation Research

Editorial Board, 1974 – 1977

Editorial Board, 2015 – present

Current Opinion in Nephrology and Hypertension

Editorial Board, 2004

Current Treatment Options in Cardiovascular Medicine

Editorial Board, 2002 – 2010

European Heart Journal

Editorial Board, 2009 – 2011

International Editorial Board, 2011 – present

General Pharmacology: The Vascular System

Editorial Board, 1998

Hypertension

Associate Editor, 1979 – 1983

Editorial Board, 1984 –

Consulting Editor, 2009 – present

Hypertension Research,

Editorial Board, 2009 –

International Associate Editor, 2009 – present

Guest Editor, Special Review “Gender Difference in Hypertension”, 2011

International Circulation

Editorial Board, 2009 – present

Journal of the American Society of Hypertension

Editorial Board, 2007 – present

Journal of Chinese Clinical Medicine

Editorial Board, 2009 – present

Journal of Hypertension,

Editorial Board, 1989 – present

Proceedings of the Society for Experimental Biology and Medicine

Editorial Board, 1978 – 1982

The American Journal of Clinical Hypertension – For the Practicing Physician

Editorial Board, 1999

The American Journal of Hypertension

Editorial Board, 2001 – 2007

The American Journal of Medicine

Editorial Board, 2001 – 2002

Editorial Boards (Continued)

The American Journal of the Medical Sciences

Editor, 1984

Editorial Board, 1985 –

Emeritus Editor, 2009 – present

The Journal of Clinical Hypertension

Senior Editor, 2006 – present

The Medical Roundtable

Editorial Board, 2009 – present

The Open Hypertension Journal

Editorial Advisory Board, 2008 – present

Vascular Pharmacology

Editorial Board, 2005

Cardiovascular Innovations & Applications, *American-based, supported by China*

(CVIA) Editorial Board, 2015 – present

Editorial Boards (Section Editor, Editor-In-Chief)

A Companion to Brenner and Rector's The Kidney (Hypertension)

Section Editor, 2000

Cardiovascular Therapeutics, 2nd Edition, W.B. Saunders Co.,

Section Editor, Hypertension Section, 2002

Cardiovascular Therapeutics, 3rd Edition, W.B. Saunders Co.,

Section Editor, Hypertension Section, 2007

Cardiovascular Therapeutics, 4th Edition, W.B. Saunders Co.,

Section Editor, Hypertension Section, 2013

Current Hypertension Reports, Volume 12, *Secondary Hypertension*

Co-Section Editor, 2009

Current Hypertension Reports, Volumes 13, 14, 15, *Secondary Hypertension*

Section Editor, 2010 – 2012

Current Hypertension Reports,

Editor-In-Chief, 2013 – 2018

Writing Committees (since 2010)

ACCF/AHA/NHLBI 2010 Expert Consensus Document on Hypertension in the Elderly, Hypertension in the Elderly Expert Consensus Document, Committee Member, 2010

American Heart Association, 2011 Update: Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women, Expert Panel Member, 2010-2011

Kidney Disease Improving Global Outcomes (KDIGO) Guideline for Blood Pressure Management in CKD, Work Group Member, 2010 – 2011

AHA/ACC Writing Group: "Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease", Writing Committee Member, 2011-2012

Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8), Co-Chair, 2007-2013 (Publication # 742. James PA, et al. JAMA. 2014)

White Paper on Salt and Cardiovascular Disease, Writing Group for SALT Recommendations (WHF), Writing Committee Member, World Heart Federation (WHF), European Society of Hypertension (ESH), European Public Health Association (EPH), Writing Group Member, 2015 – present

Federal Editorial (Review Assignments, since 2009)

NHLBI, Program Project in Cardiovascular Disease, Special Emphasis Panel Reviewer
Panel Member, 2009

NHLBI Loan Repayment Program (LRP) Special Emphasis Panel
Member/Reviewer, 2010

Agency for Healthcare Research and Quality (AHRQ) Health Care Program, Report Review
Expert Reviewer, 2010

NIH, Special Emphasis Panel, Transformative Research Projects Program (R01)
Editor, 2011

NHLBI Loan Repayment Program (LRP) Special Emphasis Panel
Member/Reviewer, 2011

NIH, Special Emphasis Panel, Transformative Research Projects Program (R01)
Editor, 2012

NHLBI Loan Repayment Program (LRP) Special Emphasis Panel
Member/Reviewer, 2012

NHLBI Loan Repayment Program (LRP) Special Emphasis Panel
Member/Reviewer, 2013

Institute of Medicine of the National Academy of Sciences
External Expert Reviewer, 2013

NIH, Center for Scientific Review Special Emphasis Panel, (U10) NHLBI Initiative
Panel Member, 2013

NIH Population Sciences and Epidemiology (PSE) IRG Special Emphasis Panel
Member/Reviewer, 2014

NHLBI Loan Repayment Program (LRP) Special Emphasis Panel
Member/Reviewer, 2014

NHLBI Loan Repayment Program (LRP) Special Emphasis Panel
Member/Reviewer, 2015

NHLBI/NINDS & PCORI - Hypertension Disparities Reduction Program (HDRPP)
Special Emphasis Panel Member/Reviewer, 2015

PCORI Hypertension Disparities Reduction Program (RCU) Review
Special Emphasis Panel Member/Reviewer, 2015

NHLBI Loan Repayment Program (LRP) Special Emphasis Panel
Member/Reviewer, 2016

NHLBI Clinical Trials Review (CTR) Committee, Panel Reviewer
Member/Reviewer, 2016 (June 23, 2016)

NIH Review Panel for Small Business: Cardiovascular Sciences, ZRG1 CVRS-C (10)
Member/Panel Reviewer, 2016 (November 17-18, 2016)

NIH Review Panel for Small Business: Cardiovascular Sciences, ZRG1 CVRS-C (10)
Member/Panel Reviewer, 2017 (March 16-17, 2017)

NIH/NHLBI, Hypertension Outcomes for T4 Research, ZHL1 CSR-B (M4) 1
Chair, Review Group, 2017 (March 23, 2017)

NHLBI Loan Repayment Program (LRP) Special Emphasis Panel (Clinical/Pediatric)
Member/Reviewer, 2017 (April 2017)

NIH/NHLBI, Special Emphasis Panel, ZHL1 CSR-G O2 1, CLTR Single Site
Member/Reviewer, 2017 (June 21, 2017)

Honors:

International Society of Hypertension, Young Investigator Award, 1979
Annual Award of the National Board of the Medical College of Pennsylvania, 1984
Who's Who in America, 1992 –
Fellow, American College of Cardiology (FACC), 1985
Fellow, American Heart Association (FAHA), 1986
Lewis K. Dahl Memorial Lecture, American Heart Association, 1993
Selkurt Lectureship, Indiana University School of Medicine, 1994
Honorary Professor from Peking Union Medical College, 1994
Founder's Award of the Southern Society for Clinical Investigation, 1995
Louis Gross-Harold Segall Lecture, Jewish General Hospital, Montreal, Quebec, 1995
SSCI Founder's Medal, 1995
President's Achievement Award, UAB, 1995
The Nation's Top 20 Women Health Leaders, The Medical Herald, September 1995
Joy Goodwin Distinguished Lecturer, Auburn University, February 1996
A. Ross McIntyre Award, University of Nebraska, May 1996
Distinguished Faculty Lecturer, University of Alabama at Birmingham, 1997
Gertrude Florian Nelson CV Research Lecture, University of Mississippi Medical Center, 1998
R. Douglas Wright Lecture, High Blood Pressure Research Council of Australia, 1998
Arthur A. Corcoran Memorial Lecture, American Heart Association, 1998
Ben O'Connell Memorial Lecture, Boston University, 1998
Edward J. and Eileen D. Prendergast White Memorial Lecture, 1999
COSEHC Lifetime Achievement Award, 2000
Lila Wallace Lecture, Cornell University Medical College, 2000
Inaugural Earl H. Morris Lectureship, Wright State University School of Medicine, 2000
Distinguished Visiting Professor Award, University of California at San Francisco,
February 2001
The Max Cooper Award for Research Excellence, UAB Department of Medicine, July 2001
Carl Ludwig Distinguished Lecturer, American Physiological Society-2002
Irving Page-Alva Bradley Lifetime Achievement Award of the HBPR Council of the AHA-2002
Who's Who in Health Care, Birmingham, AL
Leonard Share Distinguished Visiting Professor, University of Tennessee-2002
Inaugural Lecture for the Annual Oberman Lecture on Preventive Medicine, the UAB
Division of Preventive Medicine, Birmingham, Alabama, October 2003
Caroline Duncan Distinguished Woman in Medicine Visiting Professor, Louisiana State
University School of Medicine, November 2003
44th Gertrude Victorson Ratner Visiting Professor, Evanston Hospital, Evanston IL, Nov 2003
Guest Lecturer at the Women's Cardiovascular Health Symposium of the Centennial
Celebration of the University of Georgia, College of Pharmacy, March 2004
Profesor Distinguido Honoris Causa, La Sociedad de Hipertensión Arterial de México, October
2006
Irene Tamagna Lecture, George Washington University Medical Center, May 2007
Jay N. Cohn Lecture, University of Minnesota, June 2007
The Fourth Annual Lectureship Sponsored by the Hypertension Foundation, Presented in
Honor of Dr. Marvin Moser, Yale University Medical Center, January 2008
The Fifth Annual Leslie Baer, M.D.'63 Memorial Lecture Sponsored by the Beatrice and
Samuel A. Seaver Foundation, Columbia University Medical Center, March 2008
Harriet Dustan Award Lecture, AHA Council for High Blood Pressure Research, September
2008
Honorary Member, Czech Society of Hypertension, December 2008

Honorary Member of the Hungarian Society of Hypertension, December 2009
Fellow, American Society of Hypertension (FASH), May 2010
Virginia Frantz '22 Award for Distinguished Women in Medicine, May 2010
Designated Specialist in Clinical Hypertension, American Society of Hypertension, April 2010
Annual Lectureship, Dr. Carlos Ferrario Founder Lecture, Consortium for Southeastern Hypertension Control (COSEHC) Annual Scientific Sessions, October 2010
Dr. John Foerster Distinguished Lecture Award for Lifetime Achievements in the Field of Cardiovascular Medicine, Institute of Cardiovascular Sciences, Winnipeg Heart International Conference, October 2011
Distinguished Service Award for Recognition of Exceptional Leadership and Devoted Service to Gulf Central Chapter American Society of Hypertension, November 2011
Nominee, 34th Annual Louis and Artur Lucian Award for Research in Circulatory Diseases, McGill University
Katz Visiting Professorship in Cardiovascular Research, Columbia University Medical Center, December 2012
2013 Distinguished Scientist Award (Translational Domain), American College of Cardiology, Convocation, March 11, 2013
The 9th Annual Lectureship Sponsored by the Hypertension Foundation, Presented in Honor of Dr. Marvin Moser, Yale University Medical Center, April 2013
Recipient, American Society of Hypertension (ASH) Foundation Honoree Award, Presented by ASH Foundation for professional work in advancing the vision and mission of the ASH Foundation, during Annual ASH Meeting, San Francisco, California, May 16, 2013.
Annual Russell Lectureship, 22nd Annual Scientific Meeting of the Alabama Chapter of the American College of Cardiology, Jointly Sponsored and Co-provided by the American College of Cardiology Foundation, June 2013.
'14 Elected Honorary Member, Association of University Cardiologists, by the Council of the Association of University Cardiologists, May 2013.
Appointed as *Distinguished Professor* in the Department of Medicine, Division of Cardiovascular Disease, School of Medicine, University Alabama at Birmingham by *The Board of Trustees of The University of Alabama*, 2014
Tulane Health Sciences BIRCVH Distinguished Faculty Lecturer, April 2, 2014.
American Society of Hypertension Harriet Dustan Award, presented by the Scientific Awards Committee & Board of Directors of the American Society of Hypertension, May 19, 2014.
Fellow, American Physiological Society (FAPS), August 2015
Recipient, 2015 Southern Society for Clinical Investigation (SSCI) Mentor of the Year Award – Postgraduate Division, presented – SSCI Annual Sessions, February 19 2016, New Orleans, Louisiana.
Recipient, National Physician of the Year Award – 2016 Honoree for Clinical Excellence, Castle Connolly Top Doctors, presented during Castle Connolly Top Doctors Eleventh Annual National Ceremony, March 21, 2016.
Elected Honoree Member, Alabama Healthcare Hall of Fame, Class of 2016, Awards Ceremony, Montgomery, Alabama, July 23, 2016.
Recipient, 2016 Excellence Award for Hypertension Research (sponsored by Novartis), by the American Heart Association (AHA) Council on Hypertension Awards Committee, presented at AHA 2016 Hypertension Scientific Sessions, Orlando, Florida, September 16, 2016.
Recipient, P&S Alumni Association Gold Medal for Outstanding Achievement in Medical Research, Columbia University College of Physicians & Surgeons Alumni Association Honors & Awards Committee, presented during Alumni Reunion Weekend, May 13, 2017.

Teaching/Training

*Past 10 years.

2002 – 2008	Sophomore Correlative Pathology Course
2012 – 2013	ASH Clinical Hypertension Review Course Faculty Member/Presenter
2008 – present	UAB Cardiovascular (CV) Module, 1 st Year Medical Students

Module Lecturer on Topics: Dr. Oparil is participating faculty - UAB CV Module: Small Group Preceptor and Module Lecturer, teaching on topics of *Pathophysiology of Hypertension*, and *Women and Cardiovascular Disease*; “Hypertension: Overview and Pathophysiology” (2016).

2007 – present	UAB Cardiology Fellow Orientation Lecturer on Topic: <i>Hypertension</i>
----------------	---

Reoccurring Lectures

*Past 5 years.

Ongoing	<u>UAB Medical Grand Rounds</u> *Presenter	(Department of Medicine)
Ongoing	<u>UAB Cardiology Grand Rounds</u> *Presenter	(Department of Medicine)
Ongoing	<u>Vascular Biology & Hypertension Grand Rounds</u> *Presenter	(Department of Medicine)

Training Experience/Mentorship (past 20 years)

Doctoral and/or Postdoctoral Training

Primary Mentor

Co-Mentor/Joint Mentorship

NAME	YRS	CRED	CURRENT POSITION
Chen, Shi Juan	92-00	MD	Sr. Scientist, Merck & Co.
Mori, Tatsuhiko	97-00	MD	Assistant Professor, Osaka Medical College, Japan
Gregory, Shawn	99-00	MD	Instructor, Massachusetts General Hosp. & Harvard Med. School
Chrysant, George	99-00	MD	Assistant Professor, University of Oklahoma
Thakkar, Roopal	00-01	MD	Abbott Laboratories Research Laboratory, Chicago, IL
Kelpke, Stacey	00-03	PhD	Instructor, University of Alabama at Birmingham
Li, Guohong	00-03	PhD	Assistant Professor, University of Virginia
Wang, Dajun	00-05	MD	Research Staff Scientist, University of South Dakots
Miller, Andrew P.	01-03	MD	Private Practice, CVA, Birmingham, Alabama
Zaman, Mohammad A.	01-04	MBBS	Private Practice, Internal Medicine, Troy, Illinois
Feng, Wenguang	01-06	MD/PhD	Instructor, Division of Nephrology, UAB DOM
Xing, Dongqi	01-06	MD/PhD	Assistant Prof., Div CV Disease, Univ. of AL-Birmingham (UAB)
Franco, Veronica	03-06	MD	Assistant Professor, Ohio State University
Pratt-Ubunama, Monique	04-05	MD	Nephrology Private Practice, Jupiter, Florida
Gaddam, Krishna	05-08	MD	Electrophysiologist, Heart South Cardiovascular Group, Alabaster, Alabama Senior Med Advisor- CVD, Bayer, Austr. Pharma. Physicians Assoc., Univ-Queensland, Australia
Pimenta, Eduardo	06-08	MD	
Lucas, Jason	06-09	PhD	Senior Scientist, Cardiac Rhythm Dis. Management, Medtronic Associate Professor and Director, Nuclear Cardiology; UAB, Division of Cardiovascular Disease; Director, Cardiac Care Unit, Birmingham VAMC
Hage, Fadi	06-09	MD	
Gonzaga, Carolina	07-08	MD	Staff Physician, Instituto Dante Pazzanese de Cardidogia Brazil
Acelajado, Maria Czarina	08-10	MD	Resident/Clinical Fellow; DOM, University of South Alabama, Mobile, AL Research Assistant Professor, Department of Anesthesiology, Texas Tech University-Health Science Center, Lubbock, Texas
Hilgers, Robert H.	09-11	BSc/PhD	
Pacurari, Maricica	11-12	MSc/PhD	Assistant Professor, Dept. of Biology, Jackson State Univ., Jackson, MS
Breaux-Shropshire, T.	11-12	PhD/MPH	VA National Quality Scholars (VAQS) Interprofessional Fellowship Program Assistant Professor; Division of Nephrology, Dept of Medicine, Univ AL-BHM (UAB)
Judd, Eric	11-14	MD	
Zhao, Xiangmin	11-14	PhD	Faculty-Research Specialist, DOM, University of Illinois at Chicago Senior Research Analyst; Truven Health Analytics (IBM Company); Birmingham, AL (<i>*formerly Postdoctoral Fellow, UAB Department of Epidemiology (Muntner, P.)</i>)
Kent, Shia	12-14	MSPH/PhD	
Ghazi, Lama	14-16	MD	<i>*formerly Clinical CV Fellow; VB&H Program (Minnesota) Postdoctoral Fellow; Division of Cardiovascular Disease, UAB Department of Medicine, Roger White, PhD-Mentor ("HDL and Cellular Repair Mechanisms"; R01DK108836)</i>
Giordano, Sam	14-16	PhD	<i>(*Translational Researcher/Fellow; supported by T32 HL007457) Fellow, Cardiology; Department of Cardiovascular Disease; Einstein Medical Center; Philadelphia, Pennsylvania (<i>*formerly Cardiovascular Clinical Fellow; supported by T32 HL007457</i>)</i>
Bhatt, Hemal	14-16	MD	<i>*formerly (Chief) Fellow, Cardiology; Division of Cardiovascular Disease; UAB Department of Medicine (<i>Cardiovascular Clinical Fellow; supported by T32 HL007457</i>)</i>
Payne, Gregory	14-pres	MD/PhD	<i>*Translational Researcher/Fellow; supported by T32 HL007457</i>
Oduk, Yasin	15-pres	PhD	(Primary Mentor: Zhang, Biomedical Engineering)

Summer/Short-Term Mentorships

NAME	DEGREE	Summer/Term/Rotation under Mentorship/Supervision
Keenum, J.	BS	2007
Tamm-Daniels, I.	BS	2007
Habeeb, F.	MD	2009
Coleman, C.	MD	2009
Aksut, B.	BS	2009
Black, J.	BS	2010
Kapadia, A.	BS	2011
Chintalapani, S.R.	MBBS	2011
Sahinoglu, E.	BS	2011
Bowling, M.	MD	2011, 2012, 2013
Allon, S.	BS	2014
Chen, C.	AB	2014
Colon, C.	BS	2014
Liu, M.	BS	2014
Wang, T.	MD	2014
Ives, C.	BS	2015, 2016
German, C.A.	MD	2015, 2016 (UAB-Internal Medicine Resident/CV Rotation)
Donaldson, S.	BS	2016
Hughes, Z.	BS	2016
Ahmad, A.	MD	2016, 2017
George, D.C.	MD	2016, 2017
		2017 (MD Candidate, MS-2), UAB SOM MSSRP (Physician-Scientist Research Program) <i>O'Brien Core Center for Acute Kidney Injury Research</i>
Pounders, J.	MS	2017 (Graduate Student, Univ-AL; summer observership, Class of 2018)
Holt, C.	*	

Invited Lectures (Since 2011)

January 2011 – December 2011

- “Hypertension Diagnosis and Management: Challenging the Old Mantras.” University of Medicine and Dentistry of New Jersey DOM Grand Rounds, Newark, New Jersey, January 4, 2011.
- “Hypertension: Novel Treatment Strategies.” Advanced Revascularization Chapter V (ARCH V) Percutaneous Cardiac and Peripheral Vascular Therapeutics 2011, Washington University, St. Louis, Missouri, January 22, 2011.
- “Is There Benefit for Antihypertensive Therapy in Patients Without Hypertension?” Vascular Biology Working Group. VBWG Chapter Meeting at ACC. New Orleans, Louisiana, April 2, 2011.
- “Vasculoprotective Effects of Estrogen.” University of Utah Department of Medicine Nephrology Research Conference. Salt Lake City, Utah, April 13, 2011.
- “Forefront in Clinical Hypertension.” University of Utah Department of Medicine Medical Grand Rounds. Salt Lake City, Utah, April 14, 2011.
- “Role of the Renin-Angiotensin-Aldosterone System (RAAS).” NIA-NHLBI Exploratory Workshop, Arterial Stiffness: Clinical Trials Opportunities, Bethesda, Maryland, April 27, 2011.
- “Catheter Based Antihypertensive Therapy” Alabama Chapter American College of Cardiology (AL-ACC) 20th Annual Meeting, San Destin, Florida, June 4, 2011.
- “Then and Now: Medicine” Then and Now Class Forum, Cornell University Class of 1961, 50th Class Reunion, Ithaca, New York, June 10, 2011.
- “Hypertension”, University of Alabama at Birmingham Cardiology Fellows’ Orientation Lecture, Division of Cardiovascular Disease, Department of Medicine, July 12, 2011.
- “SPRINT to Evidence Based Antihypertensive Treatment” University of Alabama at Birmingham Cardiology Grand Rounds Lecture, August 3, 2011.
- “Hormones and the Heart: Promises, Problems, and Unresolved Issues” John Foerster Distinguished Award Lecture, Institute of Cardiovascular Sciences, Winnipeg Heart International Conference, Winnipeg, Canada, October 14, 2011.
- “Sympathetic nervous system activation in hypertension and the therapeutic role of α -adrenargic antagonist” Morning Seminar Session, 34th Annual Meeting of the Japanese Society of Hypertension, Utsunomiya, Japan, October 21, 2011.
- “American Perspective: JNC 8” Special Lecture, Global Perspective of Hypertension Guidelines Session, 34th Annual Meeting of the Japanese Society of Hypertension, Utsunomiya, Japan, October 22, 2011.
- “JNC 8” NHLBI Cardiovascular Disease Prevention Guidelines Plenary Session, American Heart Association Scientific Sessions, Orlando, Florida, November 14, 2011.

January 2011 – December 2011 (Continued)

“Device Therapy for Refractory Hypertension” American Society of Hypertension (ASH) Gulf Central (GC) Chapter Annual Meeting, New Orleans, Louisiana, November 19, 2011.

“JNC 8” American Society of Hypertension (ASH) Gulf Central (GC) Chapter Annual Meeting, New Orleans, Louisiana, November 19, 2011.

“Blood Pressure Variability: Emerging Role in Risk Assessment and Therapeutics” 4th International Conference on Fixed Combination in the Treatment of Hypertension, Dyslipidemia and Diabetes Mellitus, Paris, France, December 4, 2011.

January 2012 – December 2012

“Hypertension: Pathophysiology” University of Alabama at Birmingham, Cardiovascular Module Lecture, Freshman Medical Students, January 13, 2012.

“JNC 8” American College of Cardiology Winter Professional Practice Improvement Conference for Cardiac Physicians & Cardiac Advance Practice Clinicians, Birmingham, AL, January 14, 2012.

“JNC 8: New US Guidelines for Hypertension Management” University of Alabama at Birmingham, Department of Epidemiology Seminar, Birmingham, Alabama, January 23, 2012.

“JNC 8” University of Alabama at Birmingham, Department of Medicine, Medical Grand Rounds, Birmingham, Alabama, January 25, 2012.

“Women and Cardiovascular Disease” University of Alabama at Birmingham, Cardiovascular Module Lecture, Freshman Medical Students, January 13, 2012.

“Updates and New Guidelines for Hypertension Management in 2012” American College of Cardiology (ACC) Hypertension Guidelines 2012 Session, 61st Annual Scientific Session, Chicago, Illinois, March 24, 2012.

“Hypertension Management in Contemporary Practice” American College of Cardiology (ACC) *Clinical Focus Session*, 61st Annual Scientific Session, Chicago, Illinois, March 24, 2012.

“Hypertension and CVD: Epidemiology, Evaluation and Management” World Congress of Cardiology 2012 Annual Meeting, Course in Preventive Cardiology for cardiology trainees and medical students: Part I, Dubai United Arab Emirates, April 18, 2012.

“Hypertension” Session: “Women and cardiovascular disease: what are the differences?” World Congress of Cardiology 2012, Dubai United Arab Emirates, April 19, 2012.

“Management of Hypertension in the Elderly” Session: “Hypertension” World Congress of Cardiology 2012, Dubai United Arab Emirates, April 20, 2012.

“American Guidelines” 22nd European Meeting on Hypertension and Cardiovascular Protection, London, UK, April 27, 2012.

“Hypertension Update” Cardiology Fellows Lecture, Cardiology Division, Heart and Vascular Center, Lehigh Valley Health Network, Allentown, Pennsylvania, May 4, 2012.

January 2012 – December 2012 (Continued)

- “Catheter-Based Renal Denervation” Cardiology Grand Rounds Lecture, Cardiology Division, Heart and Vascular Center, Lehigh Valley Health Network, Allentown, Pennsylvania, May 4, 2012.
- “Resistant Hypertension: Incidence, Prevalence, and Pathophysiology” American Society of Hypertension Annual Scientific Meeting and Exposition, New York City, New York, May 21, 2012.
- “Optimizing Individual Drugs - Is There a Mandate for First and Second-Line Therapy?” American Diabetes Association 72nd Scientific Sessions, Philadelphia, Pennsylvania, June 11, 2012.
- “The Brain-Kidney Axis in Hypertension” Division of Nephrology, Nephrology Research Conference, Medical University of South Carolina, Charleston, South Carolina, June 18, 2012.
- “The Systolic Blood Pressure Intervention Trial (SPRINT)” Department of Medicine Grand Rounds, Medical University of South Carolina, Charleston, South Carolina, June 19, 2012.
- “Hypertension”, University of Alabama at Birmingham Cardiology Fellows’ Orientation Lecture, Division of Cardiovascular Disease, Department of Medicine, July 10, 2012.
- “Hypertension Guidelines around the World” 35th Annual Meeting of the Japanese Society of Hypertension (JSH), Nagoya, Japan, September 20, 2012.
- “JNC 8” Session, In-Depth Discussion on Hypertension Guidelines around the World, 35th Annual Meeting of the Japanese Society of Hypertension (JSH), Nagoya, Japan, September 22, 2012.
- “JNC 8-Guideline Updates & Implications for Clinical Practice” 2012 Cardiometabolic Health Congress, Boston, Massachusetts, October 11, 2012.
- “Treat Thresholds of CV Risk Factors”, Ask the Experts Session, American Heart Association 2012 Scientific Sessions, Los Angeles, California, November 6, 2012.
- “Hormones and the Heart: Promises, Problems and Unresolved Issues”, Columbia Katz Prizes in Cardiovascular Research, Lecture, New York, New York, December 6, 2012.

January 2013 – December 2013

- “Hypertension: Pathophysiology” University of Alabama at Birmingham, Cardiovascular Module Lecture, Freshman Medical Students, January 16, 2013.
- “Women and Cardiovascular Disease” University of Alabama at Birmingham, Cardiovascular Module Lecture, Freshman Medical Students, February 6, 2013.
- “Hypertension: How Low Should I Go?”, Symposium Session 626, “Chronic CAD-What You Need to Know from the New Guidelines”, American College of Cardiology 62nd Annual Scientific Session & Expo, San Francisco, California, March 9, 2013.
- “What’s New in Hypertension in 2013?”, Symposium Session 734, “Hypertension: From Guidelines to Clinical Practice”, American College of Cardiology 62nd Annual Scientific Session & Expo, San Francisco, California, March 11, 2013.

January 2013 – December 2013 (Continued)

- “It’s a Long, Long Time from Bench to the Cath Lab: The Saga of Renal Denervation as Antihypertensive Treatment”, Fifth Annual Marvin Moser Hypertension Lecturer, SUNY Downstate Medical Center, Brooklyn, New York, April 11, 2013.
- “Medical Research in the time of sequestration: What to do until things get better”, 4th Annual Former AFMR/AFCR President’s Address, American Federation for Medical Research Eastern Regional Meeting, Washington, DC, April 17, 2013.
- “Treatment of Hypertension in Women”, 15th National Congress of Hypertension and Renal Diseases, Sponsored by the Turkish Society of Hypertension and Renal Diseases, Antalya, Turkey, April 25, 2013.
- “Novel Strategies for Treatment of Refractory Hypertension”, 15th National Congress of Hypertension and Renal Diseases, Sponsored by the Turkish Society of Hypertension and Renal Diseases, Antalya, Turkey, April 25, 2013.
- “Pharmacologic Treatments for Obesity”, Hypertension Highlights 2013, Part II: Obesity and Cardiometabolic Diseases, American Society of Hypertension, Inc., 28th Annual Scientific Meeting and Exposition, San Francisco, California, May 15, 2013.
- “The Target Should Be Higher”, Debate: The Target for Blood Pressure Therapy, American Society of Hypertension, Inc., 28th Annual Scientific Meeting and Exposition, San Francisco, California, May 16, 2013.
- “Results of a Study to Assess Patient Perceptions about the Impact of Uncontrolled and Resistant Hypertension on Their Lives”, Original Communication (OR-11), American Society of Hypertension, Inc., 28th Annual Scientific Meeting and Exposition, San Francisco, California, May 16, 2013.
- “Resistant Hypertension: Incidence, Prevalence, and Pathophysiology”, Embedded Symposium, “Update on Resistant Hypertension: A Patient Case Analysis of the Current and Future Treatment Approaches”, American Society of Hypertension, Inc. 28th Annual Scientific Meeting and Exposition, San Francisco, California, May 17, 2013.
- “When Should You Initiate Drug Treatment in Hypertension”, Session, “Hypertension for the Primary Care Clinician 2013: Part II”, Theme 5: Blood Pressure Treatment Strategies for Primary Care, American Society of Hypertension, Inc. 28th Annual Scientific Meeting and Exposition, San Francisco, California, May 18, 2013.
- “Cardiovascular Disease in Women”, Richard Russell Lecture, Alabama Chapter of the American College of Cardiology, 22nd Annual Meeting, Sandestin, Florida, June 1, 2013.
- “Hypertension”, University of Alabama at Birmingham Cardiology Fellows’ Orientation Lecture, Division of Cardiovascular Disease, Department of Medicine, July 30, 2013.
- “Resistant Hypertension: Prevalence, Burden and Current Treatment Options”, Satellite Symposium, Device-Based Approaches to Treatment Resistant Hypertension, Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand (CSANZ), Gold Coast, Australia August 8, 2013.

January 2013 – December 2013 (Continued)

- “Novel Strategies for the Management of Resistant Hypertension”, Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand (CSANZ), Gold Coast, Australia August 10, 2013.
- “US Hypertension Guidelines 2013: Product and Process at the Crossroads”, Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand (CSANZ), Gold Coast, Australia 11, 2013.
- “Guidelines to Practice: Practical Aspects of Hypertension Management”, American College of Cardiology Interactive Webinar Series, Educational Outreach (India), September 21, 2013.
- “Role of Antihypertensives Beyond BP Control”, American College of Cardiology Interactive Webinar Series, Educational Outreach (India), September 21, 2013.
- “Management of Hypertension According to Guidelines and Where the Resistant Hypertension Patient Fits”, Luncheon Seminar, 36th Annual Meeting of the Japanese Society of Hypertension, Osaka, Japan, October 25, 2013.
- “U.S. Hypertension Guidelines – Product and Process at the Crossroads”, 36th Annual Meeting of the Japanese Society of Hypertension, Osaka, Japan, October 26, 2013.
- “Novel Strategies for Treatment of Resistant Hypertension”, Rutgers Robert Wood Johnson Medical School, Cardiovascular Institute Grand Rounds, New Brunswick, New Jersey, November 13, 2013.
- “Resistant hypertension: Definition, Pathophysiology and Novel Therapies”, Lankenau Medical Center Grand Rounds, Wynnewood, Pennsylvania, November 15, 2013.
- “Resistant Hypertension: Scope of the Problem, Pathophysiology and Available Therapies”, American Heart Association Annual Scientific Sessions, Dallas, Texas, November 19, 2013.
- “Optimizing Therapy for Patients with Resistant and Refractory Hypertension”, The 5th International Conference on Fixed Combination in the Treatment of Hypertension, Dyslipidemia and Diabetes Mellitus, Bangkok, Thailand, November 22, 2013.

January 2014 – December 2014

- “Hypertension: Pathophysiology”, University of Alabama at Birmingham, Cardiovascular Module Lecture, Freshman Medical Students, January 16, 2014.
- “2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults – *Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8)*”, Cardiology Grand Rounds, Department of Medicine, University of Alabama at Birmingham, March 5, 2014.
- “Guideline on Guidelines: The Evolution of NIH/NHLBI's Thinking on Guidelines”, Hypertension Guidelines Session, American College of Cardiology (ACC) 63rd Annual Scientific Session, Washington, D.C., March 29, 2014.
- “Hormones and the Heart: Promises, Problems and Unresolved Issues”, Tulane Health Sciences Research Days, Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Distinguished Lecture Series, Tulane University, New Orleans, Louisiana, April 2, 2014.

January 2014 – December 2014 (Continued)

- “Hypertension”, 4th International Conference on Women, Heart Disease and Stroke, World Heart Federation (WHF)/World Congress of Cardiology (WCC) 2014 Scientific Sessions, Melbourne, Australia, May 4, 2014.
- “The Impact of Female Hormones on the Heart – Why Cardiovascular Disease is Still the Biggest Threat to Women Globally”, Keynote Lecture, Baker IDI, Melbourne, Australia, May 6, 2014.
- “Hypertension in Women: Is a Different Approach Required for Women and Men”, Symposium - CVD in women: unmet needs in diagnosis and treatment, World Heart Federation (WHF)/World Congress of Cardiology (WCC) 2014 Scientific Sessions, Melbourne, Australia, May 7, 2014.
- “Epidemiology: Global Trends in Prevalence, Long-term Prognosis”, American College of Cardiology *Hypertension* Session, World Heart Federation (WHF)/World Congress of Cardiology (WCC) 2014 Scientific Sessions, Melbourne, Australia, May 7, 2014.
- “2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults – *Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8)*”, Grand Rounds Lecture, Division of Cardiology, New York University School of Medicine, May 16, 2014.
- “Hypertension at the Crossroads: Progress, Problems and Unresolved Issues”, 2014 Distinguished Scientist Award Lecture, American Society of Hypertension (ASH) Annual Meeting, New York City, New York, May 19, 2014.
- “The Case for JNC 8”, 23rd Annual Meeting of the Alabama Chapter of the American College of Cardiology, Sandestin, Florida, June 1, 2014.
- “A Critical Appraisal of JNC 8 Guidelines for Hypertension Management”, Irene Tamagna Lecture in Hypertension, Department of Medicine Grand Rounds, June 5, 2014.
- “Therapy of Hypertension”, Advanced Nurse Practitioner Pharmacology Workshop, University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama, August 2, 2014.
- “Hypertension”, University of Alabama at Birmingham Cardiology Fellows’ Orientation Lecture, Division of Cardiovascular Disease, Department of Medicine, August 5, 2014.
- “Hypertension Management in 2014”, Heart, Lung, Vascular Update for Primary Care Providers, University of Tennessee School of Medicine, Knoxville, Tennessee, September 6, 2014.
- “Highlights of the Recommendations from the Panel Members Appointed to the Eighth Joint National Committee (JNC8)”, *Hypertension Perspectives*, Review of Hypertension Session: A review of the leading edge in clinical and experimental hypertension, American Heart Association (AHA) Council for High Blood Pressure Research Conference, San Francisco, California, September 9, 2014.
- “Recent Clinical Guidelines for Treating Hypertension – Need and Value of Titrating Anti-Hypertensive Medications”, Food and Drug Administration (FDA) Cardio and Renal Drugs Advisory Meeting (CRDAC), Silver Spring, Maryland, September 10, 2014.
- “Systolic Blood Pressure Intervention Trial (SPRINT)”, UAB Comprehensive Cardiovascular Center (CCVC), Division of Cardiovascular Disease Research Conference Series, September 18, 2014.

January 2014 – December 2014 (Continued)

“2014 Evidence-Based Guideline for Management of High Blood Pressure in Adults –Report from the Eighth Joint National Committee (JNC 8)”, Symposium 2: Similarities and differences among Japanese, American, European and British Hypertension Guidelines, 37th Annual Scientific Meeting of the Japanese Society of Hypertension (JSH), Yokohama, Japan, October 17, 2014.

“How to Manage Difficult-to-Treat Hypertension”, Luncheon Seminar 9, 37th Annual Scientific Meeting of the Japanese Society of Hypertension (JSH), Yokohama, Japan, October 17, 2014.

“Hypertension: New Guidelines”, Cardiology Update 2014 – St. Vincent’s Birmingham, Alabama Cardiovascular Group, P.C., Birmingham, Alabama, October 31, 2014.

“Management of High Blood Pressure”, *Session JS.12 - Joint AHA/Brazilian Society of Cardiology Session: Hypertension Treatment*, American Heart Association Scientific Sessions 2014, Chicago, Illinois, November 18, 2014.

“The Case for JNC 8”, LA-ACC & ASH-GC Joint Meeting, New Orleans, Louisiana, November 22, 2014.

January 2015 – December 2015

“The Case for JNC 8”, Medical Grand Rounds, Rutgers New Jersey Medical School, Newark, New Jersey, February 10, 2015.

“Diagnosis and Treatment of Resistant Hypertension”, 13th Annual Cardiovascular Disease Prevention Symposium, Baptist Health South Florida, Miami, Florida, February 20, 2015.

“Low Sodium Intake: Cardiovascular Health Benefit or Risk?”, 13th Annual Cardiovascular Disease Prevention Symposium, Baptist Health South Florida, Miami, Florida, February 20, 2015.

“JNC 8 Blood Pressure Guidelines”, 13th Annual Cardiovascular Disease Prevention Symposium, Baptist Health South Florida, Miami, Florida, February 20, 2015.

“New Blood Pressure Guidelines (JNC 8): Right or Wrong?”, American Heart Association (AHA) Epidemiology and Prevention and Lifestyle and Cardiometabolic Health 2015 Scientific Sessions, Baltimore, Maryland, March 6, 2015.

“Background: Diet, blood pressure, mortality”, American Society for Nutrition (ASN) Sponsored Satellite Program: Neural-Physiologic Mechanisms Regulating Sodium Appetite, Annual Experimental Biology Meeting, Boston, Massachusetts, March 27, 2015.

“The Treatment of Hypertension – How Did We Get Here and Where are We Going?”, President’s Symposium Series – Physiology: Answers to Big Questions ~ The Future of Hypertension Research, Annual Experimental Biology Meeting, Boston, Massachusetts, March 31, 2015.

January 2015 – December 2015 (Continued)

“Low Sodium Intake: Cardiovascular Health Benefit or Risk?”, Grocery Manufacturers Association (GMA) Annual Science Forum, National Harbor, Maryland, April 13, 2015.

“Uric Acid and Other Mediators of Vascular Change in Hypertension.” GOUT-CORT Enrichment Series - Research in Progress Seminar Series, University of Alabama at Birmingham (UAB), April 23, 2015.

“Hormones and the Heart: Promises, Problems and Unresolved Issues”, Columbia College of Physicians & Surgeons (P&S) Class Reunion, Alumni Day Presentation, New York, May 9, 2015.

“Blood Pressure Management in Type 2 Diabetes”, American Diabetes Association (ADA) 75th Scientific Sessions, Boston, Massachusetts, June 6, 2015.

“Resistant and Refractory Hypertension: Definitions, Prevalence, Pathogenesis, and Therapy”, Inova Fairfax Hospital/Georgetown University Transitional Residency Program-Hospital, Falls Church, Virginia, August 4, 2015.

“Renal Denervation – Current Status”, LA-ACC and ASH-GC Joint Annual Meeting, New Orleans, Louisiana, October 10, 2015.

“Resistant Hypertension” Department of Physical Medicine and Rehabilitation Grand Rounds, University of Alabama at Birmingham, Birmingham, Alabama, October 30, 2015.

“Dilemmas Faced With Dose Optimization and Hyperkalemia in Renal Disease”, Educational Program – “New Tools for Managing Hyperkalemia: Cases in Heart Failure and Renal Disease”, American Heart Association Scientific Sessions, Orlando, Florida, November 8, 2015.

“Responses to Antihypertensive Therapy”, SS.03, Sex-Based Differences in Cardiovascular Disease”, American Heart Association Scientific Sessions, Orlando, Florida, November 9, 2015.

“120 is Right”, Debate: How Much Should We Lower Systolic Blood Pressure: to Below 140 or 120 mmHg? Two NIH-funded Trials with the Same Design give us Two Different Answers!”, Session II: Hypertension, Controversies and Advances in the Treatment of Cardiovascular Disease, The Fifteenth in the Series, Cedars-Sinai Heart Institute, Beverly Hills, California, November 19, 2015.

“20% of our Patients”, Debate: How Often does Aldosterone Cause Hypertension?”, Controversies and Advances in the Treatment of Cardiovascular Disease, The Fifteenth in the Series, Cedars-Sinai Heart Institute, Beverly Hills, California, November 19, 2015.

January 2016 – December 2016

“The SPRINT Trial: What Does it Show and What Does it Mean for our Patients?”, Mount Sinai Beth Israel Department of Medicine Grand Rounds, New York, New York, February 16, 2016.

“Hypertension: How Low Can you Go?”, CS.03 Prevention Debates – Session, American Heart Association (AHA) Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2016 Scientific Sessions, Phoenix, Arizona, March 1, 2016.

January 2016 – December 2016 (Continued)

- “Gender and Cardiovascular Disease Management”, Consortium for Southeastern Hypertension Control (COSEHC) 2016 Annual Scientific Sessions, Charleston, South Carolina, March 4, 2016.
- “Hypertension and Diabetes – Should we be SPRINTING or Reaching an ACCORD?”, Diabetes *In and Out* Conference, University of Rochester School of Medicine and Dentistry, Rochester, New York, March 12, 2016.
- “Is Sodium Restriction Beneficial for Blood Pressure and Cardiovascular Morbidity?”, Session – “Debates in Hypertension – Making Sense of Current Controversies”, American College of Cardiology (ACC) 65th Annual Scientific Session and Expo, Chicago, Illinois, April 4, 2016.
- “SPRINT Trial Overview”, *Richard Lewar Lecture*, Session – Novel Developments in Cardiovascular Prevention: From Bench to Bedside, Michael J. Sole Annual Cardiovascular Scientific Day, Heart & Stroke Richard Lewar Centre of Excellence, Department of Medicine, University of Toronto, Toronto, Ontario, Canada, April 14, 2016.
- “Blood Pressure Intervention and Control in the Systolic Blood Pressure Intervention Trial (SPRINT)”, American Society of Hypertension (ASH) Annual Scientific Session, New York, New York, May 14, 2016.
- “Unanticipated Findings from ALLHAT”, Hypertension Highlights Session, American Society of Hypertension (ASH) Annual Scientific Session, New York, New York, May 14, 2016.
- “SPRINT: What does it show and what does it mean for our patients?”, Cardiology Grand Rounds, University of Alabama at Birmingham, Birmingham, Alabama, May 25, 2016
- “Sodium Intake Reduction in Low- and Middle-Income Countries”, World Congress of Cardiology and Cardiovascular Health 2016, Mexico City, Mexico, June 7, 2016.
- “Is it necessary to revise BP targets after SPRINT? YES”, Plenary Session Debates, 26th Meeting on Hypertension and Cardiovascular Protection of the European Society of Hypertension (ESH), Paris, France, June 13, 2016.
- “The Systolic Blood Pressure Intervention (SPRINT) Trial: *What does it show and what does it mean for our patients?*”, Medical Education Speakers Lecture, St. Vincent’s Health System, St. Vincent’s East, Birmingham, Alabama, July 19, 2016.
- “Is Sodium Restriction Beneficial for Blood Pressure and Cardiovascular Morbidity?”, Renal Grand Rounds, Division of Nephrology, Department of Medicine, Medical University of South Carolina (MUSC), Charleston, South Carolina, August 3, 2016.
- “The Systolic Blood Pressure Intervention (SPRINT) Trial: *What does it show and what does it mean for our patients?*”, Southern Society for Clinical Investigation (SSCI) Invited Visiting Professor (2016-2017 Program), Medicine Grand Rounds, Department of Medicine, Medical University of South Carolina (MUSC), Charleston, South Carolina, August 4, 2016.
- “The Systolic Blood Pressure Intervention (SPRINT) Trial: *What does it show and what does it mean for our patients?*”, Cardiovascular Grand Rounds, Section of Cardiology, Center for Heart and Vascular Health, Christiana Care Health System, Newark, Delaware, August 24, 2016.

January 2016 – December 2016 (Continued)

- “The Systolic Blood Pressure Intervention (SPRINT) Trial: *What does it show and what does it mean for our patients?*”, Cardiovascular Grand Rounds, Section of Cardiology, Center for Heart and Vascular Health, Christiana Care Health System, Newark, Delaware, August 24, 2016.
- “My Road to Academic Cardiology”, Birmingham Physiology Network (BPN) First Annual Fall 2016 Event, *The Scientific Method: How to pursue a Career in Science*, Birmingham, Alabama, September 10, 2016.
- “Is It Time to Reappraise Blood Pressure Thresholds and Targets? YES”, Session 1 – Recent Advances in Hypertension, American Heart Association Council on Hypertension 2016 Scientific Sessions, Orlando, Florida, September 14, 2016.
- “Hormones and the Heart: Promises, Problems and Unresolved Issues”, The Excellence Award for Hypertension Research, American Heart Association Council on Hypertension 2016 Scientific Sessions, Orlando, Florida, September 16, 2016.
- “Conflicting data from hypertension treatment trials: Whom and what you should believe”, Joint Symposium ISH-CVCT Forum, 26th Meeting of the International Society of Hypertension (Hypertension Seoul 2016), 12th Congress of the Asian Pacific Society of Hypertension (APSH), 25th Annual Scientific Meeting of the Korean Society of Hypertension (KSH), Seoul, Korea, September 26, 2016.
- “Targeted delivery of rat induced pluripotent stem cell-derived endothelial cells overexpressing Interleukin-8 receptors attenuates liposaccharide-induced lung injury”, PP1602 “Best Poster” Oral Presentation, 26th Meeting of the International Society of Hypertension (Hypertension Seoul 2016), 12th Congress of the Asian Pacific Society of Hypertension (APSH), 25th Annual Scientific Meeting of the Korean Society of Hypertension (KSH), Seoul, Korea, September 27, 2016.
- “Hypertension in women: More dangerous than in men?”, Symposium II, 26th Meeting of the International Society of Hypertension (Hypertension Seoul 2016), 12th Congress of the Asian Pacific Society of Hypertension (APSH), 25th Annual Scientific Meeting of the Korean Society of Hypertension (KSH), Seoul, Korea, September 28, 2016.
- “Blood Pressure Management”, 5th Annual Symposium of the UAB Comprehensive Cardiovascular Center: Focus on Ischemic Heart Disease, Birmingham, Alabama, September 30, 2016.
- “Update and Clinical Implications of the SPRINT Trial”, Cardiometabolic Health Congress, Boston, Massachusetts, October 7, 2016.
- “My Road to Academic Cardiology”, University of Mississippi Medical Center (UMMC) Department of Physiology and Biophysics, *2017 UMMC Physiologists in Training Distinguished Lecture*, Jackson, Mississippi, August 23, 2017.

Publications:

1. Cizek LJ, Nocenti MR and Oparil S. Sex difference in fluid exchange during food deprivation in the rabbit. *Endocrinology* 78:291-299, 1966.
2. Oparil S, Vassaux C, Sanders CA and Haber E. Role of renin in acute postural homeostasis. *Circulation* 26:89-95, 1970.
3. Oparil S, Sanders CA and Haber E. In vivo and in vitro conversion of angiotensin I to II. *Circ Res* 26:591-599, 1970.
4. Oparil S and Haber E. Renin in differential diagnosis of hypertension. *Am Heart J* 82:568- 579, 1971.
5. Oparil S, Tregear GW, Koerner T, Barnes BA and Haber E. Mechanism of pulmonary conversion of angiotensin I to angiotensin II in the dog. *Circ Res* 29:682-690, 1971.
6. Oparil S, Tregear GW and Haber E. Role of the C-terminal sequence of angiotensin I on immunologic reactivity and on conversion to angiotensin II in vivo and in vitro. In: Structure-Activity Relationships of Protein and Polypeptide Hormones, Part 2 of the Proceedings of the Second International Symposium on Protein and Polypeptide Hormones, Liege, Belgium, 1971, pp. 262-266.
7. Oparil S, Goldblatt A and Hendren WH. Left superior vena cava steal syndrome. *N Engl J Med* 286:303-304, 1972.
8. Haber E, Oparil S and Tregear GW. Sites and mechanisms of the conversion of angiotensin I to II. In: Hypertension -1972, J Genest and E Koiw, Eds, Springer-Verlag, 1972, pp. 563-569.
9. Oparil S and Haber E. Conversion of angiotensin I to II in vivo and in vitro. *Adv Exp Med Biol* 17:151-157, 1972.
10. Oparil S, Koerner T, Tregear GW, Barnes BA and Haber E. Substrate requirements for angiotensin I conversion in vivo and in vitro. *Circ Res* 32:415-423, 1973.
11. Oparil S and Swartwout JR. Heart disease in pregnancy. *J Reprod Med* 11:2-6, 1973.
12. Zacest R, Oparil S and Talamo RC. Studies of plasma bradykininases using radiolabeled substrates. *Aust J Exp Biol Med Sci* 52:601-606, 1974.
13. Oparil S, Lindheimer MD and Ehrlich EN. Effects of progesterone on volume homeostasis in man: Alterations in intrarenal sodium reabsorption, aldosterone excretion and renin activity. In: Symposium on Oral Contraceptives and High Blood Pressure, University of Florida Press, 1974, pp. 170-183.
14. Ehrlich EN, Oparil S and Lindheimer MD. Role of augmented aldosterone secretion in regulation of volume homeostasis in pregnancy. In: Symposium on Oral Contraceptives and High Blood Pressure, University of Florida Press, 1974, pp. 274-293.

15. Oparil S and Bailie MD. Mechanism of renal handling of angiotensin II in the dog. *Circ Res* 33:500-507, 1973.
16. Oparil S, Koerner T and O'Donoghue J K. Structural requirements for substrates and inhibitors of angiotensin I converting enzyme in vivo and in vitro. *Circ Res* 34:19-26, 1974.
17. Oparil S and Haber E. The renin-angiotensin system. *N Engl J Med* 291:389-401,446-457, 1974.
18. Oparil S. Radioimmunoassay of plasma renin activity: New techniques and clinical applications. In: Searle Radioimmunoassay Workshop Manual, Part XIV, 1974, pp. 1-10.
19. Pullman T, Oparil S and Carone F. Fate of labeled angiotensin II microinfused into individual nephrons in the rat. *Am J Physiol* 228:747-751, 1975.
20. Oparil S, Koerner T J and Haber E. Effects of pH and enzyme inhibitors on apparent generation of angiotensin I in human plasma. *J Clin Endocrinol Metabol* 39:965-968, 1974.
21. Oparil S, Ehrlich EN and Lindheimer MD. Effect of progesterone on renal sodium handling in man: Relation to aldosterone excretion and plasma renin activity. *Clin Sci Mol Med* 49:139-147, 1975.
22. Coe FL, Oparil S, Norton ER and Pullman TN. Physician acceptance of computer recommended antihypertensive therapy. *Comput Biomed Res* 8:492-502, 1975.
23. Low J and Oparil S. Oral contraceptive pill hypertension. *J Reprod Med* 15:201-208, 1975.
24. Erinoff L, Heller A and Oparil S. Prevention of hypertension in the SH rat: Effects of differential central catecholamine depletion. *Proc Soc Exp Biol Med* 150:748-754, 1975.
25. Oparil S. Plasma renin activity in hypertension. *Compr Ther* 1:57-64, 1975.
26. Oparil S. Digitalis assay and its clinical application. *Med Clin North Am* 60:193-207, 1976.
27. Carone FA, Pullman TN, Oparil S and Nakamura S. Micropuncture evidence of rapid hydrolysis of bradykinin by rat proximal tubule. *Am J Physiol* 230: 1420-1424, 1976.
28. Oparil S. Heart disease in pregnancy. *RN Magazine* 39:ICU-1-8, 1976.
29. Oparil S. Estimations of plasma renin levels: Theoretical approaches to analysis. *Clin Chem* 22:583-593, 1976.
30. Lindheimer MD, Landau RL and Oparil S. Oral contraceptive induced hypertension in an adrenalectomized and hypophysectomized patient. *Arch Intern Med* 136:1029-1031, 1976.
31. Oparil S, Carone FA, Pullman TN and Nakamura S. Inhibition of proximal tubular hydrolysis and reabsorption of bradykinin by small peptides. *Am J Physiol* 231:743-748, 1976.
32. Ehrlich EN, Noltén WE, Oparil S and Lindheimer MD. Mineralocorticoids in normal pregnancy. In: *Proceedings of the International Symposium on Hypertension in Pregnancy*, John Wiley and Sons, 1976, pp. 189-199.

33. Oparil S, Ehrlich EN and Lindheimer MD. The renin-angiotensin system in mother and fetus at caesarean section: A preliminary communication. In: Proceedings of the International Symposium on Hypertension in Pregnancy, John Wiley and Sons, 1976, pp. 287-290.
34. Oparil S, Low J and Koerner T J. Altered angiotensin I conversion in pulmonary disease. *Clin Sci Mol Med* 51:537-543,1976.
35. Simon DB, Oparil S and Kimball CP. The transcendental meditation program and essential hypertension. In: Scientific Research on the Transcendental Meditation Program, Collected Papers, Volume 1, DW Orme-Johnson and T J Farrow, Eds. Maharishi European Research University Press, 1976, pp. 268-269.
36. Oparil S. Low renin hypertension. *JAMA* 236:1994-1995, 1976.
37. Coe FL, Norton E, Oparil S, Tatar A and Pullman TN. Treatment of hypertension by computer and physician: A prospective controlled study. *J Chronic Dis* 30:81-92, 1977.
38. Oparil S, Erinoff L and Cutilletta AF. Catecholamines, blood pressure, renin and myocardial function in the spontaneously hypertensive rat. *Clin Sci Mol Med* 51:4555-4595, 1976.
39. Cutilletta AF, Erinoff L, Heller A, Low J and Oparil S. Development of left ventricular hypertrophy in young spontaneously hypertensive rats after peripheral sympathectomy. *Circ Res* 40:428-434, 1977.
40. Peterson DR, Oparil S, Flouret G and Carone FA. Hydrolysis of angiotensin II but not oxytocin by isolated renal tubular segments perfused in vitro. *Am J Physiol* 232:F319-F324, 1977.
41. Lindheimer MD, Katz AI, Nolten WE, Oparil S and Ehrlich EN. Sodium et mineralocorticoides au cours de la grossesse normale et pathologique. In: Actualities Nephrologiques de l'Hopital Necker, J Hamburger, J Crosnier and L Funck-Brentano, Eds, Flammarion Medecine-Sciences, Paris, pp. 195-220, 1977.
42. Oparil S. Angiotensin I converting enzyme and inhibitors. In: Hypertension, J Genest, E Koiw and O Kuchel, Eds., McGraw-Hill, pp. 156-168, 1977.
43. Goldberg LI, Rick JH and Oparil S. Pharmacology of antihypertensive agents. In: Hypertension, J Genest, E Koiw and a Kuchel, Eds., McGraw-Hill, pp. 990-1024, 1977.
44. Oparil S. Renin.1976. Eden Press, Montreal, Canada, 1977.
45. Rick J and Oparil S. Drug treatment of hypertension. *Comp Ther* 3:34-46, 1977.
46. Oparil S. Systemic hypertension. In: Practice Theory and Science of Clinical Cardiology in the 1970's, JT Willerson and CA Sanders, Eds, Grune and Stratton, New York, pp. 404- 419, 1977.
47. Bailie MD and Oparil S. Relation of renal hemodynamics to metabolism of angiotensin II by the canine kidney. *Circ Res* 41:283-287, 1977.

48. Oparil S and Katholi RE. Renin. Volume 11.1977. Eden Press, Montreal, Canada, 1977.
49. Lindheimer MD, Katz AI, Nolten WE, Oparil S and Ehrlich EH. Sodium and mineralocorticoids in normal and abnormal pregnancy. In: Advances in Nephrology. Volume 7, J Hamburger, J Crosnier, JP Grunfeld and MH Maxwell, Eds, Yearbook Publishers, pp. 33-59, 1978.
50. Pullman TN, Carone FA, Oparil S and Nakamura S. Effects of constituent amino acids on tubular handling of microinfused angiotensin II. *Am J Physiol* 234:F325-F331, 1978.
51. Oparil S, Koerner T J and Lindheimer MD. Plasma angiotensin converting enzyme activity in mother and fetus. *J Clin Endocrinol Metab* 46:434-439, 1978.
52. Page E and Oparil S. Effect of peripheral sympathectomy on left ventricular ultrastructure in young spontaneously hypertensive rats. *J Mol Cell Cardiol* 10:301-305, 1978.
53. Naftilan AJ and Oparil S. Inhibition of renin release from rat kidney slices by the angiotensins. *Am J Physiol*235:F62-F68, 1978.
54. Cutilletta AF, Benjamin M, Culpepper WS and Oparil S. Myocardial hypertrophy and ventricular performance in the absence of hypertension in spontaneously hypertensive rats. *J Mol Cell Cardiol* 10:689-703, 1978.
55. Nolten WE, Lindheimer MD, Oparil S and Ehrlich EN. Desoxycorticosterone in normal pregnancy. I. Sequential studies of the secretory patterns of desoxycorticosterone, aldosterone and cortisol. *Am J Obstet Gynecol* 132:414-420, 1978.
56. Nolten WE, Rueckert PA, Lindheimer MD, Oparil S and Ehrlich EN. A simple method for determining the free cortisol index in plasma: Measurements in human pregnancy. *J lab Clin Med* 93:146-153, 1979.
57. Gaynes RP, Szidon JP and Oparil S. In vivo and in vitro conversion of des-I-Asp angiotensin I to angiotensin III. *Biochem Pharmacol* 27:2871-2877, 1979.
58. Oparil S, Koerner T and O'Donoghue JK. Mechanism of angiotensin I converting enzyme inhibition by SQ 20,881 (1/2 Glu-Trp-Pro-Arg-Pro-Gin-Ile-Pro-Pro) in vivo. Further evidence for extrapulmonary conversion. *Hypertension* 1:13-22, 1979.
59. Peterson DR, Chrabaszcz G, Peterson WR and Oparil S. Mechanism for renal tubular handling of angiotensin. *Am J Physiol* 236:F365-F372, 1979.
60. Oparil S. Evaluation of patients for secondary causes of hypertension. In: Cardiology Update: Reviews for Physicians. 1979 Edition, E Rapaport, Ed., Elsevier, New York, pp. 303-328, 1979.
61. Oparil S and Katholi RE. Renin. Volume 3. Eden Press, Montreal, Canada, 1978.
62. Katholi RE, Oparil S, Urthaler F and James TN. Mechanism of postarrhythmic renal vasoconstriction in the anesthetized dog. *J Clin Invest* 64:17-31, 1979.
63. Gupta RG, Oparil S and Szidon JP. Clinical significance of serum angiotensin-converting enzyme levels in sarcoidosis. *J Lab Clin Med* 93:940-949, 1979.

64. Bishop SP, Oparil S, Reynolds RH and Drummond JL. Regional myocyte size in normotensive and spontaneously hypertensive rats. *Hypertension* 1:378-383, 1979.
65. Nolten WE, Lindheimer MD, Oparil S, Rueckert PA and Ehrlich EN. Regulation of desoxycorticosterone secretion in normal pregnancy. In: Hypertensive Disorders in Pregnancy, FK Beller and I MacGillivray, Eds., International Symposium Munster, George Thieme Publishers, Stuttgart, pp. 40-44, 1978.
66. Carone FA, Peterson DR, Oparil S and Pullman TN. Renal tubular transport and catabolism of proteins and peptides. *Kidney Int* 16:271-278, 1979.
67. Oparil S and Cutilletta AF. Hypertrophy in the denervated heart: A comparison of central sympatholytic treatment with 6-hydroxydopamine and peripheral sympathectomy with nerve growth factor antiserum. *Am J Cardiol* 44:970-978, 1979.
68. Nolten WE, Lindheimer MD, Oparil S, Rueckert PA and Ehrlich EN. Desoxycorticosterone in normal pregnancy: II. Cortisol dependent fluctuations in free plasma desoxycorticosterone. *Am J Obstet Gynecol* 133:644-648, 1979.
69. Oparil S. Key references: Drug management of hypertension. *Circulation* 61:210-212, 1980.
70. Szidon P, Bairey N and Oparil S. Effect of acute hypoxia on the pulmonary conversion of angiotensin I to angiotensin II in dogs. *Circ Res* 46:221-226, 1980.
71. Oparil S, Katholi RE and Winternitz SR. Renin, Volume 4. Eden Press, Montreal Canada, 1980.
72. Oparil S. Multiclinic double-blind evaluation of timolol combined with hydrochlorothiazide in essential hypertension. *Curr Ther Res* 27:527-537, 1980.
73. Katholi RE, Naftilan AJ and Oparil S. The importance of renal sympathetic tone in the development of DOCA-salt hypertension in the rat. *Hypertension* 2:266-273, 1980.
74. Cutilletta AF and Oparil S. Hemodynamic response to vascular expansion following immunosympathectomy in spontaneously hypertensive rats. *Hypertension* 2:304-310, 1980.
75. Urry DW, Trapane TL, Andrews SK, Long MM, Overbeck HW and Oparil S. NMR observation of altered sodium interaction with human erythrocyte membranes of essential hypertensives. *Biochem Biophys Res Commun* 96:514-521, 1980.
76. Wallach R, Karp RB, Reves JG, Oparil S, Smith LR and James TN. Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: A study of hemodynamic and humoral factors. *Am J Cardiol* 46:559-565, 1980.
77. Nolton WE, Lindheimer MD, Rueckert PA, Oparil S and Ehrlich EN. Diurnal patterns and regulation of cortisol secretion in pregnancy. *J Clin Endocrinol Metab* 51:466-472, 1980.
78. Winternitz SR, Katholi RE and Oparil S. Role of the renal sympathetic nerves in the development and maintenance of hypertension in the spontaneously hypertensive rat. *J Clin Invest* 66:971-978, 1980.

79. Winternitz SR and Oparil S. Hypertension in children. *Diagnosis* 2:40-47, 1980.
80. Oparil S, Katholi RE and Winternitz SR. Renin. Volume 5. Eden Press, Montreal, Canada, 1981.
81. Katholi RE, Bishop SP, Oparil S and James TN. Renal function during reflexly activated catecholamine flow through an adrenorenal rete. *Am J Physiol* 240:F30-F37, 1981.
82. Carone FA, Peterson DR, Oparil S and Pullman TN. Renal tubular transport and catabolism of small peptides. In: Functional Ultrastructure of the Kidney, AB Maunsbach, TS Olsen and EI Christensen, Eds. Academic Press, New York, pp. 326-340, 1980.
83. Oparil S. Hypertension and oral contraceptives. *J Cardiovasc Med* 6:381-387, 1981.
84. Oparil S. Special therapeutic considerations in the treatment of secondary hypertension. In: Secondary Forms of Hypertension: Current Diagnosis and Management, M.D. Blafox and C. Bianchi, Eds, Grune and Stratton, New York, p. 119, 1981.
85. Naftilan AJ and Oparil S. Effects of sodium intake and Goldblatt hypertension on renin release in rat kidney slices. *Am J Physiol (Renal Fluid Electrolyte Physiol)* 240:F501-F507, 1981.
86. Katholi RE, Winternitz SR and Oparil S. Role of the renal nerves in the pathogenesis of one-kidney renal hypertension in the rat. *Hypertension* 3:404-409, 1981.
87. Reves JG, Samuelson PN, Lell, WA and Oparil S. Comparison of enflurane and halothane anaesthetic techniques: haemodynamic and catecholamine response to intubation in patients with ischemic heart disease. *Seventh World Congress of Anaesthesiologist*, Excerpta Medica, Amsterdam-Oxford-Princeton, p. 149, 1980.
88. Wallace KP, Oparil S and Bailie MD. Angiotensin II metabolism by tissues from developing rats. *Pediatr Res* 15: 1088-1092, 1981.
89. Casey L, Krieger B, Kohler J., Rice C, Oparil S and Szidon P. Decreased serum angiotensin converting enzyme in adult respiratory distress syndrome associated with sepsis: a preliminary report. *Crit Care Med* 9:651-654, 1981.
90. Wilkins LH, Winternitz SR, Oparil S, Smith LR and Dustan HP. Lofexidine and clonidine in moderate essential hypertension. *Clin Pharmacol Ther* 30:752-757, 1981.
91. Katholi RE, Winternitz SR and Oparil S. Decrease in peripheral sympathetic nervous system activity following renal denervation or unclipping in the one-kidney one-clip Goldblatt hypertensive rat. *J Clin Invest* 69:55-62, 1982.
92. Winternitz SR, Katholi RE and Oparil S. Decrease in hypothalamic norepinephrine content following renal denervation in the one-kidney one-clip Goldblatt hypertensive rat. *Hypertension* 4:369-373, 1982.
93. Peterson DR, Carone FA, Oparil S and Christensen EI. Differences between renal tubular processing of glucagon and insulin. *Am J Physiol* 242:F112-F118, 1982.

94. Oparil S. Review of therapeutic modalities acting directly via central pathways. *Clin Exp Hypertension A4*:579-593, 1982.
95. Katholi RE, Whitlow PL, Winternitz SR and Oparil S. Importance of the renal nerves in established two-kidney one clip Goldblatt hypertension in the rat. *Hypertension 4*:II-166-II-174, 1982.
96. Katholi RE, Winternitz SR and Oparil S. Decrease in sympathetic nervous system activity and attenuation in response to stress following renal denervation in the one-kidney one-clip Goldblatt hypertensive rat. *Clin Exp Hypertension A4*:707-716, 1982.
97. Winternitz SR and Oparil S. Sodium-neural interactions in the development of spontaneous hypertension. *Clin Exp Hypertension A4*:751-760, 1982.
98. Oparil S, Winternitz S, Gould V, Baerwaldt M and Szidon P. Effect of hypoxia on the conversion of angiotensin I to II in the isolated perfused rat lung. *Biochem Pharmacol 31*:1375-1379, 1982.
99. Reves JG, Karp RB, Buttner EE, Tosone S, Smith LR, Samuelson PN, Kreuzsch GR and Oparil S. Neuronal and adrenomedullary catecholamine release in response to cardiopulmonary bypass in man. *Circulation 66*:49-54, 1982.
100. Oparil S. The AFGR: Is there life after 41? *Clin Res 30*:316-321, 1982.
101. Winternitz SR and Oparil S. Importance of the renal nerves in the pathogenesis of experimental hypertension. *Hypertension 4*:II-108-II-114, 1982.
102. Naftilan AJ and Oparil S. The role of calcium in the control of renin release. *Hypertension 4*:670-675, 1982.
103. Gupta RG, Bekerman C, Sicilian L, Oparil S and Szidon JP. Gallium-67 citrate scanning and serum angiotensin converting enzyme levels in sarcoidosis. *Radiology 144*:895-898, 1982.
104. Okuno T, Lindheimer MD and Oparil S. Central effects of prostaglandin E₂ on blood pressure and plasma renin activity in rats: Role of the sympathoadrenal system and vasopressin. *Hypertension 4*:809-816, 1982.
105. Winternitz SR, Wyss JM, Meadows JR and Oparil S. Increased noradrenaline content of hypothalamic nuclei in association with worsening of hypertension after high sodium intake in the young spontaneously hypertensive rat. *Clin Sci 63*:339s-342s, 1982.
106. Winternitz SR and Oparil S. The evaluation and Management of Hypertension in children and adolescents. In: Cardiology Update. Review for Physicians, 1983 Edition. E Rapaport, Editor-in-Chief. Elsevier Biomedical, New York, pp. 323-338, 1983.
107. Winternitz SR and Oparil S. Cardiovascular Disease: Risks and prognosis for women as compared with men. *Consultant 23*:118-132, 1983.

108. Gupta RG, Sicilian L, Catchatourian R, Szidon JP, Bekerman C and Oparil S. Angiotensin converting enzyme in alveolar macrophages in sarcoidosis. *Respiration* 43:153-157, 1982.
109. Okuno T, Winternitz SR, Lindheimer MD and Oparil S. Central catecholamine depletion, vasopressin and blood pressure in the DOCA/NaCl rat. *Am J Physiol*, 244:H807-H813, 1983.
110. Katholi RE, Naftilan AJ, Bishop S, and Oparil S. DOCA-salt hypertension in the rat. Influence on the renal vasculature and sodium excretion. *Hypertension* 5:427-435, 1983.
111. Lindheimer MD, Katz AI, Koeppe BM, Ordonez NG and Oparil S. Kidney function and sodium handling in the pregnant spontaneously hypertensive rat. *Hypertension* 5:498-506, 1983.
112. Oparil S. Angiotensin I converting enzyme inhibitors and analogs of angiotensin II. In Hypertension: Physiopathology and Treatment. Edited by Genest J, Kuchel O, Hamet P and Cantin M. McGraw Hill, New York, New York, 1983, pp. 250-270.
113. Szidon P, Oparil S, Booyse FM and Osikowicz G. Effect of hypoxia on the conversion of angiotensin I to II in cultured porcine pulmonary endothelial cells. *Biochem Pharmacol* 32:1201-1205, 1983.
114. Rosivall L, Rinder DF, Champion J, Navar LG and Oparil S. Intrarenal conversion of angiotensin I to angiotensin II at normal and reduced renal blood flow in the anesthetized dog. *Am J Physiol* 245:F408-F415, 1983.
115. Berecek KH, Okuno T, Nagahama S and Oparil S. Altered vascular reactivity and baroreflex sensitivity induced by chronic central administration of captopril in the spontaneously hypertensive rat (SHR). *Hypertension* 5:689-700, 1983.
116. Okuno T, Nagahama S, Lindheimer M and Oparil S. Attenuation of the development of spontaneous hypertension in rats by chronic central administration of captopril. *Hypertension* 5:653-662, 1983.
117. Wilkins L, Dustan HP and Oparil S. MK-421 (Enalapril Maleate) in mild to moderate low renin essential hypertension. *Clin Pharmacol Ther* 34:297-302, 1983.
118. Ody CE, Wilgis FP and Oparil S. Immunoreactive bradykinin and [Des-Arg⁹]-bradykinin in low renin essential hypertension - before and after treatment with enalapril (MK 421). *J Lab Clin Med* 102:714-721, 1983.
119. Winternitz SR, Wyss JM and Oparil S. Renal afferent nerves: Evidence for a role in cardiovascular regulation and the pathogenesis of experimental hypertension. In: The Kidney and Hypertension. Martinus Nijhoff Publishers, pp. 65-75, 1983.
120. Oparil S and Winternitz SR. Comprehensive drug management of hypertension. In: Cardiac Drug Therapy. F. Davis Publishing Co., pp. 73-91, 1983.

121. Oparil S. Cardiac hypertrophy and hypertension. In: Growth of the Heart in Health and Disease. Raven Press, pp. 275-336, 1983.
122. Nagahama S, Chen YF and Oparil S. Mechanism of the depressor effect of bromocriptine in the spontaneously hypertensive rat. *J Pharmacol Exp Ther* 228:370-375, 1984.
123. Hjelle J, Oparil S and Peterson OR. Subcellular sites of insulin hydrolysis in renal proximal tubules. *Am J Physiol* 246 (Renal Fluid Electrolyte Physiol15):F409-F416, 1984.
124. Buttner EE, Karp RB, Reves JG, Oparil S, Brummett C, McDaniel HG, Smith LR and Kreuzsch G. A randomized comparison of crystalloid and blood-containing cardioplegic solutions in 60 patients. *Circulation* 69:973-982, 1984.
125. Reves JG, Buttner E, Karp RB, Oparil S, McDaniel HG and Smith LR. Elevated catecholamines during cardiac surgery: Consequences of reperfusion of the postarrested heart. *Am J Cardiol* 53:722-728, 1984.
126. Oparil, S. Evaluation and treatment of secondary hypertension. In: Cardiology Update, Elsevier North Holland, Inc., New York, New York, pp. 1-31, 1984.
127. Rubin E, Keller FS, Oparil S and Diethelm AG. Renovascular hypertension in middle-aged females. *Ala J Med Sci* 21:272-274, 1984.
128. Gelman S, Rivas JE, Erdemir H, Oparil S, Proctor J, MacKrell T and Smith L. Hormonal and haemodynamic responses to upper abdominal surgery during isoflurane and balanced anaesthesia. *Can Anaesth Soc J* 31:509-516, 1984.
129. Oparil S. Systemic hypertension. In: Signs and Symptoms in Cardiology, LD Horwitz and BM Groves, Eds, J.B. Lippincott Co., Philadelphia, 1984, pp. 332-380.
130. Oparil S. Sodium, the nervous system and hypertension. In: Dialogues in Hypertension, Hypertension Update II, Hunt JC, Dreifus LS, Dustan HP, Frohlich ED, Gifford, RW Jr., Kaplan NM, Maxwell, MM, Eds., Health Learning System's Inc., Lyndhurst, NJ, 1984, pp. 15-24.
131. Oparil S. Hypertension in the young. In: The Developing Heart, Legato MJ, Ed., Martinus Nijhoff Publishing, Boston, 1984, pp. 211-243.
132. Winternitz SR, Wyss JM and Oparil S. The role of the posterior hypothalamic area in the pathogenesis of hypertension in the spontaneously hypertensive rat. *Brain Res* 324:51-58, 1984.
133. Oparil S, Bishop SP and Clubb FJ. Myocardial cell hypertrophy or hyperplasia. *Hypertension* (Suppl 3)6:111-38-111-43, 1984.
134. Peterson DR, Carone FA, Oparil S, Christensen EI and Hjelle JT: Renal handling of glucagon and insulin. In: Contributions to Nephrology, Vol. 42: Kidney, Small Proteins and Drugs, C Bianchi, A Bertelli and CG Duarte, Eds., S. Karger, Basel, 1984, pp. 30-37.

135. Berecek KH, Nagahama S and Oparil S. Effect of central administration of MK-422 (the diacid form of enalapril) on the development of hypertension in the spontaneously hypertensive rat. *J Hyperten (Suppl 3)*:63-66, 1984.
136. Oparil S. Pathogenesis of Ventricular Hypertrophy. *J Am Coll Cardiol* 5:57B-65B, 1985.
137. Nagahama S, Chen YF and Oparil S. Enhanced depressor effect of bromocriptine in the DOCA/NaCl hypertensive rat: Evidence for reduced central dopaminergic activity. *Am J Physiol* 249 (Heart Circ Physiol 18):H64-H70, 1985.
138. Chen YF, Nagahama S, Winternitz SR and Oparil S. Hyperresponsiveness of central and peripheral monoaminergic mechanisms to cold stress in DOCA/NaCl hypertensive rats. *Am J Physiol* 249 (Heart Circ Physiol 18): H71-H79, 1985.
139. Oparil S, Bishop SP and Clubb FJ. Myocardial cell hypertrophy or hyperplasia. In: Hypertension: Pathophysiology and Clinical Implications of Early Structural Changes. Proceedings of a Symposium held in Kiruna, Sweden 18-21 June 1983. B Folkow, M Nordlander, B-E Strauer and J Wikstrand, Eds., AB Hassle, Molndal, Sweden, 1985.
140. Oparil, S. Hypertension in a 74-year-old man with hydronephrosis and coronary disease. *Hypertension* 7:824-833, 1985.
141. Nagahama S, Dawson R and Oparil S. Enhanced depressor effect of muscimol in the DOCA/NaCl hypertensive rat: evidence for altered GABAergic activity in brain. *Proc Soc Exp Biol Med* 180:277-283, 1985.
142. Dawson R, Steves JP, Lorden JF and Oparil S. Reverse-phase separation and electrochemical detection of neuropeptides. *Peptides* 6:1173-1178, 1985.
143. Perry G and Oparil S. Use in heart disease. In: The Physiological Basis of Diuretic Therapy in Clinical Medicine, G Eknoyan and M Martinez-Maldonado, Eds, Grune and Stratton, Inc., 1986, pp. 153-177.
144. Wyss JM, Aboukarsh N and Oparil S. Sensory denervation of the kidney attenuates renovascular hypertension in the rat. *Am J Physiol (Heart Circ Physiol)* 19:H82-H86, 1986.
145. Chen YF, Lindheimer MD and Oparil S. Increased vasopressinergic activity following DOCA administration in the rat. *Brain Res Bull* 16: 93-98, 1986.
146. Nagahama S, Chen YF, Lindheimer MD, and Oparil S. Mechanism of the pressor action of LY171555, a specific dopamine D-2 receptor agonist in the conscious rat. *J Pharmacol Exp Ther* 236:735-742, 1986.
147. Oparil S. Increased sympathetic nervous system activity in salt-dependent hypertension. In: USA-Poland Symposium, Cardiovascular Disease. U.S. Department of Health and Human Services, National Institutes of Health, pp. 41-57, 1986.
148. Navar LG, Rosivall L, Carmines, PK and Oparil S. Effects of locally formed angiotensin II on renal hemodynamics. *Fed Proc* 45:1448-1453, 1986.

149. Jackson R, Narkates AJ, Oparil S. Impaired pulmonary conversion of angiotensin I to angiotensin II in rats exposed to chronic hypoxia. *J Appl Physiol* 60:1121-1127, 1986.
150. Olson KR, Kullman D, Narkates AJ, Oparil S. Angiotensin extraction by trout tissues in vivo and metabolism by the perfused gill. *Am J Physiol* 250 (Regulatory Integrative Comp. Physiol. 19):R532-R538, 1986.
151. Oparil S, Dawson R, Jope R and Wyss JM. Role of the central nervous system in the pathogenesis of hypertension. In: NIH Blood Pressure Regulation and Aging: Proceedings from a Symposium, Washington, DC, Sept. 19-20, 1984, MJ Horan, GM Steinberg, JB Dunbar, EC Hadley, Eds., Biomedical Information Corp, New York, NY, 1986, pp. 85-117.
152. Oparil S and Wyss JM. Neural-renal interactions: Evidence in experimental hypertension. In: Renovascular Hypertension: Pathophysiology, Diagnosis and Treatment, N Glorioso, JH Laragh, and A Rappelli, eds. Raven Press, NY, 1986, pp. 125-158.
153. Reynertson RH, Parmley RT, Roden L and Oparil S. A biochemical and ultrastructural study of aorta glycosaminoglycans in spontaneously hypertensive rats. *Collagen Relat Res* 6:77-103, 1986.
154. Oparil S. The sympathetic nervous system in clinical and experimental hypertension. *Kidney International* 30:437-452, 1986.
155. Nagahama S, Chen YF, Lindheimer MD and Oparil S. Mechanism of the depressor action of LY171555, a specific dopamine D-2 receptor agonist, in the anesthetized rat. *J Pharmacol Exp Ther* 239:426-432, 1986.
156. Oparil S, Donovan MK and Wyss JM. Neural-renal interactions: Evidence in experimental hypertension. In: Handbook of Hypertension, Vol. 8: Pathophysiology of Hypertension - Regulatory Mechanisms. A Zanchetti and RC Tarazi, Eds, Elsevier/North-Holland Biomedical Press B.V., 1986, pp. 173-202.
157. Oparil S, Daise M, Abrahams C, Winternitz SR and Szidon JP .Hyperoxia-induced converting enzyme insufficiency in conscious rat: Cardiovascular effects. *Exp Lung Res* 12:37-56, 1986.
158. Peterson DR, Green EA, Oparil S and Hjelle JT. Transport and hydrolysis of glucagon in the proximal nephron. *Am J Physiol* 251 :F460-F467 , 1986.
159. Chen YF and Oparil S. Enhanced response to the inhibitory action of LY171555, a dopamine D₂ agonist, on in vivo striatal dopamine release in DOCA/NaCl hypertensive rats. *Brain Res* 400:225-231, 1987.
160. Dawson R and Oparil S. Genetic and salt-related alterations in monoamine neurotransmitters in Dahl salt-sensitive and salt-resistant rats. *Pharmacology* 33:322-333, 1986.
161. Oparil S. Angiotensin-converting enzyme inhibitors in the treatment of hypertension. In: Cardiology Update, Elsevier North Holland, Inc., New York, NY, pp. 157-192, 1986.
162. Sripanidkulchai B, Dawson R, Oparil S and Wyss JM. Two renal α_2 -adrenergic receptor sites revealed by p-aminoclonidine binding. *Am J Physiol* 252 (Renal Fluid Electrolyte Physiol 21):F283-F290, 1987.

163. Reynertson RH, Oparil S and Roden L. Proteoglycans and hypertension III. Aorta proteoglycans in Dahl salt-sensitive hypertensive rats. *Am J Med Sci* 293:171-176, 1987.
164. Jin H, Yang R, Chen YF, Jackson R and Oparil S. Arginine vasopressin lowers pulmonary arterial pressure in rats adapted to chronic hypoxia. *Am J Med Sci* 293:274-278, 1987.
165. Lawler JE, Sanders BJ, Chen YF, Nagahama S and Oparil S. Hypertension produced by a high sodium diet in the borderline hypertensive rat (BHR). *Clin and Exp Hypertens*, A9: 1713-1731, 1987.
166. Chen YF, Jin H, Gist RG and Oparil S. Blunted responsiveness of posterior hypothalamic norepinephrine to quinpirole in DOCA/NaCl hypertensive rats. *Brain Res Bull* 118:563-568, 1987.
167. Chen YF, Jin H, Gist RG and Oparil S. Altered responsiveness of regional brain dopamine and DOPAC levels of systemic administration of quinpirole, a dopamine D₂ agonist, in DOCA/NaCl-hypertensive rats. *Brain Res* 413:15-22, 1987.
168. Wyss JM, Liomsiricharoen M, Sripairojthikoon W, Brown D, Gist R, and Oparil S. Exacerbation of hypertension by high chloride, moderate sodium diet in the salt-sensitive spontaneously hypertensive rat. *Hypertension* 9 (Suppl. III):III-171-III-175, 1987.
169. Dawson R and Oparil S. Renal catecholamines and α_2 -adrenergic receptors in salt-related and genetic hypertension. *Pharmacology* 34:131-142, 1987.
170. Dawson R, Nagahama S and Oparil S. Yohimbine-induced alterations of monoamine metabolism in the spontaneously hypertensive rat of the Okamoto strain. I. The peripheral nervous system. *Brain Res Bull* 19:101-108, 1987.
171. Nagahama S, Ann HS, Chen YF, Lindheimer MD and Oparil S. Role of vasopressin in the cardiovascular effects of LY171555, a selective dopamine D₂ receptor agonist: Studies in conscious Brattleboro and Long-Evans rats. *J Pharmacol Exp Ther* 242:143-151, 1987.
172. Wyss JM, Chen YF, Jin H, Gist R and Oparil S. Spontaneously hypertensive rats exhibit reduced hypothalamic noradrenergic input after NaCl loading. *Hypertension* 10:313-320, 1987.
173. Igarashi Y, Chen YF, Wyss JM, Lindheimer MD and Oparil S. Continuous intravenous infusion of LY171555, a potent selective D₂ receptor agonist, lowers blood pressure in the conscious rat. *Pharmacology* 35: 194-202, 1987.
174. Berecek KH, Kirk KA, Nagahama S and Oparil S. Sympathetic function in spontaneously hypertensive rats after chronic administration of captopril. *Am J Physiol* 252:H796-H806, 1987.
175. Rosivall L, Narkates AJ, Oparil S and Navar LG. De Novo intrarenal formation of angiotensin II during control and stimulated renin secretion in anesthetized dog. *Am J Physiol (Renal Fluid Electrolyte Physiol 21):F1118-F1123*, 1987.

176. Jin H, Oparil S, Ann HS, Yang R and Jackson RM. Hypoxia-induced inhibition of converting enzyme activity: role in vascular regulation. *J Appl Physiol* 63(3):1012-1018, 1987.
177. Oparil S, Sriparojthikoon W and Wyss JM. The renal afferent nerves in the pathogenesis of hypertension. *Can J Physiol Pharmacol* 65:1548-1558, 1987.
178. Dawson R, Nagahama S and Oparil S. Yohimbine-induced alterations of monoamine metabolism in the spontaneously hypertensive rat of the Okamoto strain (SHR). 11. The central nervous system (CNS). *Brain Res Bull* 19:525-534, 1987.
179. Meng Q, Chen YF, Oparil S. Role of the dissolution mechanism in determining chromatographic separation of biogenic amines from their precursors and metabolites by HPLC-EC. *J Liquid Chromatography* 10:2047-2053, 1987.
180. Oparil S, Horton R, Wilkins LH, Irvin J, Hammett, DK. Antihypertensive effect of enalapril in low renin hypertension: role of prostacyclin. *Am J Med Sci* 294:395-402, 1987.
181. Oparil S. Arterial Hypertension. In: Wyngaarden JB and Smith LH Jr (Eds), Cecil's Textbook of Medicine, Philadelphia, PA, WB Saunders Co, 1988, pp 276-293.
182. Chen YF, Meng QC, Wyss JM, Jin H, Oparil S. High NaCl reduces hypothalamic norepinephrine turn over in hypertensive rats. *Hypertension* 11:55-62, 1988.
183. Berecek KH, Coshatt G, Narkates AJ, Oparil S, Wilson KM, Robertson J. Captopril and the response to stress in the spontaneously hypertensive rat. *Hypertension* 11 (Suppl I):1-144-1-147, 1988.
184. Dawson R Jr, Nagahama S, Oparil S. Central serotonergic alterations in deoxycorticosterone acetate/NaCl (DOCA/NaCl)-induced hypertension. *Neuropharmacology* 27:417-426, 1988.
185. Elton TS, Dion LD, Bost KL, Oparil S, Blalock JE. Purification of an angiotensin II binding protein using antibodies to a peptide encoded by angiotensin II complementary RNA. *Proc Natl Acad Sci* 85:2518-2522, 1988.
186. Wyss JM, Sriparojthikoon W, Oparil S. Failure of renal denervation to attenuate hypertension in Dahl NaCl-sensitive rats. *Can J Physiol Pharmacol* 65:2428-2432, 1988.
187. Oparil S, Chen YF, Meng QC, Yang RH, Jin H, Wyss JM. The neural basis of salt sensitivity in the rat: altered hypothalamic function. *Am J Med Sci*, 295:360-369, 1988.
188. Bolzano K, Arriaga J, Bernal R, Bernardes H et al. The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension. *J Cardiovasc Pharmacol* 9(Suppl 3):S43-S47, 1987.
189. Klangkalya B, Sriparojthikoon W, Oparil S, Wyss JM. High NaCl diets increases anterior hypothalamic α_2 adrenoceptors in SHR. *Brain Res* 451:77-84, 1988.

190. Chen YF, Nagahama S and Oparil S. Role of dopamine in blood pressure regulation and pathogenesis of hypertension. Proceedings of the Third Symposium on Recent Advances in Biological and Medical Sciences. Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, Republic of China, 1988, p. 23-45.
191. Jin H, Chen YF, Yang RH, Meng Q, Oparil S. Impaired release of atrial natriuretic factor in NaCl loaded spontaneously hypertensive rats. Hypertension 11:739-744, 1988.
192. Chen YF, Yang RH, Jin H, Wyss JM, Cragoe EJ, Oparil S. Exaggerated depressor response to 6-iodoamiloride in NaCl-sensitive spontaneously hypertensive rats. Am J Med Sci 296:78-83, 1988.
193. Oparil S, Narkates AJ, Jackson R, Ann HS. Altered angiotensin- converting enzyme in lung and extra pulmonary tissues of hypoxia adapted rats. J Appl Physiol 65:218-227, 1988.
194. Meng QC, Chen YF, Delucas LJ, Oparil S. Effect of steric exclusion on the separation of proteins by hydrophilic size exclusion chromatography. J. Chromatog 445:29-36, 1988.
195. Jackson RM, Ann HS, Oparil S. Lung MK-351A uptake after hypoxia adaptation and subsequent hyperoxia exposure. Lung 166:209-219, 1988.
196. Jin H, Yang RH, Thornton RM, Chen YF, Jackson R, Oparil S. Atrial natriuretic peptide lowers pulmonary arterial pressure hypoxia-adapted rats. J Appl Physiol 65:1729-1735, 1988.
197. Oparil S, Meng QC, Chen YF, Yang RH, Jin H, Wyss JM. Genetic basis of NaCl sensitive hypertension. J Cardiovasc Pharmacol 12(Suppl 3):S56-S69, 1988.
198. Jin H, Yang RH, Chen YF, Jackson RM, Oparil S. Chronic infusion of atrial natriuretic peptide prevents pulmonary hypertension in hypoxia adapted rats. Transactions of the Association of American Physicians, Vol C1:185-192, 1988.
199. Thornton RM, Davidson JM, Oparil S. Enhanced cold pressor response in spontaneously hypertensive rats on a high NaCl diet. Am J Physiol 255:H1018-H1023, 1988.
200. Wyss JM, Yang RH, Jin H, Oparil S. Hypothalamic microinjection of alpha₂-adrenoceptor agonists causes greater sympathoinhibition in spontaneously hypertensive rats on high NaCl diets. J Hypertension 6:805-813, 1988.
201. Oparil S, Chen YF, Yang RH, Jin H, Meng QC, Wyss JM, The neuronal basis of salt sensitivity. In: Salt and Hypertension, R Rettig, D Ganten, FC Luft (eds), Springer-Verlag, Berlin, Heidelberg, 1989, p. 83-96.
202. Jackson RM, Ann HS, Oparil S. Hypoxia-induced oxygen tolerance: maintenance of endothelial metabolic function. Exp Lung Res 14:887-896, 1988.
203. Yang RH, Jin H, Chen YF, Oparil S, Wyss JM. Dietary Ca⁺⁺ supplementation prevents the exaggerated responsiveness of anterior hypothalamic α₂ adrenoceptors in NaCl loaded spontaneously hypertensive rats. J Cardiovasc Pharmacol 13:162-167, 1989.

204. Meng QC, King SJ, Chen YF, DeLucas LJ, Oparil S. Purification of angiotensin-converting enzyme by gel high-performance liquid chromatography. *J Chromatog* 461:271-275, 1989.
205. Jin H, Yang RH, Chen YF, Thornton RM, Jackson RM, Oparil S. Hemodynamic effects of arginine vasopressin in rats adapted to chronic hypoxia. *J Appl Physiol* 66:151-160, 1989.
206. Oparil S. Treating the older hypertensive patient - An overview. *Am J Med* 85:I, 1988.
207. Elton TS, Oparil S, Blalock JE. The use of complementary peptides in the purification of an angiotensin II binding protein. *J Hypertension* 6 (Suppl 4):S404-S407, 1988.
208. Oparil S and Calhoun D. Hypertension. In: Bone RC (ed) Disease-A-Month, Year Book Medical Publishers, Inc., Vol. XXXV, No.3, 1989.
209. Meng QC, Chen YF, Oparil S. A simple method for concentration of biogenic amines and their metabolites from biological samples for analysis by HPLC-EC. *Life Sciences* 44:1207-1213, 1989.
210. Jin H, Yang RH, Chen YF, Wyss JM, Oparil S. Dietary NaCl loading enhances antihypertensive effect of guanabenz in spontaneously hypertensive rats. *Am J Hypertension* 2:435-439, 1989.
211. Oparil S, Yang RH, Jin H, Wyss JM, Chen YF. Central mechanisms of hypertension. *Am J Hypertension* 2:477-485, 1989.
212. King SJ, Booyse FM, Lin PH, Traylor M, Narkates AJ, Oparil S. Hypoxia stimulates angiotensin-converting enzyme antigen synthesis. *Am J Physiol* 256 (Cell Physiol 25):C1231-1238, 1989.
213. Sripairojthikoon W, Oparil S, Wyss JM. Renal nerves do not contribute to NaCl-induced hypertension in spontaneously hypertensive rats. *Hypertension* 14:184-190, 1989.
214. Wyss JM, Chen YF, Meng Q, Jin H, Jirikulsomchok S, Oparil S. Dietary Ca⁺⁺ prevents NaCl induced exacerbation of hypertension and increases hypothalamic NE turnover in SHR-S. *J Hypertension* 7:711-719, 1989.
215. Jin H, Chen YF, Yang RH, Oparil S. Atrial natriuretic peptide in NaCl sensitive and resistant spontaneously hypertensive rats. *Hypertension* 14:404-412, 1989.
216. Jin H, Chen YF, Yang RH, McKenna TM, Jackson RM, Oparil S. Arginine vasopressin lowers pulmonary artery pressure in hypoxic rats by releasing atrial natriuretic peptide. *Am J Med Sci* 298(4):227-236, 1989.
217. Thornton RM, Wyss JM, Oparil S. Impaired reflex response to volume expansion in NaCl-sensitive spontaneously hypertensive rats. *Hypertension* 14:518-523, 1989.
218. Liu L, Cheng H, Chin W, Jin H, Oparil S. Atrial natriuretic peptide lowers pulmonary arterial pressure in patients with high altitude disease. *Am J Med Sci* 298:397-401, 1989.

219. Wyss JM, Oparil S, Chen YF. The role of the central nervous system in hypertension. In: Hypertension, Pathophysiology, Diagnosis and Management, Laragh JH and Brenner BM (eds), Raven Press, New York, 1990.
220. Jin H, Yang RH, Chen YF, Jackson RM, Oparil S. Atrial natriuretic peptide attenuates the development of pulmonary hypertension in rats adapted to chronic hypoxia. *J Clin Invest*, 85:115-120, 1990.
221. Mozaffari MS, Jirakulsomchok S, Oparil S, and Wyss JM. Changes in cerebrospinal fluid Na⁺ concentration do not underlie hypertensive responses to dietary NaCl in spontaneously hypertensive rats. *Brain Research* 506:149-152, 1990.
222. Jin H, Yang RH, Chen YF and Oparil S. Atrial natriuretic factor prevents NaCl-sensitive hypertension in spontaneously hypertensive rats. *Hypertension* 15: 170-176, 1990.
223. Burris JF, Weir MR, Oparil S, Weber M, Cady WJ, and Stewart WH. An assessment of diltiazem and hydrochlorothiazide in hypertension. Application of factorial trial design to a multicenter clinical trial of combination therapy. *JAMA* 263:1507-1512, 1990.
224. Lipke DW, Oparil S, and Olson KR. Vascular effects of kinins in trout and bradykinin metabolism by perfused gill. *Am J Physiol* 258:R515-R522, 1990.
225. Jin H, Chen YF, Yang RH, Jackson RM and Oparil S. Atrial natriuretic peptide clearance receptor agonist lowers pulmonary pressure in hypoxic rats. *J Appl Physiol* 68:2413-2418, 1990.
226. Yang RH, Jin H, Chen YF, Jackson RM and Oparil S. Atrial natriuretic peptide prevents hypoxia induced pulmonary hypertension in rats. In: American Society of Hypertension Symposium Series. Volume 3. Progress in Atrial Peptide Research, Laragh JH and Brenner BM (eds), Raven Press, New York, NY, 1989, pp 529-533.
227. Oparil S and Katholi R. Humoral Control of the Circulation. In: Current Concepts in Cardiovascular Physiology, Garfein OB (ed), Academic Press, New York, 1990, pp 209-287.
228. Chen YF, Meng QC, Wyss JM, Jin H, Rogers CF and Oparil S. NaCl does not affect hypothalamic noradrenergic input in deoxycorticosterone acetate/NaCl and Dahl sensitive rats. *Hypertension* 16:55-62, 1990.
229. Meng QC, Chen YF, Cragoe EJ and Oparil S. High-performance liquid chromatographic analysis of amiloride and its analogs in plasma. *J Chromatogr* 529:201-209, 1990.
230. Oparil S, Wyss JM, Yang RH, Jin H and, Chen YF. Dietary Ca²⁺ prevents NaCl-sensitive hypertension in spontaneously hypertensive rats by a sympatholytic mechanism. *Am J Hypertension* 3:179S-188S, 1990.
231. Pascual DW, Jin H, Bost KL and Oparil S. Interleukin-2 does not attenuate hypertension in spontaneously hypertensive rats. *Hypertension* 16:468-471, 1990.
232. Calhoun DA and Oparil S. Treatment of hypertensive crisis. *New Eng J Med* 323:1177-1183, 1990.

233. Elton TS, Oparil Sand Blalock JE. Purification of an angiotensin II receptor. In: Receptor Purification, Litwack G (ed), The Humana Press, Inc., Clifton, New Jersey, 1990, pp 355-371.
234. Wyss JM, Yang RH and Oparil S. Lesions of the anterior hypothalamic area increase arterial pressure in NaCl-sensitive spontaneously hypertensive rats. *J Auton Nerv Syst* 31:21-30, 1990.
235. Jirakulsomchok S, Mozaffari MS, Oparil S and Wyss JM. Dietary Ca^{2+} increases natriuretic and diuretic responses to volume loading in NaCl-sensitive spontaneously hypertensive rats. *J Hypertens* 8:947-951, 1990.
236. Yang RH, Jin H, Chen YF, Wyss JM and Oparil S. Blockade of endogenous anterior hypothalamic atrial natriuretic peptide with monoclonal antibody lowers blood pressure in spontaneously hypertensive rats. *J Clin Invest* 86:1985-1990, 1990.
237. Jain S, Pinheiro L, Nanda NC, Gross G and Oparil S. Noninvasive assessment of renal artery stenosis by combined conventional and color doppler ultrasound. *Echocardiography* 7:679-688, 1990.
238. Calhoun DA, Wyss JM and Oparil S. High NaCl diet enhances arterial baroreceptor reflex in NaCl-sensitive spontaneously hypertensive rats. *Hypertension* 17:363-368, 1991.
239. Jin H, Yang RH, Chen YF, Wyss JM and Oparil S. Altered stores of atrial natriuretic peptide in specific brain nuclei of NaCl-sensitive spontaneously hypertensive rats. *Am J Hypertension* 4:449-455, 1991.
240. Jin H, Yang RH, Esunge P, Chen YF, Durand J and Oparil S. Antihypertensive effect of cicletanine is exaggerated in NaCl-sensitive hypertension. *Am J Med Sci* 301:383-389, 1991.
241. King SJ, Oparil S and Berecek KH. Neuronal angiotensin-converting enzyme (ACE) gene expression is increased by converting enzyme inhibitors (CEI). *Mol Cell Neurosci* 2:13-20, 1991.
242. Oparil S and Calhoun DA. The calcium antagonists in the 1990s: An Overview. *Am J Hypertens* 4:396S-405S, 1991.
243. Jin H, Yang RH, Wyss JM, Chen YF and Oparil S. Intrahypothalamic clonidine infusion prevents NaCl-sensitive hypertension. *Hypertension* 18:224-229, 1991.
244. Oparil S, Wyss J M and Sripairojthikoon W. The role of the renal nerves in the pathogenesis of hypertension. In: Reflex Control of the Circulation, Zucker IH and Gilmore JP (eds), CRC Press, Boca Raton, Florida, 1991, pp 451-491.
245. Oparil S, Chen YF, Jin H, Yang RH and Wyss JM. Dietary Ca^{2+} prevents NaCl-sensitive hypertension in spontaneously hypertensive rats via sympatholytic and renal effects. *Am J Clin Nutr* 54:S227-S236, 1991.
246. Jin H, Yang RH, Chen YF, Jackson RM, Itoh H, Mukoyama M, Nakao K, Imura H and Oparil S. Atrial natriuretic peptide in acute hypoxia-induced pulmonary hypertension in rats. *J Appl Physiol* 71:807-814, 1991.

247. Oparil S, Chen YF and Wang Ruoping. Atrial natriuretic peptide inhibits sympathetic outflow in NaCl sensitive spontaneously hypertensive rats. *J Hypertens* 9: 1177-1185, 1991.
248. Oparil S, Chen YF, Naftilan AJ, and Wyss JM. Pathogenesis of hypertension. In: The Heart and Cardiovascular System, Fozzard HA, Jennings RB, Katz AM, Morgan HE, and Haber E (eds), Raven Press, New York, 1992, pp 295-333.
249. Chen CW, Chen YF, Meng QC, Wyss JM and Oparil S. Decreased norepinephrine release in anterior hypothalamus of NaCl-sensitive hypertensive rats during high NaCl intake. *Brain Res* 565:135-141, 1991.
250. Oparil S, Jin H, Wyss JM, Meng QC, Yang RH, Chen YF. New concepts in the pathogenesis of NaCl sensitive hypertension. In: The 1989 Distinguished Visiting Professorship Lectures, Hamner JE (ed), The University of Tennessee, Memphis, Office of Special Programs, Memphis, Tennessee, 1990, pp 115-158.
251. Oparil S. Arterial hypertension. In: Cecil's Textbook of Medicine, Wyngaarden JB, Smith LH Jr., and Bennett, JC (eds), WB Saunders Co, Philadelphia, PA, 1992, pp 253-269.
252. Pascual VH, Oparil S, Eldridge JH, Jin H, Bost KL and Pascual DW. Spontaneously hypertensive rat: lymphoid depression is age dependent and mediated via a mononuclear cell subpopulation. *Am J Physiol* 31:R1-R7, 1992.
253. Yang RH, Jin H, Wyss JM, Chen YF and Oparil S. Pressor effect of blocking atrial natriuretic peptide in nucleus tractus solitarii. *Hypertension* 19:198-205, 1992.
254. Chen YF, Elton TS and Oparil S. Quantitation of hypothalamic atrial natriuretic peptide messenger RNA in hypertensive rats. *Hypertension* 19:296-300, 1992.
255. Contreras RJ and Oparil S. Sex difference in blood pressure of spontaneously hypertensive rats influenced by perinatal NaCl exposure. *Physiol Behav* 51:449-455, 1992.
256. Jin H, Mathews C, Chen YF, Yang RH, Wyss JM, Esunge P and Oparil S. Effects of acute and chronic blockade of neutral endopeptidase with SCH 34826 on NaCl-sensitive hypertension in spontaneously hypertensive rats. *Am J Hypertens* 5:210-218, 1992.
257. Chen YF, Naftilan AJ and Oparil S. Androgen-dependent angiotensinogen and renin messenger RNA in hypertensive rats. *Hypertension* 19:456-463, 1992.
258. Yang RH, Jin H, Wyss JM and Oparil S. Depressor effect of blocking angiotensin subtype 1 receptors in anterior hypothalamus. *Hypertension* 19:475-481, 1992.
259. Elton TS, Stephan CC, Taylor GR, Kimball MG, Martin MM, Durand JN and Oparil S. Isolation of two distinct type I angiotensin II receptor genes. *Biochem Biophys Res Commun* 184:1067 - 1073, 1992.
260. Jin H, Yang RH and Oparil S. Cicletanine blunts the pulmonary pressor response to acute hypoxia in rats. *Am J Med Sci* 304:14-19, 1992.
261. Yang RH, Jin H, Wyss JM, Chen YF and Oparil S. Salt supplementation does not alter the

- pressor effect of blocking atrial natriuretic peptide in nucleus tractus solitarii. *Hypertension* 20:242-246, 1992.
262. Meng QC, King SJ, Branham KE, Delucas LJ, Lorber B and Oparil S. Preparative isolation of angiotensin-converting enzyme from human lung. *J Chromatogr* 579:63-71, 1992.
 263. Jin H, Yang RH, Calhoun DA, Wyss JM and Oparil S. Atrial natriuretic peptide modulates baroreceptor reflex in spontaneously hypertensive rat. *Hypertension* 20:374-379, 1992.
 264. King SJ and Oparil S. Converting enzyme (CE) inhibitors increase CE mRNA and activity in endothelial cells. *Am J of Physiol: Cell Physiol* 263:C743-C749, 1992.
 265. Wyss JM, Oparil S and Sriparojthikoon W. Neuronal control of the kidney: contribution to hypertension. *Can J Physiol Pharmacol* 70:759-770, 1992.
 266. Jin H, Yang RH, Chen YF and Oparil S. Ganglion atrial natriuretic peptide in NaCl-sensitive spontaneously hypertensive rats. *Am J Hypertens* 5:806-810, 1992.
 267. Elton TS, Oparil S, Taylor GR, Hicks PH, Yang RH, Jin H and Chen YF. Normobaric hypoxia stimulates endothelin-1 expression in the rat. *Am J Physiol* 263:R1260-R1264, 1992.
 268. Yang RH, Jin H, Wyss JM and Oparil S. Blocking hypothalamic AT₁ receptors lowers blood pressure in salt sensitive rats. *Hypertension* 20:755-762, 1992.
 269. Pascual DW, Oparil S, Pascual VH, Bost KL, McGhee JR and Oparil S. Nitric oxide mediates immune dysfunction in the spontaneously hypertensive rat. *Hypertension* 21:185-194, 1993.
 270. Oparil S and Calhoun DA. Hypertensive Crisis: Recognition and management. *Chances Are: Handbook of Clinical Probabilities in Hypertension* 3:3-6, 1992.
 271. Oparil S. Pathophysiology of hypertension. *Editorial* overview. *Curr Opinion in Nephrology & Hypertension* 2:253-257, 1993.
 272. Meng QC, Durand J, Chen YF, Oparil S. Simplified method for quantitation of angiotensin peptides in tissue. *J Chromatogr* 614:19-25, 1993.
 273. Oparil S. Antihypertensive therapy - efficacy and quality of life. *New Eng J Med* 328: 959-961, 1993
 274. Bittner V and Oparil S. Hypertension. In: PM Douglas, Ed, Cardiovascular Health and Disease in Women, Philadelphia: W.B. Saunders Company, 1993, pp. 63-103.
 275. Calhoun DA and Oparil S. Topics in acute care handling hypertension emergencies. *Hospital Medicine* 29:39-46, 1993.
 276. Nakamura Y, Calhoun DA, Chen YF, Wyss JM and Oparil S. Excitatory sympathetic reflex in NaCl-sensitive spontaneously hypertensive rats. *Hypertension* 22:285-291, 1993.
 277. Oparil S and Wyss JM. Atrial natriuretic factor in central cardiovascular control. *News in Physiol Sci* 8:223-228, 1993.

278. Lipke DW, McCarthy KJ, Elton TS, Arcot SS, Oparil S, Couchman JR. Coarctation induces alterations in basement membranes in the cardiovascular system. *Hypertension* 22:743-753, 1993.
279. Calhoun DA, Mutinga ML, Collins AS, Wyss JM, and Oparil S. Normotensive blacks have heightened sympathetic response to cold pressor test. *Hypertension* 22:801-805, 1993.
280. Calhoun DA and Oparil S. Treatment of hypertensive encephalopathy. In: Izzo JL Jr, Black HR (eds), Hypertension Primer, Dallas, TX: American Heart Association, 1993, pp. 342-343,
281. Oparil S, Yang RH, Jin HG, Chen SJ, Meng QC, Berecek KH and Wyss JM. Role of anterior hypothalamic angiotensin II in the pathogenesis of salt sensitive hypertension in the spontaneously hypertensive rat. *Am J Med Sci* 307(suppl 1):S26-S37, 1994.
282. Oparil S. Antihypertensive therapy in the context of total cardiovascular risk: the rational basis for therapeutic recommendations. *Current Opinion in Nephrology and Hypertension* 3:195-199,1994.
283. Li H, Elton TS, Chen YF and Oparil S. Increased endothelin receptor gene expression in hypoxic rat lung. *Am J Physiol* 266(Lung Cell and Mol Physiol 10):L-553-L560, 1994.
284. Calhoun DA, Zhu S, Wyss JM and Oparil S. Diurnal blood pressure variation and dietary salt in spontaneously hypertensive rats. *Hypertension* 24: 1-7, 1994.
285. Oparil S and Calhoun DA. α_1 and α_2 -Adrenergic Receptors In: Bennett WM, McCarron DA, and Stein JH (eds), Contemporary Issues in Nephrology, Vol. 28, Churchill Livingstone: New York, NY, 1994, pp. 247-265.
286. Chen YF, Yang RH, Meng QC, Cragoe EJ and Oparil S. Sodium-Proton (Na^+/H^+) exchange inhibition increases blood pressure in spontaneously hypertensive rat. *Am J Med Sci* 308:145-151,1994.
287. Alderman M, Elliott WJ, Oparil S and Wood AJ. Addressing multiple risks in hypertension therapy. *Patient Care* 28:64-76, 1994.
288. Li H, Chen SJ, Chen YF, Meng QC, Durand J, Oparil S and Elton TS. Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. *J Appl Physiol* 77:1451-1459, 1994.
289. Chen SJ, Chen YF, Miller DM, Li H and Oparil S. Mithramycin inhibits myointimal proliferation after balloon injury of the rat carotid artery in vivo. *Circulation* 90:2468-2473, 1994.
290. Calhoun DA, Mutinga ML, Wyss JM, and Oparil S. Muscle sympathetic nervous system activity in Black and Caucasian hypertensive subjects. *J Hypertension* 12:1291-1296, 1994.
291. Bittner V and Oparil S. Hypertension in postmenopausal women: Brief review of the literature and future research directions. In: Safar M, Stimpel M, Zanchetti A, eds. Hypertension in Postmenopausal Women. Berlin: Springer-Verlag, 1995, pp. 73-87.

292. Oparil S, Chen SJ, Meng QC, Elton TS, Yano M and Chen YF. Endothelin-A receptor antagonist prevents acute hypoxia induced pulmonary hypertension in the rat. *Am J Physiol: Lung Cell Mol Physiol* 268:L95-L100, 1995.
293. Oparil S, Chen YF, Berecek K, Calhoun D, Wyss JM. The role of the central nervous system in hypertension. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. Raven Press, NY 1995; pp. 713-740.
294. Oparil S. AHA President's Address-Cardiovascular health at the crossroads: Outlook for the 21st century. *Circulation* 91:1304-1310,1995.
295. Li H, Oparil S, Meng QC, Elton TS and Chen YF. Selective down-regulation of ANP clearance receptor gene expression in lung of rats adapted to hypoxia. *Am J Physiol: Lung Cell Mol Physiol* 268:L328-L335, 1995.
296. Oparil S. Initial medication selection for treatment of high blood pressure. Guest editorial, *JABFP* 8:70-72, 1995.
297. Calhoun DA and Oparil S. Hypertensive crisis since FDR -A partial victory. *N Engl J Med* 332:1029-1030, 1995.
298. Peng N, Meng QC, King K, Oparil S and Wyss JM. Acute hypertension increases norepinephrine release in the anterior hypothalamic area. *Hypertension* 25:828-833, 1995.
299. Rosen MR and Oparil S. Fighting the NIH funding crisis. *Circulation* 91:2502, 1995.
300. Smith SC Jr, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, Gotto AM, Gould KL, Greenland P, Grundy SM, Hill MN, Hlatky MA, Houston-Miller N, Krauss RM, LaRosa J, Ockene IS, Oparil S, Pearson TA, Rapaport E, Starke RD, and the Secondary Prevention Panel. Preventing heart attack and death in patients with coronary disease. *Circulation* 92:2-4, 1995.
301. Oparil S and Calhoun DA. Calcium antagonists: Antihypertensive and vascular considerations. *Cardiovasc Rev Rpts* 16:16-34, 1995.
302. Oparil S. SSCI Founders Medal Recipient's Address. *Am J Med Sci* 310:4-5,1995.
303. Oparil S. Hypertension in postmenopausal women: pathophysiology and management. Review article. *Curr Opin Nephrol Hypertens* 4:438-442, 1995.
304. Calhoun DA, Zhu ST, Chen YF, and Oparil S. Gender and dietary NaCl in spontaneously hypertensive and Wistar-Kyoto rats. *Hypertension* 26:285-289, 1995.
305. Oparil S. The elusive role of atrial natriuretic peptide in hypertension. Editorial. *Mayo Clin Proc* 70:1015-1017, 1995.
306. DiCarlo VS, Chen SJ, Meng QC, Durand J, Yano M, Chen YF and Oparil S. ET_A-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. *Am J Physiol* 269(Lung Cell Mol Physiol):L690-L697, 1995.

307. Meng QC, Balcells E, Dell'Italia LJ, Durand J and Oparil S. Sensitive method for quantitation of angiotensin-converting enzyme (ACE) activity in tissue. *Biochem Pharmacol* 50:1445-1450, 1995.
308. Dell'Italia LJ, Meng QC, Balcells E, Straeter-Knowlen IM, Hanks GH, Dillon R, Cartee RE, Orr R, Bishop SP, Oparil S and Elton TS. Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation. *Am J Physiol* 269:H2065-H2073, 1995.
309. Meng QC, Durand J, Chen Y and Oparil S. Effects of dietary salt on angiotensin peptides in kidney. *J Am Soc Nephrol* 6:1209-1215, 1995.
310. Oparil S. Salt restriction as a public health measure: Where is the evidence? *Perspect Appl Nutr* 3:131-133, 1995.
311. Calhoun D and Oparil S. Racial differences in the pathogenesis of hypertension. *Am J Med Sci* 310(suppl1):S86-S89, 1995.
312. Chen SJ, Chen YF, Meng QC, Durand J, DiCarlo VS and Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. *J Appl Physiol* 79:2122-2131, 1995.
313. Bittner V and Oparil S. Evaluation and clinical findings. In: FH Messerli, ed. Hypertension in Postmenopausal Women. New York: Marcel Dekker, Inc. 1996, pp. 101-112.
314. Chen SJ, Li H, Durand J, Oparil S and Chen YF. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. *Circulation* 93:577-584, 1996.
315. Zhu ST, Chen YF, Wyss JM, Nakao K, Imura H, Oparil S, Calhoun D. Atrial natriuretic peptide blunts arterial baroreflex in spontaneously hypertensive rats. *Hypertension* 27:297-302, 1996.
316. Oparil S. Cardiovascular risk reduction in women. *J Women's Health* 5:23-32, 1996.
317. Calhoun DA and Oparil S. Hypertension: Initial evaluation. *ACC Curr J Rev* pp. 60-62, 1996.
318. Oparil S. Arterial hypertension. In: Cecil Textbook of Medicine, Twentieth Edition, Bennett JC and Plum F (eds), W.B. Saunders Company, Philadelphia, PA. pp. 256-271, 1996.
319. Peng N, Meng QC, Oparil S and Wyss JM. Acute saline infusion decreases norepinephrine release in the anterior hypothalamic area. *Hypertension* 27:578-583, 1996.
320. Oparil S, Chen YF, Peng N, Wyss JM. Anterior hypothalamic norepinephrine, atrial natriuretic peptide, and hypertension. *Front Neuroendocrinol* 17:212-246, 1996.
321. Oparil S. Antihypertensive therapy in the era of evidence based medical practice: What to do until the facts are in. Editorial. Commentary. *Curr Opin Nephrol Hypertens* 5:159-161, 1996.
322. Davis BR, Cutler A, Gordon D, Furberg CD, Wright J, Cushman W, Grimm R, LaRosa J, Whelton P, Perry HM, Alderman M, Ford CE, Oparil S, Francis C, Proscham M, Pressel S, Black H and Hawkins CM. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). *Am J Hypertens* 9:342-360, 1996.

323. Dell'Italia LJ and Oparil S. The cardiac renin angiotensin system in hypertrophy and the progression to heart failure. *Heart Failure Review* 63-72, 1996.
324. Oparil S, Levine RL and Chen YF. Sex hormones and the vasculature. In: Endocrinology of the Vasculature, Sowers JR (ed), Humana Press, Totowa, New Jersey, pp. 225-237, 1996.
325. Oparil S, Meng QC, Sun S, Chen YF and Dell'Italia LJ. Tissue angiotensin converting enzyme. In: Vascular Endothelium: Responses to Injury, Catravas JD, Callow AD and Ryan US (eds), Plenum Press, New York, NY pp 205-239, 1996.
326. Oparil S, Elkins M, Liss C, Vrecenak A, Barr E and Edelman J. Efficacy, tolerability, and effects on quality of life of losartan alone or with hydrochlorothiazide, versus amlodipine in patients with essential hypertension. *Clin Ther* 18:608-625, 1996.
327. Campese VM, Tawadrous T, Bigazzi R, Bianchi S, Mann A, Oparil S, and Raij L. Salt intake and plasma atrial natriuretic peptide and nitric oxide in hypertension. *Hypertension* 28:335-340, 1996.
328. Oparil S. Antihypertensive therapy and atherosclerosis in coronary heart disease. *Cardiovascular Risk Factors: An International Journal* 6:222-232, 1996.
329. Levine RL, Chen SJ, Durand J, Chen YF and Oparil S. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. *Circulation* 94:2221-2227, 1996.
330. Meng QC and Oparil S. Purification and assay methods for angiotensin-converting enzyme. *J Chromatogr A* 743:105-122, 1996
331. Oparil S and Chen YF. Cardiovascular disease in women: an overview. In: Hypertension after Menopause, Stimpel and A Zanchetti (eds), Walter de Gruyter & Co, Berlin, New York pp 4-19, 1996.
332. Peng N, Oparil S, Meng QC and Wyss JM. Atrial natriuretic peptide regulation of noradrenaline release in the anterior hypothalamic area of spontaneously hypertensive rats. *J Clin Invest* 98:2060-2065, 1996.
333. Oparil S. Classic Papers Symposium of the Southern Clinical Research Meetings: White coat hypertension - fact or fancy? *Am J Med Sci* 312:219-220, 1996.
334. Hatton DC, Haynes RB, Oparil S, Kris-Etherton AP, Pi-Sunyer FX, Resnick LM, Stern JS, Clark S, McMahon M, Morris C, Metz J, Ward A, Holcomb S and McCarron DA. Improved quality of life in patients with generalized cardiovascular metabolic disease on a prepared diet. *Am J Clin Nutr* 64: 935-943, 1996.
335. Oparil S, Dyke S, Harris F, Kief J, James D, Hester A, Fitzsimmons S. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. *Clin Ther* 18:797-810, 1996.

336. McCarron DA, Weder AB, Egan BM, Krishna GG, Morris CD, Cohen M and Oparil S. Blood pressure and metabolic response to moderate sodium chloride restriction in isradipine-treated hypertensive patients. *Am J Hypertens* 10:68-76, 1997.
337. Proschan M, Davis B, Cutler J, Ford C, Furberg C, Grimm R and Oparil S for the ALLHAT Research Group. ALLHAT and calcium blockers. *Am J Hypertens* 10:142-143, 1997.
338. McCarron DA, Oparil S, Chait A, Kris-Etherton P, Stern JS, Haynes RB, Resnick LM, Clark S, Morris CD, Hatton DC, Metz JA, McMahon M, Holcomb S, Snyder GW and Pi-Sunyer FX. Nutritional management of cardiovascular risk factors: A randomized, controlled clinical trial. *Arch Intern Med* 157:169-177, 1997.
339. Oparil S, Levine RL, Chen SJ, Durand J, Chen, YF. Sexually dimorphic response of the balloon injured rat carotid artery to hormone treatment. *Circulation* 95: 1301-1307, 1997.
340. Bittner V and Oparil S. Hypertension. In: Hypertension in Women, Julian DG and Wenger NK (eds), Martin Dunitz Ltd, United Kingdom pp 299-327, 1997.
341. Wyss JM, Peng N, Meng QC, Chen YF, Oparil S. The role of anterior hypothalamic area noradrenaline release in salt-sensitive hypertension in spontaneously hypertensive rats. *Fundam Clin Pharm* 11 (suppl 1):31s-5s, 1997.
342. White CR, Darley-Usmar V, Oparil S. Gender and cardiovascular disease: recent insights. *Trends Cardiovasc Med* 7:94-100, 1997.
343. Tian B, Meng QC, Chen YF, Krege JH, Smithies O, Oparil S. Blood pressures and cardiovascular homeostasis in mice having reduced or absent angiotensin converting enzyme gene function. *Hypertension* 30:128-133, 1997.
344. Calhoun DA, Oparil S. High blood pressure in women. *Int J Fertil* 42:198-205, 1997.
345. Dell'Italia LJ, Meng QC, Balcells E, Wei CC, Palmer R, Hageman GR, Durand J, Hankes GH and Oparil S. Compartmentalization of angiotensin II generation in the dog heart: evidence for independent mechanisms in intravascular and interstitial spaces. *J Clin Invest* 100:253-258, 1997.
346. Chen SJ, Chen YF, Opgenorth T J, Wessale JL, Meng QC, Durand J, DiCarlo VS and Oparil S. The orally active nonpeptide Endothelin A receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats. *J Cardiovasc Pharmacol* 29:713-725, 1997.
347. Oparil S, Kobrin I, Albernethy DR, Levine BS, Reif MC, Shepherd AM. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. *Am J Hypertens* 10:735-742, 1997.
348. Oparil S, Bernik P, Bursztyn M, Carney S and Kobrin I. The antihypertensive effects of mibefradil in the treatment of mild-to-moderate hypertension: placebo-controlled studies. *Am J Cardiol* 80:12C-19C, 1997.

349. Metz JA, Kris-Etherton PM, Morris CD, Mustard VA, Stern JS, Oparil S, Chait A, Hayes RB, Resnick LM, Clark S, Hatton DC, McMahon M, Holcomb S, Snyder GW, Pi-Sunyer FX, McCarron DA. Dietary compliance and cardiovascular risk reduction with a prepared meal plan compared to a self-selected diet. *Am J Clin Nutr* 66:373-385,1997.
350. Oparil S. The sexual dimorphism of cardiovascular disease: lessons from rodent models. *Jpn Heart J* 38:555-556, 1997
351. Dahlof B, Devereux R, deFaire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm L, Nieminen MS, Omvik P, Oparil S and Wedel H for the LIFE Study Group. The Losartan Intervention for Endpoint reduction (LIFE) study in hypertension. Rationale, design and methods. *Am J Hypertens* 10:705-713,1997.
352. Dell'Italia LJ, Balcells E, Meng QC, Su X, Schultz D, Bishop SP, Machida N, Straeter-Knowlen IM, Hanks GH, Dillon R, Cartee RE and Oparil S. Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs. *Am J Physiol* 42:H961-H970, 1997.
353. White CR, Shelton J, Chen SJ, Darley-Usmar V, Allen L, Nabors C, Sanders PW, Chen YF , Oparil S. Estrogen restores endothelial cell function in an experimental model of vascular injury. *Circulation* 96:1624-1630, 1997.
354. Oparil S. Clinical crossroads - A 42-year-old man with hypertension. *JAMA* 278:1015-1021, 1997.
355. Oparil S and Calhoun DA. High blood pressure. In: Dale DC, Federman DD, eds. *Sci Am Med*, New York: Scientific American, 1997. Vol.1, Sect 1, Subsect III; pp.1-14.
356. Aversa C, Oparil S, Caro J, Li H, Sun S-D, Chen Y, Swerdel M, Monticello T, Surham S, Minchenko A, Lira S, Webb M. Hypoxia stimulates human preproendothelin-1 promoter activity in transgenic mice. *Am J Physiol* 273:L848-L855, 1997.
357. Balcells E, Meng, QC, Johnson WC, Oparil S and Dell'Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. *Am J Physiol* 273:H1769-H1774, 1997.
358. White CR, Darley-Usmar V and Oparil S. No role for NO in estrogen-mediated vasoprotection? Editorial. *Circulation* 96:2769-2771, 1997.
359. Calhoun DA, Oparil S. Hypertensive emergencies. Cardiac Intensive Care, Brown DL (ed), WB Saunders Co, Philadelphia, PA pp. 447-459, 1998.
360. Oparil S, Calhoun DA. Managing the patient with hard-to-control hypertension. *Am Family Physician* 57:1007-1014, 1998.
361. Calhoun DA, Oparil S, Mathur V, Luther R and Ellis D. Fenoldopam: A novel, peripherally acting dopamine-1 agonist for parenteral treatment of hypertension. *Drugs of Today* 33(10):729-738, 1997.
362. Oparil S, Gradman A, Papademetriou V, and Weber M. Tolerability profile of tasosartan, a long-acting angiotensin II AT1 receptor blocker, in the treatment of patients with essential hypertension. *Curr Ther Res* 58, 12: 930-943, 1997.

363. McCarron DA, Oparil S, Resnick LM, Chait A, Haynes RB, Kris-Etherton P, Pi-Sunyer FX, Stem JS, Morris CD, Clark S, Hatton DC, Metz JA, McMahon M, Holcomb S, and Snyder GW. Comprehensive nutrition plan improves cardiovascular risk factors in essential hypertension. *Am J Hypertens* 11:31-40, 1998.
364. Carter BL, Oparil S, Pieper JA and Roberts RW. AphA Special Report: "A Review of the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure". American Pharmaceutical Association, May, 1998.
365. Oparil S. Pathophysiology of sudden death in women: implications for prevention. *Circulation* 97: 2103-2105, 1998.
366. Stimpel M, Koch B and Oparil S. Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide). *Cardiology* 89:271-276, 1998.
367. Oparil S, Mibefradil, a T-channel-selective-calcium antagonist: clinical trials in hypertension. *Am J Hypertens* 11:88S-94S, 1998.
368. Oparil S, Guthrie R, Lewis AJ, Marbury T, Reilly K, Triscari J, Witcher JA, on behalf of the Irbesartan/Losartan Study Investigators. An elective-titration study of the comparative effectiveness of two angiotensin II receptor blockers, irbesartan and losartan. *Clin Ther* 20:398-409, 1998.
369. Fallon MB, Abrams GA, Abdel-Razek TT, Dai J, Chen SJ, Chen YF, Luo B, Oparil S, and Ku DD. Garlic prevents hypoxic pulmonary hypertension in rats. *Am J Physiol* 275 (Lung Cell Mol Physiol 19): L283-287, 1998.
370. Reif M, White WB, Fagan TC, Oparil S, Flanagan TL, Edwards DT, Cushing, and Michelson EL, for the Candesartan Cilexetil Study Investigators. Effects of candesartan cilexetil in patients with systemic hypertension. *Am J Cardiol* 82:961-965, 1998.
371. Oparil S. The evolving role of angiotensin-II receptor blockers in cardiovascular risk reduction. Case study. *Am J Hypertens* 11 (11 Pt 2):192S-194S, 1998.
372. Chen YF, Oparil S. Effects of sex steroids in vascular injury. In: Endocrinology of Cardiovascular Function, Levin ER and Nadler JL (eds), Kluwer Academic Publishers, Boston/Dordrecht/London, pp 45-59, 1998.
373. Calhoun DA and Oparil S. Gender and blood pressure. In: Hypertension Primer, 2nd ed., Izzo, JL Jr and Black HR (eds), Baltimore, Williams & Wilkins, pp 229-232, 1998.
374. Dahlof B, Beevers G, Devereux RB, Faire Ud, Fyhrquist F, Ibsen H, Julius S, Lederballe-Pederson O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. The losartan intervention for endpoint (LIFE) reduction in hypertension study - Baseline characteristics of 9,194 patients with left ventricular hypertrophy. *Hypertension* 32:989-997, 1998.
375. Calhoun DA, Oparil S. The sexual dimorphism of high blood pressure. *Cardiology in Review* 6:356-363, 1998.

376. Pool J, Oparil S, Hedner T, Glazer R., Oddou-Stock P, and Hester A. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. *Clin Ther* 20:1106-1114, 1998.
377. Hatton DC, Metz JA, Kris-Etherton PM, Holcomb S, Morris CD, Oparil S, Haynes RB, Stern JS, Resnick LM, Pi-Sunyer FX, Chait A, Clark S, McMahon M, Reusser ME, McCarron DA. Healthier diets improve quality of life while reducing cardiovascular disease risk factors. *Dis Manage Clin Outcomes* 1:106-113, 1998.
378. Oparil S. Arthur C. Corcoran Memorial Lecture: Hormones and Vasoprotection. *Hypertension* 33:170-176, 1999.
379. Oparil S. Eprosartan versus enalapril in hypertensive patients with angiotensin-converting enzyme inhibitor-induced cough. *Current Therapeutic Research* 60:1-14, 1999.
380. Pi-Sunyer FX, Maggio CA, McCarron DA, Reusser ME, Stern JS, Haynes RB, Oparil S, Kris-Etherton P, Resnick LM, Chait A, Morris CD, Hatton DC, Metz JA, Snyder GW, Clark S, McMahon M. Multicenter randomized trial of a comprehensive prepared meal program in type 2 diabetes. *Diabetes Care* 22:191-197, 1999.
381. Oparil S. Choosing antihypertensive drug treatment. *Hypertens Mgmt* 1:10-13, 1998.
382. Oparil S. Long-term morbidity and mortality trials with Amlodipine. *J Cardio Pharm* 33:S1-S6, 1999.
383. Oparil S. Management of the hypertensive patient with coronary artery disease. *Am J Hypertens* 12:56S-62S, 1999.
384. Dias VC, Tendler B, Oparil S, Reilly PA, Snarr P and White WB. Clinical experience with transdermal Clonidine in African-American and Hispanic-American patients with hypertension: Evaluation from a 12-week prospective, open-label clinical trial in community-based clinics. *Am J Therap* 6:19-24, 1999.
385. Mosca L, Judelson D, King K, Limacher M, Oparil S, Pasternak R, Pearson T, Redberg R, Smith S, Winston M and Zinberg S. AHA/ACC Scientific Statement: A guide to preventive cardiology for women. *Circulation* 99:2480-2484, 1999.
386. Mosca L, Grundy S, Judelson D, King K, Limacher M, Oparil S, Pasternak R, Pearson TZ, Redberg RF, Smith SC, Winston M, Zinberg S. Guide to preventive cardiology for women. *J Am Coll Cardiol* 33:1751-5, 1999.
387. Chait A, Malinow MR, Nevin DN, Morris CD, Eastgard RL, Kris-Etherton P, Pi-Sunyer FX, Oparil S, Resnick LM, Stern JS, Haynes RB, Hatton DC, Metz JA, Clark S, McMahon M, Holcomb S, Reusser ME, Snyder GW, McCarron DA. Effects of increased dietary micronutrients on serum homocysteine in patients at high risk for cardiovascular disease. *Am J Clin Nutr* 70:881-887, 1999.
388. Oparil S and Oberman A. Nontraditional cardiovascular risk factors. *Am J Med Sci* 317:193-207, 1999.

389. Oparil S and Chen YF. Endothelin and pulmonary hypertension. In: Vascular Endothelium: Mechanisms of Cell Signaling. Catravas JD, Callow AD, Ryan USR (eds), IOS Press, Amsterdam/Berlin/Oxford/Tokyo/Washington DC, pp117-131, 1999.
390. Wei C-C, Meng QC, Palmer R, Hageman GR, Durand J, Bradley WE, Farrell DM, Hankes GH, Oparil S, Dell'Italia LJ. Evidence for angiotensin-converting enzyme - and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo. *Circulation* 99:2583-2589, 1999.
391. Koch B, Oparil S and Stimpel M. Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women. *J Human Hypertens* 13:337-342, 1999
392. Oparil S. Hypertension in Women. *Cardiovascular Health for Women: A Clinical Practitioner's Guide*. Pp 9-15, 1999.
393. Hedner T, Oparil S, Rasmussen K, Rapelli A, Gatlin M, Kobi P, Sullivan J and Oddou-Stock P. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. *Am J Hypertens* 12:414-417,1999.
394. Su X, Wei C-C, Machida N, Bishop SP, Hankes GH, Dillon AR, Oparil S and Dell'Italia LJ. Differential expression of angiotensin-converting enzyme and chymase in dogs with chronic mitral regurgitation. *J Mol Cell Cardiol* 31:1033-1045, 1999.
395. Neutel JM, Frishman WH, Oparil S, Papdemitriou V, Guthrie G. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. *Am J Ther* 6:161-166,1999.
396. Oparil S, Aronson S, Deeb MG, Epstein M, Levy JH, Luther R, Prielipp and Taylor A. Fenoldopam: A new parenteral antihypertensive. Consensus roundtable on the management of perioperative hypertension and hypertensive crises. *Am J Hypertens* 12:653-664,1999.
397. Bakir S, Oparil S. Recent outcome trials of newer antihypertensives. *Current Hypertens Reports*. 3:238-240, 1999.
398. Alberts BM, Ayala FJ, Botstein D, Frank E, Holmes EW, Lee RD, Macagno ER, Marrack P, Oparil S, Orkin SH, Rubenstein AH, Slayman CW, Sparling PF, Squire LR, von Hippel PH, Yamamoto KR. Proposed changes for NIH's center for scientific review. *Science* 285:666-667, 1999.
399. Oparil S, Levine JH, Zuschke CA, Gradman AH, Ripley E, Jones DW, Hardison JD, Cushing DJ, Prasad R, Michelson EL, for the Candesartan Cilexetil Study Investigators. Effects of candesartan cilexetil in patients with severe systemic hypertension. *Am J Cardiol* 84:289-293, 1999.
400. Li G, Chen YF, Greene GL, Oparil S and Thompson JA. Estrogen inhibits vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. *Circulation* 100:1639-1645, 1999.
401. Chrysant GS, Bakir S and Oparil S. Dietary salt reduction in hypertension - What is the evidence and why is it still controversial? *Prog Cardiovasc Dis* 42:23-38, 1999.

402. Oparil S, Weber M. (eds) Hypertension: A Companion to Brenner and Rector's the Kidney, W. B. Saunders Company, Philadelphia, PA 1999.
403. Oparil S. Diet - Micronutrients -Special Foods, In: Hypertension: A Companion to Brenner and Rector's the Kidney, Oparil S and Weber M (eds), W. B. Saunders Company, Philadelphia, PA, pp 433-457, 1999.
404. August P, Oparil S. Hypertension in Women, In: Hypertension: A Companion to Brenner and Rector's the Kidney, Oparil S and Weber M (eds), W. B. Saunders Company, Philadelphia, PA, pp 546-550, 1999.
405. Haynes RB, Kris-Etherton P, McCarron DA, Oparil S, Chait A, Resnick LM, Morris CD, Clark S, Hatton DC, Metz JA, McMahan M, Holcomb S, Snyder GW, Pi-Sunyer FX, Stern JS. Nutritionally complete prepared meal plan to reduce cardiovascular risk factors: a randomized clinical trial. *J Am Diet Assoc* 99:1077-1083, 1999.
406. Bakir S, Oparil S. Sexual Dimorphism in Cardiovascular Disease. In: Molecular Cardiology in Clinical Practice, Saunders M and Kostis J (eds), Kluwer Academic Publishers, Norwell, MA, pp 187-217, 1999.
407. Heaney RP, McCarron DA, Dawson-Hughes B, Oparil S, Berga S, Stern JS, Barr SI and Rosen CJ. Dietary changes favorably affect bone remodeling in older adults. *J Am Diet Assoc* 99:1228-1233,1999.
408. Oparil S. Treating multiple-risk hypertensive populations. *Am J Hypertens* 12:121S-129S, 1999.
409. Oparil S. Arterial hypertension. In: Cecil Textbook of Medicine. Twenty-First Edition, Goldman L and Bennett JC (eds), WB Saunders, Philadelphia, PA, pp 258-273, 2000.
410. Oparil S. The need to treat hypertension in postmenopausal women. *Hypertension Management* 1:6- 7, 1999.
411. Wolkowicz PE, Urthaler F, Forrest C, Shen H, Durand J, Wei C-C, Oparil S, and Dell'Italia LJ. 2-Tetradecylglycidic acid, an inhibitor of carnitine palmitoyltransferase-1, induces myocardial hypertrophy via the AT1 receptor. *J Mol Cell Cardiol* 31, 1405-1412 , 1999
412. Oparil S. In memoriam for Harriet Pearson Dustan. *Circulation* 100:2122-2123, 1999.
413. Oparil S. Candesartan cilexetil in combination with low dose hydrochlorothiazide is effective in severe hypertension. *Am J Cardiol* 84:35S-41S, 1999.
414. Dell'Italia LJ, Oparil S. Bradykinin in the heart: friend or foe. *Circulation* 100:2305-2307, 1999.
415. Oparil S, Chen SJ, Chen YF, Durand JN, Allen L, Thompson JA. Estrogen attenuates the adventitial contribution to neointima formation in injured rat carotid arteries. *Cardiovasc Res* 44:608-614, 1999.
416. Su X, Brower G, Janicki JS, Chen YF, Oparil S, Dell'Italia LJ. Differential expression of natriuretic peptides and their receptors in volume overload cardiac hypertrophy in the rat. *J Mol Cell Cardiol* 31:1927-1936, 1999.

417. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. *Circulation* 101: 329-335, 2000.
418. Carretero OA, Oparil S. Essential hypertension. Part II: treatment. *Circulation* 101:446-453, 2000.
419. Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. *Am J Hypertens* 13:18S-24S, 2000.
420. Li G, Chen S, Oparil S, Chen YF, Thompson JA. Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries. *Circulation* 101:1362-1365, 2000.
421. Bakir S, Mori T, Durand J, Chen YF, Thompson JA, Oparil S. Estrogen-induced vasoprotection is estrogen receptor dependent: Evidence from the balloon injured rat carotid artery model. *Circulation* 101:2342-44, 2000.
422. Tumlin J, Dunbar L, Oparil S, Buckalew V, Ram V, Mathur V, Ellis D, McGuire D, Fellmann J, Luther R. Fenoldopam, a Dopamine agonist, for hypertensive emergency: a multicenter randomized trial. *Academic Emergency Medicine* 7:653-62, 2000.
423. Bakir SE, Oparil S. Antihypertensive drug therapy in the third millennium: Are there benefits beyond blood pressure? *Current Hypertension Reports* 2:291-4, 2000.
424. White CR and Oparil S. Estrogen and the vascular injury response. In: Biology of Menopause, Bellino FL (ed), Springer, New York, NY. pp 159-170, 2000.
425. Mori T, Durand J, Chen YF, Thompson JA, Bakir S, Oparil S. Effects of short-term estrogen treatment on the neointimal response to balloon injury of rat carotid artery. *Am J Cardiol* 85: 1276-1279, 2000.
426. Oparil S, Calhoun DA. High blood pressure. *Sci Am Med*, New York: Scientific American, Vol. XXIII, Sect 1, Subsect III; pp1-16, 2000.
427. Li G, Chen YF, Kelpke SS, Oparil S, Thompson JA. Estrogen attenuates integrin- β_3 - dependent adventitial fibroblast migration after inhibition of osteopontin production in vascular smooth muscle cells. *Circulation* 101:2949-2955, 2000.
428. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Faire UD, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H for LIFE Study Group. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy. The LIFE Study. *Am J Hypertens* 13:899-906, 2000
429. Metz JA, Stern JS, Kris-Etherton P, Reusser ME, Morris CD, Hatton DC, Oparil S, Haynes RB, Resnick LM, Pi-Sunyer FX, Clark S, Chester L, McMahon M, Snyder G, McCarron DA. A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients. *Arch Intern Med* 160:2150-2158, 2000.

430. Peng N, Wei CC, Oparil S, Wyss JM. The organum vasculosum of the lamina terminalis regulates noradrenaline release in the anterior hypothalamic nucleus. *Neuroscience* 99:149-156, 2000.
431. Barr SI, McCarron DA, Heaney RP, Dawson-Hughes B, Berga SI, Stern JS, Oparil S. Effects of increased consumption of fluid milk on energy and nutrient intake, body weight, and cardiovascular risk factors in healthy older adults. *J Am Diet Assoc.* 100:810-817, 2000
432. Oparil S, Bakir SE. Les inhibiteurs calciques dans les affections cardiovasculaires. In: Drugs, Zannad F, Girerd X, Weber S (eds), Adis International France, LePecq, France, pp:25-37, 2000.
433. Resnick LM, Oparil S, Chait A, Haynes RB, Kris-Etherton P, Stern JS, Clark S, Holcomb S, Hatton DC, Metz JA, McMahon M, Oi-Sunyer FX, McCarron DA. Factors affecting blood pressure responses to diet: The Vanguard Study. *Am J Hypertens* 13:956-965, 2000.
434. Oparil S, Bakir S. Hypertension and the use of hormone replacement therapy in treated hypertensives. *Menopausal Medicine* 8:8-12, 2000.
435. Chen YF, Oparil S. Endothelial dysfunction in the pulmonary vascular bed. *Am J Med Sci* 320:223-32, 2000.
436. Rosenthal T, Oparil S. Review Article. Hypertension in women. *J of Human Hypertension* 14:691-704, 2000.
437. Calhoun DA, Oparil S. The National Health and Nutrition Examination Survey III: How are we doing with blood pressure control? In: Hypertension Medicine, Weber MA (ed), Humana Press, Totowa, New Jersey, pp 351-365, 2000.
438. Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (Benazepril) with calcium antagonist (either Nifedipine or Amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. *Am J Cardiol* 86:1182-1187, 2000.
439. Calhoun DA, Bakir SE, Oparil S. Etiology and pathogenesis of essential hypertension. In: Cardiology, Crawford MH, DiMarco JP (eds), Mosby International Ltd, London, England, pp 3.1- 3.10, 2000.
440. Oparil S. Management of hypertension. *Clinical Reviews* 80-87, 2000
441. Chen YF, Oparil S. Endothelin and pulmonary hypertension. *J Cardiovasc Pharma* 35:S49-S53, 2000.
442. Tolbert T, Oparil S. Hormone replacement therapy and stroke – Are the results surprising? *Circulation* 103:620-622, 2001.
443. August P, Oparil S. Acute and long-term management of hypertension in nonpregnant women. In: Hypertensive Disorders in Women, Sibai BM (ed), W.B. Saunders Company, Philadelphia, PA, 15:237-254, 2001.

444. Moser M, Cushman W, Oparil S, Glasser S. Treating hypertension in the elderly – whom to treat, when and with what? *J Clin Hypertension* 3:103-109, 2001.
445. Perry GJ, Mori T, Wei CC, Xu XY, Chen YF, Oparil S, Lucchesi P, Dell'Italia LJ. Genetic variation in angiotensin-converting enzyme does not prevent development of cardiac hypertrophy or upregulation of angiotensin II in response to aortocaval fistula. *Circulation* 103:1012-1016, 2001.
446. Oparil S, Aurup P, Snavely D, Goldberg A. Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. *Am J Cardiol* 87:721-726, 2001.
447. Dahlof B, Devereaux R, de Faire U, Fyhrquist F, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. The LIFE Study. Losartan Intervention For Endpoint reduction in hypertension. In: Clinical Trials in the Pharmacological Management of Hypertension, Black HR (ed), Marcel Dekker, Inc., New York, NY, pp. 605-624, 2001.
448. Cheng S, Oparil S. Current concepts in management of essential hypertension. CME monograph. Jointly sponsored by Medical Education Collaborative and Aetna U.S. Healthcare. R. McDonough (ed), 2001.
449. Thakkar RB, Oparil S. Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs. *Clinical Trials Report, Current Hypertension Reports* 3:227-228, 2001.
450. Tolbert T, Oparil S. Cardiovascular effects of estrogen. *Am J Hypertens* 14:186S-193S, 2001.
451. Thakkar, RB, Oparil S. Primary Aldosteronism: A practical approach to diagnosis and treatment. *J Clin Hypertens* 3:189-195, 2001.
452. Sun JZ, Oparil S, Lucchesi P, Thompson JA, Chen YF. Tyrosine kinase receptor activation inhibits NPR-C in lung arterial smooth muscle cells. *Am J Physiol Lung Cell Mol Physiol* 281:L155-L163, 2001.
453. Pool J, Kaihlanen P, Lewis G, Ginsberg D, Oparil S, Glazer R, Messerli FH. Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. *J Human Hypertens* 15:495-498, 2001.
454. Wang J, Chen YF, Oparil S, Cooper MD. Aminopeptidase A(APA/BO01): An immunological overview. IN: S. Mizutani et al (eds), *Cell-Surface Aminopeptidases: Basic and Clinical Aspects*, Elsevier Science B.V. 2001, pp 75-84.
455. Oparil S. Efficacy of perindopril in the treatment of systemic hypertension. *Am J Cardiol* 88:3i-12i, 2001.
456. Thakkar RB and Oparil S. Very-low-dose combination therapy in the new guidelines for the management of hypertension. *Medicographia* 23:250-56, 2001.

457. Dell'Italia LJ, Perry GJ, Oparil S. Angiotensin-converting enzyme ACE clinical and experimental insights. In: Angiotensin-converting Enzyme (ACE) and Chymase in Cardiovascular Disease, T. Giles (ed), Healthcare Communications, Fort Lee, NJ, pp 91-101, 2001.
458. Oparil S, Williams D, Chrysant SG, Marbury TC Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. *J Clin Hypertens* 3:283-91, 2001.
459. Fang, Z, Carlson SH, Chen YF, Oparil S, and Wyss JM. Estrogen depletion induces NaCl-sensitive hypertension in female spontaneously hypertensive rats. *Am J. Physiol Regul Integrative Comp Physiol* 281:R1934-R1939, 2001.
460. Tolbert T, Thompson JA, Bouchard P, Oparil S. Estrogen-induced vasoprotection is independent of inducible nitric oxide synthase expression: evidence from the mouse carotid artery ligation model. *Circulation* 104:2740-2745, 2001.
461. Chrysant GS, Oparil S. Treatment of hypertension in the patient with cardiovascular disease. In: Cardiovascular Therapeutics, a Companion to Braunwald's Heart Disease, 2nd edition, Antman EM (ed), W. B. Saunders, Philadelphia, PA, pp. 768-795, 2001.
462. Sun JZ, Chen SJ, Majid-Hassan E, Oparil S, Chen YF. Dietary salt-supplementation selectively downregulates natriuretic peptide clearance receptor expression in kidney independent of atrial natriuretic peptide. *Am J Physiol Renal Physiol* 282:F220-F227, 2002.
463. Goyal MK, Oparil S. Direct Estrogen Effects on the Cardiovascular System. In: Selective Estrogen Receptor Modulators: Research and Clinical Applications, Manni A and Verderame MF (ed), Humana Press, Totowa, NJ, pp. 99-119, 2002.
464. Franco V, Oparil S. Hormone replacement therapy and hypertension. *Current Opinion in Nephrology and Hypertension* 11:229-235, 2002.
465. Gregory SA, Bakir SE, Oparil S. Failure of antihypertensive treatment in the population. In: Manual of Hypertension, Mancia G, Chalmers J, Julius S, Saruta T, Weber M, Ferrari A, Wilkinson I (ed), Harcourt Publishers, Ltd., London, pp. 643-672, 2002.
466. Oparil S. Are there meaningful differences in blood pressure control with current antihypertensive agents? *Am J Hypertens* 15:14S-21S, 2002.
467. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. *Lancet* 359:995-1003, 2002.
468. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, Faire U, Fyhrquist F, Julius S, Kjeldson SE, Kristiansson K, Lederballe-Pedersen O, Nieminen M, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 359:1004-10, 2002.

469. Carlson, SH, Oparil S, Chen YF, Wyss, JM. Blood pressure and NaCl-sensitive hypertension are influenced by angiotensin-converting enzyme gene expression in transgenic mice. *Hypertension* 39:214-218, 2002.
470. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. *Cardiovas Res* 53: 688-708, 2002.
471. Oparil S, Wang JG, Bakir S, and Staessen JA. New outcome trials of antihypertensive therapy. In: New Frontiers in Hypertension, Kaplan N and Schachter M (ed), Lippincott Williams & Wilkins, London, pp: 61-99, 2002.
472. Bittner V, Oparil S. Hypertension. In: Cardiovascular Health and Disease in Women, Douglas PS (ed), W. B. Saunders, Philadelphia PA., pp: 93-139, 2002.
473. Oparil S. Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists. *J. Human Hypertens* 16:S17-S23, 2002.
474. Oparil S. Do angiotensin receptor antagonists have benefits beyond blood pressure lowering? *Curr Hypertens Rep* 4:219-220, 2002.
475. Rosenthal T, Oparil S. The effect of hypertensive drugs on the fetus. *J Human Hypertens* 16:293-298, 2002.
476. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin system. *Nature Reviews/Drug Discovery* 1:621-636, 2002.
477. Calhoun D, Oparil S. Gender and blood pressure. In: Hypertension Primer, Second Edition, Izzo JL and Black HR (eds), Lippincott, Williams & Wilkins, Baltimore, MD, pp:229-235, 2002.
478. Gregory SA, Oparil S. Systemic Hypertension. In: PanVascular Medicine, Lanzer P and Topal EJ (eds), Springer Verlag Berlin Heidelberg New York, Germany, pp: 1015-64, 2002.
479. Wei CC, Tian B, Perry G, Meng QC, Chen YF, Oparil S, Dell'Italia LJ. Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene. *Am J Physiol Heart Circ Physiol* 282:H2254-H2258, 2002.
480. Thakkar RB and Oparil S. Beyond the monotherapy strategy. IN: New Frontiers in Hypertension, Servier, No. 5, pp 1-4, 2001.
481. Li G, Oparil S, Kelpke SS, Chen YF, Thompson JA. Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. *Circulation* 106:854-859, 2002.
482. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Beevers G, De Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM, Snapinn S. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. *J Hypertens* 20:1879-1886, 2002.

483. Kjeldsen SE, Dahlöf J, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pederson O, Lindholm L, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H, for the LIFE Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. *JAMA* 288:1491-1498, 2002.
484. Ambalavanan N, Philips III JB, Bulger A, Oparil S, Chen YF. Endothelin-A receptor blockade in neonatal porcine pulmonary hypertension. *Pediatr Res* 52:913-921, 2002.
485. Miller AP and Oparil S. Secondary prevention of CHD in women: A call to Action. *Ann Int Med* 138:150-151E, 2002.
486. Zaman MA and Oparil S. Identifying hypertension in postmenopausal women: Understanding the effects of age and sex. *Women Health Primary Care* 5:571-577, 2002.
487. Zaman MA and Oparil S. Options for managing hypertension in postmenopausal women: Consider sex-specific factors when selecting pharmacotherapy. *Women Health Primary Care* 5:651-656, 2002.
- 487a. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 288:2981-2997, 2002.
488. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, Yang Y, Krause SL, Workman D, Saunders E. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white Patients. *J Am Coll Cardiol* 41:1148-55, 2003.
489. Oparil S. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): lessons for clinical practice and health care policy. *Hypertension* 41:1006-1009, 2003.
490. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo, JL Jr, Jones DW, Materson BJ, Oparil S, Wright, JT Jr, and Roccella EJ. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. *JAMA* 289:2560-72, 2003.
491. Calhoun DA, Oparil S. Gender and blood pressure. In: Hypertension Primer, Third Edition. Izzo JL and Black HR (eds), Lippincott, Williams & Wilkins, Baltimore, MD, pp: 253-257, 2003.
492. Feng J-A, Perry G, Mori T, Hayashi T, Oparil S, Chen YF. Pressure independent enhancement of cardiac hypertrophy in atrial natriuretic peptide-deficient mice. *Clin Exp Pharmacol Physiol* 30: 343-9; 2003.
493. Wang D, Oparil S, Feng JA, Peng L, Perry G, Chen LB, Dai M, John SWM, Chen YF. Effects of pressure overload on cardiac gene expression in the atrial natriuretic peptide null mouse. *Hypertension* 42:88-95, 2003.
494. Oparil S, Calhoun DA. High blood pressure. In: *WebMD Scientific American Medicine, 2003 Edition*. Dale DC, Federman DD (eds), WebMD, New York, NY, Vol. 1, pp:195-210.

495. Peng L, Oparil S, Sun J-Z, Thompson JA, Chen YF. Tyrosine kinase receptor activation induces endothelin receptor expression in lung artery smooth muscle cells. *J Appl Physiol* 95:643-651, 2003.
496. Peng N, Chambless BD, Oparil S, Wyss JM. α_{2A} -Adrenergic receptors mediate sympathoinhibitory responses to atrial natriuretic peptide in the mouse anterior hypothalamic nucleus. *Hypertension* 41:571-575, 2003.
497. Devereux RB, Dahlof B, Kjeldsen SE, Julius S, Aurup P, Beevers G, Edelman JM, de Faire U, Fyhrquist F, Berg SH, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H, for the LIFE Study Group. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: A substudy of the LIFE randomized trial. *Ann Intern Med* 139:169-177, 2003.
498. Miller AP, Chen YF, Xing D, Feng W, Oparil S. Hormone replacement therapy and inflammation: interactions in cardiovascular disease. *Hypertension* 42:657-663, 2003.
499. Miller AP, Bouchard P, Oparil S. Preventing CVD in women: Are there gender-related differences with therapeutic implications? IN: Hot Topics in Hypertension: A TRIP with the experts. Egan BM, Basile JN, and Lackland DT (eds.) Hanley & Belfus, Philadelphia, PA, pp. 379-397, 2003.
500. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. *Ann Intern Med* 139:761-776, 2003.
501. Shelton J, Wang D, Gupta H, Wyss JM, Oparil S, White CR. The neointimal response to endovascular injury is increased in obese Zucker rats. *Diabetes, Obesity and Metabolism* 5:415-423, 2003.
502. Calhoun DA, Zaman MA, Oparil S. Etiology and pathogenesis of systemic hypertension. In: Cardiology, Second Edition. Crawford MH, DiMarco JP, and Paulus WJ (eds) Mosby, Philadelphia, PA, pp.463-471, 2003.
503. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ, and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension* 42:1206-1252, 2003.
504. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study. *Ann Intern Med* 139:901-906, 2003.
505. Oparil S. Improving outcomes for women after coronary artery bypass grafting: a case for prevention. *J. Thorac Cardiovasc Surg* 126:1704-1706, 2003.
506. Burgess E, Lacourciere Y, Ruilope LM, Oparil S, Kleinman JH, Krause S, Roniker B, Maurath C. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients

with essential hypertension. *Clin Ther* 25: 2388-2404, 2003.

507. Xing D, Miller AP, Novak L, Rocha R, Chen YF, Oparil S. Estradiol and progestins differentially modulate leukocyte infiltration after vascular injury. *Circulation* 109:234-241, 2004.
508. Oparil S, Wyss JM. The anterior hypothalamus and salt-sensitive hypertension. In: Neural Mechanisms of Cardiovascular Regulation. Dun NJ, Machado BH, and Pilowsky PM (eds). Kluwer Academic Publishers, Norwell, MA, pp. 165-185, 2004.
509. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Srobos N, Clancy CM, Fabunmi RP, Grady D, Haan CK, Hayes SN, Judelson DR, Keenan NL, McBride P, Oparil S, Ouyang P, Oz MC, Mendelsohn ME, Pasternak RC, Pinn VW, Robertson RM, Schenck-Gustafsson K, Sila CA, Smith SC, Sopko G, Taylor A, Walsh BW, Wenger NK, Williams CL. American Heart Association evidence-based guidelines for cardiovascular disease prevention in women expert panel/writing group. *Circulation* 109:672-693, 2004.
510. Mori T, Chen YF, Feng JA, Hayashi T, Oparil S, Perry GJ. Volume overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide knockout mouse. *Cardiovascular Res* 61:771-779, 2004.
511. Hoiegggen A, Alderman MA, Kjeldsen SE, Julius S, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Chen C, Dahlöf B for the LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. *Kidney International* 65:1014-1049, 2004.
512. Reims HM, Kjeldsen SE, Brady WE, Dahlöf B, Devereux RB, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study. *J Hum Hypertens* 18:381-389, 2004.
513. Wyss JM, Carlson SH, Oparil S. The pathogenesis of hypertension: Role of the autonomic nervous system. In: Basic and Clinical Neurocardiology, Armour JA and Ardell JL (eds). Oxford UP, Oxford, UK, pp 368-392, 2004.
514. Franco V, Oparil S, Carretero OA. Hypertensive therapy: part I. *Circulation* 109:2953-2958, 2004.
515. Franco V, Oparil S, Carretero OA. Hypertensive therapy: part II. *Circulation* 109:3081-3088, 2004.
516. Franco V, Oparil S. Women's health- hormone replacement treatment. In: The Year in Hypertension: 2004. Gavras H, ed. Clinical Publishing, Oxford, UK, pp109-134, 2004.
517. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, De Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. *J Hypertens* 22:1805-1811, 2004.
518. Miller AP, Feng W, Xing D, Weathington NM, Blalock JE, Chen YF, Oparil S. Estrogen

modulates inflammatory mediator expression and neutrophil chemotaxis in injured arteries.
Circulation 110:1664-1669, 2004.

519. Li P, Oparil S, Chen YF. Hypoxia-responsive growth factors upregulate periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells. *J Appl Physiol* 97:1550-1558, 2004.
520. Franco V, Chen YF, Oparil S, Feng JA, Wang D, Hage F, Perry GJ. Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling. *Hypertension* 44:746-750, 2004.
521. Oparil S, Li P, Chen YF. Pulmonary vascular remodeling in pulmonary hypertension: evidence from animal models to man IN: The Endothelin System in Cardiopulmonary Diseases. Clozel M and Rubin LJ (eds). FRV, Switzerland, pp.143-158, 2004.
522. Weber M, Basile J, Izzo J, Oparil S. Blood pressure goal attainment: meeting the challenges of JNC7's blood pressure goals and the role of renin-angiotensin-aldosterone system blockade. *J Clin Hypertens* 6:699-705, 2004.
523. Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA, Oparil S. AGE cross-link breakers: a novel approach to cardiovascular pathologies related to the aging process. *Am J Hypertens* 17:23S-30S, 2004.
524. Reims HM, Oparil S, Kjeldsen SE, Devereux RB, Julius S, Brady WE, Fyhrquist F, Ibsen H, Lindholm LH, Omvik P, Wedel H, Beevers G, de Faire U, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Dahlöf B; LIFE Study Group. Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. *Blood Press* 13:376-384, 2004.
- 524a. Calhoun DA, Oparil S. Hypertension and sympathetic nervous system activity. In: Primer on the autonomic nervous system. Second Ed. Robertson D (ed). Elsevier Academic Press London, UK, pp. 241-244, 2004.
- 524b. Os I, Oparil S, Gerds E, Høieggen A. Essential hypertension in women. *Blood Press* 13:272-278, 2004.
525. Kizer JR, Dahlof B, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Wachtell K, Edelman JM, Snapinn SM, Harris KE, Devereux RB. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. *Hypertension* 45:46-52, 2005.
526. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention For Endpoint reduction in hypertension study. *Hypertension* 45:198-202, 2005.
527. Oparil S, Wright JT. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) IN: Hypertension: A Companion to Brenner and Rector's the Kidney, Second Edition, Oparil S and Weber M (eds), Elsevier Saunders, Philadelphia, PA, pp 340-351, 2005.

528. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers DG, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omik P, Oparil S, Wedel H, Edelman JM, Snapinn S, Harris KE, Gleim GW. The LIFE Study. In: Hypertension: A Companion to Brenner and Rector's the Kidney, Second Edition, Oparil S and Weber M (eds), Elsevier Saunders, Philadelphia, PA, pp 352-365, 2005.
529. Oparil S, Miller AP. Gender and blood pressure. *J Clin Hypertens* 7:300-309, 2005.
530. Ambalavanan N, Bulger A, Murphy-Ullrich J, Chen YF, Oparil S. Endothelin-A receptor blockade prevents and partially reverses neonatal hypoxic pulmonary vascular remodeling. *Pediatr Res* 57:1-6, 2005.
531. Kjeldsen SE, Lyle PA, Kizer JR, Dahlof B, Devereux RB, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Ledeballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn SM, Harris KE, Wedel H, for the LIFE Study Group. The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. *J Clin Hypertens* 7:152-158, 2005.
532. Fyhrquist F, Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Ibsen F, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Hille DA, Lyle PA, Edelman JM, Snapinn SM, Wedel H for the LIFE Study Group. Pulse pressure and treatment effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy: the LIFE study. *Hypertension* 45:580-585, 2005.
533. de Simone G, Wachtell K, Palmieri V, Hille DA, Beevers G, Dahlof B, de Faire U, Fyhrquist F, Ibsen H, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Devereux RB. Body build and risk of CV events in hypertension: the LIFE study. *Circulation* 111:1924-1931, 2005.
534. Oparil S, Wright JT. Ethnicity and blood pressure. *J Clin Hypertens* 7:357-364, 2005.
535. Fossum E, Moan A, Kjeldsen SE, Devereux RB, Julius S, Snapinn SM, Edelman JM, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Dahlöf B, for the LIFE study group. Effect of losartan vs. atenolol on cardiovascular morbidity and mortality in patients taking aspirin: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. *J Am Coll Cardiol* 46:770-775, 2005.
536. Wang D, Oparil S, Chen YF, McCrory M, Skibinski GA, Feng W, Szalai AJ. Estrogen treatment abrogates neointima formation in human c-reactive protein transgenic mice. *Atheroscler Thromb Vasc Biol* 25:2094-2099, 2005.
537. Kjeldsen SE, Os I, Hoiieggen A, Beckey K, Gleim GW, Oparil S. Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. *Am J Cardiovasc Drugs* 5:17-22, 2005.

538. Kjeldsen SE, Lyle PA, Terhakovec AM, Devereux RB, Oparil S, Dahlof B, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Wedel H. Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. *Expert Opin Emerging Drugs* 10:729-745, 2005.
539. Moser M, Giles T, Oparil S. Conflicting and confusing data from the hypertension treatment trials: whom and what should you believe? *J Clin Hypertens* 7:403-408, 2005.
540. Miller AP, Bittner VB, Oparil S. Hypertension. In: Women and Heart Disease, Second Edition. Wenger N, and Collins P (eds). Taylor and Francis, London, UK, 2005, pp 441-453.
541. Mishra RG, Stanczyk FZ, Burry KA, Oparil S, Katzenellenbogen B, Nealen ML, Katzenellenbogen J, Hermsmeyer RK. Metabolite ligands of estrogen receptor β reduce primate coronary hyperreactivity. *Am J Physiol Heart Circ Physiol* 290:H295-H303, 2006.
542. Chen YF, Feng JA, Li P, Xing D, Zhang Y, Serra R, Ambalavanan N, Majid-Hassan E, Oparil S. Dominant negative mutation of the TGF-beta receptor blocks hypoxia-induced pulmonary vascular remodeling. *J Appl Physiol* 100:564-571, 2006.
543. Oparil, S. Women's Health: hormone replacement therapy. In: The Year in Hypertension: 2005. Brunner, H, ed. Clinical Publishing, Oxford, UK, pp 197-234, 2006.
544. Mirza MF, Xing D, Chen YF, Oparil S, Miller AP. Proteasomal Inhibition: a novel pathway of atherosclerosis and restenosis. *Vasc Dis Prevent* 3:345-352, 2006.
545. Oparil S, Izzo JL. Pulsology rediscovered: commentary on the Conduit Artery Function Evaluation (CAFÉ) Study. *Circulation* 113:1162-1163, 2006.
546. Julius SE, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH, Leonard D, Messerli FH, Oparil S, Schork MA, for the TROPHY Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. *N Eng J Med* 54:1685-1697, 2006.
547. Oparil S. Clinical Trials Report: The ASCOT Blood Pressure Lowering Trial. *Curr Hypertens Rep* 8:229-231, 2006.
548. Chen YF, Feng JA, Li P, Xing D, Ambalavanan N, Oparil S. Atrial natriuretic peptide-dependent modulation of hypoxia-induced pulmonary vascular remodeling. *Life Sci* 79:1357-1365, 2006.
549. Franco V, Oparil S. Salt sensitivity, a determinant of blood pressure, cardiovascular disease, and survival. *JACN* 25:247S-255S, 2006.
550. Os I, Gudmundsdottir H, Kjeldsen SE, Oparil S. Treatment of isolated systolic hypertension in diabetes mellitus type 2. *Diabetes Obes Metab* 8:381-7, 2006.

551. Piller LB, Ford CE, Davis BR, Nwachuku C, Black HR, Oparil S, Retta TM, Probstfield JL, for the ALLHAT Collaborative Research Group. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *J Clin Hypertens* 8:649-656, 2006.
552. Franco V, Chen YF, Feng JA, Li P, Wang D, Hasan E, Oparil S, Perry GJ. Eplerenone prevents adverse cardiac remodeling induced by pressure overload in atrial natriuretic peptide-null mice. *Clin Experimen Pharmacol Physiol* 33:773-779, 2006.
553. Li G, Oparil S, Sanders JM, Chumley JW, Dai M, Chen LB, Conway SJ, McNamara CA. Phosphatidylinositol-3 kinase signaling mediates expression of periostin in balloon injured rat carotid arteries and vascular smooth muscle cell migration in vitro. *Atherosclerosis* 188:292-300, 2006.
554. Li P, Oparil S, Novak L, Cao X, Shi W, Lucas J, Chen YF. ANP signaling inhibits TGF-beta-induced smad2 and smad3 nuclear translocation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells. *J Appl Physiol* 102:390-398, 2006.
555. Franco V, Oparil S. Is there a new treatment for hypertensive disease in the horizon?: role of soluble guanylate cyclase. *Hypertension* 48: 822-823, 2006.
556. Oparil S. Women and hypertension: what did we learn from the Women's Health Initiative? *Cardiol Rev* 14:267-275, 2006.
557. Neutel JM, Franklin SS, Oparil S, Bhaumik A, Ptasynska A, LaPuerta P. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. *J Clin Hypertens* 8:850-857, 2006.
558. Devereux RB, Beevers G, de Faire U, Edelman JM, Fyhrquist F, Harris KE, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Hille DA, Dahlof B. Blood pressure reduction and antihypertensive medication use in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertension. *Curr Med Res and Opin* 23: 259-270, 2007.
559. Miller AP, Xing D, Feng W, Fintel M, Chen YF, Oparil S. Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries. *Menopause* 14:251-260, 2007. PMID17194962.
560. Franco V, Calhoun DA, Oparil S. Pathophysiology of hypertension. In: Hypertension: A companion to Braunwald's Heart Disease. Black HR and Elliot WJ (eds). Saunders Elsevier, Philadelphia, PA, pp. 25-46, 2006.
561. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, Ganiats TG, Gomes AS, Gornik HL, Gracia C, Gulati M, Haan CK, Judelson DR, Keenan N, Kelepouris E, Michos ED, Newby LK, Oparil S, Ouyang P, Oz MC, Petitti D, Pinn VW, Redberg RF, Scott R, Sherif K, Smith SC Jr, Sopko G, Steinhorn RH, Stone NJ, Taubert KA, Todd BA, Urbina E, Wenger NK. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. *Circulation* 115:1481-1501, 2007.

562. Giles TD, Oparil S, Silfani TN, Wang A, Walker JF, on behalf of the study investigators. Comparison of increasing doses of olmesartan medoximil, losartan potassium, and valsartan in patients with essential hypertension. *J Clin Hypertens* 9:187-195, 2007.
563. Xing D, Feng W, Weathington NM, Miller AP, Chen YF, Novak L, Blalock JE, Oparil S. Estrogen modulates TNF α -induced inflammation in rat aortic SMCs through ER β activation. *Am J Physiol Heart Circ Physiol* 292: H2607-H2612, 2007. PMID17237237.
564. Chrysant G, Oparil S. Treatment of hypertension in the patient with cardiovascular disease. In: Cardiovascular Therapeutics: A companion to Braunwald's Heart Disease. Antman EM (ed). Saunders Elsevier, Philadelphia, PA, pp. 625-646, 2007.
565. Miller AP, Oparil S. Sex steroids and hypertension. In: Hypertension and Hormone Mechanisms, 2nd ed. Carey RM, (ed). Humana: Totowa, New Jersey, pp. 313-340, 2007.
566. Ambalavanan N, Li P, Bulger A, Murphy-Ullrich J, Oparil S, Chen YF. Endothelin-1 mediates hypoxia-induced increases in vascular collagen in the newborn mouse lung. *Pediatr Res* 61: 559-564, 2007.
567. Gaddam KK, Oparil S. Are current guidelines optimal for treatment of blood pressure in patients with coronary artery disease? *Curr Hypertens Rep* 9: 211-212, 2007.
568. Moser M, Oparil S, Cushman W, Papademetriou V. The ALLHAT study revisited: do newer data from this trial and others indicate changes in treatment guidelines? *J Clin Hypertens* 9: 372-380, 2007.
569. Kjeldsen SE, Lyle PA, Kizer JR, Oparil S, Høieggen A, Os I. Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. *Vasc Health Risk Manag* 3:299-305, 2007.
570. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr, Kaplan NM, O'Connor CM, Gara PT, Oparil S. AHA scientific statement: treatment of hypertension in the prevention and management of ischemic heart disease. *Circulation* 115: 2761-2788, 2007.
571. Oparil S, Yarrows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. *Lancet* 370: 221-229, 2007.
572. Hedner T, Kjeldsen S, Narkiewicz K, Oparil S. Blood pressure control – slowly getting there through new strategies? *Editorial*. *Blood Press* 16:68-71, 2007.
573. Oparil S. Does improving hypertension control involve more than just pills? *Nat Clin Pract Cardiovasc Med* 4:182-183, 2007.
574. Rosenthal T, Oparil S. Chpt 70: Oral contraceptives, hormone replacement therapy, and hypertension. In: Comprehensive Hypertension. Lang and Jones (eds). Mosby Elsevier, Philadelphia, PA, pp. 865-882, 2007.
575. Woodham RM, Oparil S. Chpt 86: Fixed low dose antihypertensive therapy. In: Comprehensive Hypertension. Lang and Jones (eds). Mosby Elsevier, Philadelphia, PA, pp. 1061-1073, 2007.

576. Pimenta E, Calhoun DA, Oparil S. Mechanisms and treatment of resistant hypertension. Review Article. *Arq Bras Cardiol* 88:604-613, 2007.
577. Shreenivas S, Oparil S. The role of endothelin-1 in human hypertension. *Clin Hemorheol Microcirc* 37:157-78, 2007.
578. Oparil S. Renin inhibitors in the management of hypertension. Commentary. *J Clin Hypertens* 9:706-707, 2007.
579. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Cofield SS, Oparil S, Calhoun DA. Aldosterone excess and resistance to 24-h blood pressure control. *J Hypertens* 25:2131-2137, 2007.
580. Calhoun DA, Oparil S. Hypertension and sympathetic nervous system activity. In: Autonomic Neuroscience Jiritsu-Shinkei-Gaku (Japanese translation of Primer on the Autonomic Nervous System, Robertson D, Biaggioni I, Burnstock G, and Low PA, editors. 2nd English Edition, 2004) Takahashi A, Mano T, translators, Tokyo: Elsevier 2007. ISBN-13:978-4860348656.
581. Kjeldsen SE, Oparil S, Narkiewicz K, Hedner T. Ambulatory blood pressure adds to explaining benefits of AT-1 receptor blockade in the treatment of left ventricular hypertrophy. *Editorial*. *Blood Press* 16:344-346, 2007.
582. Narkiewicz K, Kjeldsen SE, Oparil S, Hedner T. Hypertension and cardiovascular disease: is arterial stiffness the heart of the matter? *Editorial*. *Blood Press* 16:236-237, 2007.
583. Hedner T, Narkiewicz K, Kjeldsen SE, Oparil S. New ESH/ESC guidelines signal progress in hypertension management. *Editorial*. *Blood Press* 16:132-134, 2007.
- 583a. Giles T., Oparil S, Pickering T. Where are we going? Beyond JNC 7. *Prev Cardiol* 10:222-227, 2007.
584. Li P, Wang D, Lucas J, Oparil S, Xing D, Cao X, Novak L, Renfrow MB, Chen Y. Atrial natriuretic peptide inhibits transforming growth factor β -induced smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. *Circ Res* 102:185-192, 2008. PMID: 17991884
585. Ambalavanan N, Nicola T, Li P, Bulger A, Murphy-Ullrich J, Oparil S, Chen YF. Role of matrix metalloproteinase-2 in newborn mouse lungs under hypoxic conditions. *Pediatr Res* 63:26-32, 2008. PMCID: PMC2517580.
586. Xing D, Hage FG, Chen YF, McCrory MA, Feng W, Skibinski GA, Majid-Hassan E, Oparil S, Szalai AJ. Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (Fc γ RI)-dependent. *Am J Pathol* 172:22-30, 2008. PMCID: PMC2189617.
587. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta ES, Aban I, Oparil S, Calhoun D. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. *Arch Intern Med* 168:1159-1164, 2008. PMCID:PMC2748247.

588. Pimenta E, Oparil S. Chapter B82: Gender and blood pressure. Hypertension in special populations. In: Hypertension Pimer, Fourth Edition. Izzo JL, Jr., Black HR, and Sica DA (eds). Lippincott, Williams & Wilkins, Philadelphia, PA., pp 269-273, 2008.
589. Pimenta E, Gaddam KK, Oparil S. Mechanisms and treatment of resistant hypertension. *J Clin Hypertens* 10:239-244, 2008. PMID: 18326968.
590. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, Calhoun DA. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. *Hypertension* 51:339-344, 2008. PMID: 18086955.
591. Os I, Franco V, Kjeldsen SE, Manhem K, Devereux RB, Gerds E, Hille DA, Lyle PA, Okin PM, Dahlof B, Oparil S. Effects of losartan in women with hypertension and left ventricular hypertrophy results from the Losartan Intervention For Endpoint reduction in hypertension study. *Hypertension* 51:1103-1108, 2008. PMID: 18259029.
592. Oparil S, Abate N, Chen E, Creager MA, Galet V, Jia G, Julius S, Lerman A, Lyle PA, Pool J, Tershakovec. A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension. *Curr Med Res Opin* 24:1101-1114, 2008. PMID: 18328120.
593. Carter BL, Einhorn PT, MD, Brands M, He J, Cutler JA, Whelton PK, Bakris GL, Brancati FL, Cushman WC, Oparil S, MD, Wright JT Jr; working group from the National Heart, Lung, and Blood Institute. Thiazide-induced dysglycemia: call for research from a working group from the National Heart, Lung, and Blood Institute. *Hypertension* 52:30-36, 2008. PMID: 18504319.
594. Guimbellot JS, Fortenberry JA, Siegal GP, Moore B, Wen H, Venglarik C, Chen YF, Oparil S, Sorscher EJ, Hong JS. Role of oxygen in cystic fibrosis transmembrane conductance regulator expression and function. *Am J Respir Cell Mol Biol* 39: 514-21, 2008. PMCID: PMC2574524.
595. Ambalavanan N, Nicola T, Hagood J, Bulger A, Serra R, Murphy-Ullrich J, Oparil S, Chen YF. Transforming growth factor-beta signaling mediates hypoxia-induced pulmonary arterial remodeling and inhibition of alveolar development in newborn mouse lung. *Am J Physiol Lung Cell Mol Physiol* 295:L86-95, 2008. PMCID: PMC24947779.
596. Pimenta E, Oparil S. Beyond brachial pressure effect. *Curr Hypertens Rep* 10:213-215, 2008. PMID: 18765092.
597. Xing D, Feng W, Nöt LG, Miller AP, Zhang Y, Chen YF, Majid-Hassan E, Chatham JC, Oparil S. Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury. *Am J Physiol Heart Circ Physiol* 295:H335-H342, 2008. PMCID: PMC2494765.
598. Pratt-Ubunama M, Oparil S. Thiazide and loop diuretics. In: Clinical Pharmacology and Therapeutics of Hypertension. Birkenhager WH and Reid JL (eds). Elsevier, Edinburgh, UK. pp 87-118, 2008.
599. Pimenta E, Oparil S. Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination. *Vasc Health Risk Manag* 4: 653-64, 2008. PMCID: PMC2515425.

600. Kjeldsen SE, Oparil S, Narkiewicz K, Hedner T. A stunning day in hypertension research – Results of ONTARGET, ACCOMPLISH and HYVET. *Editorial*. *Blood Press* 17:68-69, 2008. PMID: 18568694.
601. Hedner T, Kjeldsen SE, Narkiewicz K, Oparil S. Urgent need to address quality control issues of out-of-office blood pressure measurement and patient risk assessment. *Editorial*. *Blood Press* 17: 5-6, 2008. PMID: 18568686.
602. Biederman RW, Doyle M, Young AA, Devereux RB, Kortright E, Perry G, Bella JN, Oparil S, Calhoun D, Pohost GM, Dell'Italia L. Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients. A losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy. *Hypertension* 52:279-286, 2008. PMID: PMC2693884.
603. Pimenta E, Oparil S. Should we prefer different drugs to treat hypertension in older and younger adults? – practical implications of clinical trials. *Pol Arch Med Wewn* 118:508-512, 2008. PMID: 18846986.
604. Gaddam KK, Oparil S. Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients? *Curr Opin Nephrol Hypertens* 17:484-490, 2008. PMID: 18695389.
605. Pimenta E, Oparil S. Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering? *Cardiol Clin* 26:527-535, 2008. PMID: 18929229.
606. Oparil S, Chrysant S, Kereiakes D, Xu J, Chavanu K, Wawerczak W, Dubiel R. Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients. *J Clin Hypertens* 10:911-921, 2008. PMID: 19120717.
607. Kjeldsen S, Weber M, Oparil S, Jamerson K. Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective. *Blood Press* 17:260-269, 2008. PMID: 19061055.
608. Yarows SA, Oparil S, Patel S, Fang H, Zhang J. Aliskiren and valsartan in stage 2 hypertension: A subgroup analysis of a randomized, double-blind study. *Adv Ther* 25:1288-1302, 2008. PMID: 19066757.
- 608a. Narkiewicz K, Oparil S, Kjeldsen S, Hedner T. Benefits of hypertension management in diabetes: an opportunity not to be missed. *Blood Press* 17:248-249, 2008. PMID: 19085534.
- 608b. Kjeldsen SE, Hedner T, Narkiewicz K, Oparil S. More is less? Optimal combination therapy for adequate blood pressure lowering in hypertension. *Blood Press* 17:132-133, 2008. PMID: 18665471.
609. Laczy B, Hill BG, Wang K, Paterson AJ, White CR, Xing D, Chen Y, Darley-Usmar V, Oparil S, Chatham JC. Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. Review article. *Am J Physiol Heart Circ Physiol* 296:H13-H28, 2009. PMID: PMC2637779.
610. Gaddam KK, Oparil S. Diastolic dysfunction and heart failure with preserved ejection fraction: rationale for RAAS antagonist/CCB combination therapy. *J Am Soc Hypertens* 3:52-68, 2009.

611. Pimenta E, Calhoun D, Oparil S. Sleep apnea, aldosterone, and resistant hypertension. *Prog Cardiovasc Dis* 51:371-380, 2009. Review Article. PMID: 19249443.
612. Xing D, Nozell S, Chen Y, Hage F, Oparil S. Estrogen and mechanisms of vascular protection. *Arterioscler Thromb Vasc Biol* 29:289-295, 2009. PMCID: PMC2700771.
613. Oparil, S. Hormone therapy of premature ovarian failure: the case for "natural" estrogen. *Hypertension* 53:745-746, 2009. PMID: 19332657.
614. Oparil S, Weber M. Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy. *Postgrad Med* 121:25-39, 2009. PMID: 19332960.
615. Nicola T, Hagood J, James M, MacEwen M, Williams T, Hewitt M, Schwiebert L, Bulger A, Oparil S, Chen Y, Ambalavanan N. Loss of Thy-1 inhibits alveolar development in the newborn mouse lung. *Am J Physiol Lung Cell Mol Physiol* 296:L738-L750, 2009. PMCID: PMC2681351.
616. Zanchetti A, Mancia G, Black H, Oparil S, Waeber B, Schmieder, R, Bakris G, Messerli, F, Ruilope L. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. *J Hypertens* 27:673-679, 2009. PMID: 19516168.
617. Pimenta E, Oparil S. Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. *Vasc Health Risk Manag* 5:453-463, 2009. PMCID: PMC2686262.
618. Olsen MH, Wachtell K, Beevers G, Dahlöf B, de Simone G, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Lyle PA, Nieminen MS, Omvik P, Oparil S, Wedel H. Losartan has positive effects compared with atenolol on lipid metabolism in patients with hypertension and left ventricular hypertrophy: the LIFE study. *J Hypertens* 27:567-574, 2009. PMID: 19262226.
619. Olsen MH, Wachtell K, Beevers G, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Narayan P, Nieminen MS, Omvik P, Oparil S, Wedel H. Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. *Am Heart J* 157:177-184, 2009. PMID: 19081416.
620. Pimenta E, Gaddam KK, Husain S, Aban I, Oparil S, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. *Hypertension* 54:475-481, 2009. PMCID: PMC2771382.
621. Kjeldsen S, Oparil S, Hedner T, Narkiewicz K. Does GISSI-AF change the concept of using RAS inhibitors in the primary prevention of atrial fibrillation in hypertensive patients? *Blood Press* 29:1-2, 2009. PMID: 19484619.
622. Wright JT Jr, Probstfield JL, Cushman WC, Pressel S, Cutler JA, Davis BR, Einhorn PT, Rahman M, Whelton PK, Ford CE, Haywood LJ, Margolis K, Oparil S, Black HR, Alderman MH for the ALLHAT Collaborative Research Group. ALLHAT findings revisited in the context of subsequent analyses, other trials and meta-analyses. *Arch Intern Med* 169:832-842, 2009. PMCID: PMC2803011.

623. Oparil S, Kjeldsen SE, Hedner T, Narkiewicz K. ONTARGET, TRANSCEND and PROFESS – clarifying, confusing and misleading? *Blood Press* 18:4-6, 2009. PMID: 19191085.
624. Pimenta E, Oparil S. Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. *Ther Clin Risk Manag* 5:459-464, 2009. PMID: PMC2701487.
625. Chrysant SG, Oparil S, Melino M, Karki S, Lee J, Heyrman R. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. *J Clin Hypertens* 11:475-482, 2009. PMID: 19751459.
626. Hassanein AH, Desai A, Verma A, Oparil S, Izzo J, Rocha RA, Hilker R, Seifu Y, Pitt B, Solomon SC. EXCEED: Exforge[®]-intensive control of hypertension to evaluate efficacy in diastolic dysfunction: study rationale, design, and participant characteristics. *Ther Adv Cardiovasc Dis* 3:429-439, 2009. PMID: 19638366.
627. Peti-Peterdi J, Navar LG, Bell PD, Casellas D, Carmines PK, Inscho EW, Oparil S. A true champion of Hungarian kidney research and nephrology education – Tribute to László Rosivall. *Acta Physiol Hung* 96:375-382, 2009.
628. Acelajado MC, Oparil S. Hypertension in the elderly. *Clin Geriatr Med* 25:391-412, 2009. Review. PMID: 19765488.
629. Pimenta E, Calhoun D, Oparil S. Etiology and Pathogenesis of Systemic Hypertension. In: Cardiology. 3rd Ed. Crawford MH, DiMarco JP, Paulus WJ (Eds). Philadelphia, PA: Elsevier Ltd., pp 511-522, 2009.
630. Pimenta E, Oparil S. JNC 7 and ALLHAT: Guidelines/Changes in American and European Guidelines. In: Atlas of Hypertension, 6th Edition. Hollenberg N.K. (ed), Current Medicine Group LLC, Philadelphia PA, pp 321-327, 2009.
631. Neutel J, Franklin S, Bhaumik A, Lapuerta P, Oparil, S. Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide as initial treatment for rapid control of severe hypertension. *Clin Exp Hypertens* 31:572-584, 2009.
632. Oparil S, Lee J, Karki S, Melino M. Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. *J Cardiovasc Pharmacol* 54:427-436, 2009. PMID: 19730391.
633. Giles TD, Oparil S, Wang A, Dubiel R. An evaluation of the efficacy of olmesartan medoxomil in Black patients with hypertension. *J Am Soc Hypertens* 3:395-402, 2009.
634. Kjeldsen SE, Hille DA, Lyle PA, Julius S, Dahlöf B, Devereux RB, Snapinn SM, de Faire U, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H for the LIFE Study Group. Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy. The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study. *Blood Press* 18:348-361, 2009.
635. Kjeldsen SE, Oparil S, Narkiewicz K, Hedner T. Should we treat prehypertension? *Blood Press* 18:298-299, 2009.

636. Acelayado MC, Calhoun DA, Oparil S. Reduction of blood pressure in resistant hypertension patients. *Review Expert Opin Pharmacother* 10:2959-2971, 2009.
- 636a. Hedner T, Oparil S, Narkiewicz K, Kjeldsen S. The J-curve phenomenon revisited. *Blood Press* 18:167-170, 2009.
- 636b. Hedner T, Narkiewicz K, Oparil S, Kjeldsen S. Critical aspects in hypertension diagnosis and treatment. *Blood Press* 18(Suppl 1):3-4, 2009.
637. Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA. Spironolactone reduces severity of obstructive sleep apnea in patients with resistant hypertension: A preliminary report. *J Hum Hypertens* 24:532-537, 2010. PMID:PMC2891919.
638. Solomon S, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, Lacourciere Y, Lee J, Seifu Y, Hilkert R, Rocha R, Pitt B, (EXCEED) Investigators. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. *Hypertension* 55:241-248, 2010.
639. Oparil S, Pimenta E. Efficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or gender. *J Clin Hypertens (Greenwich)* 12:3-13, 2010. PMID: 20047622.
640. Lucas J, Zhang Y, Li P, Gong K, Miller A, Hassan E, Hage F, Xing D, Wells B, Oparil S, Chen YF. Inhibition of Transforming Growth Factor (TGF)- β signaling induces left ventricular dilation and dysfunction in the pressure overloaded heart. *Am J Physiol Heart Circ Physiol* 298:H424-H432, 2010. PMID: PMC2822586.
641. Oparil S, Chrysant S, Melino M, Lee J, Karki S, Heyrman R. Long-term efficacy of a combination of amlodipine and olmesartan medoxomil +/- hydrochlorothiazide in patients with hypertension stratified by age, race, and diabetes status: A substudy of the COACH trial. *J Hum Hypertens* 24:831-838, 2010. PMID: PMC2990108.
642. Hedner T, Kjeldsen S, Narkiewicz K, Oparil S. Hypertension research in the new millenium. *Blood Press* 19:1-2, 2010. *Editorial*.
643. Feng W, Xing D, Hua P, Zhang Yun, Chen YF, Oparil S, Jaimes E. The transcription factor ETS-1 mediates pro-inflammatory responses and neointima formation in carotid artery endoluminal vascular injury. *Hypertension* 55:1381-1388, 2010. PMID: PMC2963081.
644. Gonzaga C, Gaddam K, Ahmed M, Pimenta E, Thomas SJ, Harding S, Oparil S, Cofield S, Calhoun, D. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. *J Clin Sleep Med* 6:363-368, 2010. PMID: PMC2919667.
645. Oparil S. A STITCH saves time and lowers blood pressure. *Curr Hypertens Rep* 12:146-148, 2010. *Editorial*.

646. Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, Inusah S, Gupta H, Lloyd SG, Oparil S, Husain A, Dell'Italia LJ, Calhoun DA. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism – a prospective clinical study. *Hypertension* 55:1137-1142, 2010. PMID: PMC2864599.
647. Hage F, Oparil S, Xing D, Chen YF, McCrory M, Szalai AJ. C-reactive protein mediated vascular injury requires complement. *Arterioscler Thromb Vasc Biol* 30:1189-1195, 2010. PMID: PMC2897052.
648. Pimenta E, Calhoun DA, Oparil S. Hypertensive Emergencies. In: Cardiac Intensive Care. 2nd Ed. Jeremias A, Brown DL (Eds). Philadelphia, PA: Saunders-Elsevier Inc., pp 355-367, 2010.
649. Ruilope L, Izzo J, Haller H, Waeber B, Oparil S, Weber M, Bakris G, Sowers J. Prevention of microalbuminuria in patients with type 2 diabetes: What do we know? *J Clin Hypertens* 12:422-430, 2010.
650. Kjeldsen S, Hedner T, Narkiewicz K, Oparil S. *Blood Pressure* celebrates 20-years of dedication to Nordic hypertension research. *Blood Press* 19:130-131, 2010. *Editorial*.
651. Pimenta E, Oparil S. Prehypertension: Epidemiology, consequences and treatment. *Nat Rev Nephrol* 6:21-30, 2010.
652. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine, besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. *Clin Ther* 32:1252-1269, 2010. PMID: 20678674.
653. Mansur S, Hage F, Oparil S. Have the Renin-Angiotensin-Aldosterone System Perturbations in Cardiovascular Disease Been Exhausted? *Curr Cardiol Rep* 12:450–463, 2010. Review. PMID: 20827517.
654. Pimenta E, Oparil S. Impact of olmesartan on blood pressure, endothelial function and cardiovascular outcomes. *Integrated Blood Pressure Control* 3:113–123, 2010. PMID: PMC3172062.
655. Pimenta E, Oparil S. Hypertension in Women (Hipertensión en la mujer). In: Tratado De Mecánica Vascul ar E Hipertensión Arterial. Esper R (Ed). Buenos Aires, República Argentina: Inter-Médica S.A.I.C.I., pp 679-686, 2010.
656. Asmar R, Oparil S. Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/ HCTZ combination therapy: Impact of age and gender. *Clin Exp Hypertens* 32:499-503, 2010. PMID: 21091220.

657. Hedner T, Oparil S, Narkiewicz K, Os I. Cardiovascular risks in HIV patients. *Blood Press* 19:325-327, 2010. *Editorial*.
658. Kjeldsen S, Hedner T, Oparil S, Narkiewicz K. Angiotensin receptor blockers and cancer – relationship dismissed by VALUE data while waiting for EMA and FDA reports. *Blood Press* 19:271-272, 2010. *Editorial*.
- 658a. Oparil S, Kjeldsen S, Narkiewicz K, Hedner T. Blood pressure variability: Emerging role in risk assessment and therapeutics. *Blood Press* 19:209-11, 2010. *Editorial*.
- 658b. Hedner T, Kjeldsen S, Narkiewicz K, Oparil S. Blood pressure and migration. *Blood Press* 19:65-66, 2010. *Editorial*.
659. Appel LJ, Giles TD, Black HR, Izzo JL Jr, Materson BJ, Oparil S, Weber MA. ASH position paper: dietary approaches to lower blood pressure. *J Am Soc Hypertens* 4:79-89, 2010. *ASH Position Paper*.
660. Pickering TG, White WB, Giles TD, Black HR, Izzo JL, Materson BJ, Oparil S, Weber MA. When and how to use self (home) and ambulatory blood pressure monitoring. *J Am Soc Hypertens* 4:46-61, 2010. *ASH Position Paper*.
661. Oparil S. Hypertension in 2010: New challenges in blood pressure goals and assessment. *Nat Rev Cardiol* 8:74-75, 2011. Review. PMID: 21270846.
662. Muntner P, Shimbo D, Tonelli M, Reynolds K, Arnett D, Oparil S. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988-1994. *Hypertension* 57:160-166, 2011. PMID:21200000.
663. Oparil S, Giles T, Ofili, Pitt, Seifu Y, Samuel R, Hilkert R, Sowers R. Moderate vs intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. *J Hypertens* 29:161-170, 2011. NIHMSID:472386.
664. Chrysant SG, Izzo J, Kereaikis D, Littlejohn T, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Efficacy and safety of triple combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in patients with hypertension and diabetes: A subpopulation analysis of the TRINITY Study. *J Am Soc Hypertens* 6(2):132-141, 2012. 2011 Oct 25. [Epub ahead of print]. PMID: 22030597.
665. Mosca L, Benjamin E, Berra K, Bezanson J, Dolor R, Lloyd-Jones D, Newby LK, Pina I, Roger V, Shaw L, Zhao D, on behalf of the AHA Executive Writing Committee and Expert Panel Members. Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update: A guideline from the American Heart Association. *Circulation* 123:1243-1262, 2011. PMID: PMC3182143.
666. Kjeldsen S, Hedner T, Narkiewicz K, Oparil S. Treatment of high blood pressure in acute stroke – The SCAST study. *Blood Press* 20:67-68, 2011. *Editorial*.

667. Giles T, Oparil S, Ofili E, Pitt B, Purkayastha D, Hilkert R, Samuel R, Sowers J. The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. *Blood Press Monit* 16:87-95, 2011. PMID: 21386706.
668. Ofili E, Oparil S, Giles T, Pitt B, Purkayastha D, Hilkert R, Samuel R, Sowers J. Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups. *J Am Soc Hypertens* 5:249-258, 2011. PMID: 21482217.
669. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forciea MA, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *J Am Coll Cardiol* 57:2037-2114, 2011. PMID: 21524875.
- 669a. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forciea MA, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *J Am Soc Hypertension* 5:259-352, 2011. PMID: 21771565.
- 669b. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Forciea MA, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. *Circulation* 123:2434-2506, 2011. PMID: 21518977.
670. Pisoni R, Acelajado M, Cartmill F, Dudenbostel T, Dell'Italia LJ, Cofield S, Oparil S, Calhoun D. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. *J Human Hypertens Epub* 2011 Jun 16. doi:10.1038/jhh.2011.60. 2012 Aug; 26(8):502-6. PMID: 21677673.
671. Hage F, Mansur S, Oparil S. Rationale for the use of multiple blockers of the renin-angiotensin-aldosterone system in specific patient populations. *Therapy* 8:227-236, 2011. Review.
672. Piller LB, Baraniuk S, Cushman W, Cuyjet AB, Dart RA, Davis BR, Einhorn P, Ford C, Furberg C, Graumlich J, Jafri S, Massie B, Oparil S, Parish D, Probstfield JL, Retta TM, Saklayen MG, Simpson L, Thadhani U, for the ALLHAT Collaborative Research Group. Long-term follow-up of participants with heart failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Circulation* 124:1811-1818, 2011. PMID: 21969009. [NCT00000542]. PMCID: PMC3217334.
673. Gong K, Chen YF, Li P, Lucas J, Zhang W, Hage F, Yang Q, Nozell S, Oparil S, Xing D. Transforming growth factor (TGF)- β 1 inhibits myocardial PPAR γ expression in overload-induced cardiac fibroblasts and remodeling in mice. *J Hypertens* 29:1810-1819, 2011. PMCID: PMC3325019.

674. Nicola T, Ambalavanan N, Zhang W, James M, Rehan V, Halloran B, Olave N, Bulger A, Oparil S, Chen YF. Hypoxia-induced inhibition of lung development is attenuated by the peroxisome proliferator-activated receptor- γ agonist rosiglitazone. *Am J Physiol Lung Cell Mol Physiol* 301:L125-L135, 2011. PMID: PMC3129902.
675. Oparil S. Can catheter-based renal denervation be used safely and effectively to substantially reduce blood pressure in treatment-resistant hypertensive patients? *Curr Cardiol Rep* 13:478-480, 2011. PMID: 21845443.
676. Shah A, Lam C, Cheng S, Verma A, Desai A, Rocha R, Hilkert R, Izzo J, Oparil S, Pitt B, Thomas J, Zile M, Aurigemma G, Solomon SD. The relationship between renal impairment and left ventricular structure, function, and ventricular-arterial interaction in hypertension. *J Hypertens* 29:1829-1836, 2011. PMID: 21799444.
677. Kjeldsen S, Oparil S, Narkiewicz K, Hedner T. High mortality explained by mildly elevated blood pressure in Scandinavian adolescent conscripts – a plea for early drug treatment? *Blood Press* 20:188-189, 2011. *Editorial*. PMID: 21780952.
678. Hedner T, Narkiewicz K, Kjeldsen S, Oparil S. Antihypertensive therapy and cancer risks? *Blood Press* 20:127-128, 2011. *Editorial*. PMID: 21599451.
679. Gong K, Xing D, Li P, Hilgers R, Hage F, Oparil S, Chen YF. cGMP inhibits TGF- β signaling by sequestering Smad3 with cytosolic β 2-tubulin in pulmonary artery smooth muscle cells. *Mol Endocrinol* 25:1794-1803, 2011. PMID: PMC3182417.
680. Oparil S, Narkiewicz K, Kjeldsen S, Hedner T. Renal Nerve Ablation: Emerging Role in Therapeutics. *Blood Press* 20:253-255, 2011. *Editorial*. PMID: 21905971.
681. Gong K, Li P, Xing D, Aksut B, Ambalavanan N, Yang Q, Nozell S, Oparil S, Chen YF. Hypoxia induces downregulation of PPAR γ in isolated pulmonary arterial smooth muscle cells and in rat lung via transforming growth factor- β signaling. *Am J Physiol Lung Cell Mol Physiol* 301:L899-L907, 2011. PMID: PMC3233825.
682. Muntner P, Joyce C, Levitan E, Hold E, Shimbo D, Webber L, Oparil S, Re R, Krousel-Wood M. Reproducibility of visit-to-visit variability using blood pressure measured as part of routine clinical care. *J Hypertens* 29:2332-2338, 2011. PMID: 22025235.
683. Xing D, Gong K, Feng W, Nozell S, Chen YF, Chatham JC, Oparil S. O-GlcNAc modification of NF κ B p65 inhibits TNF- α -induced inflammatory mediator expression in rat aortic smooth muscle cells. *PLoS One* 6:e24021, 2011. PMID: PMC3164132.
684. Bowling M, Oparil S, Hage F, Hilgers R, Xing D. Sex Hormones and Vascular Function, In: Sex Hormones, Prof. Raghendra Dubey (Ed.), Rijeka, Croatia: InTech, 8 February 2012. DOI: 10.5772/38940. <http://www.intechopen.com/books/sex-hormones/sex-hormones-and-vascular-function>. ISBN: 978-953-307-856-4.
685. Hedner T, Narkiewicz K, Oparil S, Kjeldsen S. An appropriate SCORE to assess cardiovascular risk in hypertension? *Blood Press* 20:320-321, 2011. *Editorial*.

686. Izzo J, Chrysant C, Kereiakes D, Littlejohn T, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. 24-hour efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: The TRINITY ambulatory blood pressure substudy. *J Clin Hypertens (Greenwich)* 13:873–880, 2011. PMID: 22142346.
687. Acelajado MC, Calhoun DA, Oparil S. Pathogenesis of hypertension, In: Hypertension: A Companion to Braunwald's Heart Disease, 2nd Ed. (Black H, Elliott W Eds). Saunders Elsevier, Philadelphia, PA, pp 12-26, 2012. ISBN: 978-1-4377-2766-1.
688. Hage F, Mansur SJ, Oparil S (2012). Chapter 5: RAAS Inhibitors in Combination Therapy, In: *Renin–Angiotensin Blockade*. Future Science Group. doi:10.2217/EBO.11.275. pp. 53-64 (Future Medicine Group).
689. Acelajado MC, Pisoni R, Dudenbostel T, Oparil S, Calhoun DA, Glasser SP. Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients. *J Am Soc Hypertens* 6:66-72, 2012. PMID: 22024668.
690. Barzilay J, Baimbridge C, Davis B, Pressel S, Cutler J, Einhorn P, Black H, Cushman W, Ford C, Kostis J, Margolis K, Moloo J, Oparil S, Piller L, Simmons D, Sweeney M, Whelton P, Wong N, Wright J, for the ALLHAT Collaborative Research Group. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Diabetes Extension Study. *Circ Cardiovasc Qual Outcomes* 5:153-162, 2012. PMCID: PMC3359874.
691. Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B, Cofield S, Oparil S, Calhoun DA. Refractory hypertension: Definition, prevalence and patient characteristics. *J Clin Hypertens (Greenwich)* 14:7-12, 2012. PMCID:PMC3400427.
692. Olave N, Nicola T, Zhang W, Bulger A, James M, Oparil S, Chen YF, Ambalavanan N. Transforming growth factor-beta regulates endothelin-1 signaling in the newborn mouse lung during hypoxia exposure. *Am J Physiol Lung Cell Mol Physiol* 302:L857-L865, 2012. PMCID:PMC3362161.
693. Acelajado MC and Oparil S. Antiplatelet therapy for transient ischemic attack. *J Clin Hypertens* 14:103-111, 2012. PMID: 22277143.
694. Kereiakes DJ, Chrysant S, Izzo J, Littlejohn T, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide for hypertension. *J Clin Hypertens (Greenwich)* 14:149-157, 2012.
695. Kjeldsen S, Hedner T, Narkiewicz K, Oparil S. Increased time varying heart rate and cardiovascular risk in hypertension – benefit of selective I_f channel inhibitor? *Blood Press* 21:1-2, 2012. *Editorial*.

696. Cushman WC, Davis BR, Pressel S, Cutler J, Einhorn PT, Ford CE, Oparil S, Probstfield JL, Whelton PK, Wright JT, Alderman MH, Basile JN, Black HR, Grimm RH, Hamilton BP, Haywood LJ, Ong ST, Piller LB, Simpson LM, Stanford C, Weiss RJ, for the ALLHAT Collaborative Research Group. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *J Clin Hypertens* 14:20-31, 2012. PMID: PMC3261592.
697. Muntner P, Levitan E, Reynolds K, Mann D, Tonelli M, Oparil S, Shimbo D. Within-visit variability of blood pressure and all-cause and cardiovascular mortality among US adults. *J Clin Hypertens* 14:165-171, 2012.
698. Pimenta E, Oparil S. Renal sympathetic denervation for treatment of hypertension. *Curr Treat Options Cardiovasc Med* 14 (2):127-135, 2012. PMID: 22294071
699. Xing D, Li P, Gong K, Yang Z, Yu H, Hage F, Oparil S, Chen YF. Endothelial cells overexpressing interleukin-8 (IL8) receptors reduce inflammatory and neointimal responses to arterial injury. *Circulation* 125:1533-1541, 2012. PMID: PMC3685282.
700. Pimenta E, Oparil S. Management of hypertension in the elderly. *Nat Rev Cardiol* 9:286-296, 2012.
701. Alderman MH, Piller L, Ford C, Probstfield J, Oparil S, Cushman W, Einhorn P, Franklin S, Papademetriou V, Ong S, Eckfeldt J, Furberg C, Calhoun D, Gauer E, Davis B, for the ALLHAT Collaborative Research Group. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in ALLHAT: A randomized controlled trial. *Hypertension* 59:926-933, 2012.
702. Rahman M, Ford C, Cutler J, Davis B, Piller L, Whelton P, Wright J, Barzilay J, Brown C, Colon P, Fine L, Grimm R, Gupta AK, Haywood J, Henriquez M, Ilamaythi E, Oparil S, Preston R, for the ALLHAT Collaborative Research Group. Long-term renal and cardiovascular outcomes in ALLHAT participants by baseline estimated GFR: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Clin J Am Soc Nephrol* 7:989-1002, 2012. PMID: PMC3362309.
703. Chrysant S, Littlejohn T, Izzo J, Kereiakes DJ, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: The TRINITY randomized, double-blind, 12-week, parallel-group study. *Am J Cardiovasc Drugs* 12:233-43, 2012. PMID: 22799613.
704. Xing D, Oparil S, Gong K, Chen YF, Feng W, Nozell S. Estrogen modulates NF κ B signaling by enhancing I κ B α levels and blocking p65 binding at the promoters of inflammatory genes through estrogen receptor- β . *PLoS One* 7:e36890, 2012. PMID: PMC3378567.
705. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack J, Katzen B, Leon MB, Massaro J, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend R, Bakris G. Catheter-based renal denervation for resistant hypertension: Rationale and design of the SYMPPLICITY Hypertension-3 Trial. *Clin Cardiol* 35:528-35, 2012.

706. Hilgers RHP, Xing D, Gong K, Chen YF, Chatham JC, Oparil S. Acute O-GlcNAcylation prevents inflammation-induced vascular dysfunction. *Am J Physiol Heart Circ Physiol* 303:H513-H522, 2012. PMID:PMC3468474.
707. Hilgers RHP, Oparil S, Wouters W, Bennink HC. Vasorelaxing effects of estetrol (E₄) in rat arteries. *J Endocrinol* 215:97-106, 2012.
708. Lam C, Shah AM, Borlaug BA, Cheng S, Verma A, Izzo J, Oparil S, Aurigemma GP, Thomas JD, Pitt B, Zile MR, Solomon SD. Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling and efficiency. *Eur Heart J* 34:676-83, 2013.
709. Dudenbostel T, Oparil S. J curve in hypertension. *Curr Cardiovasc Risk Rep* 6:281-290, 2012.
710. Levitan E, Kaciroti N, Oparil S, Julius S, Muntner P. Blood pressure measurement device, number and timing of visits, and intra-individual visit-to-visit variability of blood pressure. *J Clin Hypertens (Greenwich)* 14:744-750, 2012.
711. Hedner T, Narkiewicz K, Oparil S, Kjeldsen S. Direct renin inhibitors in hypertension – Approaching the moment of truth. *Blood Press* 21:267-268, 2012. *Editorial*.
712. Irvin M, Shimbo D, Mann D, Reynolds K, Krousel-Wood M, Limdi N, Lackland D, Calhoun D, Oparil S, Muntner P. Prevalence and correlates of low medication adherence in apparent treatment resistant hypertension. *J Clin Hypertens (Greenwich)* 14:694-700, 2012. PMID:PMC3464920.
713. Becker G, et al. KDIGO Clinical Practice Guideline for Management of Blood Pressure in Chronic Kidney Disease. *Kidney International Supplements*. Volume 2 Issue 5, December 2012.
714. Kjeldsen S, Hedner T, Narkiewicz K, Oparil S. Angiotensin receptor - neprilysin inhibition (ARNI) – a novel therapeutic concept for management of hypertension and heart failure. *Blood Press* 21:329–330, 2012. *Editorial*.
715. Bakris GL, Oparil S, Purkayastha D, Yadao AM, Alessi T, Sowers JR. Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan versus valsartan monotherapy in hypertensive subjects with type 2 diabetes mellitus. *J Clin Hypertens* 15:92-100, 2013.
716. Muntner P, Levitan E, Joyce C, Holt E, Mann D, Oparil S, Krousel-Wood M. Association between antihypertensive medication adherence and visit-to-visit variability of blood pressure. *J Clin Hypertens* 15:112-117, 2013. PMID:PMC3659162.
717. Shimbo D, Levitan EB, Booth J, Calhoun DA, Judd S, Lackland D, Safford M, Oparil S, Muntner P. The contributions of unhealthy lifestyle factors to apparent resistant hypertension: Findings from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. *J Hypertens* 31:370-376, 2013. PMID: PMC3838894.

718. Krousel-Wood M and Oparil S. Initial Evaluation and Approach to the Patient with Hypertension, In: Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease (Fourth Edition), (Antman EM, Sabatine MS, Eds), Saunders, Elsevier, Inc., Philadelphia, PA, pp 463-473, 2013. ISBN: 978-1-4557-0101-8.
719. Davidson M, Tonstad S, Oparil S, Schwiers M, Day W, Bowden CH. Changes in cardiovascular risk associated with phentermine and topiramate extended release in participants with comorbidities and a body mass index ≥ 27 kg/m². *Am J Cardiol* 111:1131-1138, 2013.
720. Pimenta E, Stowasser M, Gordon RD, Harding SM, Batlouni M, Oparil S, Calhoun DA. Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. *Chest* 143:978-983, 2013. PMID:PMC3616687.
721. Pimenta E, Oparil S. Epidemiology of hypertension. In: Current Advances in Cardiovascular Risk (Saha SA, Ed). Nova Biomedical Science Publishers, Hauppauge, NY, pp 45-54, 2013. ISBN: 978-1-62081-746-9.
722. Oparil S, Davis B, Cushman W, Ford C, Furberg C, Habib G, Haywood LJ, Margolis K, Probstfield JL, Whelton PK, Wright JT, for the ALLHAT Collaborative Research Group. Mortality and morbidity during and after ALLHAT: Results by gender. *Hypertension* 61:977-986, 2013. PMID:PMC4114223.
723. Levitan E, Kaciroti N, Oparil S, Julius S, Muntner P. Relationships between metrics of visit-to-visit variability of blood pressure. *J Hum Hypertens* 27:589-593, 2013.
724. Tanner R, Calhoun D, Bell EK, Bowling B, Gutiérrez O, Irvin MR, Lackland D, Oparil S, Warnock D, Muntner P. Prevalence of Apparent Treatment Resistant Hypertension Among Individuals with Chronic Kidney Disease: Results from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. *Clin J Am Soc Nephrol* 8:1583-1590, 2013. PMID:PMC3805064.
725. Julius S, Kaciroti N, Oparil S. Reply to visit-to-visit variability blood pressure variation: Time to reanalyze all the data from the TROPHY study. *J Clin Hypertens* 15:301, 2013.
726. Hedner T, Narkiewicz K, Oparil S, Kjeldsen SE. Primary cardiovascular prevention by Mediterranean diet – The PREDIMED trial. *Blood Press* 22:129-130, 2013. *Editorial*.
727. Kjeldsen SE, Hedner T, Narkiewicz K, Oparil S. Revisiting the pre-hypertension debate: Increasing evidence for treatment - or not? *Blood Press* 2013 May 2. [Epub ahead of print]. *Editorial*.
728. Hage F, Oparil S. Ovarian hormones and vascular disease. *Curr Opin Cardiol* 28:411–416, 2013. Invited Review. *NIH Public Access – N/A (not applicable)*.
729. Zhao X, Zhang W, Xing D, Li P, Fu J, Gong K, Hage F, Oparil S, Chen YF. Endothelial Cells Overexpressing IL-8 Receptor Reduce Cardiac Remodeling and Dysfunction Following Myocardial Infarction. *Am J Physiol Heart Circ Physiol* 305:H590-H598, 2013. PMID:PMC3891247.

730. Margolis K, Davis B, Baimbridge C, Ciocon J, Cuyjet A, Dart R, Einhorn P, Ford C, Gordon D, Hartney T, Haywood LJ, Holtzman J, Mathis D, Oparil S, Probstfield J, Simpson L, Stokes J, Wiegmann T, and Williamson J on behalf of the ALLHAT Collaborative Research Group. Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs. usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *J Clin Hypertens (Greenwich)* 15:542-554, 2013.
731. Roth EM, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Olmesartan, amlodipine, and hydrochlorothiazide in obese participants with hypertension: A TRINITY study subgroup analysis. *J Clin Hypertens (Greenwich)* 15:584-592, 2013. PMID:PMC3908371.
732. Kjeldsen SE, Narkiewicz K, Oparil S, Hedner T. 2013 European Society of Hypertension/ European Society of Cardiology Hypertension Guidelines. *Blood Press* 22:191-192, 2013. *Editorial*.
733. Phillips W, Piller L, Williamson J, Whittle J, Jafri S, Ford C, Einhorn P, Oparil S, Furberg C, Grimm R, Alderman M, Davis BR, Probstfield J, for the ALLHAT Collaborative Research Group. Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ace-inhibitor, or calcium channel blocker in ALLHAT. *J Clin Hypertens (Greenwich)* 15:825-832, 2013.
734. Kjeldsen S, Narkiewicz K, Oparil S, Hedner T. Blood pressure lowering effect of renal sympathetic denervation, or placebo? - building expectations for Symplicity-HTN 3. *Blood Press* 22:279-281, 2013. *Editorial*.
735. Hage F, Mansur SJ, Xing D, Oparil S. Hypertension in women. *Kidney Int Suppl* 3:352-356, 2013. PMID:PMC4089575.
736. Judd E and Oparil S. Novel strategies for treatment of resistant hypertension. *Kidney Int Suppl* 3:357-363, 2013. PMID:PMC4089769.
737. Oparil S, Cushman WC, Lederle FA. Chlorthalidone versus hydrochlorothiazide in hypertension treatment: Do we have the evidence to decide? [*Commentary on Dhalla IA, Gomes T, Yao Z, et al. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults. A Population-Based Cohort Study. Ann Intern Med. 2013;158(6):447-455*]. *Am J Kidney Dis* 12 December 2013. pii: S0272-6386(13)01469-8, 2013. doi:10.1053/j.ajkd.2013.11.009. *Editorial*.
738. Weber MA, Oparil S. The Human Side of Failed Hypertension Treatment. *J Clin Hypertens* 15:762-764, 2013. *Editorial*.
739. Acelajado MC and Oparil S (2013). Hypertension and Cardiovascular Risk In: Hypertension, an e-book publication (Schiffrin EL, Touyz RM Eds). Future Medicine Ltd, London, UK. pp:182-194, doi: 10.2217/9781780842462. eISBN (PDF): 978-1-78084-246-2.
740. Calhoun DA, Booth JN, Oparil S, Irvin MR, Shimbo D, Lackland D, Howard G, Safford M, Muntner P. Refractory Hypertension: determination of prevalence, risk factors and comorbidities in a large, population-based cohort. *Hypertension* 63:451-458, 2014. Epub 2013 Dec 9.

741. Tanner R, Calhoun DA, Bell EK, Bowling B, Gutiérrez OM, Irvin MR, Lackland DT, Oparil S, McClellan W, Warnock D, Muntner P. Incident ESRD and apparent treatment resistant hypertension: The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. *Am J Kidney Dis* 63:781-788, 2014. PMID:PMC4141647.
742. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E; Eighth Joint National Committee (JNC 8) Members (Oparil: Co-Chair). 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA* 311(5):507-520, 2014.
743. Lewin AJ, Kereiakes DJ, Chrysant SG, Izzo JL, Oparil S, Lee J, Fernandez V, Melino M. Triple-combination treatment with OM/AML/HCTZ in Hispanic/Latino patients with hypertension: The TRINITY Study. *Ethn Dis* 24:41-47, 2014.
744. Cheng S, Lam C, Shah A, Claggett B, Desai AS, Hilkert RJ, Izzo J, Oparil S, Pitt B, Solomon SD. Age and the effectiveness of anti-hypertensive therapy on improvement in diastolic function. *J Hypertens* 32:174-80, 2014.
745. Bromfield S, Bowling CB, Tanner R, Odden M, Oparil S, Muntner P. Trends in hypertension prevalence, awareness, treatment, and control among US adults 80 years and older, 1988-2010. *J Clin Hypertens (Greenwich)* 16(4):270-276, 2014.
746. Muntner P, Levitan EB, Lynch A, Simpson L, Whittle J, Davis B, Kostis J, Whelton PK, Oparil S. Effect of chlorthalidone, amlodipine and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *J Clin Hypertens (Greenwich)* 16:323-330, 2014.
747. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Esler M, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Sobotka PA, Townsend RR, Bakris GL, for the SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. *N Engl J Med* 370:1393-1401, 2014.
748. Szalai A, McCrory MA, Xing D, Hage FG, Miller A, Oparil S, Chen YF, Mazzone M, Early R, Henry SP, Zanardi T, Graham M, Crooke RM. Inhibiting C-reactive protein for the treatment of cardiovascular disease: Promising evidence from rodent models. *Mediators Inflamm* 2014:353614, 2014. PMID:PMC3996300.
749. Calhoun DA, Booth JN 3rd, Oparil S, Irvin MR, Shimbo D, Lackland DT, Howard G, Safford MM, Muntner P. Response to should more significance be granted to medication response to antihypertensives in patients with resistant hypertension? *Hypertension* 63(4):e84.
750. Fu J, Chen YF, Zhao X, Creighton J, Guo YY, Hage FG, Oparil S, Xing D. Targeted Delivery of Pulmonary Arterial Endothelial Cells Overexpressing Interleukin-8 Receptors Attenuates Monocrotaline-Induced Pulmonary Vascular Remodeling. *Arterioscler Thromb Vasc Biol* 34(7):1539-1547, 2014.

751. Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, Flack JM, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL, for the SYMPLICITY HTN-3 Investigators. Impact of renal denervation on 24-hour ambulatory blood pressure: Results from SYMPLICITY HTN-3. *J Am Coll Cardiol* 64:1071-1078, 2014. (Epub 2014 May 20). pii: S0735-1097(14)02516-9.
752. Bowling M, Xing D, Kapadia A, Chen YF, Szalai A, Oparil S, Hage F. Estrogen effects on vascular inflammation are age-dependent. *Arterioscler Thromb Vasc Biol* 34(7):1477-1485, 2014.
753. Oparil S. Updated guidelines for management of high blood pressure in Japan. *Hypertens Res* 37(6):484-487. *Commentary*.
754. Kjeldsen SE, Narkiewicz K, Oparil S, Hedner T. Renal denervation in treatment-resistant hypertension – Oslo RDN, Symplicity HTN-3 and INSPiRED randomized trials. *Blood Press* 23:135-137, 2014. *Editorial*.
755. Vemulapalli S, Ard J, Bakris GL, Bhatt DL, Brown AS, Cushman WC, Ferdinand KC, Flack JM, Fleg JL, Katzen BT, Kostis JB, Oparil S, Patel CB, Pepine CJ, Piña IL, Rocha-Singh KJ, Townsend RR, Peterson ED, Califf RM, Patel MR. Proceedings from duke resistant hypertension think tank. *Am Heart J* 167:775-788.e1.
756. Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Williamson JD, Wright JT Jr, Whelton PK, and the SPRINT Study Research Group. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT). *Clin Trials* 11:532-546, 2014. Link to Article: <http://ctj.sagepub.com/content/early/2014/06/02/1740774514537404>.
757. Oparil S. Low sodium intake – cardiovascular health benefit or risk? *N Engl J Med* 371(7):677-679, 2014. *Invited Editorial*.
758. Ortiz E, Oparil S, James PA. Guidelines for managing high blood pressure – reply. *JAMA* 312(3):295-306, 2014.
759. Yamal JM, Oparil S, Davis BR, Alderman MH, Calhoun DA, Cushman WC, Fendley HF, Franklin SS, Habib GB, Pressel SL, Probstfield JL, Sastrasin S; ALLHAT Collaborative Research Group. Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. *J Am Soc Hypertens* 8: 808-819, 2014.
760. Kent ST, Shimbo D, Huang L, Diaz KM, Kilgore M, Oparil S, Muntner P. Antihypertensive medication classes used among medicare beneficiaries initiating treatment in 2007-2010. *PLoS One* 9(8):e105888, 2014. PMID:PMC4143342.
761. Gupta A, Schiros CG, Gaddam KK, Aban I, Denney TS, Lloyd SG, Oparil S, Dell'Italia LJ, Calhoun DA, Gupta H. Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy. *J Hum Hypertens* 29:241-246, 2015 (Epub 2014 Sep 18).

762. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. *Eur Heart J* 36:219-227, 2015. (Epub 2014 Nov 16).
763. Cheng S, Shah AM, Albisu JP, Desai AS, Hilkert RJ, Izzo J, Oparil S, Pitt B, Solomon SD. Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart disease. *J Hypertens* 32:2479-2487, 2014.
764. Shimbo D, Kent ST, Diaz KM, Huang L, Viera AJ, Kilgore M, Oparil S, Muntner P. The use of ambulatory blood pressure monitoring among Medicare beneficiaries in 2007-2010. *J Am Soc Hypertens* 8:891-897, 2014.
765. Kent ST, Shimbo D, Huang L, Diaz KM, Viera AJ, Kilgore M, Oparil S, Muntner P. Rates, amounts and determinants of ambulatory blood pressure monitoring claim reimbursements among Medicare beneficiaries. *J Am Soc Hypertens* 8:898-908, 2014.
766. Oparil S, Schmieder RE. New approaches in the treatment of hypertension. *Circ Res* 116(6):1074-1095, 2015.
767. Howard VJ, Tanner RM, Anderson A, Irvin MR, Calhoun DA, Lackland DT, Oparil S, Muntner P. Apparent Treatment-resistant hypertension among individuals with history of stroke or transient ischemic attack. *Am J Med.* 128(7):707-714, 2015. PMID: PMC4475646.
768. Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D'Agostino R, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL; SYMPLICITY HTN-3 Investigators. 12-Month Blood Pressure Results of Catheter-Based Renal Artery Denervation for Resistant Hypertension: The SYMPLICITY HTN-3 Trial. *J Am Coll Cardiol* 65(13):1314-1321, 2015.
769. Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, Cannon CP, de Lemos JA, Elliott WJ, Findeiss L, Gersh BJ, Gore JM, Levy D, Long JB, O'Connor CM, O'Gara PT, Ogedegbe O, Oparil S, White WB; *American Heart Association, American College of Cardiology, and American Society of Hypertension*. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. [Epub Ahead of Print] in the following journals: *Circulation*. 2015 Mar 31. *Hypertension*. 2015 Mar 31. *J Am Coll Cardiol*. 2015 Mar 25. *J Am Soc Hypertens*. 2015 Mar 30. Citations 769a/b/c/d.
770. Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. *Hypertension* 66:126-133, 2015.
771. Howard G, Banach M, Cushman M, Goff DC, Howard VJ, Lackland DT, McVay J, Meschia JF, Muntner P, Oparil S, Rightmyer M, Taylor HA. Is blood pressure control for stroke prevention the correct goal? The lost opportunity of preventing hypertension. *Stroke* 46:1595-1600, 2015.

772. Tita AT, Sibai BM, Oparil S. Less-tight versus tight control of hypertension in pregnancy. *N Engl J Med*. 372(24):2366-2367, 2015. Comment on: Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, Menzies J, Sanchez J, Singer J, Gafni A, Gruslin A, Helewa M, Hutton E, Lee SK, Lee T, Logan AG, Ganzevoort W, Welch R, Thornton JG, Moutquin JM. Less-tight versus tight control of hypertension in pregnancy. *N Engl J Med*. 2015 Jan 29;372(5):407-417.
773. Giordano S, Hage FG, Xing D, Chen YF, Allon S, Chen CJ, Oparil S. Estrogen and cardiovascular disease: Is timing everything? *Am J Med Sci* 350(1):27-35, 2015.
774. Still CH, Craven TE, Freedman Bi, Van Buren P, Sink KM, Killeen AA, Bates JT, Bee A, Contreras G, Oparil S, Pedley C, Wall B, White S, Woods D, Rodriguez C, Wright JT Jr, for the SPRINT Study Research Group. [JASH-D-15-00111]. Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention Trial (SPRINT). *J Am Soc Hypertens* 9(9):670-9, 2015.
775. Muntner P, Whittle J, Lynch AI, Colantonio LD, Simpson LM, Einhorn PT, Levitan EB, Whelton PK, Cushman WC, Louis GT, Davis BR, Oparil S. Visit-to-Visit variability of blood pressure and coronary heart disease, stroke, heart failure, and mortality: A cohort study. *Ann Intern Med* 163:329-338, 2015. *PMCID: PMC Journal – In Process*.
776. Oparil S. Tribute: John H. Laragh, MD. *J Am Soc Hypertens* 9:500-501, 2015.
777. Flack JM, Bhatt DL, Kandzari DE, Brown D, Brar S, Choi JW, D'Agostino R, East C, Katzen BT, Lee L, Leon MB, Mauri L, O'Neill WW, Oparil S, Rocha-Singh K, Townsend RR, Bakris G; SYMPLICITY HTN-3 Investigators. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. *J Am Soc Hypertens* 9(10):769-779, 2015.
778. Giles TD, Bakris G, Oparil S, Weber MA, Li H, Mallick M, Bharucha DB, Chen C, Ferguson WG; NAC-MD-01 Substudy Investigators. Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. *J Am Soc Hypertens* 9(11):845-854, 2015.
779. Kjeldsen SE, Oparil S, Narkiewicz K, Hedner T. The J-curve phenomenon revisited again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg. *Blood Press* 13:1-3, 2015. PMID:26462684.
780. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT; for the SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med* 373(22):2103-2116, 2015. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9.
781. Cushman WC, Whelton PK, Fine LJ, Wright JT Jr, Reboussin DM, Johnson KC, Oparil S. SPRINT Trial Results: Latest News in Hypertension Management. *Hypertension* 67(2):263-265, 2016. doi: 10.1161/HYPERTENSIONAHA.115.06722. Epub 2015 Nov 9.

- 781a. Biederman RW, Young AA, Doyle M, Devereux RB, Kortright E, Perry G, Bella JN, Oparil S, Calhoun D, Pohost GM, Dell'Italia LJ. Regional Heterogeneity in 3D Myocardial Shortening in Hypertensive Left Ventricular Hypertrophy: A Cardiovascular CMR Tagging Substudy to the Life Study. *J Biomed Sci Eng.* 2015 Mar 1;8(3):213-225. Epub 2015 Mar 26.
782. Alderman MH, Davis BR, Piller LB, Ford CE, Baraniuk MS, Pressel SL, Assadi MA, Einhorn PT, Haywood LJ, Ilamathi E, Oparil S, Retta TM; ALLHAT Collaborative Research Group. Should antihypertensive treatment recommendations differ in patients with and without coronary heart disease? from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Am J Cardiol* 117(1):105-115, 2016. Epub 2015 Oct 19. doi:10.1016/j.amjcard.2015.10.012.
783. Oparil S. SPS3 Evidence Supports Intensive Blood Pressure Control. *Editorial. Circulation* 133:552-554, 2016. DOI: 10.1161/CIRCULATIONAHA.116.021125.
784. Giordano S, Zhao X, Xing D, Hage F, Oparil S, Cooke JP, Lee J, Nakayama KH, Huang NF, Chen YF. Targeted delivery of human iPS-ECs overexpressing IL-8 receptors inhibit neointimal and inflammatory responses to vascular injury in the rat. *Am J Physiol Heart Circ Physiol* 310(6):H705-H715, 2016.
785. Chang TI, Evans G, Cheung AK, Cushman WC, Diamond MJ, Dwyer JP, Huan Y, Kitzman D, Kostis JB, Oparil S, Rastogi A, Roumie CL, Sahay R, Stafford RS, Taylor AA, Wright JT Jr, Chertow GM; SPRINT Study Research Group. Patterns and correlates of baseline thiazide-type diuretic prescription in the Systolic Blood Pressure Intervention Trial (SPRINT). *Hypertension* 67:550-555, 2016.
786. Kent ST, Bromfield SG, Burkholder GA, Falzon L, Oparil S, Overton ET, Mugavero MJ, Schwartz JE, Shimbo D, Muntner P. Ambulatory blood pressure monitoring in individuals with HIV: A systematic review and meta-analysis. *PLoS One* 11(2): e0148920, 2016. doi:10.1371/journal.pone.0148920. Epub 2016 Feb 16.
787. Whittle J, Lynch AI, Tanner RM, Simpson LM, Davis BR, Rahman M, Whelton PK, Oparil S, Muntner P. Visit-to-visit variability of blood pressure and chronic kidney disease outcomes: Results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Clin J Am Soc Nephrol* 11(3):471-480, 2016. doi: 10.2215/CJN.04660415. Epub 2016 Feb 18.
788. Hedner T, Kjeldsen SE, Narkiewicz K, Oparil S. The polypill: An treatment alternative for secondary prevention of cardiovascular disease. *Blood Press* 13:1-4, 2016.
789. Oparil S. SPRINT Trial Results. *Euro Heart J CardioPulse* 37:924-936, 2016. doi:10.1093/eurheartj/ehw016.
790. Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA. Refractory hypertension: A novel phenotype of antihypertensive treatment failure. *Hypertension* 67(6):1085-1092, 2016.
791. Ghazi L, Dudenbostel T, Lin CP, Oparil S, Calhoun DA. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status. *J Hypertens* 34(5):1005-1010, 2016.

792. Bhatt H, Siddiqui M, Judd E, Oparil S, Calhoun D. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. *J Am Soc Hypertens* 10(6):493-499, 2016.
793. Kostis JB, Oparil S. HOPE-3 and SPRINT: Two landmark trials with different outcomes? *J Am Soc Hypertens* 10(6):477-481, 2016.
794. Kario K, Bhatt DL, Kandzari DE, Brar S, Flack JM, Gilbert C, Oparil S, Robbins M, Townsend R, Bakris G. Impact of renal denervation on patients with obstructive sleep apnea and resistant hypertension: Insights from the SYMPLICITY HTN-3 trial. *Circ J* 80(6):1404-1412, 2016.
795. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodriguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT Jr, Pajewski NM; SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥ 75 years: A randomized clinical trial. *JAMA* 315(24):2673-2682, 2016. PMID: PMC4988796.
796. Kronish IM, Lynch AI, Oparil S, Whittle J, Davis BR, Simpson LM, Krousel-Wood M, Cushman WC, Chang TI, Muntner P. The association between antihypertensive medication nonadherence and visit-to-visit variability of blood pressure: Findings from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Hypertension* 68(1):39-45, 2016.
797. Saddekni MB, Saag KG, Dudenbostel T, Oparil S, Calhoun DA, Sattui SE, Feig DI, Muntner P, Redden DT, Foster PJ, Rahn EJ, Biggers SR, Li P, Gaffo AL. The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale. *Contemp Clin Trials* 50:238-244, 2016. doi: 10.1016/j.cct.2016.08.016.
798. Dudenbostel T, Ghazi L, Liu M, Li P, Oparil S, Calhoun DA. Body mass index predicts 24-hour urinary aldosterone levels in patients with resistant hypertension. *Hypertension* 68(4):995-1003, 2016. doi: 10.1161/HYPERTENSIONAHA.116.07806. Epub 2016 Aug 15.
799. Bhatt H, Ghazi L, Calhoun DA, Oparil S. BP targets in hypertension: What should we do now that SPRINT is out? *Curr Cardiol Rep* 18(10):98, 2016. doi: 10.1007/s11886-016-0775-0. *Review Article*.
800. Townsend RR, Chang TI, Cohen DL, Cushman WC, Evans GW, Glasser SP, Haley WE, Olney C, Oparil S, Del Pinto R, Pisoni R, Taylor AA, Umanath K, Wright JT Jr, Yeboah J; SPRINT Study Research Group. Orthostatic changes in systolic blood pressure among SPRINT participants at baseline. *J Am Soc Hypertens* 10(11):847-856, 2016. [Epub ahead of print 2016 Aug 26] pii: S1933-1711(16)30488-0. doi: 10.1016/j.jash.2016.08.005.
801. Oparil S and Lewis CE. Should patients with cardiovascular risk factors receive intensive treatment of hypertension to $<120/80$ mm Hg target? A protagonist view from the SPRINT trial (Systolic Blood Pressure Intervention Trial). *Circulation* 134:1308-1310, 2016. doi:10.1161/CIRCULATIONAHA.116.023263 (Epub Ahead of Print 12 Sept 2016). *Invited Point-Of-View Article*.

802. Miller AP, Navar AM, Roubin GS, Oparil S. Cardiovascular care for older adults: Hypertension and stroke in the older adult. *J Geriatr Cardiol* 13(5):373-379, 2016.
803. Kjeldsen SE, Narkiewicz K, Oparil S. *Blood Pressure* in 2016: Increased impact factor and change of editors. *Blood Press* 3:1-2, 2016.
804. Puttnam R, Davis BR, Pressel S, Whelton PK, Cushman WC, Louis GT, Margolis KL, Oparil S, Williamson J, Ghosh A, Einhorn PT, Barzilay JI; for the ALLHAT Collaborative Research Group. Hip and pelvic fracture risk in older adults randomized to three different anti-hypertensive medications. *JAMA Int Med* 177(1):67-76, 2017. [Epub ahead of print 21 Nov 2016]. doi:10.1001/jamainternmed.2016.6821.
805. Chen DP, Davis BR, Simpson LM, Cushman WC, Cutler JA, Dobre M, Ford CE, Louis GT, Muntner P, Oparil S, Piller LB, Pressel SL, Sarnak MJ, Whelton PK, Wright JT, Rahman M; for the ALLHAT Collaborative Research Group. Association between chronic kidney disease and cancer mortality: A report from ALLHAT. *Clin Nephrol* 87(1):11-20, 2017. [Epub ahead of print 30 Nov 2016].
806. Gong K, Chen M, Li R, He Y, Zhu H, Yao D, Oparil S, Zhang Z. Smad3-mSin3A-HDAC1 complex is required for TGF- β 1-induced transcriptional inhibition of PPAR γ in mouse cardiac fibroblasts. *Cell Physiol Biochem* 40(5):908-920, 2016.
807. Ernst ME, Davis BR, Soliman EZ, Prineas RJ, Okin PM, Ghosh A, Cushman WC, Einhorn PT, Oparil S, Grimm R; ALLHAT Collaborative Research Group. Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering to Prevent Heart Attack Trial. *J Am Soc Hypertens* 10(12):930-938, 2016. doi: 10.1016/j.jash.2016.10.010. PMCID: PMC5161112.
808. Kjeldsen SE, Narkiewicz K, Burnier M, Oparil S. The Global Burden of Disease Study 2015 and blood pressure. *Blood Press* 26:1, 2017. *Editorial*. Epub 12 Dec 2016.
809. George DC, Bhambhani PG, Oparil S. ^{123}I -mIBG scintigraphy: Clinical tool for assessing renal sympathetic activity? *Invited Editorial*. *J Nucl Cardiol* (2016). Epub 30 Dec 2016. doi:10.1007/s12350-016-0764-0.
810. Ghazi L, Dudenbostel T, Xing D, Ejem D, Turner-Henson A, Joiner CI, Affuso O, Azuero A, Oparil S, Rice M, Hage FG. Assessment of vascular function in low socioeconomic status preschool children: A pilot study. *J Am Soc Hypertens* (2016). Epub 24 Dec 2016. pii: S1933-1711(16)30605-2. doi: 10.1016/j.jash.2016.12.006.

811. Yano Y, Rakugi H, Bakris GL, Lloyd-Jones DM, Oparil S, Saruta T, Shimada K, Matsuoka H, Imai Y, Ogihara T. On-treatment blood pressure and cardiovascular outcomes in older adults with isolated systolic hypertension. *Hypertension* 69(2):220-227, 2017. Epub 3 Jan 2017. <https://doi.org/10.1161/HYPERTENSIONAHA.116.08600>.
812. Mancia G, Oparil S, Whelton PK, McKee M, Dominiczak A, Luft FC, AlHabib K, Lanus F, Damasceno A, Prabhakaran D, La Torre G, Weber M, O'Donnell M, Smith SC, Narula J. The technical report on sodium intake and cardiovascular disease in low- and middle-income countries by the joint working group of the World Heart Federation (WHF), the European Society of Hypertension (ESH) and the European Public Health Association (EUPHA). *Eur Heart J* 38(10):712-719, 2017. [Epub 21 Jan 2017]. doi: <https://doi.org/10.1093/eurheartj/ehw549>
813. Le Jemtel TH, Richardson W, Samson R, Jaiswal A, Oparil S. Pathophysiology and potential non-pharmacologic treatments of obesity or kidney disease associated refractory hypertension. *Curr Hypertens Rep* 19(2):18, 2017. doi: 10.1007/s11906-017-0713-6.
814. Ghazi L, Dudenbostel T, Hachem ME, Siddiqui M, Lin CP, Oparil S, Calhoun DA. 11-beta dehydrogenase type 2 activity is not reduced in treatment resistant hypertension. *Am J Hypertens* (2017). Epub 9 Feb 2017. doi: 10.1093/ajh/hpx002.
815. Giordano S, Zhao X, Chen YF, Litovsky SH, Hage FG, Townes TM, Sun CW, Wu LC, Oparil S, Xing D. Induced pluripotent stem cell-derived endothelial cells overexpressing interleukin-8 receptors A/B and/or C-C chemokine receptors 2/5 inhibit vascular injury response. *Stem Cells Transl Med* (2017). Epub 24 Feb 2017. DOI:[10.1002/sctm.16-0316](https://doi.org/10.1002/sctm.16-0316).
816. Kjeldsen SE, Narkiewicz K, Burnier M, Oparil S. The INTERSALT Study and the complex relationship between salt intake and blood pressure. *Blood Press* 26(2):65-66, 2017.
817. Miller-Hodges E, Dominiczak AF, Jennings GL, Oparil S, Battle DC, Eljovich F, Basile JN, Laffer CL, Oliveras A, Dhaun N. Hypertension and its complications in a young man with autoimmune disease. *Hypertension* 69(4):536-544, 2017.
818. Kjeldsen SE, Narkiewicz K, Burnier M, Oparil S. The INTERSTROKE Study: hypertension is by far the most important modifiable risk factor for stroke. *Blood Press* 26(3):131-132, 2017.
819. Upadhyaya B, Rocco M, Lewis CE, Oparil S, Lovato LC, Cushman WC, Bates JT, Bello NA, Aurigemma G, Fine LJ, Johnson KK, Rodriguez C, Raj DS, Rastogi A, Tamariz L, Wiggers A, Kitzman DW; for the SPRINT Research Group. The effect of intensive blood pressure treatment on heart failure events in the Systolic Blood Pressure Intervention Trial (SPRINT). *Circ Heart Fail*. 2017. 10(4). pii: e003613. doi: 10.1161/CIRCHEARTFAILURE.116.003613. SPRINT Manuscript # M0098.
820. Ghazi L, Oparil S, Calhoun DA, Lin CP, Dudenbostel T. Distinctive risk factors and phenotype of younger patients with resistant hypertension: Age is relevant. *Hypertension*. 2017 Mar 27. pii: HYPERTENSIONAHA.116.08632. [Epub ahead of print].
821. Ahmad A, Oparil S. Hypertension in women: Recent advances and lingering questions. *Hypertension* 2017 May 8. pii: HYPERTENSIONAHA.117.08317. doi: 10.1161/HYPERTENSIONAHA.117.08317. [Epub ahead of print]. *Invited Review*.

822. Samson R, Qi A, Moore R, Jaiswal A, Le Jemtel TH, Oparil S. Obesity-associated hypertension: The upcoming phenotype in African American women. *Curr Hypertens Rep* 19(5):41, 2017. doi: 10.1007/s11906-017-0738-x. Review.
823. Kent ST, Schwartz JE, Shimbo D, Overton ET, Burkholder GA, Oparil S, Mugavero MJ, Muntner P. Race and sex differences in ambulatory blood pressure measures among HIV+ adults. *J Am Soc Hypertens* (2017). doi: 10.1016/j.jash.2017.05.002.
824. Weiner DE, Gaussoin SA, Nord J, Auchus AP, Chelune GJ, Chonchol M, Coker L, Haley WE, Killeen AA, Kimmel PL, Lerner AJ, Oparil S, Saklayen MG, Slinin YM, Wright CB, Williamson JD, Kurella Tamura M; for the SPRINT Study Research Group. Cognitive function and kidney disease: Baseline data from the SPRINT trial. *Am J Kidney Dis*. 2017 pii: S0272-6386(17)30703-5. doi: 10.1053/j.ajkd.2017.04.021 (Epub ahead of print 09Jun2017). SPRINT MS 0004.
825. Cheung AK, Rahman M, Hawfield A, Johnson KC, Kimmel P, Lewis CE, Oparil S, Reboussin D, Rocco M, Sink K, Whelton P, Wright JT, Basile J, Beddhu S, Bhatt U, Chang T, Chertow G, Chonchol M, Craven T, Freedman B, Greene T, Haley W, Ix JH, Katz L, Killeen A, Vasiliou Papademetriou V, Ricardo A, Servilla K, Wall B, Wolfgram D, Yee J; for the SPRINT Research Group. Effect of intensive blood pressure control in CKD. *J Am Soc Nephrol. In Press. May 2017*.
826. Bress AP, Bellows BK, King J, Hess R, Beddhu S, Zhang Z, Berlowitz D, Controy MB, Fine L, Oparil S, Morisky DE, Kazis LE, Ruiz-Negrón N, Powell J, Tamariz L, Whittle J, Wright JT Jr, Supiano MA, Cheung AK, Weintraub WS, Moran AE; for the SPRINT Research Group and the SPRINT Economics and Health Related Quality of Life Subcommittee. Cost-effectiveness of intensive versus standard blood pressure control. *N Engl J Med. In Press. May 2017*.
827. Berlowitz DR, Foy C, Kazis L, Bolin L, Conroy M, Fitzpatrick P, Gure T, Kimmel P, Kirchner K, Newman J, Olney C, Oparil S, Pajewski N, Powell J, Ramsey T, Snyder J, Supiano M, Weiner D, Whittle J; for the SPRINT Research Group. Impact of intensive blood pressure therapy on patient-reported outcomes: Results from the Systolic Blood Pressure Intervention Trial (SPRINT). *N Engl J Med. In Press. June 2017*.

Web Features:

- Oparil S. Hypertension in the elderly: Optimizing management in the real world. Medscape Cardiology 2006. <http://www.medscape.com/viewarticle/527792>.
- Pimenta E, Oparil S. Hypertension PDA – AHA.
- Giles TD, Oparil S, Black HR. Introduction to the Hypertension Curriculum. From the American Society of Hypertension. <http://www.medscape.org/viewarticle/573921>.
- Oparil S. The AHA 2009 Roundup: ARBITER 6-HALTS, PLATO, the two CHAMPIONS, and CASCADE. The Cardiology Show. Valentin Fuster, MD. theheart.org. From American Heart Association Annual Scientific Meeting, 2009. <http://www.theheart.org/editorial-program/1018761.do>.
- Oparil S. ASH: Novel Combo Antihypertensive Pill Better than Its Parts. Guest: Suzanne Oparil. From American Society of Hypertension (ASH) Annual Scientific Meeting, 2010. Medpagetoday. Com. <http://www.medpagetoday.com/MeetingCoverage/ASHMeeting/19881>.
- Oparil S. Life and times of leading cardiologists with Rob Califf. Guest: Suzanne Oparil. theheart.org. <http://www.theheart.org/editorial-program/1185181.do>. March 24, 2011.
- Oparil S. Forefront in Clinical Hypertension. University of Utah Grand Rounds. Department of Medicine CME Grand Rounds Course. April 14, 2011. <http://medicine.utah.edu/internalmedicine/Education/grandRounds/2011/Apr2011.htm>.
- Oparil S (Interview/Quote), by Lauran Neergaard and Matthew Perrone. “New approach tested for hard-to-treat hypertension”. <http://www.washingtontimes.com/news/2012/may/29/new-approach-tested-for-hard-to-treat-hypertension/?page=all#pagebreak>. Associated Press, May 29, 2012.
- Guest Author, *Gender Differences in Blood Pressure Control, eHypertension Review.* <http://www.hopkinscme.net/ofp/eHypertensionReview/>. Johns Hopkins University School of Medicine, eLiterature Review, August (Vol. 1, Iss 3), October (podcast release), 2012.
- Guest Faculty, “High Blood Pressure Assessment, Proper Blood Pressure Measurement & Patient Referral”, *Hypertension: Guidelines into Practice*, <https://learn.heart.org/Activity/2695030/Detail.aspx>, American Heart Association (AHA) Continuing Education Course, 2013-2015.
- ACC Video Conference, Bridging the Gap between Recommendations and Practice, American College of Cardiology-India, Topic Presentations, September 21, 2013.
- Oparil S, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). Special Communication. The Journal of the American Medical Association. jnc8.jamanetwork.com/. December 18, 2013.
- Oparil S. Committee releases new guideline for management of high blood pressure. UAB Media Relations (Greer, Tyler). <http://www.uab.edu/news/latest/item/4007-committee-releases-new-guideline-for-management-of-high-blood-pressure>. December 18, 2013.

Web Features (Continued):

- Expertscape (Pubmed Analysis), Hypertension Experts, Institutions_Oparil S. <http://www.expertscape.com/ex/hypertension>. Published online May 26, 2014. Top expert at a top institution.
- Oparil S. Research questioning sodium intake guidelines supported in New England Journal of Medicine editorial. UAB Media Relations (Greer, Tyler). <http://www.uab.edu/news/faculty/item/5099-research-questioning-sodium-intake-guidelines-supported-in-new-england-journal-of-medicine-editorial>. August 13, 2014.
- Oparil S. Low-Salt Diets May Pose Health Risks, Study Finds. Findings Are Latest Challenge to Benefits of Aggressively Low Sodium Targets. Wall Street Journal (with Ron Winslow, WSJ). <http://online.wsj.com/articles/recommended-salt-levels-could-do-more-harm-than-good-study-suggests-1407964274?KEYWORDS=ron+winslow>. August 13, 2014.
- Oparil S. Hypertension: Here's Why to Wait on the SPRINT Trial Strategy. A conversation with investigator Suzanne Oparil. <http://www.medpagetoday.com/Cardiology/Hypertension/53661>. September 21, 2015.
- UAB News Release. Landmark blood pressure study, published today by NEJM, confirms benefits of lower blood pressure. <http://www.uab.edu/news/faculty/item/6712-landmark-blood-pressure-study-published-today-by-nejm-confirms-benefits-of-lower-blood-pressure>. Published online 09 November 2015.
- Oparil one of three doctors to receive national clinical excellence award. (Adam Pope, UAB Media). <http://www.uab.edu/news/faculty/item/7074-oparil-one-of-three-doctors-to-receive-national-clinical-excellence-award>. March 7, 2016.
- Research Spotlight: Suzanne Oparil, MD. <http://www.uab.edu/medicine/dom/research/spotlight/413-march-2016-suzanne-oparil-md>. University of Alabama Department of Medicine Faculty Research Spotlight. March 2016.
- UAB MedCast: Refractory Hypertension (2017). Suzanne Oparil, MD. Medical Education Podcast Series. RadioMD.com. <https://www.uabmedicine.org/web/medicalprofessionals/medcast-home>. <https://radiomd.com/uab/item/35018-refractory-hypertension?print=yes>. UABMedicine.org/Physician.

Abstracts:

1. Oparil S, Sanders CA and Haber E. 10. In vivo conversion of angiotensin I and II. Fed Proc 28:580, 1969.
2. Oparil S, Vassaux C, Sanders CA and Haber E. Role of renin in homeostasis of posture. Clin Res 17:257, 1969.
3. Oparil S, Koerner TJ and Haber E. Mechanism of in vivo conversion of angiotensin I to II. Fed Proc 29:282, 1970.
4. Oparil S, Yano M, Powell J and Haber E. Metabolism of angiotensin II by muscle capillary beds. Fed Proc 30:1425, 1971.
5. Zacest R, Oparil S and Talamo RC. Characterization of bradykininases in human plasma by use of radiolabeled substrates. Fed Proc 30: 1434, 1971.
6. Oparil S, Tregear GW and Haber E. Role of C-terminal sequence of angiotensin I on immunologic reactivity and on conversion of angiotensin II in vivo and in vitro. Second International Symposium on Protein and Polypeptide Hormones, Liege, Belgium, 1971.
7. Oparil S and Haber E. Conversion of angiotensin I to II in vivo and in vitro. Conference on Control of Renin Secretion, Santa Ynez, California, August, 1971.
8. Oparil S, Tregear GW, Koerner TJ, Barnes BA and Haber E. Mechanism of pulmonary conversion of angiotensin I to II. Circulation 44:II-93, 1971.
9. Oparil S, Koerner T, Barnes B and Haber E. Specificity for angiotensin converting enzyme in vivo and in vitro. Fed Proc 31:1679, 1972.
10. Oparil S and Haber E. Mechanism of angiotensin I conversion in vivo. Proceedings of the Fifth International Congress of Pharmacology, p. 173, 1972
11. Lindheimer MD, Ehrlich EN and Oparil S. Evidence for an effect of progesterone on proximal tubular Na⁺ reabsorption in man. Clin Res 20:763, 1972.
12. Oparil S and Bailie M. Metabolism of angiotensin II by dog kidney. Fed Proc 32:760, 1973.
13. Lindheimer MD, Ehrlich EN and Oparil S. Effects of progesterone (p) on renal Na⁺ handling in man. Society of Gynecologic Investigation XX, 1973, p. 43.
14. Oparil S, Ehrlich EN and Lindheimer MD. Acute effects of progesterone (P) on renal function, Intrarenal sodium (Na⁺) and the renin-angiotensin-aldosterone systems. Proceedings of the Endocrine Society 54th Annual Meeting, Abstract #52, 1973.
15. Oparil S, Koerner TJ and O'Donoghue JK. Polypeptide inhibitors of angiotensin converting enzyme. Clin Res 21:441,1972.
16. Coe FL, Pullman TN and Oparil S. Computerized guidance system for hypertension treatment. Circulation 58(Suppl 4):155, 1973.

17. Lindheimer MD, Ehrlich EN and Oparil S. Evidence for non-aldosterone dependent saluretic effect of progesterone. Clin Res 21 :895, 1973.
18. Oparil S, Koerner T and Haber E. Modifications in the radioimmunoassay for plasma renin activity: Implications for the low renin state. Clin Res 22:345, 1974.
19. Coe F, Oparil S, Norton E and Pullman TN. Comparison of antihypertensive treatment by computer and physician. Clin Res 22:376, 1974.
20. Oparil S, Koerner TJ and O'Donoghue JK. Antihypertensive action of converting enzyme inhibitor SQ 20881. Fed Proc 33:543, 1974.
21. Oparil S, Koerner TJ and O'Donoghue JK. New polypeptide inhibitors of angiotensin conversion. Clin Res 22:292,1974.
22. Oparil S, Carone F and Pullman TN. Micropuncture study of disposition of angiotensin II in rat tubules. Clin Res 22:656, 1974.
23. Oparil S, Koerner T and Haber E. Effects of pH and enzyme inhibitors on apparent generation of angiotensin I in human plasma. Circulation 49:II-121,1974.
24. Erinoff L, Heller A and Oparil S. Central catecholamine depletion and the prevention of hypertension. Fed Proc 34:817, 1975.
25. Oparil S, Carone FA, Pullman T and Nakamura S. Handling of small peptides by rat renal tubules. Clin Res 23:371, 1975.
26. Carone FA, Oparil S, Peterson DR, Pullman TN and Nakamura S. Renal tubular handling of angiotensin II and bradykinin. Fed Proc 34:878, 1975.
27. Coe FL, Norton E, Oparil S, Pullman TN and Tatar A. Treatment of hypertension by computer and physician: A prospective controlled study. Clin Res 23:264, 1975.
28. Low J, Oparil S, Erinoff L and Sauls R. Catecholamines, blood pressure and renin in the spontaneously hypertensive rat. Circulation 52:II-387, 1975.
29. Oparil S, Low J and Koerner T. Altered angiotensin I conversion in pulmonary disease. Circulation 52:II-382, 1975.
30. Oparil S, Pullman TN, Carone FA and Nakamura S. Inhibitors of renal tubular metabolism of bradykinin. Clin Res 24:513, 1975.
31. Nolten WE, Lindheimer MD, Oparil S, Rueckert P and Ehrlich EN. Regulation of desoxycorticosterone in pregnancy. Clin Res 24:513, 1975.
32. Oparil S, Carone FA, Pullman TN and Nakamura S. Inhibition of proximal tubular hydrolysis and reabsorption of angiotensin II by amino acids. Clin Res 24:556, 1976.
33. Oparil S, Cutilletta AF and Low J. Cardiac hemodynamics and hypertrophy in nerve growth factor antiserum treated spontaneously hypertensive rats. Am J Cardiol 37:161,1976.

34. Parent GT, Koerner TJ and Oparil S. Characteristics of plasma angiotensin I conversion in sarcoidosis and cord blood. Clin Res 24:234, 1976.
35. Cutilletta A, Erinoff L and Oparil S. Myocardial function and renin in the spontaneously hypertensive rat after central peripheral sympathectomy. Clin Res 24:214, 1976.
36. Nolten WE, Lindheimer MD, Oparil S, Biglieri EG and Ehrlich EN. Desoxycorticosterone (DOC) in pregnancy. Clin Res 24:275, 1976.
37. Oparil S and Bailie MD. Effects of renal hemodynamics on metabolism of angiotensin II (All) by the dog kidney. Fed Proc 35:704, 1976.
38. Carone FA, Oparil S, Pullman TN and Nakamura S. Inhibition of proximal tubular hydrolysis of bradykinin. Fed Proc 35:848, 1976.
39. Nolten WE, Lindheimer MD, Oparil S, Rueckert P and Ehrlich EN. Circadian patterns of plasma concentration and binding of cortisol and progesterone in pregnancy. Proceedings of the Endocrine Society 58th Annual Meeting, Abstract #534, 1976.
40. Oparil S, Benjamin M, Sodt P and Cutilletta A. Myocardial function and hypertrophy in immature spontaneously hypertensive rats after peripheral sympathectomy. Circulation 54:II-87, 1976.
41. Naftilan A and Oparil S. Structural requirements for the inhibition of renin release in vitro by the angiotensins. Circulation 54:II-176, 1976.
42. Parent G and Oparil S. Treatment of essential hypertension with a combination of hydrochlorothiazide, propranolol and methyldopa. Clin Res 24:521A, 1976.
43. Lindheimer MD, Oparil S and Katz AL. Renal function and sodium handling in pregnant (P) and nongravid (NP) spontaneous hypertensive rats. Clin Res 24:590A, 1976.
44. Cutilletta AF, Culpepper WS, Benjamin M and Oparil S. Cardiac hypertrophy in young spontaneously hypertensive rats before the onset of hypertension. Pediatr Res 11:388, 1977.
45. Peterson DR, Oparil S, Flouret G and Carone FA. Handling of angiotensin II and oxytocin by renal tubular segments perfused in vitro. Fed Proc 36:481, 1977.
46. Cutilletta AF and Oparil S. Cardiac hypertrophy in young spontaneously hypertensive rats before the onset of hypertension. Clin Res 25:214, 1977.
47. Nolten WE, Lindheimer MD, Oparil S, Rueckert PA and Ehrlich N. Circadian pattern and regulation of cortisol (F) secretion in pregnancy. Clin Res 25:465, 1977.
48. Nolten WE, Lindheimer MD, Oparil S, Rueckert P and Ehrlich EN. Increased secretion and regulation of desoxycorticosterone in pregnancy. Proceedings of the Endocrine Society 59th Annual Meeting, Abstract #100, 1977.
49. Oparil S and Lagocki R. Acid activation of "renin" in the rat. Circulation 56:II-832, 1977.

50. Oparil S, Gaynes R and Szidon JP. Conversion of des-I-Asp angiotensin I to angiotensin II in the dog. *Circulation* 56:II-915, 1977.
51. Wallach R, Karp RB, Reves JG, Oparil S and James TN. Mechanism of hypertension after saphenous vein bypass surgery. *Circulation* 56:II-544,1977.
52. Gupta R, Beck C, Szidon JP and Oparil S. Serum angiotensin converting enzyme (SACE) in various stages of treated and untreated sarcoidosis. *Clin Res* 25:626, 1977.
53. Szidon JP, Bairey CN and Oparil S. Effect of hypoxia on in vivo conversion angiotensin I to II in dogs. *Clin Res* 25:627, 1977.
54. Nolten WE, Lindheimer MD, Oparil S and Ehrlich EN. Changing patterns of corticoid responses to ACTH during normal pregnancy. *Clin Res* 25:606, 1977.
55. Peterson DR, Chrabaszez G, Peterson WR and Oparil S. Mechanism for renal tubular handling of angiotensin. *Fed Proc* 37:467, 1978.
56. Naftilan AJ and Oparil S. Calcium dependence of angiotensin II induced inhibition of renin release in vivo. *Clin Res* 26:511A, 1978.
57. Szidon J P, Bairey CN and Oparil S. Effect of hypoxia on in vivo conversion angiotensin I to II in dogs. *Clin Res* 26:454A, 1978.
58. Nolten WE, Lindheimer MD, Oparil S and Ehrlich EN. Secretory patterns and altered tissue binding of cortisol in pregnancy. *Clin Res* 26:493A, 1978.
59. Bishop SP, Reynolds RH, Drummond JL and Oparil S. Regional cell size of isolated cardiac myocytes from spontaneously hypertensive rats. *Circulation* 58:II-241, 1978.
60. Katholi RE, Oparil S, Urthaler F and James TN. The mechanism of post-arrhythmic renal vasoconstriction in the dog. *Circulation* 58:II-213, 1978.
61. Naftilan AJ and Oparil S. Effects of altered sodium intake on sensitivity to inhibition of renin release by angiotensin II in rat renal cortical slices. *Clin Res* 26:699A, 1978.
62. Szidon JP, Bairey N and Oparil S. Effect of acute hypoxia on in vivo conversion of angiotensin I to II in dogs. *Fed Proc* 38:1380,1979.
63. Katholi RE, Naftilan AJ and Oparil S. The effect of renal denervation on the development of DOCA-salt hypertension in the rat. *Clin Res* 27:467A, 1979.
62. Oparil S, Carone FA and Pullman TN. Renal tubular handling of glucagon and insulin. *Clin Res* 27:498A, 1979.
65. Gupta RG, Bekerman C, Sicilian L, Oparil S and Szidon JP. Gallium-67 citrate scanning and serum angiotensin converting enzyme levels as indicators of disease activity in sarcoidosis. *Clin Res* 27:705A, 1979.
66. Oparil S, Daise M and Szidon JP. Release of angiotensin converting enzyme by 48/80 in isolated rat lungs. *Clin Res* 27:706A, 1979.

67. Peterson DR, Carone FA, Oparil S and Christensen EI. Effect of molecular size and structure on renal tubular processing of peptides. Clin Res 27:710A, 1979.
68. Winternitz S, Katholi R, Naftilan A and Oparil S. Role of renal sodium retention in the pathogenesis of hypertension in the spontaneously hypertensive rat. Circulation 60:II-175, 1979.
69. Nolten WE, Lindheimer MD, Oparil S and Ehrlich EN. Elevated free plasma levels and decreased tissue binding of cortisol in pregnancy: Suggestive evidence of refractoriness to cortisol. Presented at the 60th Annual Meeting of the Endocrine Society, Miami, Florida, June 14-16, 1978. Endocrinology 102:343, 1978.
70. Katholi RE, Naftilan AJ, Bishop SP and Oparil S. The effect of renal denervation on the maintenance of DOCA-salt hypertension in the rat. Clin Res 27:782A, 1979.
71. Winternitz SR, Katholi RE and Oparil S. The contribution of enhanced renal sympathetic tone to the development of hypertension in the spontaneously hypertensive rat. Clin Res 27:783A, 1979.
72. Oparil S, Winternitz SR and Szidon JP. Effects of hypoxia on conversion of angiotensin I to II in the isolated perfused rat lung. Clin Res 28:530A, 1980.
73. Katholi RE, Bishop SP, Oparil S and James TN. Renal function during reflexly activated catecholamine flow through an adreno-renal rete in the dog. Clin Res 28:451A, 1980.
74. Oparil S, Gould V, Daise M. and Szidon JP. Effects of 48/80 on angiotensin converting enzyme in isolated rat lungs. Clin Res 28:430A, 1980.
75. Winternitz S, Nikitovitch-Winer M, McLean B and Oparil S. Effect of hypothalamic deafferentation on the development of DOCA-NaCl hypertension in the rat. Seventh Scientific Meeting of the International Society of Hypertension, New Orleans, Louisiana, May, 1980, p. 144.
76. Long M, Oparil S and Katholi RE. Modification of vascular wall calcification in hypertension. Fed Proc 39:1791, 1980.
77. Naftilan A and Oparil S. Dependence of renin release on renin stores in rat renal cortical slices. Seventh Scientific Meeting of the International Society of Hypertension, New Orleans, Louisiana, May, 1980, p. 94.
78. Katholi RE, Naftilan A, Bishop S and Oparil S. Renal vasculature in established DOCA-salt hypertension in the rat. Seventh Scientific Meeting of the International Society of Hypertension, New Orleans, Louisiana, May, 1980, p. 63.
79. Oparil S. Analytic procedures for the renin-angiotensin-aldosterone system, and their implications in hypertension. Clin Chem 26:948, 1980.
80. Oparil S and Szidon JP. Effects of oxygen toxicity on conversion of angiotensin I to II in the isolated perfused rat lung. Clin Res 28:781A, 1980.

81. Reynertson R, Oparil S and Roden L. Incorporation of ³⁵S-sulfate into aortic glycosaminoglycans of spontaneously hypertensive rats. Clin Res 28:827A, 1980.
82. Wilkins LH, Winternitz SR, Oparil Sand Dustan H. Lofexidine in essential hypertension: Double blind comparison with clonidine. Clin Res 28:818A, 1980.
83. Shepard LS, Gelman S, Reves JG and Oparil S. Humoral response of hypertensive patients to laryngoscopy. 55th Congress of the International Anesthesia Society, Atlanta, Georgia, March, 1981, pp. 107-108.
84. Reves JG, Karp RB, Oparil S, Samuelson PN, Tosone S and Smith LR. Catecholamine changes during cardiopulmonary bypass: the stress response and role of the lungs in modulating it. Anesthesia and Analgesia 60:272-273,1981.
85. Shepard LS, Gelman S, Reves JG and Oparil S. Humoral response of hypertensive patients to laryngoscopy. Anesthesia and Analgesia 60:276-277, 1981.
86. Oparil S, Abrahams C and Szidon JP. Effects of oxygen toxicity on conversion of angiotensin I to II in the isolated perfused rat lung. Clin Res 29:450A, 1981.
87. Winternitz SR, Oparil S and Katholi RE. Decrease in hypothalamic catecholamines following renal denervation in one-kidney one-clip Goldblatt hypertensive rats. Clin Res 29:362A, 1981.
88. Katholi RE, Winternitz SR and Oparil S. Alterations in peripheral sympathetic activity following renal denervation in one-kidney one-clip Goldblatt hypertension in the rat. Clin Res 29:358A, 1981.
89. Oparil S, Allen DL and Winternitz SR. Effects of hyperoxia on whole body conversion of angiotensin I to II in the conscious rat. Fed Proc 40:487, 1981.
90. Winternitz SR and Oparil S. Increased sodium intake results in activity of the sympathetic nervous system in the spontaneously hypertensive rat. Proceedings of the Second Annual Conference of the Specialized Centers of Research in Hypertension, San Diego, California, April,1981.
91. Katholi RE, Winternitz SR and Oparil S. Decrease in peripheral sympathetic nervous system activity and in hypothalamic catecholamines following renal denervation in the one-kidney one-clip Goldblatt hypertensive rat. Proceedings of the Second Annual Conference of the Specialized Centers of Research in Hypertension, San Diego, California, April, 1981.
92. Oparil S. Review of therapeutic modalities acting directly via central pathways. Proceedings of the Second Annual Conference of the Specialized Centers of Research in Hypertension, San Diego, California, April, 1981.
93. Winternitz SR, Sutherland JC, Liu LS and Oparil S. Increased sodium intake results in enhanced activity of the sympathetic nervous system in the spontaneously hypertensive rat. Clin Res 29:525A, 1981.
94. Oparil S, Okuno T, Durr J and Lindheimer MD. Prevention of DOCA/NaCl hypertension in the rat by central sympatholytic treatment is unrelated to vasopressin. Clin Res 29:764A, 1981.

95. Szidon P, Oparil S, Booyse FM, Osikowicz G and Liu L-S. Effect of acute hypoxia on angiotensin metabolism by cultured endothelial cells. Clin Res 29:775A, 1981.
96. Katholi RE, Whitlow PL, Winternitz SR and Oparil S. Importance of the renal nerves in one-kidney one-clip and two-kidney one-clip Goldblatt hypertension in the rat. Proceedings of the 35th Annual Conference, Council for High Blood Pressure Research, p. 42, 1981.
97. Winternitz SR, Allen D and Oparil S. Influence of sodium intake on blood pressure and peripheral sympathetic activity during the development and maintenance of spontaneous hypertension. Circulation 64:IV-189, 1981.
98. Okuno T, Liu LS, Manning M and Oparil S. Effects of centrally administered prostaglandin E₂ on plasma renin activity and blood pressure in conscious rats. Circulation 64:IV-112, 1981.
99. Oparil S, Okuno T, Durr J and Lindheimer MD. Prevention of DOCA/NaCl hypertension in the rat by central sympatholytic treatment is unrelated to vasopressin. Circulation 64:IV-112, 1981.
100. Okuno T and Oparil S. Central effects of prostaglandin E₂ on blood pressure and plasma renin activity: role of the sympathoadrenal system and vasopressin. Clin Res 29:833A, 1981.
101. Winternitz SR, Wyss JM, Meadows JR and Oparil S. Influence of high sodium intake on blood pressure and norepinephrine content of hypothalamic nuclei in the spontaneously hypertensive rat. Clin Res 29:866A, 1981.
102. Reves JG, Buttner EE, Karp RB and Oparil S. Reperfusion of the heart with catecholamine rich whole blood during bypass: Clinical significance. Clin Res 30:215A, 1982.
103. Okuno T, Winternitz SR, Lindheimer MD and Oparil S. Central sympathectomy with 6-hydroxydopamine prevents DOCA/NaCl hypertension by mechanisms independent of vasopressin. Clin Res 30:338A, 1982.
104. Okuno T, Winternitz SR and Oparil S. Prevention of hypertension in the spontaneously hypertensive rat by chronic central administration of captopril. Clin Res 30:339A, 1982.
105. Winternitz SR, Wyss JM, Meadows JR and Oparil S. Increased noradrenergic activity in hypothalamic nuclei of spontaneously hypertensive rats on high sodium intake. Clin Res 30:511A, 1982.
106. Szidon P, Oparil S, Booyse FM, Osikowicz G and Liu L-S. Effect of acute hypoxia on angiotensin metabolism by cultured endothelial cells. Fed Proc 41:1749, 1982.
107. Berecek KH, Nagahama S and Oparil S. Altered vascular reactivity (VR) and baroreflex sensitivity induced by central administration of captopril (CP) in the spontaneously hypertensive rat (SHR). Clin Res 30:848A, 1982.
108. Wilkins LH, Oparil S, Dustan HP and Ody C. Efficacy of MK-421, a nonsulfhydryl-containing converting-enzyme inhibitor, in low renin essential hypertension. Clin Res 30:869A, 1982.
109. Winternitz SR, Okuno T, Ziegler MG and Oparil S. The role of peripheral and central noradrenergic mechanisms in the pathogenesis of DOCA-NaCl hypertension. Clin Res 30:849A, 1982.

110. Winternitz SR, Okuno T, Meadows JR and Oparil S. The influence of sodium on central adrenergic neurons in the spontaneously hypertensive rat. *Circulation* 66:II-363, 1982.
111. Rosivall L, Champion J, Navar LG, Rinder D and Oparil S. Intrarenal conversion of angiotensin I (AI) to angiotensin-11 (All) at normal and reduced renal blood flow in the anesthetized dog. *Am Soc Nephrol* 15:190A, 1982.
112. Nagahama S, Chen YF and Oparil S. Mechanism of the depressor effect of bromocriptine in the spontaneously hypertensive rat (SHR). *Fed Proc* 42:647, 1983.
113. Berecek KH, Winternitz SR and Oparil S. Enhanced sympathetic vasoconstrictor tone during high sodium (NA⁺) intake in the spontaneously hypertensive rat (SHR). *Fed Proc* 42:1261, 1983.
114. Berecek KH, Okuno T, Nagahama S and Oparil S (intr. by SR Winternitz). Altered vascular reactivity and baroreflex sensitivity induced by central administration of captopril (CP) in the spontaneously hypertensive rat (SHR). *Clin Res* 31:327A, 1983.
115. Berecek KH, Winternitz SR, Wyss JM and Oparil S. Exaggerated responsiveness to central sympathetic and alpha adrenergic stimulation in spontaneously hypertensive rats receiving high sodium intake. *Clin Res* 31:487A, 1983.
116. Oparil S, Horton R, Wilkins LH, Irvin J, Hammett DK and Dustan HP. Antihypertensive effect of enalapril (MK-421) in low renin essential hypertension: role of vasodilator prostaglandins. *Clin Res* 31:538A, 1983.
117. Larson JD, Dustan HP, Floyd ZE and Oparil S. Hemodynamic follow-up of treated hypertension with Doppler ultrasound. *Circulation* 68:III-1378, 1983.
118. Chen YF, Stamoutsos B, Lindheimer MD and Oparil S. Augmented circulating prolactin and vasopressin and hypothalamic vasopressin release in DOCA/NaCl hypertension. *Circulation* 68:III-1537, 1983.
119. Berecek KH, Nagahama S, Mitchum TN and Oparil S. Attenuated responsiveness to sympathetic stimulation in spontaneously hypertensive rats (SHR) after chronic central administration of captopril. *Circulation* 68:III-384, 1983.
120. Slate JB, Oparil S, Sheppard LC and Karp RB. Blood pressure oscillations in post surgical hypertension during automatic control. *Annals of Biomedical Engineering*, 1983.
121. O'Connor EF, Ellis TA, Chen YF and Oparil S. Basal release of striatal dopamine is higher in spontaneously hypertensive rats than in Wistar Kyoto controls. *Fed Proc* 43:925, 1984.
122. Peterson DR, Oparil Sand Hjelle JT. Renal handling of glucagon. *Fed Proc* 43:2104, 1984.
123. Nagahama S and Oparil S. Enhanced depressor effect of muscimol in the DOCA/NaCl hypertensive rat. 14th Annual Meeting of the Society for Neuroscience, Anaheim, California, 1984, p.711.

124. Chen YF, Nagahama S, Winternitz SR and Oparil S. Hyperresponsiveness of central and peripheral monoaminergic mechanisms to cold stress in 4 week DOCA/NaCl hypertensive rats. 14th Annual Meeting of the Society of Neuroscience, Anaheim, California, 1984, p. 717.
125. Dawson R, Nagahama S and Oparil S. Yohimbine-induced alterations in central and peripheral monoamines in hypertensive (SHR) and normotensive (WKY) rats. 14th Annual Meeting of the Society for Neuroscience, Anaheim, California, 1984, p. 713.
126. Sripanidkulchai B, Dawson R, Oparil S and Wyss JM. An analysis of p-aminoclonidine binding in rat kidney. 14th Annual Meeting of the Society for Neuroscience, Anaheim, California, 1984, p.714.
127. Chen YF, Dawson R and Oparil S. In Vivo determination of biogenic amine release in the DOCA/NaCl hypertensive rat. Circulation 70:II-316,1984.
128. Nagahama S, Dawson R and Oparil S. Enhanced Central α_2 -adrenergic activity in spontaneously hypertensive rat. Circulation 70:II-428, 1984.
129. Wyss JM, Aboukash N, Oparil S. Selective lesion of the renal afferents transiently lowers blood pressure in established 1 kidney, 1 clip Goldblatt hypertension. Circulation 70:II-429, 1984.
130. Dawson R, Wyss JM and Oparil S. Presynaptic control of norepinephrine release in the spontaneously hypertensive rat (SHR). Hypertension 6:786, 1984.
131. Dawson R, Wyss JM and Oparil S. Increased sodium elevates blood pressure and renal α_2 receptors and decreases renal NE in hypertensive rats. Clin Res 32:844A, 1984.
132. Nagahama S, Chen YF and Oparil S. Role of the adrenal medulla in the depressor action of bromocriptine. Clin Res 32:844A, 1984.
133. Sripanidkulchai B, Dawson R, Oparil S and Wyss JM. Multiple α_2 -noradrenergic receptors in kidney: an evaluation of their role in hypertension. Clin Res 32:845A, 1984.
134. Chen YF, Winternitz SR and Oparil S. Augmented norepinephrine content of hypothalamic and brainstem nuclei following cold stress in the DOCA-salt hypertensive rat. Clin Res 32:868A, 1984.
135. Rosivall L, Narkates AJ, Oparil S, and Navar LG. De novo formation of angiotensin II (All) in the kidney during stimulated renin secretion in anesthetized dogs. Am. Soc. Nephrology 17:165A, 1984.
136. Olson K, Kullman D, Narkates A, and Oparil S. Metabolism of angiotensin I by the trout gill. Fed Proc 44:850, 1985.
137. Lawler JF, Sanders BJ, Chen YF, Nagahama S and Oparil S. Hypertension produced by a high sodium diet in rats with one hypertensive parent. Fed Proc 44:1748, 1985.
138. Chen YF, Lindheimer MD and Oparil S. Mineralocorticoid (DOCA) stimulates hypothalamic vasopressin release in the rat. Clin Res 33:553A, 1985.

139. Chen YF and Oparil S. Reduced hypothalamic dopamine release in DOCA/NaCl hypertensive rats. Clin Res 33:553A, 1985.
140. Narkates AJ, Merrill R, Jackson R and Oparil S. Impaired pulmonary conversion of angiotensin I to angiotensin II in rats exposed to chronic hypoxia. Clin Res 33:608A, 1985.
141. Chen YF, Dawson R, Gist R and Oparil S. Reduced tuberoinfundibular dopaminergic function in DOCA/NaCl hypertensive rats. 67th Annual Meeting, The Endocrine Society, Baltimore, MD, 1985, p. 236.
142. Nagahama S, Chen YF, Lindheimer MD and Oparil S. Mechanism of the pressor action of LY171555 in conscious Sprague-Dawley rats. Hypertension 7:842, 1985.
143. Nagahama S and Oparil S. Blood pressure response to LY171555, a dopamine D-2 receptor agonist, in conscious and anesthetized rats. Circulation 72:III-53, 1985.
144. Smith SH, Bishop SP and Oparil S. Angiotensin II and cardiac hypertrophy in renal hypertension. Circulation 72:III-131, 1985.
145. Dawson R and Oparil S. Renal catecholamines in hypertension. Circulation 72:III-419, 1985.
146. Oparil S, Narkates AJ, Nagahama S and Jackson R. Functional significance of converting enzyme inhibition by chronic hypoxia in the rat. Clin Res 34:203A, 1986.
147. Oparil S, Narkates AJ and Jackson R. Chronic hypoxia inhibits angiotensin-converting enzyme in rat lung. Clin Res 34:227A, 1986.
148. Chen YF, Nagahama S and Oparil S. Hypertensive DOCA/NaCl rats exhibit reduced pressor response to the specific dopamine (D₂) agonist, LY171555. Clin Res 34:188A, 1986.
149. Chen YF and Oparil S. LY171555, a selective dopamine D₂ receptor agonist, inhibits in vivo striatal dopamine release in normotensive and hypertensive rats. Clin Res 34:177A, 1986.
150. Reynertson R and Oparil S. Hypertension-induced alterations of vascular proteoglycans in the Dahl salt-sensitive rat. Clin Res 34:189A, 1986.
151. Oparil S, Reed WG, Zusman RM, Wollam G, et al. Lisinopril compared to atenolol in hypertension. Clin Res 34:189A, 1986.
152. Chen YF, Jin HK, Gist R and Oparil S. The specific dopamine agonist, LY171555, decreases norepinephrine content of posterior hypothalamus in the normotensive rat but not in the DOCA/NaCl hypertensive rat. Clin Res 34:218A, 1986.
153. Chen YF, Jin HK, Gist R and Oparil S. The specific dopamine agonist, LY171555, selectively increases dopamine content of anterior hypothalamus in DOCA/NaCl hypertensive rat. Clin Res 34:188A, 1986.
154. Chen YF, Lindheimer MD and Oparil S. The specific dopamine agonist, LY171555, does not stimulate vasopressin release from hypothalamo-hypophyseal system in vitro. Clin Res 34:395A, 1986.

155. Oparil S, Narkates AJ and Jackson R. Reduced active site directed inhibitor binding to angiotensin-converting enzyme in lung of rats exposed to chronic hypoxia. Clin Res 34:694A, 1986.
156. Oparil S, Jin HK, Gist R and Chen YF. The specific dopamine agonist, LY171555, selectively increases dopamine content of anterior hypothalamus in DOCA/NaCl hypertensive rat. Fed Proc 45:194,1986.
157. Chen YF, Jin HK, Gist R and Oparil S. The specific dopamine agonist, LY171555, decreases norepinephrine content of posterior hypothalamus in the normotensive rat but not in the DOCA/NaCl hypertensive rat. Fed Proc 45:194, 1986.
158. Igarashi Y, Chen YF, Wyss JM and Oparil S. Rapid desensitization of the central pressor action of LY171555, a specific dopamine D₂ receptor agonist, in the conscious rat. Soc Neurosci Abstr, Vol 12, Part 2, p 964, 1986.
159. Chen YF, Jin HK, Gist R, Wyss JM and Oparil S. Decreased norepinephrine content of posterior and anterior hypothalamic areas of NaCl-sensitive spontaneously hypertensive rats during high NaCl intake. Soc Neurosci Abstr, Vol 12, Part 1, p 581, 1986.
160. Wyss JM, Liumsricharoen M, Sripairojthikoon W, Brown D, Gist R and Oparil S. Diets high in chloride but normal in sodium exacerbate hypertension in NaCl sensitive SHR. Presented at the 40th Annual Fall Conference and Scientific Sessions of the AHA Council for High Blood Pressure Research, October 7-10, 1986, Cleveland, OH.
161. Oparil S, Narkates AJ, Jackson RM. Extrapulmonary angiotensin-converting enzyme in rats exposed to chronic hypoxia. Circulation 74:II-89,1986.
162. Wyss JM, Sripairojthikoon W, Gist R, Oparil S. Renal sensory nerves do not contribute to SHR hypertension. Circulation 74:II-150,1986.
163. Sripairojthikoon W, Gist R, Oparil S, Wyss JM. The effects of renal denervation in NaCl sensitive SHR. Circulation 74:II-151,1986.
164. Jin H, Yang R-H, Chen YF, Oparil S. Arginine vasopressin lowers pulmonary arterial pressure in hypoxic rats. Clin Res 35:29A, 1987.
165. Jin H, Chen YF, Wyss JM, Meng QC, Oparil S. Reduced noradrenergic neuronal activity in anterior hypothalamus of NaCl-sensitive SHR following NaCl loading. Clin Res 35:39A, 1987.
166. Chen YF, Jin H, Oparil S. Conscious DOCA/NaCl hypertensive rats exhibit a blunted pressor response to the dopamine D₂ agonist quinpirole in the presence of enhanced sympathoadrenal discharge. Clin Res 35:16A, 1987.
167. Chen YF, Jin H, Gist R, Oparil S. Discontinuation of DOCA/NaCl treatment in chronic (4 wk) DOCA/NaCl hypertension leads to normalization of sympathetic nervous system function independent of blood pressure change. Clin Res 35:16A, 1987.
168. Igarashi Y, Wyss JM, Chen YF, Oparil S. D₂ receptors in the brainstem mediate the central pressor action of quinpirole (LY171555). Clin Res 35:18A, 1987.

169. Wyss JM, Jin H, Chen YF, Meng QC, Oparil S. Increased noradrenaline (NA) release in anterior hypothalamus may underlie the blood pressure (BP) lowering effects of Ca^{++} loading. Clin Res 35:40A, 1987.
170. Coshatt G, Narkates AJ, Robertson J, Oparil S, Berecek K. Brain renin-angiotensin (All) and the response to stress in the spontaneously hypertensive rat (SHR). Fed Proc 46:1239, 1987.
171. Yang R, Jin H, Oparil S, Wyss JM. Stimulation of anterior hypothalamic area α_2 adrenoceptors results in a greater depressor response in SHR-S on a diet containing 8% compared to 1% NaCl. Fed Proc 46:1457, 1987.
172. Chen YF, Meng Q, Jin H, Wyss JM, Oparil S. Decreased noradrenergic input in anterior hypothalamus of NaCl-sensitive SHR, but not NaCl-resistant SHR, following high NaCl intake. Fed Proc 46:1239, 1987.
173. Jin H, Yang RH, Chen YF, Jackson R, Oparil S. Arginine vasopressin lowers pulmonary arterial pressure in hypoxic rats by a V_1 receptor mediated mechanism. 30th Annual Aspen Lung Conference, Aspen, CO, June 10-13, 1987.
174. Jackson R, Ann H, Narkates A, Oparil S. ^{125}I -MK351 uptake by isolated, perfused rat lungs after hypoxia adaptation and subsequent hyperoxia exposure. Submitted 30th Annual Aspen Lung Conference, Aspen, CO, June 10-13, 1987.
175. Jin H, Yang RH, Chen YF, Jackson R, Oparil S. Infusion of arginine vasopressin induces sustained reduction in pulmonary arterial pressure in hypoxia adapted rats. Clin Res 35:534A, 1987.
176. Chen YF, Paul R, Jin H, Oparil S. The dopamine D_2 receptor agonist quinpirole stimulates atrial natriuretic peptide release in conscious normotensive and DOCA/NaCl hypertensive rats. Clin Res 35:440A, 1987.
177. Chen YF, Wyss JM, Jin H, Oparil S. Calcium loading prevents the NaCl induced exacerbation of hypertension and enhancement in sympathetic discharge in NaCl sensitive spontaneously hypertensive rats. Clin Res 35:440A, 1987.
178. Chen YF, Meng Q, Jin H, Wyss JM, Oparil S. Noradrenergic input to anterior hypothalamus of Dahl-salt sensitive rats is not altered following high NaCl intake. Soc Neurosci Abstr, Vol 13, Part 1, p. 746, 1987.
179. Thornton RM, Tucker DC, Oparil S. Enhanced pressor response to acute stress in spontaneously hypertensive rats on a high NaCl diet. Soc Neurosci Abstr, Vol 13, Part 1, p. 745, 1987.
180. Igarashi Y, Chen YF, Oparil S. Salt loading enhances pressor response to intravenous administration of a dopamine D_2 receptor agonist, quinpirole, in the spontaneously hypertensive rat. Soc Neurosci Abstr, Vol 13, Part 2, p. 747, 1987.
181. Sriparojthikoon W, Oparil S, Wyss JM. Upregulation of renal α_2 adrenoceptors in NaCl loaded SHR is not related to renal nerve activity. Soc Neurosci Abstr, Vol 13, Part 1, p. 744, 1987.

182. Jin H, Chen YF, Oparil S. Impaired release of atrial natriuretic peptide in NaCl loaded spontaneously hypertensive rats. *Hypertension* 10:372, 1987.
183. Yang RH, Jin H, Chen YF, Oparil S, Wyss JM. Ca^{++} loading prevents NaCl induced hypothalamic adrenoceptor abnormalities in SHR. *Circulation*, 76 (Suppl IV): IV-302, 1987.
184. Jin H, Yang RH, Chen YF, Jackson R, Oparil S. Arginine vasopressin infusion produces sustained attenuation of pulmonary hypertension in hypoxia adapted rats. *Circulation* 76 (Suppl IV): IV-470, 1987.
185. Shaw W, Shapiro D, Antonello J, Cressman M, Vlases P, Oparil S. Indomethacin does not blunt the antihypertensive effect of lisinopril. *Clin Pharmacol Ther* 41:219, 1987.
186. Magargal WW, King SJ, Oparil S, Booyse FM. Hypoxia stimulates thymidine incorporation by vascular smooth muscle cells cocultured with pulmonary endothelial cells. *Circulation* 76 (Suppl IV): IV-54, 1987.
187. Thornton RM, Gann DS, Oparil S. Enhanced ACTH release accompanies increased pressor response to cold stress in high NaCl fed spontaneously hypertensive rats. *Circulation* 76 (Suppl IV): IV-300, 1987.
188. Klangkalya B, Oparil S, Wyss JM. NaCl loading upregulates α_2 adrenoceptors in the anterior hypothalamic area of SHR. *Circulation*, 76 (Suppl IV): IV-346, 1987.
189. King SJ, Oparil S, Booyse FM. Hypoxia stimulates angiotensin-converting enzyme antigen synthesis in cultured porcine pulmonary artery endothelial cells. *Circulation* 76 (Suppl IV): IV-244, 1987.
190. Engstrom PC, Philips JB, King SJ, Oparil S, Booyse FM. Group B streptococcus and lung endothelial injury. *Clin Res* 36:78A, 1988.
191. Chen YF, Meng Q, Jin H, Wyss JM, Oparil S. Noradrenergic input to anterior hypothalamus of DOCA/NaCl hypertensive rats is not altered following high NaCl intake. *Clin Res* 36:17A, 1988.
192. Chen YF, Yang RH, Jin H, Wyss JM, Cragoe EJ, Oparil S. NaCl-sensitive spontaneously hypertensive rats exhibit exaggerated depressor response to the sodium (Na^+) channel blocker, 6-iodo-amiloride. *Clin Res* 36:37A, 1988.
193. Yang RH, Jin H, Chen YF, Jackson R, Oparil S. Arginine vasopressin lowers pulmonary arterial pressure in conscious rats adapted to chronic normobaric hypoxia. *Clin Res* 36:45A, 1988.
194. Jin H, Chen YF, Yang RH, Jackson R, Oparil S. Arginine vasopressin induces exaggerated release of atrial natriuretic peptide in conscious rats adapted to chronic hypoxia. *Clin Res* 36:44A, 1988.
195. Jin H, Yang RH, Chen YF, Jackson R, Oparil S. Pulmonary depressor effect of arginine vasopressin in hypoxia adapted rats is not mediated by soluble cyclic GMP or cyclo-oxygenase products. *Clin Res* 36:44A, 1988.

196. Thornton RM, Jin H, Yang RH, Oparil S. Cardiac output response to vasopressin and atrial natriuretic peptide in hypoxic and normoxic rats. *Clin Res* 36:38A, 1988.
197. Jin H, Yang RH, Chen YF, Jackson R, Oparil S. Atrial natriuretic peptide lowers pulmonary arterial pressure in conscious rats adapted to chronic normobaric hypoxia. *Clin Res* 36:44A, 1988.
198. Brown D, Sripairojthikoon W, Merrill R, Oparil S, Wyss JM. The hypotensive effect of Ca^{++} supplementation in NaCl loaded SHR is not dependent on reduced Na^{+} concentration. *Clin Res* 36:37A, 1988.
199. Mitchell V, Oparil S, Wyss JM. Sympathoinhibitory response of hypothalamic neurons to electrical stimulation is not altered by NaCl loading in salt sensitive spontaneously hypertensive rats. *Clin Res* 36:38A, 1988.
200. Jin HJ, Yang RH, Chen YF, Jackson RM, Oparil S. Chronic infusion of atrial natriuretic peptide prevents pulmonary hypertension in hypoxia adapted rats. *Clin Res* 36:625A, 1988.
201. Bounelis P, Magargal W, King SJ, Booyse FM, Oparil S, Miller DM. Hypoxia stimulates platelet-derived growth factor gene expression by pulmonary artery endothelial cells. *Clin Res* 36:503A, 1988.
202. Thornton RM, Oparil S. Vasopressin (VP) antagonist eliminates pressor response to cold exposure in spontaneously hypertensive rats (SHR). *Fed Proc* 2:A 1718, 1988 (Abstr. #8263).
203. Yang RH, Jin H, Chen YF, Jackson R, Oparil S. V_1 vasopressin receptor agonist lowers pulmonary arterial pressure in conscious hypoxic rats. *Fed Proc* 2:A724, 1988 (Abstr. #2481).
204. Jin H, Jackson R, Yang RH, Chen YF, Oparil S. Exaggerated vasodilator effect of atrial natriuretic peptide (ANP) in isolated perfused lungs from hypoxic rats. *Fed Proc* 2:A722, 1988 (Abstract #2473).
205. Engstrom PC, Philips JB, King SJ, Oparil S, Booyse FM. Endothelial cell release of angiotensin-converting enzyme is increased by group B streptococcus. American Thoracic Society, 1988.
206. Chen YF, Meng Q, Wyss JM, Jin H, Oparil S. Reduced noradrenergic input to anterior hypothalamus underlies genetically mediated NaCl sensitivity in spontaneously hypertensive rat. *J Hypertension* 6(Suppl 4):S736-S737 .
207. Elton T, Oparil S, Blalock JE. Purification of angiotensin II receptor binding protein using antibodies to a peptide encoded by angiotensin II complementary RNA. 12th Scientific Meeting of the International Society of Hypertension, 1988 (Abstr. #1140).
208. Jin H, Yang RH, Chen YF, Jackson RM, Oparil S. Chronic infusion of atrial natriuretic peptide prevents pulmonary hypertension in hypoxia adapted rats. *Am J Hypertension*, 1988.
209. Meng QC, King S, Oparil S. Purification of angiotensin-converting enzyme by HPLC. 12th International Symposium on Column Liquid Chromatography (HPLC'88), 1988.

210. Thornton RM, Wyss JM, Oparil S. Impaired reflex response to volume expansion in NaCl-sensitive spontaneously hypertensive rats. *Hypertension* 12:348, 1988.
211. Jin H, Yang RH, Chen YF, Oparil S. Enhanced depressor response to atrial natriuretic peptide in NaCl loaded spontaneously hypertensive rats. *Hypertension*, in press, 1988.
212. Yang RH, Chen YF, Wyss JM, Oparil S (SPON: King S). D₂ receptors in the posterior region of the nucleus tractus solitarius mediate the central pressor action of quinpirole (LY171555). *Soc Neurosci Abstracts*, Vol 114, Pt 1, p 502, 1988.
213. Chen YF, Jin H, Paul R, Nagahama S, Oparil S. Blunted pressor responsiveness to quinpirole, a DA D₂ agonist, in conscious DOCA/NaCl hypertensive rats is related to ANP release. *Soc Neurosci Abstracts*, Vol 14, Pt 1, p 615, 1988.
214. Thornton RM, Yang RH, Oparil S, Wyss JM. Lesions of the anterior hypothalamic area (AHA) in spontaneously hypertensive rats (SHR-S) decrease baroreflex response. *Soc Neurosci Abstracts*, Vol 14, Pt 2, p 974, 1988.
215. Jin H, Yang RH, Chen YF, Oparil S. Enhanced depressor response to atrial natriuretic peptide in NaCl loaded spontaneously hypertensive rats. *Circulation* 78:11-588, 1988.
216. Mozaffari MS, Jirakulsomchok S, Oparil S, Wyss JM. Diets high in NaCl cause only a slight transient increase in Na⁺ concentrations in the plasma and cerebrospinal fluid (CSF) in NaCl sensitive, spontaneously hypertensive rats (SHR-S). *Circulation* 78:II-542, 1988.
217. Jin H, Yang RH, Chen YF, Jackson R, Oparil S. Chronic infusion of atrial natriuretic peptide attenuates the development of pulmonary hypertension in hypoxia adapted rats. *Clin Res* 37:24A, 1989.
218. Jin H, Yang RH, Chen YF, Oparil S. Impaired release of atrial natriuretic peptide in NaCl loaded spontaneously hypertensive rats is independent of NaCl sensitivity. *Clin Res* 37:33A, 1989.
219. Chen YF, Oparil S. Gonadectomy retards the development of hypertension in young male spontaneously hypertensive rats (SHR). *Clin Res* 37: 16A, 1989.
220. Bounelis P, Anand IS, Hall MK, Oparil S. A unique yak hemoglobin may assist in adaptation to high altitude. *Clin Res* 37:16A, 1989.
221. Oparil S. Comparison between beta blockade and ACE inhibition in hypertension. Symposium on New Aspects on the Use of Converting-Enzyme Inhibition in Hypertension, Heart Failure and Kidney Diseases. Brussels, Belgium, October 8, 1988.
222. Jirakulsomchok S, Mozaffari MS, Oparil S, Wyss JM. Dietary Ca⁺⁺ prevents impaired natriuresis induced by a high NaCl diet in NaCl-sensitive spontaneously hypertensive rats (SHR-S). *Proceedings of the InterAmerican Society of Hypertension*, 1989.
223. Bounelis P, Anand IS, Hall MK, Oparil S. A unique yak hemoglobin may assist in adaptation to high altitude. *FASEB J* 3(Part 1):A839, 1989 (Abstr #3561).

224. Lipke DW, Olson KR, Meisheri KD, Oparil S. Glandular kallikrein (GK) liberates an angiotensin (A) II-like peptide from trout plasma. *FASEB J* 3(Part 1):A559, 1989 (Abstr#1940).
225. Jin H, Chen YF, Yang RH, Oparil S. Increased atrial natriuretic peptide content in anterior hypothalamic region of NaCl sensitive hypertensive rats. *FASEB J* 3(Part II):A1007, 1989 (Abstr #4539).
226. Thornton RM, Oparil S. Abnormal arterial baroreflex function in NaCl-sensitive spontaneously hypertensive rats. *FASEB J* 3(Part II):A1312, 1989 (Abstr #6313).
227. Wyss JM, Mozaffari MS, Abrahamson DR, Oparil S, Curtis JJ. Cyclosporine-A (CY-A) accelerates hypertension and renal damage in deoxycorticosterone acetate (DOCA) treated rats on a high NaCl diet. *FASEB J* 3(Part III): A1315, 1989 (Abstr #6332).
228. Chen YF, Yang RH, Cragoe EJ, Oparil S. NaCl-sensitive spontaneously hypertensive rats exhibit an exaggerated pressor response to the sodium-proton exchange inhibitor, 5-(N,N-hexamethylene) amiloride. *Clin Res* 37:393A, 1989.
229. Jin H, Yang RH, Chen YF, Jackson R, Oparil S. Peptide agonist of the atrial natriuretic peptide clearance receptor lowers pulmonary artery pressure in hypoxia adapted rats. *Clin Res* 37:579A, 1989.
230. Chen YF, Oparil S. The development of hypertension in male spontaneously hypertensive rats is androgen dependent. *Clin Res* 37:552A, 1989.
231. Chen YF, Meng Q, Wyss JM, Jin H, Oparil S. Reduced noradrenergic input to anterior hypothalamus underlies genetically mediated NaCl sensitivity in the spontaneously hypertensive rat. *J Hypertension* 6(Suppl 4):S736-S737, 1988.
232. Meng QC, King SJ, Oparil S. Purification of angiotensin-converting enzyme from human lung by HPLC. Submitted to the American Chemical Society, 1989.
233. Wang R, Chen YF, Yang RH, Oparil S. Atrial natriuretic peptide inhibits lumbar sympathetic nerve activity in NaCl-sensitive spontaneously hypertensive rats. *Hypertension* 14(3):357, 1989 (Abst #20).
234. Yang RH, Chen YF, Jin H, Shao Z, Oparil S. Impaired release of atrial natriuretic peptide in response to acute volume expansion in NaCl-sensitive spontaneously hypertensive rats. *Hypertension* 14(3):357, 1989 (Abst #67).
235. Mozaffari MS, Oparil S, Wyss JM. Unilateral nephrectomy induces salt-sensitivity in NaCl resistant SHR (SHR-R). *Circulation* 80(4):II-414, 1989 (Abstr#1644).
236. Wyss JM, Mozaffari MS, Oparil S. NaCl sensitive spontaneously hypertensive rats (SHR-S) have reduced natriuretic and diuretic responses to volume load compared to NaCl resistant SHR-S. *Hypertension* 14(3):339, 1989 (Abstr #33).
237. Weir MR, Burris JF, Oparil S, Weber MA, Cady WJ. A multifactorial evaluation of the antihypertensive efficacy of the combination of diltiazem and hydrochlorothiazide. *Am J Hypertension* 2(Part 2):21A, 1989.

238. Chen YF, Elton T, Bounelis P, Jin H, Oparil S. Altered atrial natriuretic peptide gene expression in atria of rats adapted to chronic normobaric hypoxia. *Am J Hypertension* 2(Part 2):45A, 1989.
239. Jin H, Chen YF, Yang RH, Oparil S. Chronic infusion of atrial natriuretic peptide at physiological levels prevents NaCl-induced exacerbation of hypertension in NaCl loaded spontaneously hypertensive rats. *Am J Hypertension* 2(Part 2):68A, 1989.
240. Chen YF, Elton TS, Bounelis P, Jin H, Oparil S. Acute hypoxia increases atrial natriuretic peptide (ANP) gene expression in left atrium of the rat. *Clin Res* 38:18A, 1990.
241. Jin H, Yang RH, Chen YF, Jackson R, Oparil S. Atrial natriuretic peptide abolishes the pulmonary pressor response to acute hypoxia in the rat. *Clin Res* 38:19A, 1990.
242. Lipke DW, Oparil S, Couchman JR. Increased incorporation of ³⁵S₀₄ into cardiac and vascular proteoglycans of coarctation hypertensive rats. *Clin Res* 38:30A, 1990.
243. Yang RH, Jin H, Chen YF, Jackson RM, Oparil S. Cicletanine blunts the pulmonary pressor response to acute hypoxia in the rat. *Clin Res* 38:35A, 1990.
244. Meng QC, Chen YF, Durand J, Oparil S. Ultrasensitive method for catecholamine determination by HPLC-EC with microbore columns. Submitted to the ANABIOTEC Symposium, 1990.
245. Calhoun DA, Wyss JM, Oparil S. High NaCl diet enhances arterial baroreflexes in NaCl-sensitive spontaneously hypertensive rats. *Clin Res* 38:243A, 1990.
246. Chen YF, Naftilan AJ, Oparil S. Renal angiotensinogen and renin mRNA expression in spontaneously hypertensive rats is androgen dependent. *Clin Res* 38:429A, 1990.
247. Chen YF, Naftilan AJ, Oparil S. Salt loading and androgen regulate renal angiotensinogen and renin mRNA expression in the NaCl sensitive spontaneously hypertensive rat. *Clin Res* 38:430A, 1990.
248. Chen CW, Chen YF, Meng QC, Wyss JM, Oparil S. Decreased norepinephrine release in anterior hypothalamus of NaCl-sensitive SHR (SHR-S) following high NaCl intake. *Hypertension* 16:322, 1990. (Abstract #32).
249. Jin H, Yang RH, Wyss JM, Chen YF, Oparil S. Chronic infusion of clonidine into anterior hypothalamic area prevents NaCl induced exacerbation of hypertension in spontaneously hypertensive rats. *Hypertension* 16:340, 1990. (Abstract #P13).
250. Pascual DW, Jin H, Oparil S. The ineffectiveness of interleukin-2 as an anti-hypertensive agent in spontaneous hypertensive rat (SHR). *Hypertension* 16:346, 1990. (Abstract #P38).
251. Yang RH, Jin H, Chen YF, Wyss JM, Oparil S. Blockade of endogenous hypothalamic atrial natriuretic peptide with monoclonal antibody lowers blood pressure in spontaneously hypertensive rats. *Circulation* 82:III-682, 1990. (Abstract #2709).
252. Yang RH, Jin H, Chen YF, Wyss JM, Oparil S. Blockade of endogenous atrial natriuretic peptide in nucleus tractus solitarii with monoclonal antibody increases blood pressure in the spontaneously hypertensive rat. *Clin Res* 38:947A, 1990.

253. Jin H, Yang RH, Chen YF, Wyss JM, Oparil S. Altered stores of atrial natriuretic peptide in specific brain nuclei of NaCl-sensitive spontaneously hypertensive rats. *Clin Res* 38:947A, 1990.
254. Jin H, Yang RH, Wyss JM, Chen YF, Oparil S. Exaggerated depressor response to chronic infusion of clonidine into anterior hypothalamic area in high NaCl fed NaCl-sensitive spontaneously hypertensive rats. *Clin Res* 38:948A, 1990.
255. Polansky D, Thomas S, Snyder R, Eldridge C, Oparil S, Naftilan A and Miller DM. Selective inhibition of C-MYC expression prevents smooth muscle proliferation in response to serum. *Clin Res* 38:972A, 1990.
256. Yang RH, Jin H, Chen YF, Jackson R, Nakao K, Imura H, Itoh H, Mukoyama M, and Oparil S. Monoclonal antibody against atrial natriuretic peptide enhances pulmonary pressor response to hypoxia in rats. *Am J Hypertension* 3:75A, 1990. (Abstract #1110).
257. Jin H, Yang RH, Chen YF, Durand J, Wyss JM and Oparil S. Antihypertensive effect of ciclectanine is exaggerated in NaCl-sensitive hypertension. *Am J Hypertension* 3:104A, 1990. (Abstract #1109).
258. Berecek KH, Chen YF and Oparil S. Atrial natriuretic peptide (ANP) in neuronal cells from normotensive (WKY), spontaneously hypertensive (SHR) and captopril (CAP) treated rats. *FASEB* 5:A1068, 1991 (Abstract #4051).
259. Lipke DW, Oparil S and Couchman JR. Alterations in basement membrane (BM) components in coarctation hypertensive (CH) rats. *FASEB* 5:A1482, 1991 (Abstract #6446).
260. Jin H, Yang RH, Chen YF and Oparil S. Ganglion atrial peptide in NaCl sensitive spontaneously hypertensive rats. *Clin Res* 39:172A, 1991.
261. Jin H, Yang RH, Chen YF and Oparil S. Plasma cyclic-GMP is unresponsive to dietary NaCl in NaCl sensitive spontaneously hypertensive rats. *Clin Res* 39:173A, 1991.
262. Chen YF, Elton T and Oparil S. Competitive polymerase chain reaction for quantitation of hypothalamic ANP mRNA in NaCl-sensitive spontaneously hypertensive rats. *Clin Res* 39:257A, 1991.
263. Yang RH, Jin H, Wyss JM and Oparil S. Blockade of angiotensin II receptors in anterior hypothalamus lowers blood pressure in spontaneously hypertensive rats. *Clin Res* 39:350A, 1991.
264. Yang RH, Jin H, Wyss JM, Chen YF and Oparil S. Microinjection of monoclonal antibody to atrial natriuretic peptide into nucleus tractus solitarii increases blood pressure in spontaneously hypertensive rats. *Am J Hypertens* 4:3A, 1991.
265. Oparil S, Chen YF and Wang RP. Intracerebroventricular administration of atrial natriuretic peptide inhibits lumbar sympathetic nerve activity in NaCl-sensitive spontaneously hypertensive rats. *Am J Hypertens* 4:74A, 1991 (Abstract #203).
266. King SJ, Berecek KH and Oparil S. Angiotensin converting enzyme (ACE) inhibitors enhance ACE gene expression. *Am J Hypertens* 4:81A, 1991 (Abstract #229).

267. Berecek KH, Chen YF and Oparil S. Atrial natriuretic peptide (ANP) in neuronal cells from normotensive (WKY), spontaneously hypertensive (SHR) and captopril (CAP) treated rats. *Am J Hypertens* 4:81A, 1991 (Abstract #231).
268. Calhoun DA and Oparil S. Treatment of Hypertensive Crisis. *Cardiology Digest* 5:22-23, 1991.
269. Jin H, Mathews C, Chen YF, Yang RH, Esunge P and Oparil S. Chronic blockade of neutral endopeptidase with SCH 34826 prevents NaCl-sensitive hypertension in spontaneously hypertensive rats. *Hypertension* 18:415, 1991. Abstract #P72.
270. Yang RH, Jin H, Wyss JM and Oparil S. High NaCl intake enhances the depressor effect of angiotensin II receptor blockade in anterior hypothalamic area of NaCl-sensitive spontaneously hypertensive rats. *Hypertension* 18:421, 1991. Abstract #P95.
271. Jin H, Yang RH, Wyss JM, Chen YF and Oparil S. Pressor effect of blocking endogenous atrial natriuretic peptide in nucleus tractus solitarius of spontaneously hypertensive rats is independent of NaCl sensitivity. *Circulation* 84:II-661, 1991. Abstract #2628.
272. Calhoun D, Seravalle G, Bolla G, Oparil S and Grassi G. Physical training enhances arterial baroreflex control of heart rate and sympathetic nerve activity. *Clin Res* 39:(4):834A, 1991.
273. Nakamura Y, Chen YF, Wyss JM and Oparil S. Dietary NaCl supplementation exacerbates the defect in cardiopulmonary baroreflex function in NaCl-sensitive spontaneously hypertensive rats. *Clin Res* 39:(4):834A, 1991.
274. Yang RH, Jin H, Wyss JM and Oparil S. Microinjection of atrial natriuretic peptide into nucleus tractus solitarius blunts baroreceptor reflex in spontaneously hypertensive rats. *Clin Res* 39:(4):834A,1991.
275. Jin H, Yang RH, Wyss JM and Oparil S. Acute blockade of neutral endopeptidase with SCH 34826 reverses the NaCl sensitive component of hypertension in spontaneously O. hypertensive rats. *Clin Res* 39:(4):834A, 1991.
276. King SJ, Berecek KH, Oparil S, Rydzewski B and Raizada M. Angiotensin-converting enzyme (ACE) gene expression is decreased after exposure to angiotensin II (Ang II) in vitro. *FASEB J* 6(Part I):A946, 1992 (Abstract #55).
277. Berecek KH, King SJ, Wu J-N, Oparil S, Rydzewski B and Raizada M. Effects of angiotensin II (All) in the presence and absence of subtype-specific All blockers on angiotensin converting enzyme (ACE) gene expression in central nervous system tissue. *FASEB J* 6(Part I):A1578, 1992 (Abstract 3717).
278. Pascual DW, Pascual VH, Oparil S, Bost KL, Kiyono H and McGhee JR. Macrophage depletion restores in vitro lymphoid function by immunocompromised spontaneously hypertensive rats (SHR). *FASEB J* 6(Part II):A1712, 1992 (Abstract #4491).
279. Yang RH, Jin H, Wyss JM and Oparil S. Antihypertensive effect of blocking AT₁ receptors in anterior hypothalamic area with DuP 753 in NaCl sensitive hypertension. *FASEB J* 6(Part II):A 1734, 1992 (Abstract #4622).

280. Jin H, Yang RH, Wyss JM and Oparil S. Blockade of endogenous atrial natriuretic peptide in nucleus tractus solitarii with monoclonal antibody enhances baroreceptor reflex in spontaneously hypertensive rats. *FASEB J* 6(Part II):A 1734, 1992 (Abstract #4623).
281. Oparil S, Chen YF, Hicks P and Elton TS. Normobaric hypoxia stimulates endothelin-1 gene expression in the rat. *Am J Hypertens* 5:3A, 1992.
282. Jin H, Yang RH, Wyss JM and Oparil S. Acute blockade of neutral endopeptidase with SCH 34826 reverses the NaCl sensitive component of hypertension in spontaneously hypertensive rats. *Am J Hypertens* 5:9A, 1992.
283. Yang RH, Jin H, Wyss JM, and Oparil S. Microinjection of atrial natriuretic peptide into nucleus tractus solitarii blunts baroreceptor reflex in spontaneously hypertensive rats. *Am J Hypertens* 5:16A, 1992.
284. Calhoun DA, Nakamura Y, Chen YF, Wyss JM and Oparil S. Dietary NaCl supplementation exacerbates the defect in cardiopulmonary baroreflex function in NaCl-sensitive spontaneously hypertensive rats. *Am J Hypertens* 5:23A, 1992.
285. Yang RH, Jin H, Calhoun D, Wyss JM and Oparil S. Atrial natriuretic peptide in nucleus tractus solitarii modulates baroreflex function in conscious spontaneously hypertensive rats. *Clin Res* 40:243A, 1992.
286. Jin H, Brock TA, Wyss JM, Yang RH and Oparil S. Increased intracellular calcium in hypothalamic cell preparation from salt-sensitive spontaneously hypertensive rats fed high NaCl diets. *Clin Res* 40:315A, 1992.
287. Jin H, Brock TA, Wyss JM, Yang RH and Oparil S. Increased intracellular calcium in hypothalamic cell preparation for salt-sensitive spontaneously hypertensive rats fed high NaCl diets. *International Society of Hypertension, Madrid, Spain, 1992.*
288. Jin H, Brock TA, Wyss JM, Yang RH and Oparil S. Increased intracellular calcium in hypothalamic cell preparation for salt-sensitive spontaneously hypertensive rats fed high NaCl diets. *Dietary Electrolyte Intake and Metabolic Disturbances in Hypertension, Satellite Symposium of the International Society of Hypertension, Paris, France, 1992.*
289. Oparil S, Yang RH, Jin H, Chen SJ and Wyss JM. Role of anterior hypothalamic angiotensin II in the pathogenesis of salt sensitive hypertension in the spontaneously hypertensive rat. *Dietary Electrolyte Intake and Metabolic Disturbances in Hypertension, Satellite Symposium of the International Society of Hypertension, Paris, France, 1992.*
290. Elton TS, Stephan CC, Taylor GR, Kimball MG, Martin MM, Durand JN, Oparil S. Isolation of two distinct type 1 angiotensin II receptor genes. *Hypertension* 20:411, 1992
291. Calhoun DA, Mutinga M, Collins AS, Wyss JM, Oparil S. Normotensive blacks have larger sympathetic response to cold pressor test than normotensive whites. *Clin Res* 40:(4): 843A, 1992.
292. Sun SD, Meng QC, Oparil S, Chen YF. Reduced aortic angiotensinogen mRNA expression in normotensive and hypertensive rats following high NaCl loading. *Clin Res* 41:(2): 167 A, 1993.

293. Li HB, Elton TS, Chen SJ, Oparil S, Chen YF. Acute hypoxia stimulates endothelin-A receptor gene expression in the lung of rats. *Clin Res* 41:(2):203A, 1993.
294. Meng QC, Durand J, Chen Y-F and Oparil S. A simplified method for quantitation of angiotensin peptides in tissue. *FASEB J* 7(Part II):A546, 1993 (Abstract 3169).
295. Chen SJ, Meng Q, Elton TS, Yano M, Oparil S and Chen YF. Endothelin-A receptor antagonist (BQ-123) prevents acute hypoxia induced pulmonary hypertension in rats. *FASEB J* 7(Part II):A649, 1993 (Abstract 3760).
296. Li HB, Elton TS, Chen SJ, Oparil S and Chen YF. Acute hypoxia stimulates endothelin-A receptor gene expression in the lung of rats. *FASEB J* 7(Part II):A650, 1993 (Abstract 3762).
297. Calhoun DA, Mutinga M, Wyss MJ and Oparil S. Normotensive but hypertensive blacks have greater sympathetic response to cold stress than whites. *Am J Hypertens* 6:18A, 1993.
298. Chen SJ, Meng Q, Elton TS, Yano M, Oparil S and Chen YF. Blockade of endothelin-A receptors abolishes acute hypoxia induced pulmonary hypertension in rats. *Am J Hypertens* 6:84A, 1993.
299. Wyss JM, van Groen T, Meng Q, Oparil S. Angiotensin converting enzyme (ACE) is selectively elevated in the temporal cortex of Alzheimer's patients. *Soc for Neuroscience* 19(1):80.9, 1993.
300. Kadisha I, King K, van Groen T, Oparil S and Wyss JM. Activity of anterior hypothalamic neurons is increased by high dietary NaCl in spontaneously hypertensive rats. *Soc for Neuroscience* 19(2):392.2, 1993.
301. Calhoun DA, Mutinga ML, Wyss JM and Oparil S. Blacks have greater sympathetic response to cold stress than whites. *Hypertension* 22(3):412, 1993.
302. Sun SD, Oparil S, Chen YR and Elton TS. Dietary NaCl regulates aortic angiotensin converting enzyme mRNA expression in normotensive rats. *Hypertension* 22(3):423, 1993.
303. Meng QC, Durand J, Chen YF and Oparil S. Effects of dietary salt on angiotensin peptides in kidney. *Hypertension* 22(3):441, 1993.
304. Calhoun DA, Muthoka L, Wyss JM and Oparil S. Black and white muscle sympathetic response to cold stress. *Circulation* 88:1-16, 1993. Abstract #0075.
305. Sun SD, Oparil S, Chen YF and Elton TS. Differential regulation of vascular angiotensinogen mRNA levels in normotensive and hypertensive rats by dietary salt. *Circulation* 88:I-416, 1993. Abstract #2235.
306. Li H, Elton TS, Chen SJ, Durand J, Chen YF and Oparil S. Chronic hypoxia stimulates pulmonary endothelin-1 and endothelin receptor gene transcript levels in rats. *Circulation* 88:I-285, 1993. Abstract #1521.
307. Meng QC, Durand J, Chen YF, and Oparil S. Effects of dietary salt on angiotensin peptides in kidney. *Circulation* 88:I-453, 1993. Abstract #2440.

308. Oparil S. Salt-Sensitive Hypertension: Lewis K. Dahl Memorial Lecture. *Circulation* 88: I-F, 1993.
309. Sun SD, Oparil S, Elton TS and Chen YF. Effects of dietary NaCl on tissue renin mRNA in normotensive and hypertensive rats. *Clin Res* 41:(4):757 A, 1993.
310. Chen SJ, Oparil S, Meng QC, Elton TS, Yano M and Chen YF. The endothelin-A receptor antagonist BQ-123 prevents acute hypoxia induced pulmonary hypertension in the rat. *Clin Res* 41:(4):775A, 1993.
311. Chen SJ, Oparil S, Chen YF, Thomas S and Miller DM. Mithramycin inhibits myointimal proliferation after balloon injury of the rat carotid artery in vivo. *Clin Res* 41:(4):781A, 1993.
312. Chen SJ, Oparil S, Durand J, and Chen YF. Myointimal proliferation after balloon injury of carotid artery is reduced in female rats. *Clin Res* 41:(4):782A, 1993.
313. Sun SD, Oparil S, Elton TS and Chen YF. Differential expression of vascular and renal angiotensin converting enzyme mRNA in normotensive and hypertensive rats. *Clin Res* 41:(4):793A, 1993.
314. Zhu S-T, Calhoun DA, Oparil S and Wyss JM. The effects of high NaCl diet on blood pressure and blood pressure variability in spontaneously hypertensive rats. *Clin Res* 41:(4):794A, 1993.
315. Calhoun DA and Oparil S. Arterial baroreflex control of muscle sympathetic nerve activity in normotensive black and white subjects. *Clin Res* 41:(4):795A, 1993.
316. Zhu S-T, Calhoun DA, Oparil S, Wyss JM. The effects of High NaCl diet on blood pressure and blood pressure variability in spontaneously hypertensive rats. *J Hypertens* 12:Suppl 3:S24, 1994, Abstract #136.
317. Calhoun DA, Muntinga ML, Wyss JM, Oparil S. Race, family history of hypertension, and muscle sympathetic nerve activity response to cold pressor test. *J Hypertens* 12:Suppl 3:S56, 1994, Abstract #319.
318. Oparil S, Chen SJ, Meng QC, Elton TS, Yano M, Chen YF. The endothelin-A receptor antagonist BQ-123 prevents acute hypoxia induced pulmonary hypertension in the rat. *J Hypertens* 12:Suppl 3:S 123, 1994 Abstract #684.
319. Sun SD, Oparil S, Elton TS, Chen YF. Effects of dietary salt on tissue angiotensin converting enzyme mRNA levels in normotensive and hypertensive rats. *J Hypertens* 12:Suppl 3:S123, 1994, Abstract #685.
320. Oparil S, Chen SJ, Chen YF, Thomas S, Miller DM. Mithramycin inhibits myointimal proliferation after balloon injury of the rat carotid artery in vivo. *J Hypertens* 12:Suppl 3:S140, 1994 Abstract #770.
321. Chen SJ, Chen YF, Durand J and Oparil S. Gender differences in myointimal proliferation after balloon injury of carotid artery in normotensive rats. *Clin Res* 42:(2):177 A, 1994.

322. Chen YF, Chen SJ, Durand J and Oparil S. Myointimal proliferative response to balloon injury of the carotid artery is blunted in female spontaneously hypertensive rats. *Am J Hypertens* 7:22A, 1994 (Abstract #1375).
323. Chen YF, Li HB, Chen SJ, Meng QC and Oparil S. Differential regulation of hypoxia on gene expression of atrial natriuretic peptide receptors in rat lung. *Am J Hypertens* 7:96A, 1994 (Abstract #H31).
324. Chen SJ, Chen YF, Meng QC, Elton TS, Yano M and Oparil S. Chronic blockade of endothelin-A receptors with BQ-123 prevents hypoxia induced pulmonary hypertension in the rat. *Am J Hypertens* 7:96A, 1994 (Abstract #H32).
325. Calhoun DA, Zhu S-T, Wyss JM and Oparil S. Effects of high dietary NaCl on diurnal blood pressure variation in Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHR). *Am J Hypertens* 7:97 A, 1994 (Abstract #H33).
326. Calhoun DA and Oparil S. Arterial baroreflex control of muscle sympathetic nerve activity in normotensive black and white subjects. *Am J Hypertens* 7:97 A, 1994 (Abstract #H34).
327. Calhoun DA, Zhu S-T, Wyss JM and Oparil S. Atrial natriuretic peptide (ANP) Blunts baroreflex control of lumbar sympathetic nerve activity (LSNA) in spontaneously hypertensive rats (SHR). *FASEB J*(Part I):A8, 1994, (Abstract #43).
328. Oparil S, Chen SJ, Meng QC, Elton TS, Yano M and Chen YF. Chronic blockade of endothelin-A receptors with BQ-123 prevents hypoxia induced pulmonary hypertension in the rat. *Proceedings of Joint XIIth World Congress of Cardiology and XVth Congress of the European Society of Cardiology. Eur Heart J* 15:523, 1994.
329. Campese VM, Oparil S and Raji L. Atrial natriuretic factor in black salt-sensitive hypertensive patients. 48th Annual Fall Conference and Scientific Sessions AHA Council for High Blood Pressure Research. *Hypertension* 24(3):400, 1994.
330. DiCarlo VS, Chen SJ, Chen YF, Yano M and Oparil S. Chronic blockade of endothelin-A receptors with BQ-123 prevents hypoxia induced pulmonary hypertension and pulmonary vascular remodeling in rats. 67th Scientific Sessions AHA, November, 1994. *Circulation*, 90(4):I-6, 1994. (Abstract 0027)
331. Li HB, Oparil S, Meng QC and Chen YF. Selective down-regulation of atrial natriuretic peptide clearance receptor gene expression in lung of rats adapted to hypoxia. 67th Scientific Sessions AHA, November, 1994. *Circulation* 90(4):1-6,1994. (Abstract #0028)
332. Chen SJ, Chen YF, Meng QC and Oparil S. The endothelin receptor antagonist bosentan prevents short term hypoxia induced pulmonary hypertension in the rats. 67th Scientific Sessions AHA, November, 1994. *Circulation* 90(4):1-151,1994. (Abstract #807)
333. Sun S-D, Gladson C, Chen YF and Oparil S. Chronic hypoxia increases the number of endothelin-1 and endothelin-A receptor-positive vascular and alveolar cells in rat lung. 67th Scientific Sessions AHA, November, 1994. *Circulation* 90(4):1-152,1994. (Abstract #0810)

334. Zhu ST, Chen YF, Wyss JM, Calhoun D and Oparil S. C-type natriuretic peptide blunts arterial baroreflex control of sympathetic nerve activity and heart rate in spontaneously hypertensive rats. 67th Scientific Session AHA, November, 1994. *Circulation* 90(4):1-6, 1994. (Abstract #1536)
335. Dell'Italia LJ, Meng QC, Straeter-Knowlen I, Hanks GH, Bishop S, Oparil S and Elton T. Increased angiotensin peptide levels in cardiac tissue of dogs with chronic mitral regurgitation. 67th Scientific Sessions AHA, November, 1994. *Circulation* 90(4):1-451, 1994. (Abstract #2422)
336. DiCarlo VS, Chen SJ, Chen YF and Oparil S. Endothelin-A receptor antagonist, BQ-123, prevents and retards progression of chronic hypoxia-induced pulmonary hypertension in rats. *J Invest Med* 43(1):44A, 1995.
337. Sun SD, Chen YF and Oparil S. Altered angiotensin-converting enzyme gene expression in lung and extrapulmonary tissues of rats exposed to acute and chronic hypoxia. *J Invest Med* 43(1):46A, 1995.
338. Chen SJ, Chen YF and Oparil S. Sexual dimorphism of myointimal proliferation after balloon injury of rat carotid artery is estrogen dependent. *J Invest Med* 43(1):52A, 1995.
339. Meng QC, Balcells E, Elton TS, Durand J, Oparil S and Dell'Italia LJ. Relationship between angiotensin peptide levels and ace activity in blood and cardiac tissue of dogs. *J Invest Med* 43(1):53A, 1995.
340. Zhu ST, Calhoun DA, Chen YF and Oparil S. Sexual dimorphism in NaCl sensitivity of blood pressure in the spontaneously hypertensive rat. *J Invest Med* 43(1):64A, 1995.
341. Mutinga ML, Calhoun DA and Oparil S. Race and muscle sympathetic nerve reactivity to mental and physical stress. *J Invest Med* 43(1):65A, 1995.
342. Li HB, Chen YF, Elton TS and Oparil S. Hypoxia stimulates gene expression in human pulmonary microvessel endothelial cells by a mechanism that involves a heme-containing protein. *J Invest Med* 43(1):46A, 1995.
343. Peng N, Meng QC, Oparil S and Wyss M. Infusion of atrial natriuretic peptide (ANP) decreases the release of noradrenaline in spontaneously hypertensive rats of the Okamoto strain (SHR). *J Invest Med* 43(1):64A, 1995.
344. Oparil S. Natriuretic peptides in brain: Role in blood pressure. *Am J Hypertens* 8:11A, 1995.
345. Calhoun DA, Mutinga ML and Oparil S. Race and muscle sympathetic nerve reactivity to mental and physical stress. *Am J Hypertens* 8:32A, 1995.
346. Calhoun DA, Zhu ST, Chen YF and Oparil S. Sexual dimorphism in NaCl sensitivity of blood pressure in the spontaneously hypertensive rat. *Am J Hypertens* 8: 155A, 1995. (Abstract #A16)

347. Sun SD, Zhu ST, Meng QC, Chen YF, Calhoun D, Elton TS and Oparil S. Chronic administration of angiotensin-converting enzyme (ACE) inhibitors reduces blood pressure, cardiac hypertrophy and tissue ACE mRNA in spontaneously hypertensive rats. *J Invest Med* 43:265A, 1995.
348. Peng N, Meng QC, Oparil S and Wyss JM. Local infusion of atrial natriuretic peptide decreases the release of noradrenaline in the anterior hypothalamic area of spontaneously hypertensive rats: Interaction with dietary NaCl excess. *J Invest Med* 43:266A, 1995.
349. Zhu ST, Calhoun DA, Chen YF and Oparil S. Circadian variation more erratic in female than male spontaneously hypertensive (SHR) and Wistar-Kyoto normotensive rats (WKY). *J Invest Med* 43:267A, 1995.
350. Balcells E, Meng QC, Palmer R, Hageman G, Oparil S and Dell'Italia LJ. The physiologic significance of heart chymase in normal dogs. *J Invest Med* 43:268A, 1995.
351. Miller DM, Lambert C, Chen SJ, Chen YF and Oparil S. Mithramycin inhibits myointimal proliferation after balloon injury of the pig coronary artery in vivo. *J Invest Med* 43:271 A, 1995.
352. Chen SJ, Chen YF, Meng QC and Oparil S. The endothelin receptor antagonist Bosentan prevents and reverses chronic hypoxia induced pulmonary hypertension in the rat. *J Invest Med* 43:276A, 1995.
353. Li HB, Oparil S and Chen YF. Regulation of ANP-C receptor gene expression in human pulmonary vascular smooth muscle cells. *J Invest Med* 43:355A, 1995.
354. Oparil S. Natriuretic peptides in brain: role in blood pressure. *Am J Hypertens* 8:11A, 1995.
355. Calhoun DA, Mutinga ML, Oparil S. Race and muscle sympathetic nerve reactivity to mental and physical stress. *Am J Hypertension* 8:32A, 1995.
356. Calhoun DA, Zhu ST, Chen YF, Oparil S. Sexual dimorphism in NaCl sensitivity of blood pressure in the spontaneously hypertensive rat. *Am J Hypertens* 8:155A, 1995.
357. Balcells ES, Meng QC, Oparil S, Elton TS, Straeter-Knowlen I, Bishop SP, Hanks GH, Dillon RS and Dell'Italia LJ. Relationship between heart chymase and ACE activity in dogs with volume overload hypertrophy and increased cardiac angiotensin peptide levels. American College of Cardiology, 44th Annual Scientific Session, 223A, 1995. (Abstract 965-52)
358. Chen SJ, Chen YF and Oparil S. Sexual dimorphism of myointimal proliferation after balloon injury of rat carotid artery is estrogen dependent. American College of Cardiology, 44th Annual Scientific Session, 241A, 1995. (Abstract 968-28)
359. Meng QC, Balcells E, Dell'Italia LJ and Oparil S. Sensitive HPLC assay for membrane bound angiotensin converting enzyme in tissue. 4th International- 2nd Asian-Pacific Symposium on ACE Inhibition, Final Programme & Abstracts, p.99, 1995. (Abstract P.085)

360. Straeter-Knowlen IM, Hankes GH, Dillon AR, Cartee RE, Pohost GM, Meng QC, Balcells E, Oparil S and Dell'Italia LJ. Left ventricular compensation in experimental mitral regurgitation causes right ventricular compression and superfunction: Role of the local renin angiotensin system. Presented to American College of Veterinary Internal Medicine, 13th Annual Veterinary Medicine Forum, May 1995.
361. Peng N, Meng QC, Oparil S and Wyss JM. Increases in plasma sodium decrease noradrenaline release in the anterior hypothalamic area of spontaneously hypertensive rats (SHR). *Hypertension* 26(3):539, 1995.
362. Wyss JM, Peng N, Meng QC and Oparil S. Atrial natriuretic peptide regulation of noradrenaline release in the anterior hypothalamic area of spontaneously hypertensive rats (SHR). *Hypertension* 26(3):558, 1995.
363. Dell'Italia LJ, Balcells E, Meng QC, Bishop SP, Straeter-Knowlan I, Hankes G, Dillon R, Elton TS and Oparil S. Effect of ramipril on cardiac ultrastructure and intracardiac ACE activity and angiotensin II levels in chronic mitral regurgitation in the dog. *Circulation* 92:I-24, 1995. (Abstract #0114)
364. Chen SJ, Opgenorth T J, Wessale JL, Chen YF, DiCarlo VS, Meng QC and Oparil S. A-127722, an orally active antagonist of endothelin-A receptors, prevents short term hypoxia induced pulmonary hypertension in the rat. *Circulation* 92:I-323, 1995. (Abstract #1535)
365. Zhu ST, Calhoun DA and Oparil S. Ovariectomy induces NaCl-sensitivity in female spontaneously hypertensive rats. *Circulation* 92:I-348, 1995. (Abstract #1656)
366. Balcells E, Meng QC, Palmer R, Hageman GR, Oparil S and Dell'Italia LJ. Angiotensin II formation in dog heart is mediated by different pathways in-vivo and in-vitro. *Circulation* 92:I-669, 1995. (Abstract #3212)
367. Dell'Italia LJ, Meng QC, Balcells E, Bishop SF, Oparil S and Elton TS. Relative angiotensin converting enzyme and chymase activity in cardiac tissue of dogs with chronic mitral regurgitation. *J Mol Cell Cardiol* 27:A61, 1995.
368. Levine RL, Chen SJ, Durand J, Chen YF and Oparil S. 17- β estradiol but not medroxyprogesterone inhibits neointima formation after balloon injury of rat carotid arteries. *J Invest Med* 44:26A, 1996.
369. Levine RL, Anderson PG, Lyle K, Yadav SS, Oparil S and Roubin GS. 17- β estradiol inhibits restenosis after coronary angioplasty in pigs. *J Invest Med* 44:26A, 1996.
370. Chen SJ, Chen YF, Opgenorth T J, Wessale JL, Meng QC and Oparil S. A-127722, an orally active antagonist of the endothelin-A receptor, retards the progression of chronic hypoxia induced pulmonary hypertension in the rat. *J Invest Med* 44:47A, 1996.
371. Zhu ST, Calhoun DA, Chen YF and Oparil S. Ovariectomy induces NaCl-sensitivity in female spontaneously hypertensive rats. *J Invest Med* 44:66A, 1996.
372. Tian B, Meng QC, Chen YF, Krege JH and Oparil S. Phenotypic characterization of transgenic mice with "knockout" for the angiotensin converting enzyme. *J Invest Med* 44:67 A, 1996.

373. Tang W, Chen YF and Oparil S. Estrogen, but not androgen, inhibits the proliferation of cultured vascular smooth muscle cells derived from male and female spontaneously hypertensive rats. *J Invest Med* 44:68A, 1996.
374. Li H, Chen YF and Oparil S. Hypoxia enhances promoter activity of human endothelin-1 gene in transgenic mice. *J Invest Med* 44:78A, 1996.
375. Sun SO, Durand J, Chen YF and Oparil S. Hypoxia decreases atrial natriuretic peptide clearance receptor gene expression in pulmonary vascular smooth muscle cells in situ. *J Invest Med* 44:78A, 1996.
376. Balcells E, Meng QC, Oparil S, Dell'Italia LJ. Angiotensin II formation from angiotensin converting enzyme and chymase-like enzyme in the normal human heart and in hearts from various mammals. *J Am Coll Cardiol* 27:156A, 1996. (Abstract #745-2)
377. Levine RL, Anderson PG, Lyle K, Yadav SS, Oparil S, Roubin GS. 17- β estradiol inhibits neointima formation after coronary angioplasty in swine. *J Am Coll Cardiol* 27:320A, 1996. (Abstract 803-3)
378. Chen SJ, Brock T, Stavros F, Okun I, Wu C, Chan F, Mong S, Dixon RAF, Oparil S and Chen YF. TBC11251, a highly selective endothelin-a receptor antagonist, prevents and reverses acute hypoxia-induced pulmonary hypertension in the rat. *FASEB J* 10:A 104, 1996 (Abstract #601)
379. Zhu ST, Calhoun DA and Oparil S. NaCl-Sensitivity and sodium balance in spontaneously hypertensive rats. *FASEB J* 10:A632, 1996. (Abstract #3652)
380. Tian B, Chen YF and Oparil S. Selective enhancement of angiotensin converting enzyme (ACE) gene expression in the heart during the development and maintenance of pressure overload cardiac hypertrophy. *FASEB J* 10:A344, 1996. (Abstract #1988)
381. Yang GJ, Li H, Oparil S and Chen YF. Hypoxia decreases atrial natriuretic peptide clearance receptor (ANP-CR) gene expression in peripheral organs, but not in the brain, of rats. *FASEB J* 10:A27, 1996. (Abstract #155)
382. Li HB, Chen YF and Oparil S. Identification of the hypoxia-response element in the 5' flanking region of human endothelin-1 gene. *FASEB J* 10:A761, 1996. (Abstract #4399)
383. Tian B, Meng QC, Chen YF, Krege JH and Oparil S. Phenotype characterization of transgenic mice with "knockout" for the angiotensin converting enzyme (ACE). *J Hypertens* 14(1):P66, 1996.
384. Oparil S, Levine RL, Durand J, Chen YF and Chen SJ. 17- β estradiol but not medroxyprogesterone inhibits neointima formation after balloon injury of rat carotid arteries. *J Hypertens* 14(1):P319, 1996.
385. Peng N, Oparil S, Meng QC and Wyss JM. The role of anterior hypothalamic area noradrenaline in salt-sensitivity in male and female spontaneously hypertensive rats. *J Hypertens* 14(1):P789, 1996.

386. Dahlof B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm L, Nieminen M, Omvik P, Oparil S and Wedel H for the LIFE Study Group. Losartan Intervention For Endpoint Reduction in Hypertension (The LIFE Study). *J Hypertens* 14(1):P982, 1996.
387. Oparil S, Resnick LM, McCarron DA, Vanguard Study Group. Effects of a comprehensive nutrition program on CV risk factors in hypertension. *J Hypertens* 14(1):P1 097, 1996.
388. Chait A, Malinow R, Resnick L, Oparil S, Nevin D and McCarron DA on behalf of the Vanguard Study Group. A randomized control trial of the effects of a comprehensive risk reduction nutrition program on plasma homocysteine levels in hypertensives with associated cardiovascular risk factors. *Am J Hypertens* 9(4): 16A, 1996.
389. Dahlof B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm L, Nieminen M, Omvik P, Oparil S and Wedel H for the LIFE Study Group. Losartan Intervention for Endpoint Reduction in Hypertension (The Life Study). *Am J Hypertens* 9(4):26A, 1996.
390. McCarron DA, Resnick L and Oparil S on behalf of the Vanguard Study Group. Effects of a comprehensive nutrition program in subjects with a generalized cardiovascular and metabolic disease. *Am J Hypertens* 9(4):177A, 1996.
391. Levine RL, Anderson PG, Yadav SS, Lyle K, Oparil S and Roubin GS. Estrogen reduces neointima formation after coronary angioplasty in swine. *Restenosis Summit VIII*, April 1996. (Abstract #4)
392. Oparil S, Resnick LM and McCarron DA for Vanguard Study Group. Effects of a comprehensive nutrition program on cardiovascular risk factors. *Hypertens* 28(3):510, 1996. (Abstract #10)
393. Peng N, Meng QC, Oparil S and Wyss JM. Plasma volume loading increases noradrenaline release in the anterior hypothalamic area of spontaneously hypertensive rats (SHR). *Hypertens* 28(3):512, 1996. (Abstract #24)
394. Oparil S. Comparison study of a nutritionally complete meal plan with "usual care" risk reduction diet. *Circulation* 94(8):I-178, 1996. (Abstract #1032)
395. Dell'Italia LJ, Su X, Schultz D, Meng QC, Balcells E, Bishop SP, Machida N and Oparil S. Regulation of chymase gene transcript levels in the normal and volume overloaded dog heart in vivo. *Circulation* 94(8):I-187, 1996. (Abstract #1088)
396. Su X, Schultz D, Meng QC, Balcells E, Oparil S and Dell'Italia LJ. Regulation of angiotensin II type 1 receptor gene transcript levels in the normal and volume overloaded dog heart. *Circulation* 94(8):I-188, 1996. (Abstract #1090)
397. Perry GJ, Tian B, Chen YF, Meng QC, Kregge J and Oparil S. DOCA salt hypertension in ACE knockout transgenic mice: influence of genotype on cardiac hypertrophy and function. *Circulation* 94(8):1-662, 1996. (Abstract #3869)

398. White CR, Chen SJ, Durand J, Chen YF and Oparil S. Estrogen therapy facilitates the restoration of endothelial cell function in balloon-injured rats. *Circulation* 94(8):705, 1996. (Abstract #4124)
399. Levine RL, Chen SJ, Durand J, Chen YF and Oparil S. 17- β Estradiol but not medroxyprogesterone inhibits neointima formation after balloon injury of rat carotid arteries. *Circulation* 94(8):I-706, 1996. (Abstract #4129)
400. Dell'Italia LJ, Meng QC Balcells E, Palmer R, Hankes GH, Hageman G, Durand J and Oparil S. Comparison of angiotensin levels in intravascular and interstitial fluid compartments in the dog heart in-vivo by microdialysis. *Circulation* 94(8):I-725, 1996. (Abstract #4240)
401. Chen SJ, Chen YF, Shelton J, White CR and Oparil S. Estrogen stimulates reendothelialization of the balloon injured carotid artery. *J Invest Med* 45(1):P23A, 1997.
402. Shelton J, White CR, Chen SJ, Chen YF and Oparil S. Vasoprotective effects of estrogen in an experimental model of vascular injury. *J Invest Med* 45(1):P23A, 1997.
403. Tian B, Meng QC, Chen YF, Yang GJ and Oparil S. Intrarenal angiotensin II generation is preserved in mice lacking the angiotensin converting enzyme gene. *J Invest Med* 45(1):P58A, 1997.
404. Peng N, Wei CC, Oparil S, and Wyss JM. Local microperfusion of neutral endopeptidase inhibitor reduces norepinephrine release in the hypothalamic region of spontaneously hypertensive rats. *J Invest Med* 45(3):P238A, 1997.
405. Tian B, Wei CC, Meng QC, Chen YF, and Oparil S. Angiotensin II is preserved in mice lacking the angiotensin enzyme gene. *J Invest Med* 45(3):P248A, 1997.
406. Shelton J, White CR, Chen SJ, Chen YF, and Oparil S. Vasoprotective effects of estrogen in the balloon injured carotid artery. *J Invest Med* 45(3):P270A, 1997.
407. Oparil S, Abernethy DR, Levine BS, Reif MC, Sheperd AM, Kobrin I. Dose-response characteristics of mibefradil, a selective t-type calcium channel blocker in the treatment of essential hypertension. *Am J Hypertens* 10(4):P23A, 1997.
408. Oddou-Stock P, Gatlin M, Kobi P, Sullivan J, Hedner T, Rassmussen K, Rappelli A, Oparil S. Comparison of the efficacy of two angiotensin II antagonists, valsartan and losartan, in essential hypertension. *Am J Hypertens* 10(4):P84A, 1997. (Abstract #H29)
409. Barzilay J, Jordan J, Grimm R, Davis B, Oparil S, and the ALLHAT investigators. Characteristics of the diabetic cohort in the ALLHAT study. *Am J Hypertens* 10(4):86A, 1997. (Abstract #H40)
410. Weir MR, Cargo PH, Colasante D, McDevitt JT, Oparil S. Differential effects of calcium channel blockers on heart rate in women. *Am J Hypertens* 10(4):106A, 1997. (Abstract #D7)
411. Shelton JE, White CR, Chen SJ, Faye-Petersen O, Chen YF, Oparil S. Effects of gender on the reendothelialization of the balloon injured rat carotid artery. *Circulation* 96(8):I-548, 1997.

412. Oparil S, Chen SJ, Chen YF, Durand JN, Allen L, Thompson JA. Estrogen reduces cellular proliferation following carotid artery balloon injury in ovariectomized rats. *Circulation* 96(8):607, 1997.
413. McCarron DI, Oparil S, Kris-Etheron PM. Improved serum homocysteine (hcy) levels with a comprehensive nutrition plan in patients with cardiovascular (cv) risk factors. *Circulation* 96(8):657, 1997.
414. Wei Ch-Ch, Meng QC, Balcells E, Hageman GR, Palmer RW, Durand J, Hankes GH, Oparil S, Dell'Italia LJ. Evidence for chymase dependent angiotensin II formation in the interstitial fluid space of the dog heart. *Circulation* 96(8):628, 1997.
415. Chen SJ, Osbakken MD, Chen YF, Allen L, Durand JN, Oparil S. Angiotensin II type (AT1) receptor antagonist irbesartan and estrogen have profound but nonadditive inhibitory effects on neointima formation in balloon injured carotid arteries of ovariectomized rats. *Circulation* 96(8):608, 1997.
416. Oparil S, Chen SJ, Chen YF, Durand JN, Allen L, Thompson JA. Estrogen reduces cellular proliferation following carotid artery balloon injury in ovariectomized rats. *Circulation* 96(8):607, 1997.
417. McCarron D, Oparil S, Kris-Etheron P. Improved serum homocysteine (hcy) levels with a comprehensive nutrition plan in patients with cardiovascular (cv) risk factors. *Circulation* 96(8):657, 1997.
418. Biedeman RWW, Doyle M, Young A, Thrupp S, Kortright E, Perry G, Bella J, Devereux R, Oparil S, Pohost GM, Dell'Italia LJ. Evidence for marked disproportionate myocardial dysfunction in the septum in hypertensive left ventricular hypertrophy. *J Am Coll Cardiol* 31 (2):431A, 1998.
419. Thompson JA, Durand J, Chen SJ, Chen YF, Oparil S. Estrogen increases apoptosis following carotid artery balloon injury in ovariectomized rats. *J Invest Med* 46(1):30A, 1998.
420. Li G, Chen SJ, Chen YF, Durand J, Oparil S and Thompson JA. Adventitial fibroblast activation and migration contribute to neointima formation in balloon injured rat carotid arteries. In: North American Vascular Biology Organization (NAVBO), April 15-18, 1998. (Abstract #26)
421. Thompson, JA, Li G, Chen YF and Oparil S. Estrogen inhibits migration of adventitial fibroblasts in vitro. In: North American Vascular Biology Organization (NAVBO), April 15-18, 1998. (Abstract #27)
422. Tian B, Chen SJ, Chen YF, Oparil S and Thompson JA. Altered estrogen receptor expression in balloon injured rat carotid arteries. In: North American Vascular Biology Organization (NAVBO), April 15-18, 1998. (Abstract #170)
423. Oparil S. Comparison of eprosartan and enalapril on incidence of cough in hypertensive patients with history of ACE inhibitor-induced cough. *Am J Hypertens* 11:74A, 1998 (Abstract #D023)

424. Neutel J, Frishman W, Oparil S, Papademitriou V, and Guthrie G. A comparison of telmisartan with lisinopril in patients with mild to moderate hypertension. *Am J Hypertens* 11:15A, 1998. (Abstract #E080)
425. Ripley E and Oparil S. The addition of candesartan cilexetil to HCTZ enhances blood pressure reduction in black patients with severe (stage 3, JNC-VI) hypertension. *Am J Hypertens* 11:119A, 1998. (Abstract #E094)
426. Oparil S and Ripley E. Candesartan cilexetil enhances blood pressure reduction in severe (stage 3, JNC-VI) hypertensive patients inadequately controlled with HCTZ. *Am J Hypertens* 11:121A, 1998. (Abstract#E101)
427. Oparil S. Comparison of eprosartan and enalapril on incidence of cough in patients with essential hypertension. *J Hypertens* 16:S237, 1998. (Abstract #P31.033)
428. Neutel J, Frishman W, Oparil S, Papademitriou and Guthrie G. A comparison of telmisartan with lisinopril in patients with mild to moderate hypertension. *J Hypertens* 16:S245, 1998. (Abstract #P31.078)
429. Li G, Chen SJ, Chen YF, Durand J, Thompson JA and Oparil S. Adventitial fibroblasts contribute to neointima formation in balloon injured rat carotid arteries. *Circulation* 98:1-182, 1998. (Abstract #940)
430. Su X, Wei CC, Farrell DM, Hankes GH, Dillon SR, Rynders P, Oparil S, et al. Differential effects of angiotensin AT₁ receptor blockade on ANG II production in volume overload heart failure. *Circulation* 98:I-82,1998 (Abstract #414)
431. Li G, Chen YF, Oparil S and Thompson JA. Estrogen indirectly inhibits adventitial fibroblast migration. *Circulation* 98:I-676, 1998. (Abstract #3553)
432. Farrell DM, Wei CC, Bradley WE, Hageman G, Babu YS, Chen YF, Oparil S and Dell'Italia LJ. Inhibition of angiotensin II formation in the dog heart in-vivo by a novel serine protease inhibitor BCX-1470. *Circulation* 98:I-719,1998. (Abstract #3780)
433. Biederman RWW, Doyle M, Young A, Thrupp S, Kortright ME, Devereux RB, Pohost GM, Oparil S, Bartolucci AA, and Dell'Italia LJ. Distinctive deviation from normal strain patterns in left ventricular hypertrophy: Observations from the LIFE study. *J Am Coll Cardiol* 33:485A, 1999. (Abstract #910-3)
434. Oparil S and Michelson EL. Effects of candesartan cilexetil in patients with severe systemic hypertension. *J Am Coll Cardiol* 33:299A, 1999. (Abstract #872-6)
435. Mori T, Durand J, Chen YF , Thompson JA, and Oparil S. Short term estrogen treatment prior to and following balloon injury of rat carotid artery effectively blunts the vascular injury response. *J Am Coll Cardiol* 33:267 A, 1999. (Abstract #1132-21)
436. White WB, Johnson MF, Fakouhi TD, Oparil S, Sica DA and Black HR. Importance of gender and age in assessing the 24-hour blood pressure response to antihypertensive therapy. *Am J Hypertens* 12: 10A, 1999.

437. Oparil S and Michelson EL. Long term efficacy, safety, and tolerability of candesartan cilexetil added to hydrochlorothiazide in patients with severe systemic hypertension. *Am J Hypertens* 12: 120A, 1999. (Abstract #0040)
438. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristianson K, Pedersen OL, Lindholm LH, Nieminen MS, Omvik P, Oparil S, and Wedel H. One year of antihypertensive treatment in patients with LVH: The LIFE Study. *Am J Hypertens* 12: 142A, 1999. (Abstract #EO14)
439. Chen SJ, Durand J, Chen YF and Oparil S. Conjugated equine estrogen, but not raloxifene, inhibits neointima formation after balloon injury of carotid artery in ovariectomized rats. *FASEB13:A524*, 1999. (Abstract #422.1)
440. Mori T, Durand J, Chen YF, Thompson JA and Oparil S. Short-term estrogen treatment effectively blunts the vascular injury response in ovariectomized female rats. *FASEB J* 13:A524, 1999. (Abstract #422.4)
441. Oparil S. Estrogen modulates adventitial responses to endovascular injury. *Faseb J* 13:5(11) A693, 1999 (Abstract #S529)
442. Fang Z, Chen YF, Oparil S, Wyss JM. Induction of dietary NaCl-sensitive hypertension in female spontaneously hypertensive rats (SHR): role of estrogen. *Hypertension* 34:336, 1999. (Abstract #50)
443. Bakir SE, Chen SJ, Li G, Chen YF, Colasante D, Durand J, Oparil S. The synthetic estrogen receptor modulator raloxifene hydrochloride is not vasoprotective in the rat carotid injury model. *Circulation* 100:I-332,1999. (Abstract #1738)
444. Chen SJ, Li G, Chen YF, Durand J, Thompson JA, Oparil S. Activation and migration of syngeneic lacZ transduced adventitial fibroblasts contribute to neointima formation following endoluminal injury of rat carotid arteries. *Circulation* 100:I-546, 1999. (Abstract #2878)
445. Wei CC, Su X, Bishop SP, Oparil S, Hankes GH, Dillon SR, Mukherjee R, Spinale FG, Dell'Italia LJ. Afterload reduction and blockade of tissue renin angiotensin system does not improve left ventricular and cardiomyocyte remodeling in chronic mitral regurgitation. *Circulation* 100:1-863, 1999. (Abstract #4558)
446. Fang Z, Chen YF, Oparil S, Wyss M. Sympathetic nervous system over activity contributes to NaCl-sensitive hypertension in estrogen depleted female spontaneously hypertensive rats. In: *Society for Neuroscience 29th Annual Meeting (ASN)*, October 23-28, 1999. (Abstract #222.7)
447. Mori T, Bakir S, Chen YF, Oparil S. Estrogen-induced vasoprotection is estrogen receptor dependent: Evidence from the balloon injured rat carotid artery model. *J Am Coll Cardiol* 35:70A, 2000. (Abstract #1155-112)
448. Li G, Bakir SE, Oparil S, Thompson JA. Estrogen attenuates osteopontin production by activated smooth muscle cells: A potential mechanism of estrogen-induced vasoprotection. *J Am Coll Cardiol* 35:70A, 2000. (Abstract #1133-47).

449. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Faire U, Fyhrquist F, Ibsen H, Kristianson K, Pedersen OL, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Age-dependent event rate and reduction of coronary risk in hypertensive patients with LVH: The LIFE study. *Am J Hypertens* 13:60A; 2000 (Abstract # B018).
450. Oparil S, Pool J, Hedner T, Glazer R, Chiang Y. Valsartan provides effective antihypertensive response in older patients: an integrated analysis. *Am J Hypertens* 13:259A; 2000 (Abstract #G020).
451. Pool J, Oparil S, Hedner T, Glazer R, Chiang Y. Valsartan provides effective antihypertensive response in African-Americans: an integrated analysis. *Am J Hypertens* 13:261A; 2000 (Abstract #G025).
452. Pool J, Oparil S, Hedner T, Glazer R, Chiang Y. Valsartan is an effective antihypertensive in both women and men: an integrated analysis. *Am J Hypertens* 13:278A; 2000 (Abstract #1008).
453. Hedner T, Pool J, Oparil S, Glazer R, Chiang Y. Valsartan provides effective antihypertensive responses in older patients: an integrated analysis. *J Hypertens* 18(suppl 2):S42:2000 (Abstract #P1.1 04).
454. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Faire U, Fyhrquist F, Ibsen H, Kristianson K, Pedersen OL, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular complications in relation to the Framingham risk score and age in hypertensive patients with LVH: the life study. *J Hypertens* 18(suppl 2):S91;2000 (Abstract #P2.8).
455. Aurup P, Smith RD, Snavely D, Oparil S. The safety and efficacy of losartan hydrochlorothiazide in the treatment of patients with severe hypertension; a multicenter study. *J Hypertens* 18(suppl 2):S99;2000 (Abstract #P2.39).
456. Messerli F, Oparil S, Feng Z. Antihypertensive treatment: Low-dose combination vs high-dose monotherapy to uptitrate or to combine? Presented at the 18th Scientific Meeting of the International Society of Hypertension. *J Hypertens* 18(Suppl 4):S14, 2000 (Abstract 7A.04).
457. Kjeldsen S, Dahlof B, Devereux R, Julius S, Faire U, Fyhrquist F, Ibsen H, Kristianson K, Pedersen O, Lindholm L, Nieminen M, Omvik P, Oparil S, Wedel H. Age-dependent event rate and reduction of coronary risk in hypertensive patients with LVH: The Life Study. Presented at the 18th Scientific Meeting of the International Society of Hypertension. *J Hypertens* 18(Suppl 4): S35, 2000. (Abstract P1.16).
458. Pool J, Oparil S, Hedner T, Glazer R, Chiang Y. Valsartan provides effective antihypertensive response in African-Americans: An integrated analysis. Presented at the 18th Scientific Meeting of the International Society of Hypertension. *J Hypertens* 18: S39, 2000. (Abstract P1.35).
459. Pool J, Oparil S, Hedner T, Glazer R, Chiang Y. Valsartan is an effective antihypertensive in both women and men: An integrated analysis. Presented at the 18th Scientific Meeting of the International Society of Hypertension. *J Hypertens* 18:S44, 2000 (Abstract P1.65).
460. Oparil S, Sun JZ, Lucchesi P, Chen YF. Tyrosine kinase receptor activation, but not hypoxia, inhibits atrial natriuretic peptide clearance receptor expression in pulmonary arterial smooth muscle cells. *J Am Coll Cardiol* 37A, 2001 (Abstract P 225A, 1025-87).

461. Manchikalapudi P, Khan M, Arani R, Visra V, Liu M, Chapman G, Oparil S, Dean L. Estrogen use is associated with reduced need for target lesion revascularization in postmenopausal diabetic women after coronary stenting. *J Am Coll Cardiol*, 37A:81A, 2001. (Abstract 1295-30).
462. Mori T, Perry GJ, Feng JA, Oparil S, Chen YF. Cardiac enlargement in response to volume overload is exaggerated in mice with homozygous deletion of the atrial natriuretic peptide gene. *J Am Coll Cardiol* 37A:81A, 2001. (Abstract 1310-63)
463. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Predictors of cardiovascular events in 9,194 hypertensive patients with left ventricular hypertrophy, The LIFE Study. *Am J Hypertens*, 14:14A, 2001. (Abstract O-30)
464. Oparil S, Chrysant SG, Marbury T, Williams D, Neutel JM. CS-866 versus losartan, valsartan, and irbesartan in patients with essential hypertension. *Am J Hypertens*, 14:180A, 2001. (Abstract P-445)
465. Li G, Oparil S, Kelpke SS, Chen YF, Thompson JA. Fibroblast growth factor stimulation of osteopontin expression in vascular smooth muscle cells is dependent upon SRC/MEK signaling. *Circulation* 104:II-258, 2001. (Abstract 1237)
466. Sun JZ, Chen SH, Hassan EM, Oparil S, Chen YF. Selective downregulation of ANP-clearance receptor gene expression in kidney of ANP knockout mice fed a high-salt diet. *Circulation* 104:II-114, 2001. (Abstract 548)
467. Saunders E, Oparil S, Roniker B, Kleiman J, Karuse S, Workman D. Eplerenone vs. Losartan in black compared to white hypertensive patients. *Hypertension Res* 11:58, 2001.
468. Tolbert T, Bouchard P, Oparil, S. Estrogen reduces neointima formation independent of iNOS expression in mouse carotid ligation model of vascular injury. *JACC* 39:68A, 2002 (Abstract 1198-3).
469. Feng JA, Perry GJ, Oparil S, Chen YF, Mori T, Hayashi T, Kitaura Y. Volume overload-induced cardiac remodeling is exaggerated in mice with homozygous deletion of the atrial natriuretic peptide gene. *JACC* 3:170A, 2002 (Abstract 838FO-3).
470. Peng L, Oparil S, Chen YF. Fibroblast growth factor-1 stimulates endothelin-A receptor expression in pulmonary arterial smooth muscle cells via transcriptional activation. *FASEB Journal* 16: A1118, 2002 (Abstract 853.20).
471. Shelton J, Wang D, Oparil S, White CR. Effects of lipid lowering therapy on the vascular response to injury in a model of Type 2 diabetes. *FASEB Journal* 16: A1206, 2002 (Abstract 909.3).
472. Oparil S, Chen RS, Yuan Y, Whyte JL, L'Italien GJ, Reilly KA, Weber MA. Hypertension control rates and hypertensive subtypes in the year 2000: An analysis comparing the clinics-based path and population-based NHANES III Surveys. *Am J Hypertens* 15:144A, 2002 (Abstract P-314).

473. Doppalapudi H, Tolbert T, Oparil S. Estrogen reduces neointima formation independent of osteopontin expression in mouse carotid ligation model of vascular injury. *Am J Hypertens* 15:227A (Abstract P538).
474. Brunner HR, Oparil S, Graveline JF, Laesis P. Clinical comparisons of olmesartan medoxomil with other angiotensin II antagonists. *J Hypertension* 20:S166. 2002 (Abstract P0697).
475. Oparil, S. Effects of transverse aortic constriction on cardiac gene expression in the atrial natriuretic peptide knockout mouse. *Satellite Symposium on the Genetics of Experimental and Human Hypertension – V: From Mendel to Humans*, pp. 7, 2002.
476. Devereux RB, Dahlöf B, Kjeldsen SE, Julius S, Aurup P, Beevers G, Edelman J, de Faire U, Fyhrquist F, Harris K, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H. Cardiovascular morbidity and mortality in patients without pre-existing vascular disease in the Losartan Intervention For Endpoint reduction in Hypertension Study (LIFE). *Circulation* 106:II-475, 2002 (Abstract 2352).
477. Lindholm LH, Ibsen H, Borch-Johnson K, Olsen MH, Wachtell K, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S. New-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. *Circulation* 106:II-573, 2002 (Abstract 2830).
478. Tolbert T, Bouchard P, Denhardt D, Oparil S. Estrogen is vasoprotective in osteopontin deficient mice. *J Am Coll Cardiol* 41:15A, 2003 (Abstract 1031-176).
479. Li G, Wang D, Chen YF, Oparil S. Vascular injury induces expression of periostin: a novel vascular extracellular matrix protein via the PI3-kinase-MAP kinase pathway. *J Am Coll Cardiol* 41:34A, 2003 (Abstract 808-3)
480. Biederman RW, Doyle M, Young AA, Oparil S. Does 3-D strain analysis invalidate 2-D strain? Observations in hypertensive left ventricular hypertrophy from the LIFE trial using magnetic resonance imaging. *J Am Coll Cardiol* 41:229A, 2003 (Abstract 1011-138).
481. Li P, Oparil S, Chen YF. Hypoxia upregulates expression of periostin, a novel extracellular matrix protein, in rat lung via PI3 kinase-MAP kinase signaling pathway. *J Am Coll Cardiol* 41:308A, 2003 (Abstract 1201-121).
482. Feng JA, Perry, GJ, Wang D, Oparil S, Chen YF. Pressure Overload in the atrial natriuretic peptide deficient mouse: A novel model of heart failure. *Am J Hypertens* 16:26A, 2003 (Abstract OR-57).
483. Sheridan A, Feng JA, Perry GJ, Wang D, Oparil S, Chen YF. Atrial natriuretic peptide modulates pathologic but not physiologic left ventricular hypertrophy. *Am J Hypertens* 16:91A, 2003 (Abstract P-145).
484. Oparil S, Masonson HN. Antihypertensive efficacy of olmesartan medoxomil in hypertensive men compared with hypertensive women. *Am J Hypertens* 16:125A, 2003 (Abstract P-242).

485. Xing D, Miller AP, Smith M, Novak L, Chen YF, Oparil S. Ovarian hormones modulate the inflammatory response to vascular injury. *Am J Hypertens* 16:259A, 2003 (Abstract P-610).
486. Oparil S. Treating hypertension in the obese patient. *Am J Hypertens* 16:266A, 2003.
487. Ambalavanan N, Bulger A, Engler J, Murphy-Ullrich J, Chen YF, Oparil S. Endothelin-A receptor blockade prevents and reverses neonatal hypoxic pulmonary vascular remodeling. *Pediatr Res* 53:431A, 2003.
488. Ambalavanan N, Bulger A, Windsor J, Engler J, Murphy-Ullrich J, Chen YF, Oparil S. Hypoxia increases matrix metalloproteinase-2 in the neonatal pulmonary vasculature. *Pediatr Res* 53:431A-432A, 2003.
489. Calhoun DA, Dai L, Oparil S, White CR. Rosuvastatin-induced modulation of NO-dependent superoxide formation. *Hypertension* 42:435, 2003 (Abstract P163).
490. Kizer J, Dahlöf B, Kjeldsen SE, Julius S, Beevers G, De Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Wachtell K, Snapinn S, Edelman J. Benefits of losartan compared to atenolol in stroke prevention among patients with hypertension and left ventricular hypertrophy: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. *Circulation* 108:601-602, 2003 (Abstract 2735).
491. Oparil S, Davis BR, Nwachuku C, Pressel S, deLeon B. Stroke results in the Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial. *Stroke* 35:235, 2004 (Abstract 4).
492. Kizer JR, Alderman MH, Kjeldsen SE, Dahlöf B, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Edelman JM, Snapinn SM, Devereux RB. Serum uric acid and ischemic stroke risk among hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. *JACC* 43:475A, 2004 (Abstract 812-4).
493. Kjeldsen SE, Dahlöf B, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn SM, Wedel H, Lyle PA, the LIFE Study Group. Benefits of losartan on preventing stroke in patients with isolated systolic hypertension: A LIFE substudy. *JACC* 43:482A, 2004 (Abstract 1085-170).
494. Wang D, Oparil S, Chen YF. Atrial natriuretic peptide inhibits collagen production in cardiac fibroblast. *J Invest Med* 52:S262, 2004 (Abstract 33).
495. Sheridan AE, Feng JA, Wang D, Li P, Oparil S, Chen YF. Atrial natriuretic peptide modulates extracellular matrix expression in pathologic but not physiologic left ventricular hypertrophy. *J Invest Med* 52:S263, 2004 (Abstract 37).
496. Li P, Oparil S, Chen YF. Fibroblast growth factor upregulates periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells. *J Invest Med* 52:S288, 2004 (Abstract 178).

497. Feng W, Miller AP, Xing D, Chen YF, Oparil S. Estrogen attenuates inflammatory mediator mRNA expression in balloon injured rat carotid arteries. *J Invest Med* 52:S290, 2004 (Abstract 184).
498. Franco V, Feng JA, Perry G, Novak L, Fintel M, Chen YF, Oparil S. Impaired ventricular function and increased cardiac collagen in atrial natriuretic peptide-null mice exposed to pressure overload. *J Invest Med* 52:S306, 2004 (Abstract 278).
499. Miller AP, Feng W, Fintel M, Smith M, Xing D, Chen YF, Oparil S. Estrogenic vasoprotection is lost in aged rats. *J Invest Med* 52:S311, 2004 (Abstract 301).
500. Ambalavanan N, Bulger A, Murphy-Ullrich J, Anderson PG, Oparil S, Chen YF. Stimulatory effect of chronic hypoxia on extracellular matrix molecule expression in the neonatal mouse lung is partially dependent on endothelin-1 (ET-1). *Pediatr Res* 55: 499A, 2004.
501. Weathington NM, Miller AP, Feng JA, Xing D, Blalock JE, Chen YF, Oparil S. Ovarian hormones modulate neointima formation in an animal vascular injury model through effects on neutrophil chemokine production. *Am J Hypertens* 17:5A. 2004 (Abstract OR-8).
502. Wang D, Oparil S, Chen YF. Atrial natriuretic peptide inhibits collagen production in cardiac fibroblast. *Am J Hypertens* 17:7A, 2004 (Abstract OR-12).
503. Franco V, Chen YF, Feng JA, Hage F, Oparil S, Perry GJ. Atrial natriuretic peptide dose dependently inhibits cardiac remodeling after exposure to pressure overload. *Am J Hypertens* 17:86A, 2004 (Abstract P-147A).
504. Oparil S, Walker JF. Blood pressure goal attainment: comparative efficacy of olmesartan medoximil, losartan potassium, valsartan, and irbesartan. *Am J Hypertens* 17:118A, 2004 (Abstract P-235).
505. Li P, Oparil S, Chen YF. Fibroblast growth factor upregulates periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells. *Am J Hypertens* 17:172A, 2004 (Abstract P-378).
506. Reims HM, Kjeldsen SE, Devereux RB, Oparil S, Julius S, Brady WE, Dahlof B, the LIFE Study Group. Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE Study. *Am J Hypertens* 17:186A, 2004 (Abstract P-415).
507. Feng W, Miller AP, Xing D, Chen YF, Oparil S. Estrogen attenuates inflammatory mediator mRNA expression in balloon injured rat carotid arteries. *Am J Hypertens* 17:242A, 2004 (Abstract P-573).
508. Miller AP, Feng W, Fintel M, Smith M, Xing D, Chen YF, Oparil S. Estrogenic vasoprotection is lost in aged rats. *Am J Hypertens* 17:244A, 2004 (Abstract P-581).
509. Xing D, Feng JA, Franco V, Wang D, Oparil S, Chen YF. Myofibroblast transformation and collagen deposition in hearts of atrial natriuretic peptide-null mice are enhanced in response to pressure overload stress compared to wild-type controls. *Circulation* 110: III-96, 2004 (Abstract 453).

510. Wang D, Oparil S, Chen YF, McCrory MA, Szalai AJ. Neointima formation in response to carotid artery ligation is exaggerated in human c-reactive protein transgenic mice and prevented by estrogen treatment. *Circulation* 110: III-208, 2004 (Abstract 992).
511. Miller AP, Xing D, Feng W, Fintel M, Chen YF, Oparil S. Aged rats lose estrogen-induced vasoprotective and anti-inflammatory effects in injured arteries. *Circulation* 110: III-315, 2004 (Abstract 1507).
512. de Simone G, Wachtell K, Palmieri V, Beevers G, Dahlof B, de Faire U, Fyrhquist F, Ibsen H, Kjeldsen SE, Lederballe-Pederson O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Hille DA, Devereux RB. Body build and risk of cardiovascular events in hypertension: the LIFE study. *Circulation* 110: III-771, 2004 (Abstract 3560).
513. Xing D, Feng W, Weathington NM, Chen YF, Blalock EJ, Oparil S. Estrogen modulates neutrophil chemotaxis activity of rat aortic smooth muscle cells treated with tumor necrosis factor α . *J Invest Med* 53:S262, 2005 (Abstract 49).
514. Feng W, Xing D, Chen YF, Oparil S. Estrogen inhibits tumor necrosis factor α -induced expression of inflammatory mediators in rat aortic smooth muscle cells in vitro. *J Invest Med* 53:S263, 2005 (Abstract 55).
515. Feng JA, Li P, Xing D, Serra R, Oparil S, Chen YF. Transgenic mice with transforming growth factor β type II receptor dysfunction have attenuated hypoxia-induced pulmonary hypertension and remodeling. *J Invest Med* 53:S291, 2005 (Abstract 217).
516. Mehta N, Chen YF, Feng JA, Franco V, Serra R, Oparil S. Blocking of profibrogenic factor transforming growth factor β blunted the pressure overload-induced cardiac interstitial fibrosis and remodeling. *J Invest Med* 53:S317, 2005 (Abstract 363).
517. Franco V, Chen YF, Feng JA, Wang D, Oparil S, Perry GJ. Adverse cardiac remodeling and fibrosis induced by pressure overload is prevented by eplerenone in atrial natriuretic peptide null mice. *J Invest Med* 53:S318, 2005 (Abstract 365).
518. Li P, Oparil S, Chen YF. Atrial natriuretic peptide and cyclic guanosine monophosphate block the stimulatory effects of transforming growth factor β 1 on extracellular matrix messenger ribonucleic acid expression in cultured pulmonary artery smooth muscle cells. *J Invest Med* 53:S318, 2005 (Abstract 366).
519. Hage FG, Sheridan AE, Feng JA, Chen YF, Oparil S. The modulatory effect of atrial natriuretic peptide on extracellular protein expression in mice subjected to pressure and volume overload. *J Invest Med* 53:S318, 2005 (Abstract 368).
520. Feng JA, Li P, Xing D, Serra R, Oparil S, Chen YF. Transgenic mice with transforming growth factor β type II receptor dysfunction have attenuated hypoxia-induced pulmonary hypertension and remodeling. *J Invest Med* 53:S327, 2005 (Abstract 418).
521. Franco V, Chen YF, Feng JA, Wang D, Oparil S, Perry GJ. Eplerenone prevents adverse cardiac remodeling induced by pressure overload in atrial natriuretic peptide null mice. *JACC* 45:143A, 2005 (Abstract 1074-157).

522. Os I, Oparil S, Kjeldsen SE, Gerdtz E, Hille DA, Lyle PA, Douad-Tarazi F, Dahlof B, Devereux RB, Julius S. Female sex and effect of losartan versus atenolol in patients with hypertension and left ventricular hypertrophy. *JACC* 45:374A, 2005 (Abstract 1014-135).
523. Feng JA, Oparil S, Li P, Xing D, Serra R, Chen YF. Transgenic mice with transforming growth factor (TGF)- β type II receptor dysfunction have attenuated hypoxia-induced pulmonary hypertension and remodeling. *JACC* 45:378A, 2005 (Abstract 1041-112).
524. Olsen MH, Wachtell K, Beevers G, Dahlof B, Devereux RB, de Faire U, Ibsen H, Julius S, Kjeldsen S, Lederballe-Pedersen O, Lindholm L, Nieminen M, Omvik P, Oparil S, Wedel H. Losartan has positive effects on lipid metabolism compared to atenolol in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study. *JACC* 45:423A, 2005 (Abstract 1129-107).
525. Kjeldsen SE, Julius S, Snapinn S, Lyle PA, Devereux RB, Dahlöf B et al. Risk predictors for cardiovascular outcomes in patients with hypertension and left ventricular hypertrophy: The LIFE Study. *JACC* 45:424A, 2005.
526. Giles T, Oparil S, Silfani, T, Walker F. Comparison of ascending doses of olmesartan medoximil, losartan potassium and valsartan in patients with essential hypertension. *Am J Hypertens* 18:59A, 2005 (Abstract P-145).
527. Piller L, Ford C, Davis B, Nwachuku C, Black H, Oparil S, Gappy S, Retta T, Probstfield J. Angioedema in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Am J Hypertens* 18:92A, 2005 (Abstract P-240).
528. Franco V, Chen YF, Feng JA, Oparil S, Perry GJ. Eplerenone reverses systolic dysfunction induced by pressure overload in atrial natriuretic peptide null mice. *Am J Hypertens* 18:153A, 2005 (Abstract P-408).
529. Li P, Oparil S, Hassan E, Hsiung MK, Shi W, Cao X, Chen YF. ANP and cGMP block TGF- β -induced nuclear translocation of phosphorylated smad2 and smad3 and expression of extracellular matrix protein in rat pulmonary arterial smooth muscle cells. *Circulation* 112;II-60, 2005 (Abstract 376).
530. Wang D, Oparil S, Xing D, Shi W, Cao X, Chen YF. Atrial natriuretic peptide (ANP) inhibits transforming growth factor TGF- β 1-induced nuclear translocation of smad3 and myofibroblast transformation in mouse cardiac fibroblasts. *Circulation* 112;II-100, 2005 (Abstract 565).
531. Chen YF, Feng JA, Li P, Xing D, Serra R, Ambalavanan N, Oparil S. TGF- β and ANP signaling play opposing roles in hypoxia-induced pulmonary vascular remodeling. *Circulation* 112;II-153, 2005 (Abstract 818).
532. Oparil S, Davis B, Nwachuku C, Pressel S. Stroke results in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Circulation* 112;II-415, 2005 (Abstract 2018).
533. Feng W, Xing D, Oparil S, Chen YF, Szalai AJ. Glycosylated C-reactive protein stimulates proinflammatory mediator expression in rat aortic smooth muscle cells. *J Invest Med* 54:S285, 2006 (Abstract 166).

534. Xing D, Oparil S, Chen YF, Feng W, Kudlow JE, Miller AP. Effects of estrogen and aging on intracellular o-glycosylation (O-GlcNAc) in the vasculature. *J Invest Med* 54:S286, 2006 (Abstract 169).
535. Neutel JM, Franklin SS, Bhaumik A, Oparil S, Ptaszynska A, LaPuerta P. Irbesartan/HCTZ combination therapy as initial treatment for severe hypertension to achieve rapid BP control. *J Clin Hypertens (Suppl A)*: 2006 (Abstract P-106 MP 34).
536. Xing D, Woodham R, Oparil S, Chen YF, Feng W, Kudlow JE, Miller AP. Effects of estrogen and aging on O-glycosylation of nucleocytoplasmic proteins in vascular smooth muscle cells. *J Clin Hypertens (Suppl A)*: 2006 (Abstract P-611 A249).
537. Feng W, Xing D, Oparil S, Chen YF, Wang D, Szalai AJ. Estrogen treatment differentially modulates FcγRIII and FCγRIIb expression in carotid arteries of human C-reactive protein transgenic mice. *J Clin Hypertens (Suppl A)*: 2006 (Abstract P-606 A247).
538. Neutel JM, Franklin S, Oparil S, Lapuerta P, Bhaumik A, Ptaszynska A. Irbesartan/HCTZ combination therapy as initial treatment for severe hypertension to achieve rapid BP control. *J Hypertens (Suppl 4)* 24:S284, 2006 (Abstract P14.494).
539. Xing D, Oparil S, Chen YF, Majid-Hassan E, Feng W, Hage FG, McCrory MA, Skibinski GA, Szalai AJ. FC gamma receptors enable human C-reactive protein to exacerbate neointima formation in transgenic mice. *J Hypertens* 24 (Suppl 6): S34, 2006 (Abstract LBBS-3).
540. Nishizaka MK, Pratt-Ubunama M, Green SA, Dell'italia LJ, Oparil S, Calhoun DA. Dietary salt intake modulates aldosterone-induced endothelial dysfunction and cardiac remodeling. *J Hypertens (Suppl 6)* 24:S88, 2006 (Abstract OS37-3).
541. Chen YF, Li P, Novak L, Cao X, Oparil S. Atrial natriuretic peptide (ANP) signaling inhibits extracellular matrix expression in rat pulmonary arterial smooth muscle cells (PASMCs) by blocking transforming growth factor (TGF)-beta-induced nuclear translocation of phosphorylated Smad 2 and Smad3. *J Hypertens (Suppl 6)* 24: S153, 2006 (Abstract PM3-01-01).
542. Xing D, Feng W, Zhang Y, Miller AP, Chen YF, Chatham JC, Oparil S. Glucosamine inhibits inflammatory response to tumor necrosis factor-alpha in vascular smooth muscle cells via augmentation of protein O-GlcNAcylation. *J Hypertens (Suppl 6)* 24: S179, 2006 (Abstract PM4-01-07).
- 542a. Xing D, Oparil S, Chen YF, McCrory M, Skibinski G, Hassan E, Feng W, Szalai A. Fcγ receptors enable human c-reactive protein to exacerbate neointima formation in transgenic mice. *Circulation (Suppl 18)* 114:II-109, 2006 (Abstract 657).
- 542b. Miller A, Robertson C, Xing D, Li P, Chen YF, Chatham J, Oparil S. The Role of O-GlcNAcylation in Aging-Related Loss of Estrogenic Vasoprotection. *Circ Res* 99:1282, 2006.
- 542c. Alderman M, Calhoun DA, Cushman W, Davis B, Eckfeldt J, Einhorn P, Ford C, Franklin S, Furberg C, Ong S, Oparil S, Papademetriou V, Piller L, Probstfield J. Relationship of 1 year hypokalemia incidence to clinical outcomes in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Circulation (Suppl II)* 114:II-576, 2006 (Abstract 2754).

- 542d. Ambalavanan N, Hagood JS, MacEwen MW, Murphy-Ullrich J, Oparil S, Chen YF. Thy-1 deficiency leads to increased TGF-beta activation and a delay in alveolar development. *Proc Am Thorac Soc* 3:A531, 2006.
- 542e. Olsen MH, Wachtell K, Beevers G, Dahlof B, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kjeldsen SE, Lederballe-Pederson O, Lindholm L, Nieminen MS, Omvik P, Oparil S, Wedel H. High hemoglobin was associated with cardiovascular events, low hemoglobin with all-cause mortality, and large fall in hemoglobin with both in patients with hypertension and left ventricular hypertrophy. The LIFE Study. *J Am Coll Cardiol* 47:361A, 2006 (Abstract 848-5).
543. Gaddam KK, Pimenta E, Pratt-Ubunama MN, Nishizaka M, Aban I, Oparil S, Calhoun DA. Aldosterone and cortisol: is there a common stimulus in subjects with resistant hypertension? *J Invest Med* 55:S247, 2007 (Abstract 4).
544. Gaddam KK, Pimenta E, Pratt-Ubunama MN, Nishizaka M, Aban I, Oparil S, Calhoun DA. Aldosterone and cortisol: is there a common stimulus in subjects with resistant hypertension? *J Invest Med* 55:S274, 2007 (Abstract 168).
545. Pimenta E, Pratt-Ubunama MN, Gaddam KK, Nishizaka MK, Oparil S, Calhoun DA. Aldosterone excess is associated with true treatment resistance as indicated by sustained ambulatory blood pressure and less white-coat effect. *J Invest Med* 55:S276, 2007 (Abstract 176).
546. Miller AP, Robertson C, Xing D, Li P, Chen YF, Chatham JC, Oparil S. Aging-related accumulation of O-GlcNAcylated proteins in the cardiovascular system. *J Invest Med* 55:S279, 2007 (Abstract 197).
547. Hage FG, Xing D, Oparil S, Chen YF, Feng W, Szalai AJ. Immunoglobulin Fc γ receptor 1 mediates exaggerated neointima formation in human C-reactive protein transgenic mice. *J Clin Hypertens (Suppl A)* 9: A2-3, 2007 (Abstract OR-4).
548. Xing D, Feng W, Chen YF, Hassan-Majid E, Chatham JC, Oparil S. Glucosamine inhibits inflammatory and vascular injury responses in balloon-injured rat carotid artery. *J Clin Hypertens (Suppl A)* 9: A3, 2007 (Abstract OR-5).
549. Gaddam KK, Pimenta E, Pratt-Ubunama MN, Oparil S, Calhoun DA. Resistant hypertension characterized by hyperaldosteronism and refractory intravascular volume expansion. *J Clin Hypertens (Suppl A)* 9: A132-133, 2007 (Abstract P-315).
550. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Oparil S, Calhoun DA. High dietary salt worsens urinary protein excretion in patients with aldosterone excess and resistant hypertension. *J Clin Hypertens (Suppl A)* 9: A135-136, 2007 (Abstract P-323).
551. Xing D, Feng W, Chen YF, Oparil S. Olmesartan inhibits neointima formation and the expression of monocyte chemoattractant protein-1 and tumor necrosis factor- α after balloon injury of rat carotid artery. *J Clin Hypertens (Suppl A)* 9: A139, 2007 (Abstract P-333).
552. Miller AP, Robertson C, Xing D, Li P, Chen YF, Chatham JC, Oparil S. Aging-related increases in O-GlcNAcylated proteins in vascular tissues are not explained by changes in OGT or O-GlcNAcase expression. *J Clin Hypertens (Suppl A)* 9: A143, 2007 (Abstract P-345).

553. Neutel J, Franklin S, Oparil S, Bhaumik A, Ptaszynska A, Lapuerta P. Safety and tolerability of fixed-dose irbesartan/HCTZ as initial treatment for rapid control of severe hypertension. *J Clin Hypertens (Suppl A)* 9: A173-174, 2007 (Abstract P-416).
554. Oparil S, Yarrows SA, Patel S, Fang H, Zhang J, Satlin A. The direct renin inhibitor aliskiren in combination with valsartan provides additional blood pressure-lowering effects compared with either agent alone in patients with hypertension. *J Clin Hypertens (Suppl A)* 9: A174-175, 2007 (Abstract P-418).
555. Yarrows SA, Oparil S, Patel S, Fang H, Zhang J, Satlin A. Aliskiren in combination with valsartan provides superior 24-hour ambulatory blood pressure reductions compared with either agent alone in patients with hypertension. *J Clin Hypertens (Suppl A)* 9: A1188-1189, 2007 (Abstract P-452).
556. Oparil S, Abate N, Chen E, Creager MA, Galet V, Jia G, Julius S, Lerman A, Lyle PA, Pool J, Tershakovec AM. A double-blind, randomized study evaluating losartan alone or in combination with hydrochlorothiazide versus placebo in obese patients with elevated systolic and diastolic blood pressure. *J Clin Hypertens* 9: 485, 2007.
557. Yarrows SA, Oparil S, Patel S, Zhang J, Fang H, Satlin A. Suppression of the renin system with the oral direct renin inhibitor aliskiren alone and in combination with valsartan in patients with hypertension. *J Hypertens (Suppl2)* 25: S257, 2007 (Abstract P28.364).
558. Lucas J, Zhang Y, Li P, Wells B, Cogar B, Hsiung R, Oparil S, Chen Y. Counterregulatory roles of TGF- β and ANP signaling pressure overload-induced cardiac remodeling and fibrosis. *Circulation* 116;16-II-247, 2007 (Abstract 1219).
559. Li P, Renfrow M, Lucas J, Oparil S, and Chen Y. Protein kinase G (PKG) over-phosphorylates smad3: potential inhibitor of TGF β -induced cardiac fibrosis and remodeling. *J Invest Med* 56:371, 2008 (Abstract 84).
560. Hage F, Xing D, Oparil S, Feng W, McCrory M, Chen Y, and Szalai A. Exaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type I (FcRI) dependent. *J Invest Med* 56:420, 2008 (Abstract 235).
561. Pimenta E, Gaddam KK, Husain S, Oparil S, and Calhoun DA. High-salt diet and aldosterone induces vascular damage in patients with resistant hypertension. *J Invest Med* 56:425, 2008 (Abstract 248).
562. Gaddam KK, Corros C, Pimenta E, Husain S, Husain A, Gupta H, Lloyd SG, Oparil S, Dell'Italia LJ, and Calhoun DA. Aldosterone induces intracardiac volume overload in patients with resistant hypertension – spironolactone but not thiazide diuretics overcomes it. *J Invest Med* 56:433, 2008 (Abstract 272).
563. Williams TA, Nicola T, Hewitt M, Schwiebert L, Bulger A, Oparil S, Chen Y, and Ambalavanan N. THY-1 null newborn mice exhibit increased lung tissue resistance and decreased compliance. *J Invest Med* 56:446, 2008 (Abstract 311).

564. Hage F, Xing D, Oparil S, Feng W, McCrory M, Chen Y, Szalai A. Exaggerated neointima formation in human C-reactive protein transgenic mice Is IgG Fc receptor type I (Fc_{RI})-Dependent. *J Invest Med* 56:454, 2008 (Abstract 335).
565. Neutel JM, Franklin SS, Bhaumik A, Lapuerta P, Oparil S. Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension. Submitted.
566. Gaddam KK, Pimenta E, Husain S, Oparil S, Calhoun DA. Spironolactone improves aldosterone related obstructive sleep apnea in subjects with resistant hypertension. *J Clin Hypertens (Suppl A)* 10: A1, 2008 (Abstract OR-3).
567. Chrysant SG, Oparil S, Bakris G, Melino M, Karki S, Lee J, Heyrman R. Efficacy of the combination of amlodipine besylate plus olmesartan medoxomil compared to monotherapy in controlling blood pressure in patients with mild-to-severe hypertension. *J Clin Hypertens (Suppl A)* 10: A14, 2008 (Abstract P-22).
568. Chrysant SG, Oparil S, Bakris G, Melino M, Karki S, Lee J, Heyrman R. Combination of amlodipine besylate+ olmesartan medoxomil (OM) is effective and safe with long term dosing while treating patients to blood pressure (BP) goal. *J Clin Hypertens (Suppl A)* 10: A15, 2008 (Abstract P-23).
569. Chrysant S, Oparil S, Kereiakes D, Xu J, Chavanu KJ, Wawerczak W, Dubiel R. An olmesartan medoxomil (OM)-based treatment (Tx) algorithm safely and effectively reduces blood pressure (BP) compared with placebo (PL) in patients (pts) with stage 1 hypertension (HTN). *J Clin Hypertens (Suppl A)* 10: A17, 2008 (Abstract P-28).
570. Kereiakes D, Oparil S, Chrysant S, Xu J, Chavanu KJ, Wawerczak W, Dubiel R. An olmesartan medoxomil (OM)-based treatment (Tx) algorithm safely and effectively reduces blood pressure (BP) compared with placebo (PL) in patients (pts) with stage 2 hypertension (HTN). *J Clin Hypertens (Suppl A)* 10: A24, 2008 (Abstract P-45).
571. Oparil S, Lee J, Melino M, Heyrman R. Long-term efficacy of a fixed-dose combination of amlodipine besylate+ olmesartan medoxomil: Treating black patients to blood pressure goal. *J Clin Hypertens (Suppl A)* 10: A29, 2008 (Abstract P-57).
572. Oparil S, Sandoval J, Karki S, Lee J, Melino M. Combination of amlodipine besylate and olmesartan medoxomil provides greater reduction in blood pressure compared with monotherapy in naïve and nonnaïve subjects. *J Clin Hypertens (Suppl A)* 10: A29-30, 2008 (Abstract P-58).
573. Oparil S, Ramstad D, Melino M, Lee J, Heyrman R. The combination of amlodipine besylate + olmesartan medoxomil provides numerically greater reductions in blood pressure compared with component monotherapies in race and ethnic subgroups. *J Clin Hypertens (Suppl A)* 10: A30, 2008 (Abstract P-59).
574. Oparil S, Herron J, Melino M, Lee J, Heyrman R. The combination of amlodipine besylate and olmesartan medoxomil safely reduces blood pressure compared with monotherapy in both patients with stage 1 and stage 2 hypertension. *J Clin Hypertens (Suppl A)* 10: A30-31, 2008 (Abstract P-60).

575. Oparil S, Chrysant S, Kereiakes D, Xu J, Chavanu KJ, Wawerczak W, Dubiel R. An olmesartan medoxomil (OM)-based treatment algorithm safely and effectively reduces blood pressure (BP) compared with placebo (PL) in patients (pts) with hypertension (HTN). *J Clin Hypertens (Suppl A)* 10: A31, 2008 (Abstract P-61).
576. Peng L, Renfrow M, Lucas J, Oparil S, Chen YF. Protein kinase G (PKG) hyperphosphorylates Smad 3: Potential inhibitor of the pro-fibrogenic effects of TGF- β in hypoxia-induced pulmonary hypertension and vascular remodeling. *J Clin Hypertens (Suppl A)* 10: A46, 2008 (Abstract P-96).
577. Verma A, Desai A, Izzo J, Oparil S, Rocha R, Pitt B, Solomon S. Relationship between arterial stiffness and left ventricular diastolic function in hypertensive patients with diastolic dysfunction. *J Clin Hypertens (Suppl A)* 10: A52, 2008 (Abstract P-111).
578. Xing D, Feng W, Miller AP, Zhang K, Chen YF, Oparil S. Estrogen promotes apoptotic and antioxidant gene expression in rat aortic smooth muscle cells. *J Clin Hypertens (Suppl A)* 10: A90, 2008 (Abstract P-207).
579. Gaddam KK, Corros C, Pimenta E, Husain S, Gupta H, Lloyd SG, Oparil S, Husain A, Dell'Italia LJ, Calhoun DA. Aldosterone excess increases left and right heart volumes in patients with resistant hypertension – spironolactone but not thiazide diuretics overcome it. *J Clin Hypertens (Suppl A)* 10: A95, 2008 (Abstract P-219).
580. Husain S, Nishizaka MK, Pratt-Ubunama MN, Oparil S, Gaddam KK, Pimenta E, Calhoun DA. Similar prevalence of hyperaldosteronism in African American and white subjects with resistant hypertension. *J Clin Hypertens (Suppl A)* 10: A161, 2008 (Abstract P-385).
581. Pimenta E, Gaddam KK, Husain S, Oparil S, Calhoun DA. High-salt diet and aldosterone induces vascular damage and fluid retention in patients with resistant hypertension. *J Clin Hypertens (Suppl A)* 10: A162, 2008 (Abstract P-388).
582. Szalai, AJ, George JF, Allon M, Oparil S. C-reactive protein as an etiological agent of arteriovenous fistula failure: A transgenic mouse model. *J Clin Hypertens (Suppl A)* 10: A168-169, 2008 (Abstract P-403).
583. Xing D, Oparil S, Feng W, Chen YF, Miller AP. Estrogen fails to modulate TNF- α induced inflammatory mediator expression in aged arterial smooth muscle cells. *J Clin Hypertens (Suppl A)* 10: A169, 2008 (Abstract P-404).
584. Yarows SA, Oparil S, Patel S, Arora V, Zhang J. Aliskiren in combination with valsartan provides additional blood pressure-lowering effects compared with either agent alone in elderly and younger patients with hypertension. *J Hypertens (Suppl 1)* 26:S19, 2008 (Abstract OS17/5).
585. Oparil S, Ramstad D, Melino M, Lee J, Heyman R. The combination of amlodipine besylate + olmesartan medoxomil provides numerically greater reductions in blood pressure compared with component monotherapies in race and ethnic subgroups. *J Hypertens (Suppl 1)* 26:S373-374, 2008 (Abstract PS26/WED/14).

586. Chrysant SG, Oparil S, Bakris G, Melino M, Karki S, Lee J, Heyman R. Combination of amlodipine + olmesartan medoxomil (OM) is effective and safe with long term dosing while treating patients (pts) to blood pressure (BP) goal. *J Hypertens (Suppl 1)* 26:S374, 2008 (Abstract PS26/WED/17).
587. Chrysant SG, Oparil S, Bakris G, Melino M, Karki S, Lee J, Heyman R. Efficacy of the combination of amlodipine besylate plus olmesartan medoxomil compared to monotherapy in controlling blood pressure in patients with mild-to-severe hypertension. *J Hypertens (Suppl 1)* 26:S375, 2008 (Abstract PS26/WED/19).
588. Oparil, S, Herron J, Melino M, Lee J, Heyman R. The combination of amlodipine besylate and olmesartan medoxomil safely reduces blood pressure compared with monotherapy in both patients with stage 1 and stage 2 hypertension. *J Hypertens (Suppl 1)* 26:S375-376, 2008 (Abstract PS26/WED/22).
589. Oparil S, Sandoval J, Karki S, Lee J, Melino M. Combination of amlodipine besylate and olmesartan medoxomil provides greater reduction in blood pressure compared with monotherapy in naïve and non-naïve subjects. *J Hypertens (Suppl 1)* 26:S376, 2008 (Abstract PS26/WED/23).
590. Oparil S, Lee J, Melino M, Heyman R. Long-term efficacy of a combination of amlodipine besylate + olmesartan medoxomil: Treating black patients to blood pressure goal. *J Hypertens* 26 (Suppl 1):S376, 2008 (Abstract PS26/WED/25).
591. Oparil S, Chrysant S, Kereiakes D, Xu J, Chavanu K, Wawerczak W, Dubiel R. An olmesartan medoxomil (OM)-based treatment algorithm safely and effectively reduces blood pressure (BP) compared with placebo (PL) in patients (Pts) with hypertension (HTN). *J Hypertens (Suppl 1)* 26:S454, 2008 (Abstract PS32/WED/12).
592. Chrysant S, Oparil S, Kereiakes D, Xu J, Chavanu K, Wawerczak W, Dubiel R. An olmesartan medoxomil (OM)-based treatment algorithm safely and effectively reduces blood pressure (BP) compared with placebo (PL) in patients (Pts) with stage 1 hypertension (HTN). *J Hypertens (Suppl 1)* 26:S454-455, 2008 (Abstract PS32/WED/14).
593. Kereiakes D, Oparil S, Chrysant S, Xu J, Chavanu K, Wawerczak W, Dubiel R. An olmesartan medoxomil (OM)-based treatment algorithm effectively reduces blood pressure (BP) compared with placebo (PL) in patients (Pts) with stage 2 hypertension (HTN). *J Hypertens (Suppl 1)* 26:S468, 2008 (Abstract PS33/THU/09).
594. Oparil S. Estrogen and the female arteries: the secret to a long life. *Vasc Health Risk Manag* 2008 (Abstract P5)
595. Oparil S. Recent advances in hypertension management. *Vasc Health Risk Manag* 2008 (Abstract P6).
596. Husain S, Nishizaka MK, Pratt-Ubunama MN, Gaddam KK, Pimenta E, Oparil S, Calhoun DA. Hyperaldosteronism is equally common in African-American and white patients with resistant hypertension. *Hypertension* 52:e42, 2008 (Abstract 039).

597. Gaddam KK, Corros C, Pimenta E, Aban I, Inusah S, Gupta H, Lloyd SG, Oparil S, Dell'Italia LJ, Husain A, Calhoun D. Hyperaldosteronism causes volume overload cardiac hypertrophy in patients with resistant hypertension. *Hypertension* 52:e76, 2008 (Abstract P104).
598. Pimenta E, Gaddam KK, Husain S, Aban I, Oparil S, Calhoun DA. High dietary salt ingestion increases blood pressure secondary to increases in intravascular volume and vascular resistance in patients with resistant hypertension. *Hypertension* 52:e76, 2008 (Abstract P211).
599. Lucas JA, Miller AP, Zhang Y, Li P, Oparil S, Chen YF. Blocking of transforming growth factor (TGF)- β signaling exacerbates pressure overload-induced left ventricular remodeling and dysfunction. *Circulation (Suppl 2)* 118:S483-485, 2008 (Abstract 3771).
600. Hassanein AH, Verma A, Shin SH, Hung CL, Juszczynska K, Desai A, Rocha R, Hilker R, Izzo J, Oparil S, Pitt B, Solomon SD. Quantitative assessment of left atrial function in patients with hypertension and impaired diastolic function. *Circulation (Suppl 2)* 118:S851, 2008 (Abstract 4240).
601. Husain S, Nishizaka MK, Pimenta E, Gaddam KK, Oparil S, Calhoun DA. Similar response to spironolactone in Whites and African American patients with resistant hypertension. *Circulation (Suppl 2)* 118:S887, 2008 (Abstract 4428).
602. Verma A, Desai A, Hassanein AH, Hung CL, Juszczynska K, Rocha R, Hilker R, Izzo J, Oparil S, Solomon SD. Parallel improvement in central and peripheral pulse pressure and plasma natriuretic peptide in hypertension with diastolic dysfunction: EXCEED trial investigators. *Circulation (Suppl 2)* 118:S957, 2008 (Abstract 4888).
603. Yarows SA, Oparil S, Patel S, Arora V, Zhang J. Aliskiren in combination with valsartan lowers blood pressure more effectively than either agent alone in patients with stage 2 hypertension: Subgroup analysis of an 8-week double-blind study. *Hypertension* 52:e97, 2008 (Abstract P208).
604. Hage F, Oparil S, Feng W, Xing D, Zhang Y, McCrory M, Chen YF, Szalai A. C-reactive protein drives inflammatory mediator expression in acute vascular injury. *J Invest Med* 57:363, 2009 (Abstract 225).
605. Xing D, Nozell S, Chen YF, Oparil S. Estrogen Inhibits NF- κ B P65 binding to the promoters of inflammatory genes in vascular smooth muscle cells. *J Invest Med* 57:393, 2009 (Abstract 332).
606. Xing D, Oparil S, Chen YF, Feng W, Nozell S. Estrogen inhibits inflammation by accelerating a negative feedback loop within the Nf κ B/I κ B Signaling Pathway in TNF- α -stimulated rat aortic smooth muscle cells. *J Am Coll Cardiol* 53:A199, 2009 (Abstract 1012-74).
607. Hage F, Oparil S, Xing D, Zhang Y, McCrory M, Chen YF, Szalai A. Complement is required for the exaggerated response to vascular injury seen in c-reactive protein transgenic mice. *J Clin Hypertens (Suppl A)* 11:A2, 2009 (Abstract OR-5).
608. Chrysant S, Oparil S, Wawerczak W, Xu J, Chavanu K, Dubiel R. The distribution of BP reductions with an olmesartan medoxomil (OM)-based treatment algorithm in patients with stage 1 and 2 hypertension. *J Clin Hypertens (Suppl A)* 11:A124, 2009 (Abstract P-267).

609. Oparil S, Kereiakes D, Wawerczak W, Xu J, Chavanu K, Dubiel R. Efficacy of an Olmesartan medoxomil (OM)-based treatment algorithm in patients with hypertension by age and gender. *J Clin Hypertens (Suppl A)* 11:A132, 2009 (Abstract P-287).
610. Xing D, Feng W, Zhang Y, Chen YF, Chatham J, Oparil S. High O-GlcNAc protein modification exaggerates inflammatory response to acute endoluminal arterial injury. *J Clin Hypertens (Suppl A)* 11:A164, 2009 (Abstract P-367).
611. Lucas J, Miller A, Zhang Y, Li P, Oparil S, Chen Y. Overexpression of dominant negative transforming growth factor type II receptor attenuates pressure overload-induced cardiac remodeling and dysfunction. *J Invest Med* 57:301, 2009 (Abstract 2).
612. Peng L, Kaizheng G, Lucas J, Oparil S, Chen YF. ANP-cGMP-PKG signaling blocks TGF- β -induced reduction of PPAR γ expression in mouse cardiac fibroblasts. *J Clin Hypertens* 11:394, 2009 (Abstract LB-OR-3).
613. Feng W, Xing D, Feng W, Hua P, Zhang Y, Chen YF, Oparil S. Role of ETS-1 as mediator of pro-inflammatory responses in carotid artery endoluminal vascular injury. *J Clin Hypertens* 11:394-395, 2009 (Abstract LB-OR-4).
614. Solomon S, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, Lacourciere Y, Mitchell J, Hippler S, Lee J, Seifu Y, Hilkert B, Rocha R, Pitt B. Effect of blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. *J Clin Hypertens* 11:397, 2009 (Abstract LB-OR-9).
615. Kaizheng G, Peng L, Lucas J, Xing D, Oparil S, Chen YF. p38MAPK and PI3K are required for angiotensin II-induced Smad3 activation in isolated rat pulmonary artery smooth muscle cells. *J Clin Hypertens* 11:398, 2009 (Abstract LB-P-3).
616. Xing D, Nozell S, Chen YF, Feng W, Oparil S. Estrogen enhances I κ B α synthesis and inhibits NF- κ B p65 binding to the promoters of inflammatory genes in rat aortic smooth muscle cells. *FASEB J* 23:805.13, 2009 (Abstract 805.13).
617. Wang K, Xing D, Ho SR, Zhang Y, Chen YF, Oparil S. O-GlcNAcylation inhibits NF κ B activation in rat aortic smooth muscle cells through proteasome inhibition. *FASEB J* 23:775.7, 2009 (Abstract 775.7).
618. Xing D, Feng W, Zhang Y, Chen YF, Chatham JC, Oparil S. PUGNAc and glucosamine exaggerate inflammatory and vascular injury response in balloon-injured rat carotid artery. *Arterioscler Thromb Vasc Biol* 29:e28, 2009 (Abstract P101).
619. Yarows SA, Oparil S, Patel S, Wright M, Zhang J. Aliskiren/valsartan combination lowers blood pressure effectively irrespective of diabetic status compared to the component monotherapies: a post-hoc analysis. *Diabetologia* 52(Suppl 1):S467, 2009 (Abstract 1208).
620. Ahmed M, Gaddam KK, Gladden JD, Desai RV, Lloyd SG, Gupta H, Denney TS, Oparil S, Dell'Italia L, Calhoun D. Spironolactone therapy is associated with rapid improvements in blood pressure control and cardiac remodeling in patients with resistant hypertension. *Circulation (Suppl 2)* 120:S1005-S1006, 2009 (Abstract 4853).

621. Li P, Gong K, Lucas J, Zhang Y, Yang Q, Oparil S, Chen YF. TGF- β downregulates PPAR γ gene expression in pulmonary arterial smooth muscle cells (PASMCs): Novel mechanism of hypoxia-induced pulmonary vascular remodeling. *Circulation (Suppl 2)* 120:S1022, 2009 (Abstract 4925).
622. Shah A, Hajime U, Hassanein A, Verma A, Desai A, Rocha R, Hihlkert R, Izzo J, Oparil S, Pitt B, Arbor A, Thomas JD, Zile MR, Aurigemma G, Solomon S. Renal function and cardiac structure and function in hypertensives with established diastolic dysfunction in the VALIDD and EXCEED trials. *Circulation (Suppl 2)* 120:S1055, 2009 (Abstract 5124).
623. Shah A, Hajime U, Hassanein A, Verma A, Desai A, Rocha R, Hihlkert R, Izzo J, Oparil S, Pitt B, Arbor A, Thomas JD, Zile MR, Aurigemma G, Solomon S. Improvement in diastolic function with anti-hypertensive therapy: an analysis from the combined VALIDD-EXCEED dataset. *Circulation (Suppl 2)* 120:S1088, 2009 (Abstract 5415).
624. Oparil S, Ramstad D, Melino M, Lee J, Reinilde H. The combination of amlodipine + olmesartan medoxomil provides numerically greater reductions in blood pressure compared with component monotherapies in race and ethnic subgroups. *Ethn Dis* 19(Suppl 5): S5-21, 2009 (Abstract 016).
625. Feng W, Xing D, Hua P, Zhang Y, Chen YF, Oparil S, Jaimes E. The transcription factor ETS-1 mediates proinflammatory responses and neointima formation in carotid artery endoluminal vascular injury. *Hypertension* 54:e28-e29, 2009 (Abstract 015).
626. Cushman W, Davis B, Pressel S, Wright JT, Whelton PK, Cutler J, Einhorn P, Barzilay J, Rahman M, Piller L, Ford C, Oparil S, Probstfield J. Long-term follow up in the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). *Circulation* 120:2160, 2009. (Abstract LB161).
627. Pisoni R, Acelajado MC, Oparil S, Calhoun DA. Effects of spironolactone in subjects with resistant hypertension and stage III chronic kidney disease. *J Invest Med* 58:430-431, 2010 (Abstract 267).
628. Gong K, Li P, Lucas J, Xing D, Aksut B, Hage FG, Yang Q, Nozell S, Oparil S, Chen YF. Disruption of transforming growth factor β (tgf β) signaling blocks pressure overload-induced downregulation of endogenous peroxisome proliferator-activated receptor γ (ppary) expression in heart. *J Invest Med* 58:433, 2010 (Abstract 275).
629. Hage FG, Oparil S, Xing D, Chen YF, McCrory M, Szalai AJ. C-reactive protein mediated vascular injury requires complement. *J Invest Med* 58:436-437, 2010 (Abstract 287).
630. Coleman CM, Szalai AJ, Xing D, McCrory M, Chen YF, Oparil S, Hage FG. C-reactive protein drives inflammatory mediator expression in mouse macrophages via an fc γ ri receptor dependent pathway. *J Invest Med* 58:445-446, 2010 (Abstract 318).
631. Oparil S, Giles T, Ofili E, Pitt B, Seifu Y, Samuel R, Hilkert R, Sowers J. Triple combination therapy with amlodipine/valsartan/HCTZ at maximal doses is safe and effective for hypertensive patients uncontrolled on ARB monotherapy: The EXTRA Study. *J Clin Hypertens* 12(Suppl 1): A2, 2010 (Abstract OR-5).

632. Chrysant SG, Oparil S, Melino M, Fernandez V, Lee J, Heyrman R. Safety and tolerability of combination olmesartan medoxomil (OM)+amlodipine besylate (AML)+hydrochlorothiazide (HCTZ) in patients with hypertension. *J Clin Hypertens* 12(Suppl 1): A31, 2010 (Abstract PO-31).
633. Oparil S, Giles T, Ofili E, Pitt B, Seifu Y, Samuel R, Hilkert R, Sowers J. Intensive treatment with combination amlodipine/valsartan provides greater antihypertensive efficacy vs moderate treatment for hypertensive patients uncontrolled on ARB monotherapy: The EXTRA Study. *J Clin Hypertens* 12(Suppl 1): A42, 2010 (Abstract PO-56).
634. Oparil S, Melino M, Fernandez V, Lee J, Heyrman R. Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine Besylate (AML)+hydrochlorothiazide (HCTZ) in patients with hypertension: The Trinity Study. *J Clin Hypertens* 12(Suppl 1): A42, 2010 (Abstract PO-57).
635. Sowers J, Giles T, Ofili E, Pitt B, Seifu Y, Samuel R, Hilkert R, Oparil S. Intensive treatment with combination amlodipine/valsartan provides greater antihypertensive efficacy vs moderate treatment for hypertensive patients with cardiometabolic syndrome uncontrolled on ARB monotherapy. *J Clin Hypertens* 12(Suppl 1): A44, 2010 (Abstract PO-62).
636. Sowers J, Giles T, Ofili E, Pitt B, Seifu Y, Samuel R, Hilkert R, Oparil S. Intensive treatment with combination amlodipine/valsartan vs moderate therapy for hypertensive patients with diabetes or CKD uncontrolled on ARB monotherapy. *J Clin Hypertens* 12(Suppl 1): A44, 2010 (Abstract PO-63).
637. Yarows SA, Oparil S, Patel S, Wright M, Yadao A, Zhang J. Initial use of the aliskiren/valsartan combination is more effective than either component monotherapy in elderly and non-elderly hypertensive patients. *J Clin Hypertens* 12(Suppl 1): A48, 2010 (Abstract PO-71).
638. Yarows SA, Oparil S, Patel S, Wright M, Yadao A, Zhang J. Initial use of the aliskiren/valsartan combination is more effective than either component monotherapy in hypertensive patients with diabetes. *J Clin Hypertens* 12(Suppl 1): A49, 2010 (Abstract PO-72).
639. Yarows SA, Oparil S, Patel S, Wright M, Yadao A, Zhang J. Initial use of the aliskiren/valsartan combination is more effective than either component monotherapy in obese and non-obese hypertensive patients. *J Clin Hypertens* 12(Suppl 1): A49, 2010 (Abstract PO-73).
640. Giles T, Oparil S, Ofili E, Pitt B, Seifu Y, Samuel R, Hilkert R, Sowers J. Initiating therapy with intensive dose of combination amlodipine/valsartan provides improved 24-H BP response compared to moderate dose in hypertensive patients uncontrolled on ARB monotherapy. *J Clin Hypertens* 12(Suppl 1): A74, 2010 (Abstract PO-136).
641. Gong K, Li P, Lucas J, Xing D, Aksut B, Hage F, Yang Q, Nozell S, Oparil S, Chen YF. Transforming growth factor β (TGF- β) – mediated the down-regulation of peroxisome proliferator-activated receptor γ (PPAR γ) in the pressure overloaded heart. *J Clin Hypertens* 12(Suppl 1): A105, 2010 (Abstract PO-217).
642. Ofili E, Oparil S, Giles T, Pitt B, Seifu Y, Samuel R, Hilkert R, Sowers J. Race/ethnic differences in antihypertensive response to moderate vs intensive dose combination amlodipine/valsartan in patients uncontrolled on ARB monotherapy. *J Clin Hypertens* 12(Suppl 1): A130, 2010 (Abstract PO-278).

643. Hage F, Coleman C, Xing D, McCrory M, Chen YF, Oparil S, Szalai, A. C-reactive protein driven vascular inflammation is regulated by macrophage FcγR receptors. *J Clin Hypertens* 12(Suppl 1): A145, 2010 (Abstract PO-313).
644. Oparil S, Aronne LJ, Najarian T, Day WW. Once-daily, low-dose, controlled-release phentermine/ topiramate (PHEN/TPM) improves blood pressure and results in weight loss in overweight/obese patients through 28 weeks. *J Clin Hypertens* 12:529-530, 2010 (Abstract LB-OR-02).
645. Chrysant SG, Oparil S, Melino M, Fernandez V, Lee J, Heyrman R. Safety and tolerability of combination olmesartan medoxomil (om)+amlodipine besylate (aml)+ hydrochlorothiazide (hctz) in patients with hypertension: The Trinity Study. *J Hypertens* 28:e97-e98, 2010 (Abstract Pp.5.166).
646. Giles T, Oparil S, Ofili E, Pitt B, Seifu Y, Samuel R, Hilkert R, Sowers J. Intensive dose of combination amlodipine/valsartan provides improved 24-h bp response compared to moderate dose in hypertensive patients uncontrolled on ARB monotherapy. *J Hypertens* 28:e112, 2010 (Abstract Pp.5.211).
647. Ofili E, Oparil S, Giles T, Pitt B, Seifu Y, Samuel R, Hilkert R, Sowers J. Race/ethnic differences in antihypertensive response to moderate vs intensive dose of combination amlodipine/valsartan in patients uncontrolled on ARB monotherapy. *J Hypertens* 28:e109, 2010 (Abstract Pp.5.204).
648. Oparil S, Melino M, Fernandez V, Lee J, Heyrman R. Efficacy and safety of combination olmesartan medoxomil (om)+amlodipine besylate (aml)+hydrochlorothiazide (hctz) in patients with hypertension: The Trinity Study. *J Hypertens* 28:e101, 2010 (Abstract Pp.5.177).
649. Oparil S, Giles T, Ofili E, Pitt B, Seifu Y, Samuel R, Hilkert R, Sowers J. Intensive treatment with combination amlodipine/valsartan provides greater efficacy vs moderate treatment for hypertensive patients uncontrolled on ARB monotherapy: The Extra Study. *J Hypertens* 28:e110-e111, 2010 (Abstract Pp.5.208).
650. Oparil S, Giles T, Ofili E, Pitt B, Seifu Y, Samuel R, Hilkert R, Sowers J. Triple combination therapy with amlodipine/valsartan/hctz at maximal doses is safe and effective for hypertensive patients uncontrolled on arb monotherapy: The Extra Study. *J Hypertens* 28:e113, 2010 (Abstract Pp.5.216).
651. Sowers J, Giles T, Ofili E, Pitt B, Seifu Y, Samuel R, Hilkert R, Oparil S. Intensive treatment with combination amlodipine/valsartan vs moderate therapy for hypertensive patients with diabetes or CKD uncontrolled on ARB monotherapy. *J Hypertens* 28:e295, 2010 (Abstract Pp.17.149).
652. Sowers J, Giles T, Ofili E, Pitt B, Seifu Y, Samuel R, Hilkert R, Oparil S. Greater efficacy with amlodipine/valsartan combination intensive vs moderate treatment for hypertensive patients with cardiometabolic syndrome uncontrolled on ARB monotherapy. *J Hypertens* 28:e578, 2010 (Abstract Pp.34.432).

653. Littlejohn T, Oparil S, Melino M, Fernandez V, Lee J, Heyrman R. Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besylate (AML)+hydrochlorothiazide (HCTZ): a subgroup analysis by ethnicity and BMI [ADA abstract 2134-PO]. *Diabetes*. 2010;59(Suppl 1). Available at: http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=81037.
654. Oparil S, Littlejohn T, Melino M, Fernandez V, Lee J, Heyrman R. Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besylate (AML)+hydrochlorothiazide (HCTZ) in patients with hypertension and diabetes (the TRINITY Study) [ADA abstract 670-P]. *Diabetes*. 2010;59(Suppl 1). Available at: http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=79615.
655. Probstfield J, Cushman W, Davis B, Pressel S, Cutler J, Einhorn P, Ford C, Oparil S, Whelton P, Wright J, for the ALLHAT Collaborative Research Group. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). *Eur Heart J* 31(Suppl):321, 2010 (Abstract 2017).
656. Cheng S, Lam C, Shah A, Desai A, Izzo J, Oparil S, Pitt B, Solomon S. Influence of age on the effect of antihypertensive therapy on diastolic function. *Eur Heart J* 31(Suppl):729, 2010 (Abstract P4199).
657. Shah A, Lam CS, Cheng S, Verma A, Oparil S, Pitt B, Zile MR, Aurigemma GP, Solomon S. Albuminuria is associated with increased systolic ventricular-arterial stiffness in asymptomatic hypertensive subjects with diastolic dysfunction. *Eur Heart J* 31(Suppl):911, 2010 (Abstract P5104).
658. Oparil S, Cushman W, Davis B, Pressel S, Cutler J, Einhorn P, Ford C, Probstfield J, Whelton P, Wright J, for the ALLHAT Collaborative Research Group. Long-term outcomes in high-risk hypertensive patients: results from an extended follow-up of the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) participants. In Press (ISH 2010).
- 658a. Oparil S, Chrysant SG, Izzo J, Kereiakes D, Littlejohn T, Melino M, Fernandez V, Lee J, Heyrman R. Efficacy of Combination Olmesartan Medoxomil+Amlodipine Besylate+Hydrochlorothiazide in Patients With Hypertension and Diabetes, Chronic Kidney Disease, or Chronic Cardiovascular Disease: The TRINITY Study. *J Hypertens*. 2010(Suppl).
659. Pimenta E, Gaddam KK, Gordon RD, Oparil S, Stowasser M. Dietary sodium and aldosterone levels are related to severity of obstructive sleep apnea in patients with hyperaldosteronism and resistant hypertension. In Press (ISH 2010).
660. Kereiakes D, Izzo J, Chrysant SG, Littlejohn T, Oparil S, Melino M, Fernandez V, Lee J, Heyrman R. The Long-Term Safety and Tolerability of Combination Olmesartan Medoxomil/Amlodipine Besylate+Hydrochlorothiazide in Patients With Hypertension: The TRINITY Study. *J Hypertens*. 2010(Suppl) (Abstract PS4/THU/273).
661. Chrysant SG, Oparil S, Kereiakes D, Izzo J, Littlejohn T, Melino M, Fernandez V, Lee J, Heyrman R. Long-Term Efficacy and Safety of Combination Olmesartan Medoxomil/Amlodipine Besylate+Hydrochlorothiazide in Patients With Hypertension: The TRINITY Study. *J Hypertens*. 2010(Suppl).

662. Li P, Xing D, Gong K, Zhang W, Hage F, Oparil S, Chen YF. Targeted Delivery of Endothelial Cells by Overexpressing Interleukin-8 (IL8) Receptors Inhibits Neointimal Responses to Vascular Injury – Novel Mechanism of Vasoprotection. *Circulation* 122 (Suppl): A12784, 2010 (Abstract 12784).
663. Xing D, Gong K, Feng W, Nozell S, Chen YF, Chatham JC, Oparil S. Increased protein O-GlcNAc inhibits TNF- α -induced NF κ B signaling in rat aortic smooth muscle cells. *Circulation* 122(Suppl): A17015, 2010 (Abstract 17015).
664. Oparil S, Littlejohn T, Melino M, Fernandez V, Lee J, Heyrman R. Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besylate (AML) + hydrochlorothiazide (HCTZ) in black and non-black patients: the TRINITY study. *Ethnic Dis* 20:S3-9, 2010 (Abstract 017).
665. Hage F, Pierce C, Zhang W, Xing D, Chen YF, McCrory MA, Oparil S, Szalai A. Aliskiren inhibits the vascular injury response attributable to c-reactive protein. *J Invest Med* 59:480, 2011 (Abstract 385).
666. Dudenbostel T, Acelayado M, Pisoni R, Oparil S, Calhoun DA. Aldosterone release is positively correlated with increasing body weight in patients with resistant hypertension. *J Invest Med* 59:480, 2011 (Abstract 387).
667. Pachika A, Shah A, Oparil S, Pitt B, Aurigemma G, Zile M, Solomon SD. Influence of obesity on improvement in diastolic function with antihypertension therapy. *J Am Coll Cardiol* 57:E541, 2011 (Abstract 1047-305).
668. Li P, Xing D, Gong K, Hage F, Ilonze OJ, Oparil S, Chen YF. Targeted Delivery of Endothelial Cells (ECs) Overexpressing IL8RA and IL8RB Receptors Promotes Structural and Functional Recovery of the Left Ventricle (LV) in Rats Following Myocardial Infarction (MI). *J Clin Hypertens* 13(Suppl 1):A16, 2011 (Abstract FP-13).
669. Acelayado MC, Pisoni R, Dudenbostel T, Oparil S, Calhoun D. Refractory hypertension characterized by heightened sympathetic tone. *J Clin Hypertens* 13(Suppl 1):A21, 2011 (Abstract PO-11).
670. Chrysant S, Kereiakes DJ, Izzo J, Littlejohn T, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Long-term efficacy and safety of combination olmesartan medoxomil/amlodipine besylate+hydrochlorothiazide – the TRINITY study: a subgroup analysis by study participant race. *J Clin Hypertens* 13(Suppl 1):A71, 2011 (PO-140).
671. Chrysant S, Kereiakes DJ, Oparil S, Izzo J, Littlejohn T, Melino M, Lee J, Fernandez V, Heyrman R. Long-term efficacy and safety of combination olmesartan medoxomil/amlodipine besylate+hydrochlorothiazide in study participants with hypertension based on age: The TRINITY study. *J Clin Hypertens* 13(Suppl 1):A71, 2011 (PO-139).
672. Hage F, Pierce C, Zhang W, Xing D, Chen YF, McCrory M, Oparil S, Szalai A. Inhibiting the renin-angiotensin system with aliskiren and/or valsartan protects against c-reactive protein mediated vascular injury response. *J Clin Hypertens* 13(Suppl 1):A63, 2011 (PO-122).

673. Dudenbostel T, Acelajado M, Pisoni R, Oparil S, Calhoun DA. Aldosterone release is positively correlated with increasing body weight in patients with resistant hypertension. *J Clin Hypertens* 13(Suppl 1):A148-A149, 2011 (PO-332).
674. Gong K, Chen YF, Li P, Zhang W, Hage F, Ambalavanan N, Oparil S, Xing D. PPAR γ Agonist Inhibits, and PPAR γ Antagonist Exacerbates, Pressure Overload-induced Cardiac Fibrosis and Dysfunction. *J Clin Hypertens* 13(Suppl 1):A99, 2011 (PO-204).
675. Oparil S, Izzo J, Melino M, Lee J, Fernandez V, Heyrman R. Long-term efficacy and safety of combination olmesartan medoxomil (OM)/amlodipine besylate (AML)+hydrochlorothiazide (HCTZ)—The Trinity Study: Subgroup analyses based on diabetes status and BMI. *J Clin Hypertens* 13(Suppl 1):A75, 2011 (PO-150).
676. Gong K, Xing D, Li P, Ambalavanan N, Oparil S, Chen YF. ANP-cGMP-PKG activation inhibits TGF- β -induced Smad3 nuclear translocation by increasing Smad3 binding to cytosolic β 2-tubulin in rat pulmonary arterial smooth muscle cells. *J Clin Hypertens* 13(Suppl 1):535-536, 2011 (LB-PO-01).
677. Kereiakes DJ, Chrysant S, Izzo J, Littlejohn T, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Long-term efficacy and safety of combination olmesartan medoxomil/amlodipine besylate + HCTZ based on hypertension severity: the TRINITY study. *J Hypertens* 29 (Suppl A):e98, 2011 (Abstract 7A.05).
678. Oparil S, Izzo J, Chrysant S, Kereiakes DJ, Littlejohn T, Melino M, Lee J, Fernandez V, Heyrman R. Long-term efficacy and safety of combination olmesartan medoxomil/amlodipine besylate+hydrochlorothiazide stratified by diabetes status and body mass index: subgroup analyses of the TRINITY study. *J Hypertens* 29(Suppl A):e98-e99, 2011 (Abstract 7A.06).
679. Chrysant S, Kereiakes DJ, Izzo J, Littlejohn T, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Long-term efficacy and safety of combination olmesartan medoxomil/amlodipine besylate+ hydrochlorothiazide stratified by race: a TRINITY study subgroup analysis. *J Hypertens* 29(Suppl A):e99, 2011 (Abstract 7A.07).
680. Littlejohn T, Kereiakes DJ, Chrysant S, Izzo J, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Distribution of systolic blood pressure reductions from the TRINITY study: efficacy of combination olmesartan medoxomil+amlodipine besylate+hydrochlorothiazide. *J Hypertens* 29(Suppl A):e99, 2011 (Abstract 7A.08).
681. Chrysant S, Kereiakes DJ, Oparil S, Izzo J, Littlejohn T, Melino M, Lee J, Fernandez V, Heyrman R. Long-term efficacy and safety of combination olmesartan medoxomil/amlodipine besylate +HCTZ stratified by age: a TRINITY study subgroup analysis. *J Hypertens* 29(Suppl A):e561, 2011 (Abstract PP.44.422).
682. Gong K, Li P, Lucas J, Yang Q, Nozell S, Oparil S, Chen YF, Xing D. Activation of PPAR γ by rosiglitazone inhibits pressure overload-induced cardiac hypertrophy and improves diastolic dysfunction through antagonizing transforming growth factor- β signaling in mice. *FASEB J* 25:1096.5, 2011 (Abstract 1096.5).

683. Hage F, Hilgers R, Li P, Yang Z, Oparil O, Chen YF. Endothelial Cell Transfusion Protects Against Chronic Kidney Disease-Induced Endothelial Dysfunction in Nephrectomized Rats. *Circulation* 124:A16558, 2011 (Abstract 16558).
684. Cheng S, O'Brien K, Albisu JP, Shah B, Shah A, Desai A, Izzo J, Oparil S. Reversibility of Contractile Dysfunction in Patients with Hypertensive Heart Disease. *Circulation* 124:A14994, 2011 (Abstract 14994).
685. Dudenbostel T, Acelajado MC, Judd E, Oparil S, Calhoun DA. Refractory Hypertension Characterized by Increased Heart Rate and Vascular Stiffness Consistent with Heightened Sympathetic Tone. *In Press* (ASH-GC 2011).
686. Judd E, Acelajado MC, Dudenbostel T, Oparil S, Calhoun DA. Severity of Sleep Apnea Similar in Resistant and Refractory Hypertension. *In Press* (ASH-GC 2011).
687. Lackland DT, Calhoun DA, Le A, Howard V, Glasser S, Cushman M, Kissela B, Howard G, Oparil S. Geographic disparities in hypertension prevalence, but not treatment and control in the Southeast: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort. *In Press* (ISC 2011).
688. Hage FG, Bowling M, Kapadia A, Chen Y, McCrory M, Szalai A, Oparil S, Xing D. Estrogen inhibits C-reactive protein-driven inflammation in young but not aged mice. *J Invest Med* 2012;60:339 (Abstract 339).
689. O'Brien, Shah B, Gennaro JA, Uraizee I, Shah A, Izzo J, Oparil S, Pitt B, Solomon S, Cheng S. Impact of obesity on reversibility of contractile dysfunction in patients with hypertensive heart disease. *JACC* (March 27 2012) 59 (13): E1143, 2012 (Abstract 1099-365).
690. Juan Pablo Albisu Di Gennaro, Susan Cheng, Kaitlyn O'Brien, Beejal Shah, Imran Uraizee, Amil Shah, Joseph Izzo, Suzanne Oparil, Bertram Pitt, Scott Solomon. Effect of Anti-Hypertensive Therapy on Left Atrial Function in Patients with Hypertensive Heart Disease. *JACC* (March 27 2012) 59 (13):E1270, 2012 (Abstract # 1096-251).
691. Gupta A, Oparil S, Bowden CH. Controlled release phentermine/Topiramate (PHEN/TPM CR) improves BP, prevents progression to hypertension, and reduces weight in subjects with pre-hypertension. *J Clin Hypertens* 14(Suppl 1):A48, 2012 (Abstract PO-65).
692. Bakris G, Oparil S, Yadao A, Purkayastha D, Alessi T, Sowers J. aliskiren/valsartan combination provides greater BP control than valsartan in hypertensive patients with diabetes. *J Clin Hypertens* 14 (Suppl 1):A101, 2012 (Abstract PO-195).
693. Chrysant S, Oparil S, Izzo J, Kereiakes DJ, Melino M, Lee J, Fernandez V, Heyrman R. Olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide in participants with diabetes and severe hypertension. *J Clin Hypertens* 14 (Suppl 1):A101-A102, 2012 (Abstract PO-196).
694. Hage F, Hilgers R, Pacurari M, Yang Z, Oparil S, Chen YF. Endothelial Cells Overexpressing interleukin-8 Receptors Reduce Neointima Formation after Acute Vascular Injury in 5/6 Nephrectomized Rats. *J Clin Hypertens* 14 (Suppl 1):A126, 2012 (Abstract PO-257).

695. Izzo J, Kereiakes DJ, Chrysant S, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. TRINITY: Long-term efficacy and safety of olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide by ethnicity. *J Clin Hypertens* 14 (Suppl 1):A103, 2012 (Abstract PO-200).
696. Lewin A, Izzo J, Oparil S, Chrysant S, Kereiakes DJ, Melino M, Lee J, Fernandez V, Heyrman R. Olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide in elderly participants with severe hypertension. *J Clin Hypertens* 14 (Suppl 1):A105, 2012 (Abstract PO-205).
697. Roth E, Oparil S, Kereiakes DJ, Izzo J, Chrysant S, Melino M, Lee J, Fernandez V, Heyrman R. TRINITY: Olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide in obese participants with severe hypertension. *J Clin Hypertens* 14 (Suppl 1):A106, 2012 (Abstract PO-208).
698. Hage FG, Szalai AJ, Xing D, McCrory MA, Chen YF, Oparil S. Aliskiren inhibits C-reactive protein driven vascular inflammation. *Circulation* 125:0207, 2012.
699. Dudenbostel T, Acelayado MC, Judd E, Oparil S, Calhoun DA. Refractory hypertension characterized by increased heart rate, central blood pressure and arterial stiffness consistent with heightened sympathetic tone. *J Clin Hypertens* 14(7):484, 2012 (Abstract LB-PO-3).
700. Judd E, Pisoni R, Dudenbostel T, Oparil S, Harding SM, Calhoun DA. Spironolactone Reduces Severity of Obstructive Sleep Apnea in Resistant Hypertension. *Circulation* 126(21):15486, 2012 (Abstract 15486). *Presented at the American Heart Association Scientific Sessions 2012.*
701. Hage F, Bowling M, Kapadia A, Chen YF, Szalai AJ, Oparil S, Xing D. Estrogen Effects on Vascular Inflammation are Age-Dependent. *Circulation* 126(21):17889, 2012 (Abstract 17889). *Presented at the American Heart Association Scientific Sessions 2012.*
702. Pacurari M, Hilgers RHP, Xing D, Oparil S, Chen YF, Hage F. Endothelial Cell Infusion Improves Chronic Kidney Disease-induced Endothelial Dysfunction in 5/6 Nephrectomized Rats. *Circulation* 126(21):17948, 2012 (Abstract 17948). *Presented at the American Heart Association Scientific Sessions 2012.*
703. Dudenbostel T, Acelayado MC, Oparil S, Calhoun DA. Increased Sympathetic Nervous System Activity in Refractory Hypertensive Patients in Contrast to Controlled and True Resistant Hypertensive Patients. *Circulation* 126(21):19101, 2012 (Abstract 19101). *Presented at the American Heart Association Scientific Sessions 2012.*
704. Pacurari M, Xing D, Hilgers R, Guo Y, Chen YF, Oparil S, Hage FG. The therapeutic use of systemically administered endothelial cells for vascular dysfunction in a rat model of chronic kidney disease. *J Invest Med* 61(2):406, 2013. *Southern Society for Clinical Investigation.*
705. Hage F, Bowling MR, Xing D, Kapadia A, Chen YF, Szalai AJ, Oparil S. Estrogen ameliorates vascular inflammation in young but not aged mice. *J Clin Hypertens* 15(Suppl 1):A104, 2013. (Abstract PO-202). *Presented at the 28th Annual American Society of Hypertension Meeting and Expo, San Francisco, California, May 2013.*
706. Oparil S, Schmieder RE. Results of a study to assess patient perceptions about the impact of uncontrolled and resistant hypertension on their lives. *J Clin Hypertens* 15(Suppl 1):A5, 2013. (Abstract OR-11). *Original Communication, 28th Annual American Society of Hypertension Meeting and Expo, San Francisco, California, May 2013.*

707. Hage FG, Pacurari M, Xing D, Hilgers R, Guo Y, Chen YF. Endothelial cell transfusion in nephrectomized rats ameliorates endothelial dysfunction by increasing eNOS activity. *J Clin Hypertens* 15(Suppl 1):____, 2013. (Abstract OR-22). *Presented at the 28th Annual American Society of Hypertension Meeting and Expo, San Francisco, California, May 2013.*
708. Zhao X, Xing D, Fu J, Hage F, Kao Y, Oparil S, Chen YF. In Vitro and in vivo characterization of adult endothelial cells overexpressing IL8RA and IL8RB receptors, which have been used to repair injured blood vessels, *J Clin Hypertens* 15(Suppl 1):A103, 2013. (Abstract PO-200). *Presented at the 28th Annual American Society of Hypertension Meeting and Expo, San Francisco, California, May 2013.*
709. Xing D, Feng W, Hage F, Paterson AJ, Chatham JC, Oparil S. Vascular Smooth Muscle Cell-selective O-GlcNAcylation protects arteries against acute injury. *Circulation* 128(Suppl 22):A13061, 2013. (Abstract 13061). *Presented at the 2013 American Heart Association Scientific Sessions.*
710. Bromfield S, Shimbo D, Diaz K, Booth J, Calhoun D, Irvin R, Krousel-Wood M, Redmond N, Oparil S, Muntner P. The association between apparent treatment resistant hypertension and low mental and physical functioning, depressive symptoms, and stress. *Circulation* 129:AP048 (Suppl 1), 2014. (Abstract P048).
711. Fu J, Zhao X, Xing D, Creighton J, Guo Y, Hage F, Oparil S, Chen YF. Targeted Delivery of Pulmonary Arterial Endothelial Cells Overexpressing IL8RA and IL8RB Receptors Attenuates Monocrotaline-Induced Pulmonary Vascular Remodeling and Hypertension in Rats. *American Society of Hypertension (ASH) 2014 Annual Meeting.*
712. Kent ST, Shimbo D, Huang L, Diaz KM, Viera AJ, Kilgore M, Oparil S, Muntner P. Reimbursement for ambulatory blood pressure monitoring among medicare beneficiaries during 2007 to 2010. *American Society of Hypertension (ASH) 2014 Annual Meeting.*
713. Muntner P, Whittle J, Lynch AI, Simpson LM, Einhorn P, Levitan EB, Whelton PK, Cushman WC, Louis GT, Davis BR, Oparil S. Visit-to-visit variability of blood pressure and coronary heart disease, stroke, heart failure, and mortality: Results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *American Society of Hypertension (ASH) 2014 Annual Meeting.*
714. Sica D, Zhao L, Oparil S, Kupfer S, Juhasz A, Hisada M, Huang P. Long-term safety of fixed-dose combinations: azilsartan medoxomil/chlorthalidone versus olmesartan medoxomil/hydrochlorothiazide in hypertensive subjects with Stage 3 chronic kidney disease. *American Society of Hypertension (ASH) 2014 Annual Meeting.*
715. Zhao X, Xing D, Hage F, Oparil S, Cooke JP, Lee J, Nakayama K, Huang NF, Chen YF. Targeted Delivery of Human iPS-Endothelial Cells with Overexpression of Interleukin-8 (IL8) Receptors Inhibits Neointimal Responses to Vascular Injury in Rat. *American Society of Hypertension (ASH) 2014 Annual Meeting.*
716. Hage FG, Xing D, Guo Y, Oparil S, Chen YF, Sanders PW. Targeted delivery of endothelial cells overexpressing interleukin-8 receptors attenuates ischemia reperfusion acute kidney injury. *Abstract submitted. American Heart Association (AHA) 2014 Scientific Sessions. [Control/Tracking: 2014-SS-A-14845-AHA].*

717. Hage FG, Xing D, Guo Y, Colon C, Szalai A, Chen YF, Oparil S. Estrogen-induced vasoprotection is preserved after prolonged estrogen deprivation. *American Heart Association (AHA) 2014 Scientific Sessions*. [Control/Tracking: 2014-SS-A-14875-AHA].
718. Giordano S, Xing D, Hage FG, Townes TM, Sun CW, Wu LC, Oparil S, Chen YF. Targeted Delivery of rat iPS-endothelial cells overexpressing neutrophil IL8-RA/RB or macrophage CCR2/CCR5 receptors inhibits neointima formation in balloon injured rat carotid artery. *Circulation* 132(Suppl 3):A11666, 2015 (Abstract 11666). *Presented at the American Heart Association Scientific Sessions 2015*.
719. Kalra R, Ghazi L, Calhoun DA, Oparil S, Dudenbostel T. Hyperreninemic aldosteronism in Caucasian and African-American patients with apparent resistant hypertension. *Circulation* 132(Suppl 3):A15037, 2015 (Abstract 15037). *Presented at the American Heart Association Scientific Sessions 2015*.
720. Xing D, Giordano S, Gaggari A, Feng W, Chen YF, Creighton J, Oparil S. Targeted delivery of pulmonary arterial endothelial cells overexpressing interleukin-8 receptors attenuates liposaccharide-induced lung injury. *Circulation* 132(Suppl 3):A16371, 2015 (Abstract 16371). *Presented at the American Heart Association Scientific Sessions 2015*.
721. Hage FG, Xing D, Giordano S, Guo Y, Oparil S, Chen YF, Sanders P. Endothelial cells overexpressing interleukin-8 receptors are renoprotective in rats with acute kidney injury. *Circulation* 132(Suppl 3):A15477, 2015 (Abstract 15477). *Presented at the American Heart Association Scientific Sessions 2015*.
722. Cushman WC, Evans GW, Rodriguez CJ, Ringer RJ, Wright JT Jr, Whelton PK, **Oparil S**. Blood Pressure Intervention and Control in the Systolic Blood Pressure Intervention Trial (SPRINT). *Abstract Accepted (Abstract OR-9) for Presentation at the 2016 Annual American Society of Hypertension Meeting, May 14, 2016*.
723. Kitzman DW, Oparil S, Lewis B, Upadhyaya B, Lovato L, Rocco M; for the SPRINT Research Group. Outcomes in patients who developed heart failure in SPRINT- Results from the SPRINT study. *Abstract submitted. American Society of Hypertension (ASH) 2016 Annual Meeting*.
724. Oparil S, Calhoun DA, Ghazi L, Dudenbostel T. (OS 33-02). In patients with resistant hypertension increased 24-h urinary cortisol level predict increased body mass index. *J Hypertens*. 2016 Sep;34 Suppl 1 - ISH 2016 Abstract Book:e393.
725. Ghazi L, Dudenbostel T, Ejem D, Turner-Henson A, Joiner CI, Affuso O, Azuero A, Calhoun DA, Rice M, Hage F, Oparil S. (OS 24-04). A pilot study assessing the feasibility of vascular function in low socioeconomic status preschool children. *J Hypertens*. 2016 Sep;34 Suppl 1 - ISH 2016 Abstract Book:e244.
726. Oparil S. (SY 11-3). Hypertension in women: More dangerous than in men? *J Hypertens*. 2016 Sep;34 Suppl 1 - ISH 2016 Abstract Book:e366.

727. Velasco A, Siddiqui M, Lloyd S, Oparil S, Calhoun D. Antihypertensive treatment failure not attributable to persistent intravascular fluid retention as determined by MRI-measured intracardiac volumes. JACC 69(11)Suppl:1728, 2017. ACC 2017 Annual Meeting (1146-037).
728. Thomas SJ, Thomas S, Siddiqui M, Harding S, Oparil S, Calhoun D. 1059 polysomnographic characteristics of patients with refractory hypertension compared to controlled resistant hypertension. Sleep 40(suppl 1):A393-A394, 2017. 31st Annual Meeting of the Associated Professional Sleep Societies, LLC.

MANUSCRIPTS IN PROGRESS, SUBMITTED, UNDER REVIEW/REVISION, ACCEPTED/IN PRESS

Bello NA, Muntner P, Kronish I, **Oparil S**, Anstey ED, Wei Y, Cheung YKK, Schwartz JE, Shimbo D. What is the optimal measurement strategy for obtaining a reproducible estimate of home blood pressure? Results from the improving the detection of hypertension study. *Manuscript in progress.*

Foy C, Lovato LC, Vitaolins MZ, Bates JT, Campbell R, Cushman WC, Glasser S, Gillespie A, Kostis W, Krousel-Wood M, Muhlestein J, Oparil S, Osei K, Pisoni R, Segal MS, Willgers A, Johnson KC. Gender, blood pressure, and cardiovascular and renal outcomes in adults with hypertension from the SPRINT trial. *Manuscript submitted. J Hypertens* (SPRINT MS 0132).

Ghazi L, **Oparil S**. Impact of the SPRINT trial on hypertension management. *Manuscript submitted. (Annual Review of Medicine)*. Vol. 69 (anticipated publication online 01/2018; print 02/2018).

Howard G, Cushman M, Moy CS, **Oparil S**, Muntner P, Lackland DT, Manly JJ, Flaherty ML, Judd SE, Wadley VG, Howard VJ. An assessment of contributors to the excess incidence of hypertension in Blacks: the REasons for Geographic And Racial Differences in Stroke (REGARDS) Study. *Manuscript submitted. JAMA.*

Irvin M, Booth J, Shimbo D, Lackland D, **Oparil S**, Howard G, Safford M, Muntner P, Calhoun D. Apparent treatment resistant hypertension and risk for stroke, coronary heart disease and all-cause mortality. *Manuscript resubmitted. J Am Soc Hypertens.*

Judd E, Pisoni R, Dudenbostel T, Zhang B, **Oparil S**, Harding SM, Calhoun DA. Spironolactone reduces severity of obstructive sleep apnea in patients with resistant hypertension: Results from a randomized controlled trial. *Manuscript under revision.*

Kitzman DW, **Oparil S**, Lewis B (*proposed*). Characteristics and Outcomes in Patients with Heart Failure (HF) with Preserved Ejection Fraction (HFpEF) in SPRINT. *Manuscript in progress.* Review by SPRINT P&P Committee.

Le Jemtel T, Oparil S, et al. Left ventricular mass in obesity and effect of bariatric surgery. *Manuscript in progress.*

Liu M, Wang T, Zhang B, **Oparil S**, Calhoun DA, Dudenbostel T. High prevalence of Type 2 diabetes mellitus in resistant hypertensive patients with primary aldosteronism on a high sodium diet. *Manuscript in progress.*

Qu X, Gan Q, Han W, Fang W, Zhang Z, Chen YF, **Oparil S**, Gong K. Central mechanisms of blood pressure regulation of bilateral renal artery denervation ablation in deoxycorticosterone acetate-induced hypertensive swine model: Restoring the imbalance between ACE2-Ang-(1-7)-Mas and ACE1-AngII-AT1 axis. *Manuscript in progress.*

MANUSCRIPTS IN PROGRESS, SUBMITTED, UNDER REVIEW/REVISION, ACCEPTED/IN PRESS

Rahman M, Hawfield A, Johnson K, Whelton P, Reboussin D, Ambrosius W, Greene T, **Oparil S**, Lewis B, Wright JTW Jr, Beddhu S, Goff D, Williamson J, Sink K, Rocco M, Cushman W, Fine L, Snyder J, Cutler J, Kimmel P, Cheung A; for the SPRINT Research Group. Renal outcomes of intensive versus standard blood-pressure control in participants with chronic kidney disease; a report from the SPRINT study. *Manuscript in progress*.

Shams T, Auchus A, **Oparil S**, Wright C, Wright JTW Jr. Baseline quality of life and risk of stroke in the ALLHAT study. *Manuscript submitted* (STROKE/2016/016062D). *Stroke*.

Shapiro BP, Ambrosius WT, Blackshear JL, Cushman WC, Whelton PK, **Oparil S**, Beddhu S, Dwyer JP, Gren LH, Kostis WJ, Lioudis M, Pisoni R, Rosendorf C, Haley WE. Differential impact of intensive as compared to standard blood pressure management by tertiles of baseline systolic blood pressure. *Manuscript in progress*. (SPRINT MS 0131).

Siddiqui M, Judd E, Oparil S, Calhoun DA. White coat effect is uncommon in patients with refractory hypertension. *Manuscript resubmitted*. *Hypertension*.

Supiano MA, Ambrosius W, Bates J, Beddhu S, Drawz P, Dwyer J, Hamburg N, Kitzman D, Lash J, Lovato L, Lustigova E, Miracle C, **Oparil S**, Raj D, Weiner D, Taylor A, Vita J (deceased), Yunis R, Chertow G, Chonchol M. Pulse wave velocity and central aortic pressure in SPRINT participants. *Manuscript in progress*. (SPRINT MS 0067; SPRINT P&P review-intended journal: JAHA).

Tajeu GS, Booth J, Gottesman RF, Howard G, Lackland DT, Oparil S, Ravenell J, Safford M, Seals SR, Shimbo D, Shea S, Spruill T, Tanner RM, Muntner P. Incident cardiovascular disease among adults with blood pressure < 140/90 mm Hg. *Accepted for Publication* (June 5, 2017). *Circulation*.

Xing D, Giordano S, Feng W, Gaggar A, Hage F, Chen YF, Well JM, **Oparil S**. Induced pluripotent stem cell-derived endothelial cells attenuate lipopolysaccharide-induced acute lung injury. *Manuscript submitted*. *Am J Physiol Lung Cell Mol Physiol*.